{"281734ccd01c879730728a6e071af52097377db7": [["BackgroundFacial skin care (FSC) is important in maintaining and improving skin function.", [["skin", "ANATOMY", 17, 21], ["skin", "ANATOMY", 75, 79], ["skin", "ORGAN", 17, 21], ["skin", "ORGAN", 75, 79], ["BackgroundFacial skin care", "TREATMENT", 0, 26], ["skin", "ANATOMY", 17, 21], ["skin", "ANATOMY", 75, 79]]], ["Ingredients of FSC products are known to improve skin problems such as wrinkles, spots, and rough skin texture [1, 2] .", [["skin", "ANATOMY", 49, 53], ["skin", "ANATOMY", 98, 102], ["FSC products", "SIMPLE_CHEMICAL", 15, 27], ["skin", "ORGAN", 49, 53], ["skin", "ORGAN", 98, 102], ["FSC products", "TREATMENT", 15, 27], ["skin problems", "PROBLEM", 49, 62], ["wrinkles, spots, and rough skin texture", "PROBLEM", 71, 110], ["skin", "ANATOMY", 98, 102]]], ["Furthermore, the use of certain hand motions during FSC is expected to have beneficial physiological effects.", [["hand", "ANATOMY", 32, 36], ["hand", "ORGANISM_SUBDIVISION", 32, 36], ["FSC", "CELL_TYPE", 52, 55], ["beneficial physiological effects", "PROBLEM", 76, 108]]], ["FSC of Japanese woman has also been reported to influence autonomic nerve system (ANS) activity [3] [4] [5] [6] [7] .", [["autonomic nerve system", "ANATOMY", 58, 80], ["woman", "ORGANISM", 16, 21], ["autonomic nerve system", "ANATOMICAL_SYSTEM", 58, 80], ["ANS", "SIMPLE_CHEMICAL", 82, 85], ["[3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 96, 115], ["FSC", "CELL_TYPE", 0, 3], ["woman", "SPECIES", 16, 21], ["nerve", "ANATOMY", 68, 73]]], ["Alternatively, facial massage by hand is thought to provide physical stimulation to both skin and muscle, leading to morphological and physical improvement [8, 9] .BackgroundMoreover, FSC combines not only cultural aspects for beauty but also the sociological significance based on communication.", [["facial", "ANATOMY", 15, 21], ["hand", "ANATOMY", 33, 37], ["skin", "ANATOMY", 89, 93], ["muscle", "ANATOMY", 98, 104], ["hand", "ORGANISM_SUBDIVISION", 33, 37], ["skin", "ORGAN", 89, 93], ["muscle", "ORGAN", 98, 104], ["FSC", "CELL_TYPE", 184, 187], ["facial massage", "TREATMENT", 15, 29], ["physical stimulation", "TREATMENT", 60, 80], ["facial", "ANATOMY", 15, 21], ["massage", "OBSERVATION", 22, 29], ["skin", "ANATOMY", 89, 93], ["muscle", "ANATOMY", 98, 104]]], ["It is important to expand the psychological and physiological potential of user by providing the method of FSC.BackgroundHowever, since FSC behavior is very personal and complicated, objective and quantitative evaluation is difficult.BackgroundThere are very few reports on the relationship between hand motions during FSC and physiological changes.BackgroundWe focused on two parameters, the approximate entropy (ApEn) [10] used for the analysis of complex systems and Rest \u03b3 [11] representing the cumulative frequency distribution of human-activity duration for the evaluation of FSC motions.", [["hand", "ANATOMY", 299, 303], ["hand", "ORGANISM_SUBDIVISION", 299, 303], ["human", "ORGANISM", 536, 541], ["FSC", "CELL_TYPE", 107, 110], ["human", "SPECIES", 536, 541], ["human", "SPECIES", 536, 541], ["quantitative evaluation", "TEST", 197, 220], ["physiological changes", "PROBLEM", 327, 348], ["the approximate entropy (ApEn)", "TREATMENT", 389, 419], ["the evaluation", "TEST", 564, 578], ["FSC motions", "PROBLEM", 582, 593], ["very", "OBSERVATION_MODIFIER", 254, 258], ["few", "OBSERVATION_MODIFIER", 259, 262]]], ["ApEn can be used to evaluate the complexity of information, even for discrete data with finite length [10, 12] .", [["ApEn", "GENE_OR_GENE_PRODUCT", 0, 4], ["ApEn", "PROTEIN", 0, 4]]], ["ApEn is smaller in the case of more regular sequenced data.", [["ApEn", "GENE_OR_GENE_PRODUCT", 0, 4], ["ApEn", "PROTEIN", 0, 4], ["smaller", "OBSERVATION_MODIFIER", 8, 15]]], ["Pincus et al. reported on the risk of sudden infant death syndrome by ApEn using electrocardiogram data [13] , while Arif et al. evaluated the change in the stability of walking with aging by ApEn [14] .", [["sudden infant death syndrome", "DISEASE", 38, 66], ["sudden infant death syndrome", "PROBLEM", 38, 66], ["electrocardiogram data", "TEST", 81, 103], ["change", "OBSERVATION_MODIFIER", 143, 149], ["stability", "OBSERVATION_MODIFIER", 157, 166]]], ["Furthermore, they reported that Rest \u03b3 indicated qualitative differences in the living activities between healthy and depressed individuals [15] .BackgroundMany relationships between skills and motion have been reported in the fields of sport [16] [17] [18] , music [19] , and dance [20] .", [["depressed", "DISEASE", 118, 127], ["Rest \u03b3", "GENE_OR_GENE_PRODUCT", 32, 38]]], ["Self-facial massage of Japanese women stimulates the parasympathetic nerve, suggesting a relaxation effect [3, [5] [6] [7] .", [["facial", "ANATOMY", 5, 11], ["parasympathetic nerve", "ANATOMY", 53, 74], ["women", "ORGANISM", 32, 37], ["parasympathetic nerve", "MULTI-TISSUE_STRUCTURE", 53, 74], ["[5] [6] [7]", "SIMPLE_CHEMICAL", 111, 122], ["women", "SPECIES", 32, 37], ["a relaxation effect", "PROBLEM", 87, 106], ["parasympathetic nerve", "ANATOMY", 53, 74]]], ["Daily FSC may have the ability to control ANS unconsciously.", [["FSC", "CELL_TYPE", 6, 9]]], ["In these studies, ANS activity is evaluated by heart rate variability (HRV) [21] .", [["heart", "ANATOMY", 47, 52], ["ANS", "GENE_OR_GENE_PRODUCT", 18, 21], ["heart", "ORGAN", 47, 52], ["these studies", "TEST", 3, 16], ["heart rate variability", "TEST", 47, 69]]], ["HRV, the cardiovascular signal variability of the R-R period, is a commonly adopted marker of cardiac ANS activity, which is both reliable and non-invasive [21] .", [["cardiovascular", "ANATOMY", 9, 23], ["cardiac", "ANATOMY", 94, 101], ["R-R", "GENE_OR_GENE_PRODUCT", 50, 53], ["cardiac", "ORGAN", 94, 101], ["HRV", "PROBLEM", 0, 3], ["variability", "OBSERVATION_MODIFIER", 31, 42], ["cardiac", "ANATOMY", 94, 101]]], ["The frequency of HRV has been analyzed using methods such as fast Fourier transform (an autoregressive model) and maximum entropy methods (MEMs).", [["methods", "TREATMENT", 45, 52], ["fast Fourier transform", "TREATMENT", 61, 83], ["an autoregressive model)", "TREATMENT", 85, 109], ["maximum entropy methods", "TREATMENT", 114, 137]]], ["When the power is separated between high frequency (HF; 0.15-0.45 Hz) and low frequency (LF; 0.04-0.15 Hz) in spectral analysis, the HF reflects the activity of the parasympathetic nervous system and the LF reflects the activities of both the sympathetic and parasympathetic nervous system [22] .", [["parasympathetic nervous system", "ANATOMY", 165, 195], ["parasympathetic nervous system", "ANATOMY", 259, 289], ["parasympathetic nervous system", "ANATOMICAL_SYSTEM", 165, 195], ["parasympathetic nervous system", "ANATOMICAL_SYSTEM", 259, 289], ["LF", "PROTEIN", 204, 206], ["spectral analysis", "TEST", 110, 127], ["the HF", "PROBLEM", 129, 135], ["parasympathetic nervous", "ANATOMY", 165, 188], ["parasympathetic nervous", "ANATOMY", 259, 282]]], ["The ratio of LF and HF (L/H) can therefore be used as an index of sympathetic nervous system activity [23] .", [["sympathetic nervous system", "ANATOMY", 66, 92], ["sympathetic nervous system", "ANATOMICAL_SYSTEM", 66, 92], ["The ratio", "TEST", 0, 9], ["LF", "PROBLEM", 13, 15], ["HF", "PROBLEM", 20, 22], ["LF", "ANATOMY", 13, 15], ["sympathetic nervous", "OBSERVATION", 66, 85]]], ["The change of HRV is also closely related to emotional change [24] [25] [26] .BackgroundThis study involved two female groups, recruited by advance questionnaire; one group consisted of women who enjoyed and soothed during FSC (E group) and the other group consisted of women who did not enjoy or soothe during FSC (NE group).", [["NE", "CHEMICAL", 316, 318], ["women", "ORGANISM", 186, 191], ["women", "ORGANISM", 270, 275], ["women", "SPECIES", 186, 191], ["women", "SPECIES", 270, 275], ["emotional change", "PROBLEM", 45, 61]]], ["The FSC behavior of both groups was compared by ApEn and Rest \u03b3.", [["FSC", "OBSERVATION_MODIFIER", 4, 7]]], ["Moreover, we compared the effect of hand motions during FSC on ANS activity change in both groups and the relationship between parameters of FSC motion and ANS activity change.SubjectsThis study included healthy females between 31 and 49 years of age.", [["hand", "ANATOMY", 36, 40], ["hand", "ORGANISM_SUBDIVISION", 36, 40], ["FSC", "CELL_TYPE", 56, 59], ["ANS activity change", "TREATMENT", 63, 82], ["FSC motion", "TEST", 141, 151], ["ANS activity change", "PROBLEM", 156, 175]]], ["Subjects who smoked, had skin issues (such as atopic dermatitis), were taking medication, or had received cosmetic surgery were excluded from this study.", [["skin", "ANATOMY", 25, 29], ["atopic dermatitis", "DISEASE", 46, 63], ["Subjects", "ORGANISM", 0, 8], ["skin", "ORGAN", 25, 29], ["skin issues", "PROBLEM", 25, 36], ["atopic dermatitis", "PROBLEM", 46, 63], ["medication", "TREATMENT", 78, 88], ["cosmetic surgery", "TREATMENT", 106, 122], ["this study", "TEST", 142, 152], ["skin", "ANATOMY", 25, 29]]], ["Subjects used all three items (lotion, emulsion, cream) every day for skin care.", [["skin", "ANATOMY", 70, 74], ["lotion", "SIMPLE_CHEMICAL", 31, 37], ["skin", "ORGAN", 70, 74], ["lotion", "TREATMENT", 31, 37], ["emulsion", "TREATMENT", 39, 47], ["cream", "TREATMENT", 49, 54], ["skin care", "TREATMENT", 70, 79], ["skin", "ANATOMY", 70, 74]]], ["Subjects were selected and classed into two groups by the advance questionnaire.", [["Subjects", "ORGANISM", 0, 8]]], ["The difference in the age of both groups was not significant (p = 0.470).", [["difference", "OBSERVATION_MODIFIER", 4, 14], ["not", "UNCERTAINTY", 45, 48], ["significant", "OBSERVATION_MODIFIER", 49, 60]]], ["There was no significant difference in subjective skin care time between the two groups (E group, 7.6 \u00b1 3.0 min; NE group, 7.4 \u00b1 3.2 min, p = 0.860).", [["skin", "ANATOMY", 50, 54], ["skin", "ORGAN", 50, 54], ["significant difference", "PROBLEM", 13, 35], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["skin", "ANATOMY", 50, 54]]], ["All subjects used the same commercially available skincare items (lotion, emulsion, and cream) for FSC in this study.ProcedureSubjects were instructed to wear a headband and ring with marker on a chair, at a table, in front of a mirror, for 10 min, and use the lotion, emulsion, and cream sequentially in the same way as their daily FSC.", [["lotion", "SIMPLE_CHEMICAL", 66, 72], ["lotion", "SIMPLE_CHEMICAL", 261, 267], ["FSC", "CELL_TYPE", 99, 102], ["FSC", "CELL_TYPE", 333, 336], ["skincare items", "TREATMENT", 50, 64], ["lotion", "TREATMENT", 66, 72], ["emulsion", "TREATMENT", 74, 82], ["cream", "TREATMENT", 88, 93], ["FSC in this study", "TEST", 99, 116], ["a headband", "TREATMENT", 159, 169], ["the lotion, emulsion", "TREATMENT", 257, 277], ["cream", "TREATMENT", 283, 288]]], ["The room was air-conditioned (25 \u00b1 1\u00b0C; humidity, 50% \u00b1 5%), and HRV was measured for 3 min before and after FSC.ProcedureThe characteristics of items used are shown below.", [["humidity", "TREATMENT", 40, 48], ["HRV", "TEST", 65, 68], ["Procedure", "TREATMENT", 113, 122]]], ["The lotion: A typical lotion solubilized with nonionic and silicone surfactants, providing compatible feeling to the skin.ProcedureThe emulsion: A typical O/W emulsion combining anionic surfactant and thickener, providing compatible feeling to the skin and elastic feeling.ProcedureThe cream: A typical O/W cream with a large amount of waterholding oil, providing soft and fast compatible feeling to the skin.", [["skin", "ANATOMY", 117, 121], ["skin", "ANATOMY", 248, 252], ["waterholding oil", "ANATOMY", 336, 352], ["skin", "ANATOMY", 404, 408], ["silicone surfactants", "SIMPLE_CHEMICAL", 59, 79], ["skin", "ORGAN", 117, 121], ["O/W emulsion", "SIMPLE_CHEMICAL", 155, 167], ["anionic surfactant", "SIMPLE_CHEMICAL", 178, 196], ["skin", "ORGAN", 248, 252], ["oil", "ORGANISM_SUBSTANCE", 349, 352], ["skin", "ORGAN", 404, 408], ["The lotion", "TREATMENT", 0, 10], ["A typical lotion", "TREATMENT", 12, 28], ["nonionic and silicone surfactants", "TREATMENT", 46, 79], ["Procedure", "TREATMENT", 122, 131], ["W emulsion", "TREATMENT", 157, 167], ["anionic surfactant", "TREATMENT", 178, 196], ["thickener", "TREATMENT", 201, 210], ["elastic feeling", "PROBLEM", 257, 272], ["Procedure", "TREATMENT", 273, 282], ["The cream", "TREATMENT", 282, 291], ["A typical O/W cream", "TREATMENT", 293, 312], ["waterholding oil", "TREATMENT", 336, 352], ["skin", "ANATOMY", 117, 121], ["skin", "ANATOMY", 248, 252], ["large", "OBSERVATION_MODIFIER", 320, 325], ["amount", "OBSERVATION_MODIFIER", 326, 332], ["soft", "ANATOMY", 364, 368], ["skin", "ANATOMY", 404, 408]]], ["The cream is softer than normal massage one.MeasurementTo measure motion of light hand during FSC, 10-mm reflective markers were affixed to the back side of the base of the right middle finger and on both ends and middle of the head band ( Fig. 1 ).", [["hand", "ANATOMY", 82, 86], ["back", "ANATOMY", 144, 148], ["right middle finger", "ANATOMY", 173, 192], ["head", "ANATOMY", 228, 232], ["finger", "ORGANISM_SUBDIVISION", 186, 192], ["head", "ORGANISM_SUBDIVISION", 228, 232], ["FSC", "CELL_TYPE", 94, 97], ["The cream", "TREATMENT", 0, 9], ["FSC", "TEST", 94, 97], ["reflective markers", "TEST", 105, 123], ["softer", "OBSERVATION_MODIFIER", 13, 19], ["back", "ANATOMY", 144, 148], ["base", "ANATOMY_MODIFIER", 161, 165], ["right middle finger", "ANATOMY", 173, 192], ["both", "ANATOMY_MODIFIER", 200, 204], ["ends", "ANATOMY_MODIFIER", 205, 209], ["middle", "ANATOMY_MODIFIER", 214, 220], ["head", "ANATOMY", 228, 232]]], ["Trajectories were recorded using a 6 camera, three-dimensional motion capture system, sampling at 100 Hz (VENUS3D v.4.1, Nobby Tech Co., Tokyo, Japan).MeasurementTo measure the HRV of subjects, the left forearm and right ankle of the subjects was fixed by clip-type electrodes (TE-43, Fukuda Denshi Co., Ltd., Tokyo) for electrocardiogram (ECG) monitoring.", [["left forearm", "ANATOMY", 198, 210], ["right ankle", "ANATOMY", 215, 226], ["left forearm", "MULTI-TISSUE_STRUCTURE", 198, 210], ["ankle", "ORGANISM_SUBDIVISION", 221, 226], ["VENUS3D", "TEST", 106, 113], ["clip-type electrodes", "TREATMENT", 256, 276], ["TE", "TEST", 278, 280], ["electrocardiogram (ECG) monitoring", "TEST", 321, 355], ["left", "ANATOMY_MODIFIER", 198, 202], ["forearm", "ANATOMY", 203, 210], ["right", "ANATOMY_MODIFIER", 215, 220], ["ankle", "ANATOMY", 221, 226]]], ["The HRV was recorded with a Marquette Holter recorder (LRR-03; GMS, Inc., Tokyo, Japan) for 3 min before and after FSC.", [["The HRV", "TEST", 0, 7], ["LRR", "TEST", 55, 58], ["GMS", "TEST", 63, 66], ["FSC", "TEST", 115, 118]]], ["HRV data were processed using HRV analysis software (Crosswell, Inc., Tokyo, Japan) [27] [28] [29] [30] [31] .Data analysisThe space of the trajectories of the marker on the right middle finger was fixed by a plane and determined by the 3 points on the head band.", [["right middle finger", "ANATOMY", 174, 193], ["head", "ANATOMY", 253, 257], ["[27] [28] [29] [30] [31]", "SIMPLE_CHEMICAL", 84, 108], ["middle finger", "ORGANISM_SUBDIVISION", 180, 193], ["head", "ORGANISM_SUBDIVISION", 253, 257], ["HRV data", "TEST", 0, 8], ["HRV analysis", "TEST", 30, 42], ["Data analysis", "TEST", 110, 123], ["the head band", "TEST", 249, 262], ["space", "OBSERVATION_MODIFIER", 127, 132], ["trajectories", "OBSERVATION_MODIFIER", 140, 152], ["marker", "ANATOMY_MODIFIER", 160, 166], ["right middle finger", "ANATOMY", 174, 193], ["head", "ANATOMY", 253, 257]]], ["Sequenced data of acceleration of the marker on the right middle finger was calculated from the corrected trajectory data.", [["right middle finger", "ANATOMY", 52, 71], ["middle finger", "ORGANISM_SUBDIVISION", 58, 71], ["acceleration", "OBSERVATION_MODIFIER", 18, 30], ["right middle finger", "ANATOMY", 52, 71]]], ["ApEn and Rest \u03b3 were calculated from the sequenced data of acceleration.Approximate entropy (ApEn)ApEn is a complexity parameter of information entropy [10, 32] .", [["ApEn", "GENE_OR_GENE_PRODUCT", 0, 4], ["Rest \u03b3", "GENE_OR_GENE_PRODUCT", 9, 15], ["ApEn", "PROTEIN", 0, 4], ["Rest \u03b3", "PROTEIN", 9, 15], ["ApEn", "TEST", 0, 4], ["Approximate entropy (ApEn)", "TREATMENT", 72, 98]]], ["It can be applied to finite length and discrete data and is calculated by the following formula [32, 33] .Approximate entropy (ApEn)A sequenced data: a = a (1), a (2), \u2026, a (n)Approximate entropy (ApEn)In this study, 2, 500, and 0.15 x (standard deviation) were substituted for n, m, and r, respectively, according to the mathematical theory of Pincus [12] .", [["discrete data", "TEST", 39, 52], ["this study", "TEST", 205, 215]]], ["The window of length of compared subsequence (500 points) was calculated and moved from the start to the end, and the averaged ApEn was determined; a smaller ApEn being indicative of a more regular motion.Rest \u03b3Using a locomotor, Nakamura et al. demonstrated that the cumulative probability distribution of resting periods in life takes a scale-free power-law form [15] .", [["ApEn", "DNA", 127, 131], ["the averaged ApEn", "TEST", 114, 131], ["a smaller ApEn", "PROBLEM", 148, 162], ["length", "OBSERVATION_MODIFIER", 14, 20], ["smaller", "OBSERVATION_MODIFIER", 150, 157], ["indicative of", "UNCERTAINTY", 169, 182], ["motion", "OBSERVATION", 198, 204]]], ["The sequenced acceleration data was processed according to the method as described by Nakamura et al. [15] .", [["The sequenced acceleration data", "TEST", 0, 31]]], ["Sequenced data was binarized into \"resting periods\" or \"active periods\" by a threshold of averaged acceleration (Fig. 2) .", [["Sequenced data", "TEST", 0, 14], ["averaged acceleration (Fig", "PROBLEM", 90, 116]]], ["Rest \u03b3 is a scaling exponent which indicates the cumulative distribution of the frequency for resting periods (Fig. 3) .", [["a scaling exponent", "PROBLEM", 10, 28], ["scaling", "OBSERVATION_MODIFIER", 12, 19], ["exponent", "OBSERVATION", 20, 28], ["cumulative", "OBSERVATION_MODIFIER", 49, 59], ["distribution", "OBSERVATION_MODIFIER", 60, 72]]], ["In this study, a lower Rest \u03b3 demonstrated a longer sustainability of slow motion or hand pressure.HRVThe power spectrum of a time series of the R-R interval was calculated using the maximum entropy method.", [["hand", "ANATOMY", 85, 89], ["hand", "ORGANISM_SUBDIVISION", 85, 89], ["R-R", "GENE_OR_GENE_PRODUCT", 145, 148], ["this study", "TEST", 3, 13], ["slow motion or hand pressure", "PROBLEM", 70, 98], ["the maximum entropy method", "TREATMENT", 179, 205], ["slow motion", "OBSERVATION", 70, 81], ["pressure", "OBSERVATION_MODIFIER", 90, 98]]], ["The LF and HF power were estimated to be within the 0.04-0.15 and 0.15-0.45 Hz frequency bands, respectively.", [["The LF and HF power", "TEST", 0, 19], ["LF", "ANATOMY", 4, 6]]], ["The LF/HF ratio and HF were taken as parameters of sympathetic and parasympathetic nerve activity,Difference in motion parameters between groupsAveraged acceleration (Avg.", [["parasympathetic nerve", "ANATOMY", 67, 88], ["parasympathetic nerve", "MULTI-TISSUE_STRUCTURE", 67, 88], ["The LF/HF ratio", "TEST", 0, 15], ["HF", "PROBLEM", 20, 22], ["sympathetic and parasympathetic nerve activity", "PROBLEM", 51, 97], ["HF", "OBSERVATION", 7, 9], ["parasympathetic nerve", "ANATOMY", 67, 88], ["acceleration", "OBSERVATION_MODIFIER", 153, 165]]], ["ACC), ApEn, and Rest \u03b3 when using each item (lotion, emulsion, and cream) during FSC in both groups were calculated and compared.", [["ACC", "SIMPLE_CHEMICAL", 0, 3], ["Rest \u03b3", "GENE_OR_GENE_PRODUCT", 16, 22], ["lotion", "SIMPLE_CHEMICAL", 45, 51], ["ApEn", "TEST", 6, 10], ["lotion", "TREATMENT", 45, 51], ["emulsion", "TREATMENT", 53, 61], ["cream", "TREATMENT", 67, 72]]], ["With regard to the averaged acceleration, the tendency of interaction between the group and item was analyzed by a two-way repeated measures ANOVA (F (1,37) = 2.441, p = 0.094).", [["the averaged acceleration", "PROBLEM", 15, 40]]], ["The simple main effect of the item was not significant at the group level (NE group, F (2,36) = 1.596, p = 0.217; E group, F (2,36) = 0.818, p = 0.449).", [["p", "TEST", 103, 104], ["p", "TEST", 141, 142], ["simple", "OBSERVATION_MODIFIER", 4, 10], ["main", "OBSERVATION_MODIFIER", 11, 15], ["effect", "OBSERVATION_MODIFIER", 16, 22], ["not", "UNCERTAINTY", 39, 42], ["significant", "OBSERVATION_MODIFIER", 43, 54]]], ["The simple main effect of the group was however significant at the level of emulsion and cream (lotion, F (1,37) = 2.139, p = 0.152; emulsion, F (1,37) = 9.127, p = 0.005; cream, F (1,37) = 8.092, p = 0.007).", [["lotion", "SIMPLE_CHEMICAL", 96, 102], ["emulsion", "TEST", 133, 141], ["p", "TEST", 161, 162], ["cream", "TEST", 172, 177], ["p", "TEST", 197, 198], ["simple", "OBSERVATION_MODIFIER", 4, 10], ["main", "OBSERVATION_MODIFIER", 11, 15], ["effect", "OBSERVATION_MODIFIER", 16, 22], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["emulsion", "ANATOMY", 76, 84]]], ["The acceleration of emulsion (p = 0.005) and cream (p = 0.007) in the E group was significantly smaller than that of the NE group by multivariate ANOVA (Fig. 4a) .", [["NE", "CHEMICAL", 121, 123], ["emulsion", "TEST", 20, 28], ["cream", "TREATMENT", 45, 50], ["acceleration", "OBSERVATION_MODIFIER", 4, 16], ["emulsion", "OBSERVATION_MODIFIER", 20, 28], ["smaller", "OBSERVATION_MODIFIER", 96, 103]]], ["With regard to the acceleration when using the lotion, the difference between both groups was not significant by multivariate ANOVA (Fig. 4a) .", [["the lotion", "TREATMENT", 43, 53]]], ["These results suggest that the E group has a lower acceleration (gentle motions) than the NE group when using emulsion and cream.", [["NE", "CHEMICAL", 90, 92], ["NE", "SIMPLE_CHEMICAL", 90, 92], ["a lower acceleration (gentle motions)", "PROBLEM", 43, 80], ["emulsion", "TREATMENT", 110, 118], ["cream", "TREATMENT", 123, 128], ["lower", "OBSERVATION_MODIFIER", 45, 50], ["acceleration", "OBSERVATION_MODIFIER", 51, 63]]], ["The slope (Rest \u03d2) is determined by the method of least squares With regard to the ApEn, the relationship between the group and item was also observed by two-way repeated measures ANOVA (F (1,37) = 2.612, p = 0.080).", [["ApEn", "PROTEIN", 83, 87], ["the ApEn", "TEST", 79, 87]]], ["The simple main effect of items in the E group was significant at the group level (NE group, F (2,36) = 0.412, p = 0.666; E group, F (2,36) = 8.508, p = 0.001).", [["p", "TEST", 111, 112], ["p", "TEST", 149, 150], ["simple", "OBSERVATION_MODIFIER", 4, 10], ["main", "OBSERVATION_MODIFIER", 11, 15], ["effect", "OBSERVATION_MODIFIER", 16, 22], ["significant", "OBSERVATION_MODIFIER", 51, 62]]], ["The ApEn of the emulsion was significantly smaller than that of lotion (p = 0.001) in the E group by multivariate ANOVA (Fig. 4b) .", [["lotion", "SIMPLE_CHEMICAL", 64, 70], ["The ApEn of the emulsion", "TEST", 0, 24], ["smaller", "OBSERVATION_MODIFIER", 43, 50]]], ["The simple main effect of the group was significant at the level of emulsion (lotion, F (1,37) = 2.469, p = 0.125; emulsion, F (1,37) = 10.163, p = 0.003; cream, F (1,37) = 3.856, p = 0.057).", [["lotion", "SIMPLE_CHEMICAL", 78, 84], ["emulsion", "TEST", 115, 123], ["p", "TEST", 144, 145], ["cream", "TEST", 155, 160], ["p", "TEST", 180, 181], ["simple", "OBSERVATION_MODIFIER", 4, 10], ["main", "OBSERVATION_MODIFIER", 11, 15], ["effect", "OBSERVATION_MODIFIER", 16, 22]]], ["The ApEn of emulsion (p = 0.003) in the E group was significantly smaller than that of the NE group by multivariate ANOVA (Fig. 4b) .", [["NE", "CHEMICAL", 91, 93], ["The ApEn of emulsion", "TEST", 0, 20], ["emulsion", "OBSERVATION_MODIFIER", 12, 20], ["smaller", "OBSERVATION_MODIFIER", 66, 73]]], ["These results suggest that the ApEn of emulsion is lower than that of lotion in the E group compared to the NE group.Difference in motion parameters between groupsWith regard to the Rest \u03b3, the interaction between the group and item was not significant by two-way repeated measures ANOVA (F (1,37) = 0.996, p = 0.374).", [["NE", "CHEMICAL", 108, 110], ["lotion", "SIMPLE_CHEMICAL", 70, 76], ["NE", "SIMPLE_CHEMICAL", 108, 110], ["the ApEn of emulsion", "TEST", 27, 47], ["lotion", "TREATMENT", 70, 76], ["Difference in motion parameters", "PROBLEM", 117, 148], ["emulsion", "OBSERVATION", 39, 47], ["lower", "OBSERVATION_MODIFIER", 51, 56]]], ["The main effect of the group was significant (F (1,37) = 5.522, p = 0.024) (Fig. 4c) .", [["p", "TEST", 64, 65], ["main", "OBSERVATION_MODIFIER", 4, 8], ["effect", "OBSERVATION_MODIFIER", 9, 15]]], ["The tendency of main effect of item was observed (F (1,37) = 3.174, p = 0.054).", [["tendency", "OBSERVATION_MODIFIER", 4, 12], ["main", "OBSERVATION_MODIFIER", 16, 20]]], ["Multiple comparisons showed that the Rest \u03b3 of emulsion was significantly lower than that of lotion (p = 0.049).", [["lotion", "SIMPLE_CHEMICAL", 93, 99]]], ["These results suggest that the E group has a lower Rest \u03b3 than the NE group.Differences in the effects of FSC on ANS activity between groupsWith regard to ccv(LF/HF), the interaction between the time and group was significant by two-way repeated measures ANOVA (F (1,37) = 4.962, p = 0.032).", [["NE", "CHEMICAL", 67, 69], ["NE", "SIMPLE_CHEMICAL", 67, 69], ["FSC", "SIMPLE_CHEMICAL", 106, 109], ["ANS", "SIMPLE_CHEMICAL", 113, 116], ["Rest \u03b3", "PROTEIN", 51, 57], ["FSC", "CELL_TYPE", 106, 109], ["ccv(LF/HF", "PROBLEM", 155, 164]]], ["The simple main effect of time in the E group was significant at the group level (NE group, F (2,36) = 0.737, p = 0.396; E group, F (2,36) = 5.339, p = 0.027) ( Table 1) .", [["p", "TEST", 110, 111], ["p", "TEST", 148, 149], ["simple", "OBSERVATION_MODIFIER", 4, 10], ["main", "OBSERVATION_MODIFIER", 11, 15], ["effect", "OBSERVATION_MODIFIER", 16, 22]]], ["Multivariate ANOVA showed that the ccv(LF/HF) significantly lowered after FSC in the E group (p = 0.013).Differences in the effects of FSC on ANS activity between groupsThe simple main effect of the group was significant at the level of time (before, F (1,37) = 10.453, p = 0.003; after, F Table 1 ).", [["FSC", "SIMPLE_CHEMICAL", 135, 138], ["ANS", "GENE_OR_GENE_PRODUCT", 142, 145], ["FSC", "CELL_TYPE", 135, 138], ["Multivariate ANOVA", "TEST", 0, 18], ["the ccv(LF/HF", "PROBLEM", 31, 44], ["FSC", "TEST", 74, 77], ["HF", "OBSERVATION", 42, 44], ["simple", "OBSERVATION_MODIFIER", 173, 179], ["main", "OBSERVATION_MODIFIER", 180, 184], ["effect", "OBSERVATION_MODIFIER", 185, 191]]], ["Multivariate ANOVA showed that the ccv(LF/HF) significantly lowered after FSC in the E group (p = 0.013).", [["Multivariate ANOVA", "TEST", 0, 18], ["the ccv(LF/HF", "PROBLEM", 31, 44], ["FSC", "TEST", 74, 77], ["HF", "OBSERVATION", 42, 44]]], ["Multivariate ANOVA showed that the ccv(LF/HF) of the E group was higher than that of the NE group before and after FSC.", [["NE", "CHEMICAL", 89, 91], ["FSC", "CELL_TYPE", 115, 118], ["Multivariate ANOVA", "TEST", 0, 18], ["the ccv(LF/HF", "PROBLEM", 31, 44], ["FSC", "TEST", 115, 118]]], ["These data showed that the ccv(LF/HF) in the E group was higher than that of the NE group and decreased after FSC.Differences in the effects of FSC on ANS activity between groupsWith regard to ccv(HF), the tendency of the interaction between time and group was analyzed by two-way repeated measures ANOVA (F (1,37) = 3.926, p = 0.055).", [["NE", "CHEMICAL", 81, 83], ["ccv", "GENE_OR_GENE_PRODUCT", 27, 30], ["FSC", "SIMPLE_CHEMICAL", 144, 147], ["ANS", "MULTI-TISSUE_STRUCTURE", 151, 154], ["LF", "PROTEIN", 31, 33], ["FSC", "CELL_TYPE", 110, 113], ["FSC", "CELL_TYPE", 144, 147], ["These data", "TEST", 0, 10], ["the ccv(LF/HF", "PROBLEM", 23, 36], ["ccv(HF", "PROBLEM", 193, 199], ["decreased", "OBSERVATION_MODIFIER", 94, 103]]], ["The simple main effect of time in the NE group was significant at the group level (NE group, F (2,36) = 5.912, p = 0.020; E group, F (2,36) = 0.119, p = 0.732) ( Table 1 ).", [["NE", "CHEMICAL", 38, 40], ["NE", "SIMPLE_CHEMICAL", 38, 40], ["NE", "PROTEIN", 38, 40], ["p", "TEST", 111, 112], ["p", "TEST", 149, 150], ["simple", "OBSERVATION_MODIFIER", 4, 10], ["main", "OBSERVATION_MODIFIER", 11, 15], ["effect", "OBSERVATION_MODIFIER", 16, 22]]], ["Multivariate ANOVA showed that the ccv(HF) significantly lowered after FSC in the NE group (p = 0.020).", [["NE", "CHEMICAL", 82, 84], ["FSC", "CELL_TYPE", 71, 74], ["Multivariate ANOVA", "TEST", 0, 18], ["the ccv(HF", "PROBLEM", 31, 41], ["FSC", "TEST", 71, 74]]], ["The simple main effect of the group was not significant at the level of time (before, F (1, 37) = 2.766, p = 0.105; after, F (1,37) = 0.812, p = 0.373) ( Table 1 ).", [["p", "TEST", 141, 142], ["simple", "OBSERVATION_MODIFIER", 4, 10], ["main", "OBSERVATION_MODIFIER", 11, 15], ["effect", "OBSERVATION_MODIFIER", 16, 22]]], ["These data show that the ccv(HF) in the NE group significantly decreases after FSC.", [["NE", "CHEMICAL", 40, 42], ["ccv", "GENE_OR_GENE_PRODUCT", 25, 28], ["NE", "SIMPLE_CHEMICAL", 40, 42], ["FSC", "CELL_TYPE", 79, 82], ["These data", "TEST", 0, 10], ["the ccv(HF", "PROBLEM", 21, 31], ["significantly", "OBSERVATION_MODIFIER", 49, 62], ["decreases", "OBSERVATION_MODIFIER", 63, 72]]], ["These data suggest that effects of FSC on HRV may be different between the NE and E groups.Differences in the effects of FSC on ANS activity between groupsThe relationship between motion parameters and the change in HRV following FSC Both ApEn and Rest \u03b3 correlated significantly with the change of ccv(LF/HF) following FSC.", [["FSC", "SIMPLE_CHEMICAL", 35, 38], ["FSC", "SIMPLE_CHEMICAL", 121, 124], ["ANS", "GENE_OR_GENE_PRODUCT", 128, 131], ["Rest \u03b3", "GENE_OR_GENE_PRODUCT", 248, 254], ["FSC", "CELL_TYPE", 121, 124], ["FSC", "CELL_TYPE", 230, 233], ["ccv", "PROTEIN", 299, 302], ["LF", "PROTEIN", 303, 305], ["FSC", "CELL_TYPE", 320, 323], ["These data", "TEST", 0, 10], ["FSC on HRV", "PROBLEM", 35, 45], ["motion parameters", "TEST", 180, 197], ["ccv(LF/HF", "TREATMENT", 299, 308]]], ["Moreover, ApEn significantly correlated with the change of ccv(HF) following FSC (Table 2, Fig. 5 ).", [["ApEn", "GENE_OR_GENE_PRODUCT", 10, 14], ["ApEn", "PROTEIN", 10, 14], ["ccv(HF", "PROBLEM", 59, 65], ["FSC", "TEST", 77, 80]]], ["Both parameters showed high correlation especially in the case of emulsion.", [["high", "OBSERVATION", 23, 27]]], ["ACC) was not correlated with Table 1 The change of HRV by FSC NE, non-enjoyment group (n = 19); E, enjoyment group (n = 20); p (1), before vs after, multiple comparison (Bonferroni correction); p(2), NE vs E, multiple comparison (Bonferroni correction) p < 0.05; *p < 0.001 change of HRV.", [["NE", "PROTEIN", 200, 202], ["NE vs E, multiple comparison (Bonferroni correction", "TREATMENT", 200, 251], ["HRV", "PROBLEM", 284, 287]]], ["These results suggest that a more regular motion (smaller ApEn) and/or an increased duration of slow motions (lower Rest \u03b3) during FSC may suppress the activity of the sympathetic nerve system, and more regular motion (smaller ApEn) during FSC may stimulate the activity of parasympathetic nerve system independently of the intensity of motion.DiscussionIn this study, we have proposed the usefulness of ApEn and Rest \u03b3 as quantitative parameters for evaluating FSC behavior.", [["sympathetic nerve system", "ANATOMY", 168, 192], ["parasympathetic nerve system", "ANATOMY", 274, 302], ["sympathetic nerve", "MULTI-TISSUE_STRUCTURE", 168, 185], ["system", "ANATOMICAL_SYSTEM", 186, 192], ["parasympathetic nerve", "MULTI-TISSUE_STRUCTURE", 274, 295], ["system", "ANATOMICAL_SYSTEM", 296, 302], ["Rest \u03b3", "GENE_OR_GENE_PRODUCT", 413, 419], ["FSC", "CELL_TYPE", 131, 134], ["FSC", "CELL_TYPE", 240, 243], ["ApEn", "PROTEIN", 404, 408], ["Rest \u03b3", "PROTEIN", 413, 419], ["FSC", "CELL_TYPE", 462, 465], ["slow motions (lower Rest \u03b3) during FSC", "PROBLEM", 96, 134], ["FSC", "TREATMENT", 240, 243], ["this study", "TEST", 357, 367], ["quantitative parameters", "TEST", 423, 446], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["sympathetic nerve", "ANATOMY", 168, 185], ["parasympathetic nerve", "ANATOMY", 274, 295]]], ["When using the lotion to the emulsion, the E group had a reduced ApEn compared to the NE group.", [["NE", "CHEMICAL", 86, 88], ["NE", "SIMPLE_CHEMICAL", 86, 88], ["ApEn", "PROTEIN", 65, 69], ["the lotion", "TREATMENT", 11, 21], ["a reduced ApEn", "PROBLEM", 55, 69]]], ["Other two parameters did not show significant change between items.", [["Other two parameters", "TEST", 0, 20], ["significant change between items", "PROBLEM", 34, 66], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["change", "OBSERVATION", 46, 52]]], ["ApEn has been applied in the field of not only neurology [37] and endocrinology [38] , but also motion analysis [39] .", [["ApEn", "GENE_OR_GENE_PRODUCT", 0, 4], ["ApEn", "PROTEIN", 0, 4], ["ApEn", "TREATMENT", 0, 4], ["motion analysis", "TEST", 96, 111]]], ["A lower ApEn indicates a more regular behavior, while higher ApEn values indicate more complex and unpredictable one [32, 40] .", [["ApEn", "GENE_OR_GENE_PRODUCT", 61, 65], ["ApEn", "PROTEIN", 8, 12], ["ApEn", "PROTEIN", 61, 65], ["A lower ApEn", "PROBLEM", 0, 12]]], ["In this study, the E group has more regular behaviors than the NE group when using the emulsion.", [["NE", "CHEMICAL", 63, 65], ["NE", "SIMPLE_CHEMICAL", 63, 65], ["this study", "TEST", 3, 13], ["the emulsion", "TREATMENT", 83, 95]]], ["Alkjaer et al. demonstrated a higher ApEn of the ankle joint angle when walking in high heels compared to walking barefoot, suggesting a variable adjusting strategy of the nervous system to control the ankle joint [41] .", [["ankle joint", "ANATOMY", 49, 60], ["nervous system", "ANATOMY", 172, 186], ["ankle joint", "ANATOMY", 202, 213], ["ankle joint", "ORGANISM_SUBDIVISION", 49, 60], ["nervous system", "ANATOMICAL_SYSTEM", 172, 186], ["ankle joint", "MULTI-TISSUE_STRUCTURE", 202, 213], ["a higher ApEn of the ankle joint angle", "PROBLEM", 28, 66], ["higher", "OBSERVATION_MODIFIER", 30, 36], ["ApEn", "OBSERVATION", 37, 41], ["ankle joint", "ANATOMY", 49, 60], ["ankle joint", "ANATOMY", 202, 213]]], ["In the context of FSC, differences in the physical property of the emulsion or skin may influence the hand motion; it is certainly known that changes in the physical properties of the object affect the hand motion [42, 43] .", [["skin", "ANATOMY", 79, 83], ["hand", "ANATOMY", 102, 106], ["hand", "ANATOMY", 202, 206], ["skin", "ORGAN", 79, 83], ["hand", "ORGANISM_SUBDIVISION", 102, 106], ["hand", "ORGANISM_SUBDIVISION", 202, 206], ["FSC", "CELL_TYPE", 18, 21], ["FSC", "PROBLEM", 18, 21], ["FSC", "OBSERVATION", 18, 21], ["skin", "ANATOMY", 79, 83]]], ["However, factors affecting hand motion are more complex due to the context such as purpose [44] and prior knowledge [45] .", [["hand", "ANATOMY", 27, 31], ["hand", "ORGANISM_SUBDIVISION", 27, 31]]], ["We must consider further in detail.DiscussionMoreover, the E group has a lower Rest \u03b3 than the NE group.", [["NE", "CHEMICAL", 95, 97], ["NE", "SIMPLE_CHEMICAL", 95, 97], ["Rest \u03b3", "PROTEIN", 79, 85]]], ["Nakamura et al. demonstrate the same value for the life activity of healthy humans and mice [15, 34] .", [["humans", "ORGANISM", 76, 82], ["mice", "ORGANISM", 87, 91], ["humans", "SPECIES", 76, 82], ["mice", "SPECIES", 87, 91], ["humans", "SPECIES", 76, 82], ["mice", "SPECIES", 87, 91]]], ["The averaged Rest \u03b3 value (emulsion) of the E group and NE group is \u2212 0.834 \u00b1 0.181 and \u2212 0.975 \u00b1 0.128, respectively (p = 0.012).", [["NE", "CHEMICAL", 56, 58], ["The averaged Rest \u03b3 value", "TEST", 0, 25]]], ["The Rest \u03b3 of the NE group is similar to the value, 1.0, of the life activity of healthy people and mice [34, 35] .", [["NE", "CHEMICAL", 18, 20], ["Rest \u03b3", "GENE_OR_GENE_PRODUCT", 4, 10], ["NE", "SIMPLE_CHEMICAL", 18, 20], ["people", "ORGANISM", 89, 95], ["mice", "ORGANISM", 100, 104], ["Rest \u03b3", "PROTEIN", 4, 10], ["NE", "PROTEIN", 18, 20], ["people", "SPECIES", 89, 95], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 100, 104]]], ["It is possible that the motion of the NE group is similar to an unconstrained motion without defect and consciousness.", [["NE", "PROTEIN", 38, 40], ["defect", "PROBLEM", 93, 99], ["consciousness", "PROBLEM", 104, 117], ["unconstrained motion", "OBSERVATION", 64, 84], ["defect", "OBSERVATION", 93, 99]]], ["The E group indicates that the duration distribution of the slow motion increases; this may reflect constrained consciousness such as concentration and enjoyment of touching.DiscussionFurthermore, we have demonstrated that hand motion during FSC may influence ANS activity.", [["hand", "ANATOMY", 223, 227], ["hand", "ORGANISM_SUBDIVISION", 223, 227], ["ANS", "GENE_OR_GENE_PRODUCT", 260, 263], ["FSC", "CELL_TYPE", 242, 245], ["the slow motion increases", "PROBLEM", 56, 81], ["constrained consciousness", "PROBLEM", 100, 125], ["slow motion", "OBSERVATION", 60, 71], ["may reflect", "UNCERTAINTY", 88, 99], ["constrained consciousness", "OBSERVATION", 100, 125]]], ["There are some reports demonstrating that FSC provides a relaxing effect as a result of the stimulation of the parasympathetic nerve of the heart [3, 5, 7] .", [["parasympathetic nerve", "ANATOMY", 111, 132], ["heart", "ANATOMY", 140, 145], ["parasympathetic nerve", "MULTI-TISSUE_STRUCTURE", 111, 132], ["heart", "ORGAN", 140, 145], ["FSC", "CELL_TYPE", 42, 45], ["parasympathetic nerve", "ANATOMY", 111, 132], ["heart", "ANATOMY", 140, 145]]], ["It is interesting that the effects of FSC on ANS activity are different in both groups.", [["FSC", "SIMPLE_CHEMICAL", 38, 41], ["ANS", "GENE_OR_GENE_PRODUCT", 45, 48], ["FSC on ANS activity", "PROBLEM", 38, 57]]], ["It is suggested that FSC of the E group has an inhibitory effect on the sympathetic nerve system (lower ccv(LF/HF)) and that FSC of the NE group has an inhibitory effect on the parasympathetic nerve system (lower ccv (HF)).", [["sympathetic nerve system", "ANATOMY", 72, 96], ["parasympathetic nerve system", "ANATOMY", 177, 205], ["NE", "CHEMICAL", 136, 138], ["sympathetic nerve system", "ANATOMICAL_SYSTEM", 72, 96], ["NE", "SIMPLE_CHEMICAL", 136, 138], ["parasympathetic nerve system", "ANATOMICAL_SYSTEM", 177, 205], ["FSC", "CELL_TYPE", 21, 24], ["FSC", "CELL_TYPE", 125, 128], ["the sympathetic nerve system", "PROBLEM", 68, 96], ["lower ccv(LF/HF", "PROBLEM", 98, 113], ["the parasympathetic nerve system", "PROBLEM", 173, 205], ["sympathetic nerve", "ANATOMY", 72, 89], ["inhibitory effect", "OBSERVATION", 152, 169], ["parasympathetic nerve", "ANATOMY", 177, 198]]], ["In this study, the NE group may have trouble carrying out the routine and/or feel stressed when using items during daily FSC.", [["NE", "CHEMICAL", 19, 21], ["FSC", "CELL_TYPE", 121, 124], ["this study", "TEST", 3, 13]]], ["In fact, Okada also suggested that the sympathetic nerve system is stimulated by self-FSC in the case of females with negative attitudes towards FSC [3] .", [["sympathetic nerve system", "ANATOMY", 39, 63], ["sympathetic nerve", "MULTI-TISSUE_STRUCTURE", 39, 56], ["the sympathetic nerve system", "PROBLEM", 35, 63], ["sympathetic nerve", "ANATOMY", 39, 56]]], ["These points require further study.DiscussionInterestingly, ApEn and Rest \u03b3 during FSC correlated with the change in ANS activity.", [["ApEn", "GENE_OR_GENE_PRODUCT", 60, 64], ["Rest \u03b3", "GENE_OR_GENE_PRODUCT", 69, 75], ["ANS", "GENE_OR_GENE_PRODUCT", 117, 120], ["ApEn", "PROTEIN", 60, 64], ["Rest \u03b3", "PROTEIN", 69, 75], ["FSC", "CELL_TYPE", 83, 86], ["further study", "TEST", 21, 34]]], ["High ApEn correlated with an increase in sympathetic nerve system activity and a decrease in parasympathetic nerve system activity.", [["sympathetic nerve system", "ANATOMY", 41, 65], ["parasympathetic nerve system", "ANATOMY", 93, 121], ["ApEn", "GENE_OR_GENE_PRODUCT", 5, 9], ["sympathetic nerve", "MULTI-TISSUE_STRUCTURE", 41, 58], ["system", "ANATOMICAL_SYSTEM", 59, 65], ["parasympathetic nerve", "MULTI-TISSUE_STRUCTURE", 93, 114], ["system", "ANATOMICAL_SYSTEM", 115, 121], ["ApEn", "PROTEIN", 5, 9], ["an increase in sympathetic nerve system activity", "PROBLEM", 26, 74], ["a decrease in parasympathetic nerve system activity", "PROBLEM", 79, 130], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["sympathetic nerve system activity", "OBSERVATION", 41, 74], ["decrease", "OBSERVATION_MODIFIER", 81, 89], ["parasympathetic nerve system activity", "OBSERVATION", 93, 130]]], ["These data suggest that more regular (lower ApEn) motion and longer duration of slow motion (lower Rest \u03b3) may lower the balance of ANS activity (sympathetic/parasympathetic nerve system activity).", [["parasympathetic nerve system", "ANATOMY", 158, 186], ["ANS", "GENE_OR_GENE_PRODUCT", 132, 135], ["parasympathetic nerve", "MULTI-TISSUE_STRUCTURE", 158, 179], ["These data", "TEST", 0, 10], ["more regular (lower ApEn) motion", "PROBLEM", 24, 56], ["slow motion", "PROBLEM", 80, 91], ["ANS activity (sympathetic/parasympathetic nerve system activity", "PROBLEM", 132, 195], ["parasympathetic nerve", "ANATOMY", 158, 179]]], ["In general, exercise greatly affects the activity of sympathetic nerve system, but it is also known that static stretching activates the parasympathetic nerve system [46, 47] .", [["sympathetic nerve system", "ANATOMY", 53, 77], ["parasympathetic nerve system", "ANATOMY", 137, 165], ["sympathetic nerve system", "ANATOMICAL_SYSTEM", 53, 77], ["parasympathetic nerve", "MULTI-TISSUE_STRUCTURE", 137, 158], ["sympathetic nerve", "ANATOMY", 53, 70], ["parasympathetic nerve", "ANATOMY", 137, 158]]], ["In this study, the relationship between the acceleration of hand motion and the change of ANS activity is not confirmed, suggesting quality of hand motion but not the intensity of one may affect the balance of ANS activity in the case of FSC.", [["hand", "ANATOMY", 60, 64], ["hand", "ANATOMY", 143, 147], ["hand", "ORGANISM_SUBDIVISION", 60, 64], ["ANS", "GENE_OR_GENE_PRODUCT", 90, 93], ["hand", "ORGANISM_SUBDIVISION", 143, 147], ["ANS", "GENE_OR_GENE_PRODUCT", 210, 213], ["FSC", "CELL_TYPE", 238, 241], ["this study", "TEST", 3, 13], ["acceleration", "OBSERVATION_MODIFIER", 44, 56], ["hand motion", "OBSERVATION", 60, 71]]], ["FSC behavior consists of various movement units such as application, tapping, massage, and hand press.", [["hand", "ANATOMY", 91, 95], ["hand", "ORGANISM_SUBDIVISION", 91, 95], ["FSC", "CELL_TYPE", 0, 3], ["various movement units", "TREATMENT", 25, 47], ["massage", "TREATMENT", 78, 85], ["various", "OBSERVATION_MODIFIER", 25, 32], ["movement", "OBSERVATION_MODIFIER", 33, 41]]], ["In the future, the relationship between each action and ApEn and Rest \u03b3 should be examined in detail.", [["ApEn", "GENE_OR_GENE_PRODUCT", 56, 60], ["Rest \u03b3", "GENE_OR_GENE_PRODUCT", 65, 71], ["ApEn", "PROTEIN", 56, 60]]], ["It will lead to constitutive understanding of FSC behavior.", [["FSC", "GENE_OR_GENE_PRODUCT", 46, 49]]], ["Feed-back system to user by monitoring ApEn and Rest \u03b3 of hand motion during FSC may bring to expand psychological potential for the balance of ANS activity in future.ConclusionApEn and Rest \u03b3 are useful parameters for evaluating quality of hand motions during FSC.ConclusionAbbreviations FSC: Facial skin care; E group: Enjoyment group; NE group: Non-enjoyment group; HRV: The heart rate variability; Avg.", [["hand", "ANATOMY", 58, 62], ["hand", "ANATOMY", 241, 245], ["skin", "ANATOMY", 301, 305], ["heart", "ANATOMY", 378, 383], ["NE", "CHEMICAL", 338, 340], ["hand", "ORGANISM_SUBDIVISION", 58, 62], ["ANS", "GENE_OR_GENE_PRODUCT", 144, 147], ["Rest \u03b3", "GENE_OR_GENE_PRODUCT", 186, 192], ["hand", "ORGANISM_SUBDIVISION", 241, 245], ["skin", "ORGAN", 301, 305], ["heart", "ORGAN", 378, 383], ["ApEn", "PROTEIN", 39, 43], ["FSC", "CELL_TYPE", 77, 80], ["ConclusionApEn", "PROTEIN", 167, 181], ["Rest \u03b3", "PROTEIN", 186, 192], ["FSC", "CELL_TYPE", 261, 264], ["ConclusionApEn", "TREATMENT", 167, 181], ["The heart rate variability", "TEST", 374, 400], ["Facial", "ANATOMY", 294, 300], ["skin", "ANATOMY", 301, 305], ["heart", "ANATOMY", 378, 383]]], ["ACC: The averaged acceleration; ApEn: Approximate entropy; ANS: Autonomic nerve system; HF: High frequency; LF: Low frequency; ANOVA: Analysis of variance", [["Autonomic nerve system", "PROBLEM", 64, 86], ["HF", "PROBLEM", 88, 90], ["High frequency", "PROBLEM", 92, 106], ["Autonomic nerve", "ANATOMY", 64, 79], ["Low frequency", "OBSERVATION_MODIFIER", 112, 125]]]], "bc2b22d0d48cda407b4d238f2eea29fbada3a868": [["Monitoring Covid-19 lethality and its variation from country to country is essential for supporting governments in selecting the appropriate decisions.", [["Covid", "TEST", 11, 16], ["lethality", "PROBLEM", 20, 29]]], ["The adoption of correct indicators to monitor the lethality of the infection in the course of the outbreak is therefore a crucial issue.", [["infection", "DISEASE", 67, 76], ["the lethality", "PROBLEM", 46, 59], ["the infection", "PROBLEM", 63, 76], ["infection", "OBSERVATION", 67, 76]]], ["2, 3 The following terms are used in this work: the infection fatality ratio, IFR, indicates the ratio between the total deaths and total infected patients within a given population; the final case fatality ratio, CFR itself in the course of an outbreak, as better clarified in the following, is a tricky and non-trivial operation.", [["infection", "DISEASE", 52, 61], ["deaths", "DISEASE", 121, 127], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["the infection fatality ratio", "PROBLEM", 48, 76], ["IFR", "TEST", 78, 81], ["non-trivial operation", "TREATMENT", 309, 330], ["total", "OBSERVATION_MODIFIER", 132, 137], ["infected", "OBSERVATION_MODIFIER", 138, 146]]], ["Large and efficient testing programs allow accounting for non-symptomatic patients, thus increasing ccc(t).IntroductionThis lowers the error (a), i.e. lowers fin CFR to values closer to IFR.", [["patients", "ORGANISM", 74, 82], ["fin", "ORGANISM_SUBDIVISION", 158, 161], ["patients", "SPECIES", 74, 82], ["Large and efficient testing programs", "PROBLEM", 0, 36]]], ["This work is instead dedicated to the evaluation of error (b).Data analysisDays from the start of the outbreakConclusionsBoth the simulation and the examples above clarify that scientists and policymakers should beware of \uf028 \uf029 CFR t as a misleading indicator for calculating the infection fatality rate in the course of the outbreak, even if our attention is only restricted to the subset of confirmed cases.", [["infection", "DISEASE", 278, 287], ["the evaluation", "TEST", 34, 48], ["Data analysisDays", "TEST", 62, 79], ["the infection fatality rate", "PROBLEM", 274, 301], ["infection", "OBSERVATION", 278, 287]]], ["More comprehensive data analysis methods based on the estimate of the average diagnosis-to-death delay time TD are needed.", [["death", "DISEASE", 91, 96], ["TD", "DISEASE", 108, 110]]], ["The fin CFR for IT, ES, FR, UK, NL are expected to be grossly comparable at the end of the epidemic, all well above 10%.", [["The fin CFR", "TEST", 0, 11], ["NL", "OBSERVATION", 32, 34], ["grossly", "OBSERVATION_MODIFIER", 54, 61], ["comparable", "OBSERVATION", 62, 72]]], ["Germany is converging to lower fin CFR .", [["fin", "ORGANISM_SUBDIVISION", 31, 34], ["lower fin", "ANATOMY_MODIFIER", 25, 34]]], ["Probably larger and more efficient testing programs contribute to this result.", [["larger", "OBSERVATION_MODIFIER", 9, 15]]]], "b41638f869301e2af9eef7913301d55516fcf4ce": [["IntroductionThe first smallpox vaccination conducted by Edward Jenner in 1796 demonstrated that inoculation of materials collected from a lesion on a milkmaid suffering from cowpox was able to protect humans from smallpox [1] .", [["lesion", "ANATOMY", 138, 144], ["cowpox", "DISEASE", 174, 180], ["smallpox", "DISEASE", 213, 221], ["cowpox", "ORGANISM", 174, 180], ["humans", "ORGANISM", 201, 207], ["humans", "SPECIES", 201, 207], ["cowpox", "SPECIES", 174, 180], ["humans", "SPECIES", 201, 207], ["The first smallpox vaccination", "TREATMENT", 12, 42], ["inoculation of materials", "PROBLEM", 96, 120], ["a lesion", "PROBLEM", 136, 144], ["a milkmaid suffering", "TREATMENT", 148, 168], ["cowpox", "PROBLEM", 174, 180], ["lesion", "OBSERVATION", 138, 144]]], ["This was a landmark moment in vaccine history since a virulent virus of one species was able to protect another species from clinical manifestations caused by a different virus that was potentially fatal.", [["a virulent virus of one species", "PROBLEM", 52, 83], ["another species", "PROBLEM", 104, 119], ["clinical manifestations", "PROBLEM", 125, 148], ["a different virus", "PROBLEM", 159, 176]]], ["In addition, rabies vaccine was the very first virus deliberately attenuated in a laboratory in order to create a weakened vaccine virus for humans [2] .", [["rabies", "ORGANISM", 13, 19], ["humans", "ORGANISM", 141, 147], ["humans", "SPECIES", 141, 147], ["rabies", "SPECIES", 13, 19], ["humans", "SPECIES", 141, 147], ["rabies vaccine", "TREATMENT", 13, 27], ["a weakened vaccine virus", "TREATMENT", 112, 136]]], ["The next breakthrough in vaccine production came out in the 1950s when mass production of vaccine virus was achieved by adaption of in vitro preparation using chicken embryos and tissue culture cells [3, 4] .IntroductionVaccines are biological preparations made from killed or attenuated pathogens that upon administration should elicit specific and adaptive immunity to the target pathogen.", [["embryos", "ANATOMY", 167, 174], ["tissue culture cells", "ANATOMY", 179, 199], ["chicken", "ORGANISM", 159, 166], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 167, 174], ["tissue culture cells", "CELL", 179, 199], ["tissue culture cells", "CELL_LINE", 179, 199], ["chicken", "SPECIES", 159, 166], ["chicken", "SPECIES", 159, 166], ["The next breakthrough in vaccine production", "PROBLEM", 0, 43], ["mass production", "PROBLEM", 71, 86], ["vaccine virus", "PROBLEM", 90, 103], ["vitro preparation", "TREATMENT", 135, 152], ["chicken embryos", "TREATMENT", 159, 174], ["tissue culture cells", "TEST", 179, 199], ["IntroductionVaccines", "TREATMENT", 208, 228], ["biological preparations", "TREATMENT", 233, 256], ["attenuated pathogens", "PROBLEM", 277, 297]]], ["The given vaccine should not cause severe diseases but stimulate the immune system of the vaccinated host so that the body's immune system can recognize the http://www.ecevr.org/ http://dx.doi.org/10.7774/cevr.2012.1.1.", [["immune system", "ANATOMY", 69, 82], ["body", "ANATOMY", 118, 122], ["body", "ORGANISM_SUBDIVISION", 118, 122], ["The given vaccine", "TREATMENT", 0, 17], ["severe diseases", "PROBLEM", 35, 50]]], ["18 pathogen and destroy it when infection occurs later.", [["infection", "DISEASE", 32, 41], ["infection", "PROBLEM", 32, 41], ["infection", "OBSERVATION", 32, 41]]], ["Vaccination constitutes the most highly cost-effective measure to prevent or reduce clinical signs after infection and to eradicate infectious diseases, compared to the cost of chemotherapies and prophylaxis against many infectious diseases that can be prevented by vaccination.IntroductionAlthough there are relative similarities between animal and human infectious diseases in the pathogenesis and outcomes derived from vaccination, however, the ultimate goal of vaccination for industry animals is definitely different from those of human vaccines [5] .", [["infection", "DISEASE", 105, 114], ["infectious diseases", "DISEASE", 132, 151], ["infectious diseases", "DISEASE", 221, 240], ["infectious diseases", "DISEASE", 356, 375], ["human", "ORGANISM", 350, 355], ["human", "ORGANISM", 536, 541], ["human", "SPECIES", 350, 355], ["human", "SPECIES", 536, 541], ["human", "SPECIES", 350, 355], ["human", "SPECIES", 536, 541], ["Vaccination", "TREATMENT", 0, 11], ["clinical signs", "PROBLEM", 84, 98], ["infection", "PROBLEM", 105, 114], ["infectious diseases", "PROBLEM", 132, 151], ["chemotherapies", "TREATMENT", 177, 191], ["prophylaxis", "TREATMENT", 196, 207], ["many infectious diseases", "PROBLEM", 216, 240], ["animal and human infectious diseases", "PROBLEM", 339, 375], ["vaccination", "TREATMENT", 422, 433], ["vaccination", "TREATMENT", 465, 476], ["human vaccines", "TREATMENT", 536, 550], ["infectious", "OBSERVATION", 221, 231], ["infectious", "OBSERVATION_MODIFIER", 356, 366]]], ["This difference is due to various factors, such as the type of animals to be vaccinated, desired outcomes after vaccination, the cost of vaccination, economic benefit earned by vaccination, and those kinds of infectious agents to be controlled.", [["various factors", "PROBLEM", 26, 41], ["vaccination", "TREATMENT", 112, 123], ["vaccination", "TREATMENT", 137, 148], ["vaccination", "TREATMENT", 177, 188], ["infectious agents", "TREATMENT", 209, 226], ["infectious", "OBSERVATION", 209, 219]]], ["For instance, the purpose of vaccination for industry animals is mainly to enhance their productivity and profitability for livestock producers, whereas vaccination for companion animals would aim at their welfare by preventing particular infectious diseases (similar to those of humans).", [["infectious diseases", "DISEASE", 239, 258], ["humans", "ORGANISM", 280, 286], ["humans", "SPECIES", 280, 286], ["humans", "SPECIES", 280, 286], ["vaccination", "TREATMENT", 29, 40], ["livestock producers", "TREATMENT", 124, 143], ["particular infectious diseases", "PROBLEM", 228, 258], ["infectious", "OBSERVATION", 239, 249]]], ["Additionally, vaccination for wildlife is applied for blocking transmission of zoonotic diseases which are prone to spread to industry animals or humans.", [["zoonotic diseases", "DISEASE", 79, 96], ["humans", "ORGANISM", 146, 152], ["humans", "SPECIES", 146, 152], ["humans", "SPECIES", 146, 152], ["vaccination", "TREATMENT", 14, 25], ["wildlife", "TREATMENT", 30, 38], ["zoonotic diseases", "PROBLEM", 79, 96], ["zoonotic diseases", "OBSERVATION", 79, 96]]], ["In the case of vaccination for zoonotic diseases in livestock, it would be expected to reduce or remove the risk of transmission of such diseases to consumers as well as to protect industry animals.", [["zoonotic diseases", "DISEASE", 31, 48], ["vaccination", "TREATMENT", 15, 26], ["zoonotic diseases", "PROBLEM", 31, 48], ["such diseases", "PROBLEM", 132, 145]]], ["Interestingly, an additional benefit resulting from such application of vaccines for industrial animals is the reduction in chemotherapy in industry animals and a subsequent reduction in their residual in meat products contributing to human public safety.", [["meat", "ANATOMY", 205, 209], ["human", "ORGANISM", 235, 240], ["human", "SPECIES", 235, 240], ["human", "SPECIES", 235, 240], ["vaccines", "TREATMENT", 72, 80], ["industrial animals", "TREATMENT", 85, 103], ["chemotherapy in industry animals", "TREATMENT", 124, 156], ["a subsequent reduction", "TREATMENT", 161, 183], ["reduction", "OBSERVATION_MODIFIER", 111, 120], ["reduction", "OBSERVATION_MODIFIER", 174, 183], ["residual", "OBSERVATION_MODIFIER", 193, 201]]], ["In fact, there have been growing evidences that the large-scale of nontherapeutic use of antibiotics in livestock production is associated with the emergence of antibiotic resistant bacteria in industry animals.", [["antibiotics", "TREATMENT", 89, 100], ["antibiotic resistant bacteria", "PROBLEM", 161, 190], ["growing", "OBSERVATION_MODIFIER", 25, 32], ["large", "OBSERVATION_MODIFIER", 52, 57], ["-scale", "OBSERVATION_MODIFIER", 57, 63]]], ["Such problem promotes the use of vaccine rather than chemotherapy because vaccination would prevent diseased animals from treatment for a cure which may result in antibiotic resistance and pharmaceutical residue in food.", [["vaccine", "TREATMENT", 33, 40], ["chemotherapy", "TREATMENT", 53, 65], ["vaccination", "TREATMENT", 74, 85], ["diseased animals", "PROBLEM", 100, 116], ["treatment", "TREATMENT", 122, 131], ["a cure", "TREATMENT", 136, 142], ["antibiotic resistance", "PROBLEM", 163, 184], ["pharmaceutical residue in food", "PROBLEM", 189, 219], ["antibiotic resistance", "OBSERVATION", 163, 184], ["pharmaceutical residue", "OBSERVATION", 189, 211]]], ["It should be noted that the use of antibiotics in industry animals has been seriously restricted in the EU [6] and Korea [7] .", [["antibiotics", "TREATMENT", 35, 46]]], ["Moreover, the a new guideline for nontherapeutic use of antibiotic in livestock was recently established in the USA [8] .IntroductionIn general, vaccines are produced by several different methods including inactivation or attenuation of the pathogen, alteration of host-specificity for the pathogen, use of immunogenic components alone, insertion of a gene of interest into a carrier vehicle to be delivered or expressed [9] , and production of virus-like particle (VLP) without specific genetic ma-terials.", [["virus-like particle", "ORGANISM", 445, 464], ["VLP", "ORGANISM", 466, 469], ["antibiotic", "TREATMENT", 56, 66], ["vaccines", "TREATMENT", 145, 153], ["the pathogen", "PROBLEM", 237, 249], ["the pathogen", "PROBLEM", 286, 298], ["immunogenic components", "TREATMENT", 307, 329], ["a carrier vehicle", "TREATMENT", 374, 391], ["virus", "PROBLEM", 445, 450]]], ["Interestingly, there are overwhelming advantages in developing animal vaccines in contrast to human vaccine development.", [["human", "ORGANISM", 94, 99], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["animal vaccines", "TREATMENT", 63, 78]]], ["One of the most evident advantages is the relative low cost for conducting research and development for animal vaccines as compared with human vaccines.", [["human", "ORGANISM", 137, 142], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 137, 142], ["animal vaccines", "TREATMENT", 104, 119], ["human vaccines", "TREATMENT", 137, 151]]], ["Additionally, there is less regulation on development of animal vaccines and clinical trials than those of human vaccines, since clinical trials for animal vaccines are allowed without preclinical phases that are mandatory steps for developing human vaccines.", [["human", "ORGANISM", 107, 112], ["human", "ORGANISM", 244, 249], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 244, 249], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 244, 249], ["animal vaccines", "TREATMENT", 57, 72], ["clinical trials", "TREATMENT", 77, 92], ["human vaccines", "TREATMENT", 107, 121], ["clinical trials", "TREATMENT", 129, 144], ["animal vaccines", "TREATMENT", 149, 164], ["developing human vaccines", "TREATMENT", 233, 258], ["less", "OBSERVATION_MODIFIER", 23, 27], ["regulation", "OBSERVATION_MODIFIER", 28, 38]]], ["As a consequence, final animal vaccine products can readily be commercialized within a short period of time.", [["final animal vaccine products", "TREATMENT", 18, 47]]], ["Nevertheless, a smaller profit from the sector of animal vaccines is anticipated due to the lower price of the products and the smaller market, unlike of the human vaccine industry.", [["human", "ORGANISM", 158, 163], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 158, 163], ["animal vaccines", "TREATMENT", 50, 65], ["the human vaccine industry", "TREATMENT", 154, 180], ["smaller", "OBSERVATION_MODIFIER", 16, 23], ["smaller", "OBSERVATION_MODIFIER", 128, 135]]], ["Animal vaccines currently account for less than one fourth of the global market for animal health products [5] .", [["Animal vaccines", "TREATMENT", 0, 15]]], ["However, the vaccine production industry has steadily grown because of the increasing demands for new animal vaccines against various pathogens re-emerging in industry animals.", [["the vaccine production industry", "TREATMENT", 9, 40], ["the increasing demands", "PROBLEM", 71, 93], ["new animal vaccines", "TREATMENT", 98, 117], ["various pathogens", "PROBLEM", 126, 143]]], ["Accordingly, the number of licensed animal vaccines for livestock and companion animals has increased over the decade.", [["licensed animal vaccines", "TREATMENT", 27, 51], ["increased", "OBSERVATION_MODIFIER", 92, 101]]], ["To make new animal vaccines successful in the market, various factors should be considered during the comprehensive research and analysis on the particular disease.", [["new animal vaccines", "TREATMENT", 8, 27], ["the particular disease", "PROBLEM", 141, 163]]], ["These include demand of commercial products, regional demand, and global prospects for marketing the vaccine.IntroductionBy virtue of greatly advanced molecular techniques and the availability of a great deal of genomic information on various pathogens, there are new opportunities to create novel concept vaccines.", [["commercial products", "TREATMENT", 24, 43], ["the vaccine", "TREATMENT", 97, 108], ["greatly advanced molecular techniques", "TREATMENT", 134, 171], ["various pathogens", "PROBLEM", 235, 252], ["novel concept vaccines", "TREATMENT", 292, 314]]], ["In the present article, we will address briefly various types of animal vaccines in each section along with current research activities on animal vaccines that have been conducted in Korea.Animal Viral VaccinesUse of vaccines to control viral diseases would be a suitable strategy since antiviral drugs cannot deal with a broad spectrum of viruses responsible for causing many infectious diseases in industry animals [10] .", [["viral diseases", "DISEASE", 237, 251], ["infectious diseases", "DISEASE", 377, 396], ["animal vaccines", "TREATMENT", 65, 80], ["each section", "TREATMENT", 84, 96], ["current research activities", "TREATMENT", 108, 135], ["animal vaccines", "TREATMENT", 139, 154], ["Animal Viral Vaccines", "TREATMENT", 189, 210], ["vaccines", "TREATMENT", 217, 225], ["viral diseases", "PROBLEM", 237, 251], ["a suitable strategy", "TREATMENT", 261, 280], ["antiviral drugs", "TREATMENT", 287, 302], ["viruses", "PROBLEM", 340, 347], ["many infectious diseases", "PROBLEM", 372, 396], ["Viral Vaccines", "OBSERVATION", 196, 210], ["viruses", "OBSERVATION", 340, 347], ["infectious", "OBSERVATION_MODIFIER", 377, 387]]], ["A plethora of viral vaccines are currently produced by many veterinary vaccine companies and have been used for livestock, companion animals, and wildlife.", [["viral vaccines", "TREATMENT", 14, 28], ["plethora", "OBSERVATION_MODIFIER", 2, 10], ["viral vaccines", "OBSERVATION", 14, 28]]], ["However, currently existing viral vaccines are unable to cope with many types of prevailing viruses in the field.Live viral vaccinesAlthough live viral vaccines are produced in several ways, the most common method for creating vaccine strains is made through passing viruses in cell cultures, embryos, or suitable materials.", [["cell cultures", "ANATOMY", 278, 291], ["embryos", "ANATOMY", 293, 300], ["cell cultures", "CELL", 278, 291], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 293, 300], ["cell cultures", "CELL_LINE", 278, 291], ["viral vaccines", "TREATMENT", 28, 42], ["prevailing viruses", "TREATMENT", 81, 99], ["Live viral vaccines", "TREATMENT", 113, 132], ["live viral vaccines", "TREATMENT", 141, 160], ["creating vaccine strains", "TREATMENT", 218, 242], ["passing viruses in cell cultures", "PROBLEM", 259, 291], ["embryos", "PROBLEM", 293, 300], ["viral", "OBSERVATION", 28, 33]]], ["For instance, a selected virus strain is serially passed in chicken embryos, resulting in better replication in chick cells but with a lost ability to replicate in animals cells of the target host.", [["embryos", "ANATOMY", 68, 75], ["chick cells", "ANATOMY", 112, 123], ["cells", "ANATOMY", 172, 177], ["chicken", "ORGANISM", 60, 67], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 68, 75], ["chick", "ORGANISM", 112, 117], ["cells", "CELL", 118, 123], ["cells", "CELL", 172, 177], ["chick cells", "CELL_TYPE", 112, 123], ["animals cells", "CELL_TYPE", 164, 177], ["chicken", "SPECIES", 60, 67], ["chicken", "SPECIES", 60, 67], ["a selected virus strain", "PROBLEM", 14, 37], ["better replication in chick cells", "PROBLEM", 90, 123], ["chick cells", "OBSERVATION", 112, 123]]], ["Also, the live vaccine viruses can be generated by inducing random mutations on viral genome and followed by selecting a non-virulent mutant incapable of causing clinical diseases.", [["viral genome", "DNA", 80, 92], ["the live vaccine viruses", "TREATMENT", 6, 30], ["random mutations on viral genome", "PROBLEM", 60, 92], ["clinical diseases", "PROBLEM", 162, 179]]], ["An alternative to creating attenuated viral strains is that viruses are serially passed in a nonadapted host until they can effectively propagate, and the loss of their pathogenicity in the original host is confirmed.", [["creating attenuated viral strains", "PROBLEM", 18, 51], ["viruses", "PROBLEM", 60, 67], ["a nonadapted host", "TREATMENT", 91, 108], ["the loss of their pathogenicity", "PROBLEM", 151, 182], ["attenuated", "OBSERVATION_MODIFIER", 27, 37], ["viral strains", "OBSERVATION", 38, 51], ["loss", "OBSERVATION_MODIFIER", 155, 159], ["pathogenicity", "OBSERVATION_MODIFIER", 169, 182]]], ["All of these methods involving passing virus in suitable matter can create a new version of the virus that can still be recognized by animal immune systems but cannot replicate well in a vaccinated host.", [["passing virus", "PROBLEM", 31, 44], ["the virus", "PROBLEM", 92, 101], ["a vaccinated host", "TREATMENT", 185, 202], ["new", "OBSERVATION_MODIFIER", 77, 80], ["virus", "OBSERVATION", 96, 101]]], ["This produces the necessary immune response in the host if the host is challenged with infection by the original pathogenic virus.", [["infection", "DISEASE", 87, 96], ["infection", "PROBLEM", 87, 96], ["the original pathogenic virus", "PROBLEM", 100, 129], ["infection", "OBSERVATION", 87, 96]]], ["Most importantly, protection efficacy derived from a live attenuated vaccine typically outlasts that provided by a killed or inactivated vaccine.", [["a live attenuated vaccine", "TREATMENT", 51, 76]]], ["Nevertheless, these vaccines still have a residual virulence or a risk of reversion to a virulent phenotype [11] .", [["these vaccines", "TREATMENT", 14, 28], ["a residual virulence", "PROBLEM", 40, 60], ["a virulent phenotype", "PROBLEM", 87, 107]]], ["A single point mutation on certain gene may tend to induce attenuation of virus but may lead to back mutation, resulting in the wild type virulent virus.", [["wild type virulent virus", "ORGANISM", 128, 152], ["A single point mutation", "PROBLEM", 0, 23], ["attenuation of virus", "PROBLEM", 59, 79], ["back mutation", "PROBLEM", 96, 109], ["the wild type virulent virus", "PROBLEM", 124, 152], ["virus", "OBSERVATION", 74, 79], ["virulent virus", "OBSERVATION", 138, 152]]], ["Considering the relatively high mutation rate of RNA viruses, it is taken into consideration that live vaccine viruses would need to have multiple mutations on various genes of the viral genome when developing an attenuated vaccine strain.", [["viral genome", "DNA", 181, 193], ["the relatively high mutation rate of RNA viruses", "PROBLEM", 12, 60], ["live vaccine viruses", "TREATMENT", 98, 118], ["multiple mutations", "PROBLEM", 138, 156], ["the viral genome", "PROBLEM", 177, 193], ["an attenuated vaccine strain", "PROBLEM", 210, 238], ["high mutation", "OBSERVATION", 27, 40], ["RNA viruses", "OBSERVATION", 49, 60], ["viral genome", "OBSERVATION", 181, 193]]], ["Despite these drawbacks of live vaccines, live vaccines play an important role in preventing and eradicating viral diseases in industry animals.", [["viral diseases", "DISEASE", 109, 123], ["live vaccines", "TREATMENT", 27, 40], ["live vaccines", "TREATMENT", 42, 55], ["eradicating viral diseases", "PROBLEM", 97, 123]]], ["Interestingly, a potent adjuvant is not necessary for the formulation of live vaccines because live vaccine viruses are capable of infecting target cells and provoking immune responses to injected viruses.", [["cells", "ANATOMY", 148, 153], ["live vaccine viruses", "ORGANISM", 95, 115], ["cells", "CELL", 148, 153], ["target cells", "CELL_TYPE", 141, 153], ["a potent adjuvant", "TREATMENT", 15, 32], ["the formulation of live vaccines", "TREATMENT", 54, 86], ["live vaccine viruses", "TREATMENT", 95, 115], ["infecting target cells", "PROBLEM", 131, 153], ["injected viruses", "PROBLEM", 188, 204]]], ["Additionally, live vaccines can easily be administered by various routes, such as injection, drinkable water, or instillation into the nasal cavity or eyes.Live viral vaccinesFor examples, modified live vaccines for avian influenza virus (AIV) have been used in many countries to control AIV infection since killed vaccines are moderately effective but multiple injections are needed to develop protective immunity [12] .", [["nasal cavity", "ANATOMY", 135, 147], ["eyes", "ANATOMY", 151, 155], ["avian influenza virus", "DISEASE", 216, 237], ["AIV infection", "DISEASE", 288, 301], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 135, 147], ["eyes", "ORGAN", 151, 155], ["avian influenza virus", "ORGANISM", 216, 237], ["AIV", "ORGANISM", 239, 242], ["AIV", "ORGANISM", 288, 291], ["avian influenza virus", "SPECIES", 216, 237], ["avian influenza virus", "SPECIES", 216, 237], ["AIV", "SPECIES", 239, 242], ["AIV", "SPECIES", 288, 291], ["live vaccines", "TREATMENT", 14, 27], ["injection, drinkable water", "TREATMENT", 82, 108], ["instillation", "TREATMENT", 113, 125], ["Live viral vaccines", "TREATMENT", 156, 175], ["modified live vaccines", "TREATMENT", 189, 211], ["avian influenza virus (AIV)", "TREATMENT", 216, 243], ["AIV infection", "PROBLEM", 288, 301], ["killed vaccines", "TREATMENT", 308, 323], ["multiple injections", "TREATMENT", 353, 372], ["nasal cavity", "ANATOMY", 135, 147], ["eyes", "ANATOMY", 151, 155]]], ["Although vaccination is not perfect, it would be the most promising control means for the low pathogenic avian influenza (LPAI) H9N2 to date [12] .", [["avian influenza (LPAI) H9N2", "DISEASE", 105, 132], ["avian influenza", "ORGANISM", 105, 120], ["LPAI) H9N2", "ORGANISM", 122, 132], ["avian influenza", "SPECIES", 105, 120], ["LPAI", "SPECIES", 122, 126], ["vaccination", "TREATMENT", 9, 20], ["the low pathogenic avian influenza", "PROBLEM", 86, 120]]], ["Porcine epidemic diarrhea virus (PEDV) is an agent causing severe entero-pathogenic diarrhea in pigs, which leads to significant economic losses in Asia.", [["Porcine epidemic diarrhea virus", "DISEASE", 0, 31], ["diarrhea", "DISEASE", 84, 92], ["Porcine epidemic diarrhea virus", "ORGANISM", 0, 31], ["PEDV", "ORGANISM", 33, 37], ["pigs", "ORGANISM", 96, 100], ["Porcine epidemic diarrhea virus", "SPECIES", 0, 31], ["pigs", "SPECIES", 96, 100], ["Porcine epidemic diarrhea virus", "SPECIES", 0, 31], ["PEDV", "SPECIES", 33, 37], ["pigs", "SPECIES", 96, 100], ["Porcine epidemic diarrhea virus", "PROBLEM", 0, 31], ["PEDV", "PROBLEM", 33, 37], ["severe entero-pathogenic diarrhea", "PROBLEM", 59, 92], ["significant economic losses in Asia", "PROBLEM", 117, 152], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["entero-pathogenic", "OBSERVATION_MODIFIER", 66, 83], ["diarrhea", "OBSERVATION", 84, 92], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["economic", "OBSERVATION_MODIFIER", 129, 137], ["losses", "OBSERVATION", 138, 144]]], ["PEDV strain DR13, a field isolate, was attenuated by serially passing the virus on Vero cells and tested for its virulence in piglets and sows.", [["Vero cells", "ANATOMY", 83, 93], ["PEDV", "CHEMICAL", 0, 4], ["DR13", "CHEMICAL", 12, 16], ["PEDV strain DR13", "ORGANISM", 0, 16], ["Vero cells", "CELL", 83, 93], ["piglets", "ORGANISM", 126, 133], ["sows", "ORGANISM", 138, 142], ["Vero cells", "CELL_LINE", 83, 93], ["piglets", "SPECIES", 126, 133], ["PEDV", "SPECIES", 0, 4], ["piglets", "SPECIES", 126, 133], ["PEDV strain", "PROBLEM", 0, 11], ["a field isolate", "TREATMENT", 18, 33], ["Vero cells", "TREATMENT", 83, 93]]], ["Vero cell-adapted virus showed reduced pathogenicity and induced protective immunity in pigs, indicating that this attenuated virus may be a vaccine candidate [13] .Inactivated vaccinesInactivated vaccines are safer than live vaccines because they cannot replicate at all in a vaccinated host, resulting in no risk of reversion to a virulent form capable of causing diseases.", [["cell", "ANATOMY", 5, 9], ["Vero cell", "CELL", 0, 9], ["pigs", "ORGANISM", 88, 92], ["pigs", "SPECIES", 88, 92], ["pigs", "SPECIES", 88, 92], ["Vero cell", "TEST", 0, 9], ["adapted virus", "PROBLEM", 10, 23], ["reduced pathogenicity", "PROBLEM", 31, 52], ["this attenuated virus", "PROBLEM", 110, 131], ["Inactivated vaccines", "TREATMENT", 165, 185], ["Inactivated vaccines", "TREATMENT", 185, 205], ["live vaccines", "TREATMENT", 221, 234], ["diseases", "PROBLEM", 366, 374], ["reduced", "OBSERVATION_MODIFIER", 31, 38], ["pathogenicity", "OBSERVATION", 39, 52]]], ["However, they generally provide a shorter length of protection than live vaccine and generally elicit weak immune responses, in particular cell-mediated immunity, as opposed to live viral vaccines.", [["cell", "ANATOMY", 139, 143], ["cell", "CELL", 139, 143], ["a shorter length of protection than live vaccine", "TREATMENT", 32, 80], ["weak immune responses", "PROBLEM", 102, 123], ["live viral vaccines", "TREATMENT", 177, 196]]], ["For this reason, inactivated vaccines are administered with potent adjuvant, and require boosters to elicit satisfactory and a long-term immunity.", [["inactivated vaccines", "TREATMENT", 17, 37], ["potent adjuvant", "TREATMENT", 60, 75], ["boosters", "TREATMENT", 89, 97], ["a long-term immunity", "TREATMENT", 125, 145]]], ["Vaccines of this type are generally created by inactivating propagated viruses by treatment with heat or chemicals such as formalin or binary ethyleneimine.", [["formalin", "CHEMICAL", 123, 131], ["ethyleneimine", "CHEMICAL", 142, 155], ["formalin", "CHEMICAL", 123, 131], ["ethyleneimine", "CHEMICAL", 142, 155], ["formalin", "SIMPLE_CHEMICAL", 123, 131], ["binary ethyleneimine", "SIMPLE_CHEMICAL", 135, 155], ["Vaccines", "TREATMENT", 0, 8], ["heat or chemicals", "TREATMENT", 97, 114], ["formalin", "TREATMENT", 123, 131], ["binary ethyleneimine", "TREATMENT", 135, 155]]], ["This procedure can destroy the pathogen's ability to propagate in the vaccinated host, but keeps it intact so that the immune system can still recognize it.", [["immune system", "ANATOMY", 119, 132], ["This procedure", "TREATMENT", 0, 14], ["intact", "OBSERVATION", 100, 106]]], ["Although inactivated virus vaccines have been used for preventing various types of viral diseases over the decades, they need further development for controlling newly emerging diseases.", [["viral diseases", "DISEASE", 83, 97], ["inactivated virus vaccines", "TREATMENT", 9, 35], ["viral diseases", "PROBLEM", 83, 97], ["controlling newly emerging diseases", "PROBLEM", 150, 185], ["viral diseases", "OBSERVATION", 83, 97]]], ["For examples, influenza virus vaccines are continually improved to contain all serotypes because many new serotypes emerge in new outbreaks.", [["influenza virus", "DISEASE", 14, 29], ["influenza virus", "ORGANISM", 14, 29], ["influenza virus", "SPECIES", 14, 29], ["influenza virus", "SPECIES", 14, 29], ["influenza virus vaccines", "TREATMENT", 14, 38], ["all serotypes", "TREATMENT", 75, 88], ["many new serotypes", "PROBLEM", 97, 115], ["influenza virus", "OBSERVATION", 14, 29], ["new", "OBSERVATION_MODIFIER", 102, 105], ["serotypes", "OBSERVATION", 106, 115], ["new", "OBSERVATION_MODIFIER", 126, 129], ["outbreaks", "OBSERVATION_MODIFIER", 130, 139]]], ["As with other approaches, many studies have been focused on searching for better adjuvants which enhance immune responses in accordance with inactivated vaccines [14] as well as help to overcome the inhibitory effects of maternal antibody.", [["maternal antibody", "PROTEIN", 221, 238], ["many studies", "TEST", 26, 38], ["better adjuvants", "TREATMENT", 74, 90], ["inactivated vaccines", "TREATMENT", 141, 161], ["maternal antibody", "PROBLEM", 221, 238]]], ["For live AIV vaccines, the possibility of reassortment between live vaccine strain and field isolates and of back mutation from low-pathogenic to highly pathogenic viruses lead to serious concerns for vaccine safety.", [["AIV", "ORGANISM", 9, 12], ["AIV", "SPECIES", 9, 12], ["live AIV vaccines", "TREATMENT", 4, 21], ["reassortment between live vaccine strain", "TREATMENT", 42, 82], ["field isolates", "TEST", 87, 101], ["back mutation", "PROBLEM", 109, 122], ["vaccine safety", "TREATMENT", 201, 215], ["back", "ANATOMY", 109, 113]]], ["Thus, prior stimulation of the immune system using some immunomodulators followed by vaccination with inactivated vaccines may be needed to confer better http://www.ecevr.org/ http://dx.doi.org/10.7774/cevr.2012.1.1.18 protective immunity within a short period of time and may be promising in controlling LPAI H9N2 [12] .Subunit/recombinant vaccinesSubunit vaccines can be classified as a type of inactivated vaccine that contains only part of the virus or other microorganisms.", [["H9N2", "DISEASE", 310, 314], ["LPAI H9N2", "ORGANISM", 305, 314], ["LPAI H9N2", "SPECIES", 305, 314], ["LPAI H9N2", "SPECIES", 305, 314], ["the immune system", "TREATMENT", 27, 44], ["some immunomodulators", "TREATMENT", 51, 72], ["vaccination with inactivated vaccines", "TREATMENT", 85, 122], ["Subunit/recombinant vaccinesSubunit vaccines", "TREATMENT", 321, 365], ["inactivated vaccine", "TREATMENT", 397, 416], ["the virus", "PROBLEM", 444, 453], ["other microorganisms", "PROBLEM", 457, 477]]], ["Subunit vaccines for pathogens can be generated as recombinant proteins in various expression systems, as long as appropriate immunogenic antigens of the target pathogen are empirically determined.", [["recombinant proteins", "PROTEIN", 51, 71], ["immunogenic antigens", "PROTEIN", 126, 146], ["Subunit vaccines", "TREATMENT", 0, 16], ["pathogens", "PROBLEM", 21, 30], ["recombinant proteins in various expression systems", "PROBLEM", 51, 101], ["the target pathogen", "PROBLEM", 150, 169]]], ["The recombinant proteins can be a component of safe and non-replicating subunit vaccines.", [["recombinant proteins", "PROTEIN", 4, 24], ["The recombinant proteins", "TREATMENT", 0, 24], ["non-replicating subunit vaccines", "TREATMENT", 56, 88]]], ["When manipulating DNA that encodes such proteins, a large quantity of proteins can be expressed, purified, and then immunized into a target host in order to stimulate immune reaction against the pathogen.", [["DNA", "CELLULAR_COMPONENT", 18, 21], ["such proteins", "PROBLEM", 35, 48], ["a large quantity of proteins", "PROBLEM", 50, 78], ["a target host", "TREATMENT", 131, 144], ["immune reaction", "PROBLEM", 167, 182], ["the pathogen", "PROBLEM", 191, 203], ["large", "OBSERVATION_MODIFIER", 52, 57]]], ["In general, vaccination with antigens alone elicits weak immune responses so that potent adjuvant and repeated vaccinations are required.", [["weak immune responses", "PROBLEM", 52, 73], ["potent adjuvant", "TREATMENT", 82, 97], ["repeated vaccinations", "TREATMENT", 102, 123]]], ["The high costs of producing subunit vaccines would deteriorate the competitiveness of such vaccine products compared to those of other types of vaccines.", [["subunit vaccines", "TREATMENT", 28, 44], ["such vaccine products", "TREATMENT", 86, 107], ["vaccines", "TREATMENT", 144, 152], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["Despite such a limitation, several subunit vaccines have been launched on the market.", [["several subunit vaccines", "TREATMENT", 27, 51]]], ["Another type of subunit vaccine can be created via genetic engineering.", [["subunit vaccine", "TREATMENT", 16, 31]]], ["A gene encoding immunogenic antigen is inserted into another carrier virus or into producer cells in culture system.", [["cells", "ANATOMY", 92, 97], ["cells", "CELL", 92, 97], ["immunogenic antigen", "PROTEIN", 16, 35], ["producer cells", "CELL_TYPE", 83, 97], ["A gene encoding immunogenic antigen", "TREATMENT", 0, 35], ["another carrier virus", "PROBLEM", 53, 74], ["culture system", "TEST", 101, 115]]], ["When the carrier virus propagates or when the producer cells metabolize, the inserted gene is also expressed and released into cytoplasm.", [["cells", "ANATOMY", 55, 60], ["cytoplasm", "ANATOMY", 127, 136], ["cells", "CELL", 55, 60], ["cytoplasm", "ORGANISM_SUBSTANCE", 127, 136], ["producer cells", "CELL_LINE", 46, 60], ["the carrier virus propagates", "TREATMENT", 5, 33], ["the producer cells metabolize", "TREATMENT", 42, 71]]], ["The end result of this approach is a recombinant vaccine; the immune system of vaccinated host will recognize the expressed protein and provide future protection against the target virus.Subunit/recombinant vaccinesFor examples, the open reading frame 2 (ORF2) protein of porcine circovirus type 2 (PCV2), a major agent responsible for developing post-weaning multi-systemic wasting syndrome in pigs, was recently produced in baculovirus expression system [15] , and the subunit vaccine containing ORF2 protein has been commercialized.", [["multi-systemic wasting syndrome", "DISEASE", 360, 391], ["open reading frame 2", "GENE_OR_GENE_PRODUCT", 233, 253], ["ORF2", "GENE_OR_GENE_PRODUCT", 255, 259], ["porcine circovirus type 2", "ORGANISM", 272, 297], ["PCV2", "ORGANISM", 299, 303], ["pigs", "ORGANISM", 395, 399], ["baculovirus", "ORGANISM", 426, 437], ["ORF2", "GENE_OR_GENE_PRODUCT", 498, 502], ["open reading frame 2", "DNA", 233, 253], ["ORF2", "DNA", 255, 259], ["ORF2 protein", "PROTEIN", 498, 510], ["porcine circovirus", "SPECIES", 272, 290], ["pigs", "SPECIES", 395, 399], ["porcine circovirus type 2", "SPECIES", 272, 297], ["PCV2", "SPECIES", 299, 303], ["pigs", "SPECIES", 395, 399], ["baculovirus", "SPECIES", 426, 437], ["this approach", "TREATMENT", 18, 31], ["a recombinant vaccine", "TREATMENT", 35, 56], ["future protection", "TREATMENT", 144, 161], ["the target virus", "PROBLEM", 170, 186], ["Subunit/recombinant vaccines", "TREATMENT", 187, 215], ["the open reading frame", "TEST", 229, 251], ["ORF2", "TEST", 255, 259], ["porcine circovirus type 2", "PROBLEM", 272, 297], ["multi-systemic wasting syndrome", "PROBLEM", 360, 391], ["the subunit vaccine", "TREATMENT", 467, 486], ["ORF2 protein", "TREATMENT", 498, 510], ["porcine circovirus", "OBSERVATION", 272, 290], ["multi-systemic", "OBSERVATION_MODIFIER", 360, 374], ["wasting syndrome", "OBSERVATION", 375, 391]]], ["This vaccine has been purchased and distributed to pig farms by government since there have been significant economic losses from PCV2.", [["pig", "ORGANISM", 51, 54], ["PCV2", "ORGANISM", 130, 134], ["pig", "SPECIES", 51, 54], ["pig", "SPECIES", 51, 54], ["This vaccine", "TREATMENT", 0, 12], ["significant economic losses from PCV2", "PROBLEM", 97, 134], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["economic losses", "OBSERVATION", 109, 124], ["PCV2", "OBSERVATION", 130, 134]]], ["From three years ago, about USD 30 million was annually required for purchase of vaccine.", [["purchase of vaccine", "TREATMENT", 69, 88]]], ["Meanwhile, a subunit vaccine capable of preventing Newcastle disease virus (NDV) in poultry was successfully registered.", [["Newcastle disease", "DISEASE", 51, 68], ["Newcastle disease virus", "ORGANISM", 51, 74], ["NDV", "ORGANISM", 76, 79], ["Newcastle disease virus", "SPECIES", 51, 74], ["NDV", "SPECIES", 76, 79], ["poultry", "SPECIES", 84, 91], ["a subunit vaccine", "TREATMENT", 11, 28], ["Newcastle disease virus", "PROBLEM", 51, 74]]], ["Hemagglutinin-neuraminidase (HN) protein, a protective antigen, of NDV was produced in plant cells and demonstrated to protect a vacci-nated chicken once challenged with wild type virus.", [["cells", "ANATOMY", 93, 98], ["Hemagglutinin-neuraminidase", "GENE_OR_GENE_PRODUCT", 0, 27], ["HN", "GENE_OR_GENE_PRODUCT", 29, 31], ["NDV", "ORGANISM", 67, 70], ["plant cells", "CELL", 87, 98], ["chicken", "ORGANISM", 141, 148], ["wild type virus", "ORGANISM", 170, 185], ["Hemagglutinin", "PROTEIN", 0, 13], ["neuraminidase (HN) protein", "PROTEIN", 14, 40], ["plant cells", "CELL_TYPE", 87, 98], ["chicken", "SPECIES", 141, 148], ["NDV", "SPECIES", 67, 70], ["chicken", "SPECIES", 141, 148], ["Hemagglutinin-neuraminidase (HN) protein", "TREATMENT", 0, 40], ["a protective antigen", "TEST", 42, 62], ["NDV", "PROBLEM", 67, 70], ["a vacci-nated chicken", "TREATMENT", 127, 148], ["wild type virus", "PROBLEM", 170, 185], ["plant cells", "OBSERVATION", 87, 98]]], ["Also, the fusion (F) and HN proteins derived from the NDV isolate and La Sota strain of NDV were expressed, purified and used as a subunit vaccine.", [["HN proteins", "GENE_OR_GENE_PRODUCT", 25, 36], ["NDV", "ORGANISM", 54, 57], ["La Sota strain", "ORGANISM", 70, 84], ["NDV", "ORGANISM", 88, 91], ["fusion (F) and HN proteins", "PROTEIN", 10, 36], ["NDV", "SPECIES", 54, 57], ["NDV", "SPECIES", 88, 91], ["NDV", "SPECIES", 54, 57], ["NDV", "SPECIES", 88, 91], ["HN proteins", "PROBLEM", 25, 36], ["the NDV isolate", "TREATMENT", 50, 65], ["NDV", "PROBLEM", 88, 91], ["a subunit vaccine", "TREATMENT", 129, 146], ["fusion", "OBSERVATION", 10, 16]]], ["The subunit vaccine reduced significantly the amount of viral shedding after a single application [16] .", [["The subunit vaccine", "TREATMENT", 0, 19], ["viral shedding", "PROBLEM", 56, 70], ["amount", "OBSERVATION_MODIFIER", 46, 52], ["viral", "OBSERVATION_MODIFIER", 56, 61]]], ["For foot-and-mouth disease virus (FMDV), VP1 is a structural protein involved in neutralization of virus, whereas 3D is a RNA-dependent RNA polymerase that is highly conserved among other serotypes and strongly immunogenic.", [["foot-and-mouth disease", "DISEASE", 4, 26], ["foot-and-mouth disease virus", "ORGANISM", 4, 32], ["FMDV", "ORGANISM", 34, 38], ["VP1", "GENE_OR_GENE_PRODUCT", 41, 44], ["VP1", "PROTEIN", 41, 44], ["structural protein", "PROTEIN", 50, 68], ["RNA-dependent RNA polymerase", "PROTEIN", 122, 150], ["foot-and-mouth disease virus", "SPECIES", 4, 32], ["FMDV", "SPECIES", 34, 38], ["foot-and-mouth disease virus", "SPECIES", 4, 32], ["FMDV", "SPECIES", 34, 38], ["foot-and-mouth disease virus", "PROBLEM", 4, 32], ["VP1", "PROBLEM", 41, 44], ["a structural protein", "PROBLEM", 48, 68], ["neutralization of virus", "PROBLEM", 81, 104], ["a RNA-dependent RNA polymerase", "PROBLEM", 120, 150], ["foot", "ANATOMY", 4, 8], ["mouth", "ANATOMY", 13, 18], ["RNA polymerase", "OBSERVATION", 136, 150]]], ["Recombinant proteins of both VP1 and 3D induce antigen-specific immune responses, indicating that they can be subunit vaccine candidates against FMDV [17] .", [["VP1", "GENE_OR_GENE_PRODUCT", 29, 32], ["antigen", "GENE_OR_GENE_PRODUCT", 47, 54], ["FMDV", "ORGANISM", 145, 149], ["Recombinant proteins", "PROTEIN", 0, 20], ["VP1", "PROTEIN", 29, 32], ["FMDV", "SPECIES", 145, 149], ["FMDV", "SPECIES", 145, 149], ["VP1", "TEST", 29, 32], ["3D induce antigen", "TEST", 37, 54], ["subunit vaccine", "TREATMENT", 110, 125], ["FMDV", "PROBLEM", 145, 149]]], ["The pre-membrane (prM) and envelop (E) proteins of Japanese encephalitis (JEV) were expressed in insect Sf9 cells.", [["Sf9 cells", "ANATOMY", 104, 113], ["Japanese encephalitis", "DISEASE", 51, 72], ["JEV", "DISEASE", 74, 77], ["envelop (E)", "GENE_OR_GENE_PRODUCT", 27, 38], ["Japanese encephalitis", "ORGANISM", 51, 72], ["JEV", "ORGANISM", 74, 77], ["Sf9 cells", "CELL", 104, 113], ["pre-membrane", "PROTEIN", 4, 16], ["prM", "PROTEIN", 18, 21], ["envelop (E) proteins", "PROTEIN", 27, 47], ["insect Sf9 cells", "CELL_LINE", 97, 113], ["JEV", "SPECIES", 74, 77], ["Sf9", "SPECIES", 104, 107], ["The pre-membrane (prM", "PROBLEM", 0, 21], ["Japanese encephalitis (JEV)", "PROBLEM", 51, 78], ["encephalitis", "OBSERVATION", 60, 72], ["Sf9 cells", "OBSERVATION", 104, 113]]], ["The immunogenicity of the recombinant prM and E proteins was demonstrated by complete protection mice from a virulent virus challenge, providing valuable information for developing efficacious subunit vaccines against JEV [18] .Viruses vector vaccinesAs a delivery vehicle, nonpathogenic live virus carrying foreign DNA can be administered into a host, creating proper immunity to the inserted proteins.", [["JEV", "DISEASE", 218, 221], ["prM", "GENE_OR_GENE_PRODUCT", 38, 41], ["E", "GENE_OR_GENE_PRODUCT", 46, 47], ["mice", "ORGANISM", 97, 101], ["JEV", "ORGANISM", 218, 221], ["live virus", "ORGANISM", 288, 298], ["DNA", "CELLULAR_COMPONENT", 316, 319], ["recombinant prM and E proteins", "PROTEIN", 26, 56], ["inserted proteins", "PROTEIN", 385, 402], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 97, 101], ["JEV", "SPECIES", 218, 221], ["the recombinant prM and E proteins", "PROBLEM", 22, 56], ["a virulent virus challenge", "TREATMENT", 107, 133], ["efficacious subunit vaccines", "TREATMENT", 181, 209], ["JEV", "PROBLEM", 218, 221], ["Viruses vector vaccines", "TREATMENT", 228, 251], ["a delivery vehicle", "TREATMENT", 254, 272], ["nonpathogenic live virus carrying foreign DNA", "PROBLEM", 274, 319]]], ["Once a live delivery virus is injected, the gene of interest introduced within the vector vehicle is expressed in the vaccinated host so that the host elicits immune responses against the expressed protein [19] .", [["a live delivery virus", "TREATMENT", 5, 26]]], ["The immune response against the expressed protein carried by vehicle virus would follow a very natural immune stimulatory pathway.", [["vehicle virus", "ORGANISM", 61, 74], ["the expressed protein", "PROBLEM", 28, 49], ["vehicle virus", "PROBLEM", 61, 74]]], ["Interestingly, host-restricted vector virus itself will not be replicated within the tissues of the vaccinated animals but is able to temporarily express the foreign protein [19] .", [["tissues", "ANATOMY", 85, 92], ["tissues", "TISSUE", 85, 92], ["restricted vector virus", "PROBLEM", 20, 43]]], ["These vaccines are free of adverse effects and are stable, nonadjuvanted, and allow for differentiating infected from vaccinated animals (DIVA).", [["These vaccines", "TREATMENT", 0, 14], ["adverse effects", "PROBLEM", 27, 42], ["stable", "OBSERVATION_MODIFIER", 51, 57]]], ["Approved vehicle viruses are currently in use for several veterinary diseases, including adenovirus, fowl pox, yellow fever and vaccinia virus.", [["fowl pox", "DISEASE", 101, 109], ["yellow fever", "DISEASE", 111, 123], ["vaccinia virus", "DISEASE", 128, 142], ["adenovirus", "ORGANISM", 89, 99], ["fowl pox", "ORGANISM", 101, 109], ["yellow fever", "ORGANISM", 111, 123], ["vaccinia virus", "ORGANISM", 128, 142], ["fowl pox", "SPECIES", 101, 109], ["yellow fever", "SPECIES", 111, 123], ["vaccinia virus", "SPECIES", 128, 142], ["fowl pox", "SPECIES", 101, 109], ["vaccinia virus", "SPECIES", 128, 142], ["vehicle viruses", "PROBLEM", 9, 24], ["several veterinary diseases", "PROBLEM", 50, 77], ["adenovirus", "PROBLEM", 89, 99], ["fowl pox", "PROBLEM", 101, 109], ["yellow fever", "PROBLEM", 111, 123], ["vaccinia virus", "PROBLEM", 128, 142], ["vehicle viruses", "OBSERVATION", 9, 24], ["yellow fever", "OBSERVATION", 111, 123]]], ["Among them, poxviruses have been widely used for the delivery of vaccine antigen due to their ability to accommodate a large amount of exogenous genes and infect various types of mammalian cells, as well as express a high level of protein.", [["cells", "ANATOMY", 189, 194], ["poxviruses", "ORGANISM", 12, 22], ["mammalian cells", "CELL", 179, 194], ["exogenous genes", "DNA", 135, 150], ["mammalian cells", "CELL_TYPE", 179, 194], ["poxviruses", "TREATMENT", 12, 22], ["the delivery of vaccine antigen", "TREATMENT", 49, 80], ["mammalian cells", "PROBLEM", 179, 194], ["large", "OBSERVATION_MODIFIER", 119, 124], ["amount", "OBSERVATION_MODIFIER", 125, 131], ["exogenous genes", "OBSERVATION", 135, 150], ["mammalian cells", "OBSERVATION", 179, 194]]], ["They can replicate in mammalian cells even though 10% of its genome was deleted.", [["cells", "ANATOMY", 32, 37], ["mammalian cells", "CELL", 22, 37], ["genome", "CELLULAR_COMPONENT", 61, 67], ["mammalian cells", "CELL_TYPE", 22, 37], ["mammalian cells", "OBSERVATION", 22, 37]]], ["In particular, both fowl pox and canary pox virus have a host-restrictive advantage compared with other vaccine viruses. consequently, animal vaccines have been developed using this system.Viruses vector vaccinesFor instance, rabies vaccine is a prototype of vector vaccine currently in use in several countries.", [["fowl pox", "ORGANISM", 20, 28], ["canary pox virus", "ORGANISM", 33, 49], ["rabies", "ORGANISM", 226, 232], ["fowl pox", "SPECIES", 20, 28], ["canary pox virus", "SPECIES", 33, 49], ["fowl pox", "SPECIES", 20, 28], ["canary pox virus", "SPECIES", 33, 49], ["rabies", "SPECIES", 226, 232], ["both fowl pox", "TREATMENT", 15, 28], ["canary pox virus", "PROBLEM", 33, 49], ["a host-restrictive advantage", "TREATMENT", 55, 83], ["other vaccine viruses", "TREATMENT", 98, 119], ["animal vaccines", "TREATMENT", 135, 150], ["this system", "TREATMENT", 177, 188], ["Viruses vector vaccines", "TREATMENT", 189, 212], ["rabies vaccine", "TREATMENT", 226, 240], ["a prototype of vector vaccine", "TREATMENT", 244, 273]]], ["An oral cowpox-rabies bait vaccine that contains G glycoprotein, a protective antigen of rabies virus, is able to prevent rabies of wild carnivores, such as foxes, raccoon, and coyotes.", [["oral", "ANATOMY", 3, 7], ["rabies of wild carnivores", "DISEASE", 122, 147], ["oral cowpox", "ORGANISM", 3, 14], ["rabies", "ORGANISM", 15, 21], ["G glycoprotein", "GENE_OR_GENE_PRODUCT", 49, 63], ["rabies virus", "ORGANISM", 89, 101], ["G glycoprotein", "PROTEIN", 49, 63], ["cowpox-rabies", "SPECIES", 8, 21], ["rabies virus", "SPECIES", 89, 101], ["rabies virus", "SPECIES", 89, 101], ["rabies", "SPECIES", 122, 128], ["An oral cowpox", "TREATMENT", 0, 14], ["rabies bait vaccine", "TREATMENT", 15, 34], ["G glycoprotein", "TREATMENT", 49, 63], ["rabies virus", "PROBLEM", 89, 101], ["cowpox", "OBSERVATION", 8, 14]]], ["A recombinant vaccinia virus containing the gene encoding the glycoprotein of rabies virus was able to administered many types of wildlife in order to protect against rabies (in use in EU, North America and Korea) .", [["rabies", "DISEASE", 167, 173], ["vaccinia virus", "ORGANISM", 14, 28], ["rabies virus", "ORGANISM", 78, 90], ["rabies", "ORGANISM", 167, 173], ["glycoprotein", "PROTEIN", 62, 74], ["rabies virus", "SPECIES", 78, 90], ["vaccinia virus", "SPECIES", 14, 28], ["rabies virus", "SPECIES", 78, 90], ["rabies", "SPECIES", 167, 173], ["A recombinant vaccinia virus", "TREATMENT", 0, 28], ["rabies virus", "PROBLEM", 78, 90], ["wildlife", "TREATMENT", 130, 138], ["vaccinia virus", "OBSERVATION", 14, 28]]], ["Interestingly, such vaccine can be used as a DIVA vaccine since fowls vaccinated with this virus do not form antibodies against matrix protein or nucleoprotein.", [["fowls", "ORGANISM", 64, 69], ["antibodies against matrix protein", "GENE_OR_GENE_PRODUCT", 109, 142], ["antibodies", "PROTEIN", 109, 119], ["matrix protein", "PROTEIN", 128, 142], ["nucleoprotein", "PROTEIN", 146, 159], ["fowls", "SPECIES", 64, 69], ["such vaccine", "TREATMENT", 15, 27], ["a DIVA vaccine", "TREATMENT", 43, 57], ["fowls vaccinated", "TREATMENT", 64, 80], ["this virus", "PROBLEM", 86, 96], ["nucleoprotein", "PROBLEM", 146, 159]]], ["For examples, the haemagglutinin (HA) gene of influenza virus is incorporated within a gene-deleted vaccine strain of fowl pox.", [["influenza virus", "DISEASE", 46, 61], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 18, 32], ["HA", "GENE_OR_GENE_PRODUCT", 34, 36], ["influenza virus", "ORGANISM", 46, 61], ["fowl pox", "ORGANISM", 118, 126], ["haemagglutinin (HA) gene", "DNA", 18, 42], ["influenza virus", "SPECIES", 46, 61], ["fowl pox", "SPECIES", 118, 126], ["influenza virus", "SPECIES", 46, 61], ["fowl pox", "SPECIES", 118, 126], ["the haemagglutinin (HA", "PROBLEM", 14, 36], ["influenza virus", "PROBLEM", 46, 61], ["fowl pox", "PROBLEM", 118, 126], ["influenza virus", "OBSERVATION", 46, 61]]], ["This provokes immune responses against HA protein in vaccinated chickens, resulted in protection against both diseases.", [["HA protein", "GENE_OR_GENE_PRODUCT", 39, 49], ["chickens", "ORGANISM", 64, 72], ["HA protein", "PROTEIN", 39, 49], ["chickens", "SPECIES", 64, 72], ["chickens", "SPECIES", 64, 72], ["immune responses", "PROBLEM", 14, 30], ["HA protein in vaccinated chickens", "PROBLEM", 39, 72], ["both diseases", "PROBLEM", 105, 118], ["diseases", "OBSERVATION", 110, 118]]], ["This vaccine has been shown to be effective in the field against morbidity and shedding of the influenza virus once it was used as a primary vaccine.", [["influenza", "DISEASE", 95, 104], ["influenza virus", "ORGANISM", 95, 110], ["influenza virus", "SPECIES", 95, 110], ["This vaccine", "TREATMENT", 0, 12], ["morbidity", "PROBLEM", 65, 74], ["the influenza virus", "PROBLEM", 91, 110], ["a primary vaccine", "TREATMENT", 131, 148]]], ["Administration of replication-incompetent glycoprotein B-expressing adenovirus induced Th1-based humoral and cellular immune response and provided effective protection against virulent pseudorabies challenge [20] .Vaccine designed for differentiating infected and vaccinated animals (DIVA vaccine)Conventional vaccines are developed to primarily control disease in animals upon infection with pathogenic microorganisms.", [["cellular", "ANATOMY", 109, 117], ["infection", "DISEASE", 378, 387], ["glycoprotein B", "GENE_OR_GENE_PRODUCT", 42, 56], ["adenovirus", "ORGANISM", 68, 78], ["Th1", "GENE_OR_GENE_PRODUCT", 87, 90], ["cellular", "CELL", 109, 117], ["pseudorabies", "ORGANISM", 185, 197], ["glycoprotein B", "PROTEIN", 42, 56], ["pseudorabies", "SPECIES", 185, 197], ["DIVA", "SPECIES", 284, 288], ["replication", "TREATMENT", 18, 29], ["incompetent glycoprotein B", "TREATMENT", 30, 56], ["adenovirus", "PROBLEM", 68, 78], ["effective protection", "TREATMENT", 147, 167], ["virulent pseudorabies challenge", "TREATMENT", 176, 207], ["Vaccine", "TREATMENT", 214, 221], ["infected and vaccinated animals", "TREATMENT", 251, 282], ["DIVA vaccine", "TREATMENT", 284, 296], ["Conventional vaccines", "TREATMENT", 297, 318], ["primarily control disease", "PROBLEM", 336, 361], ["infection", "PROBLEM", 378, 387], ["pathogenic microorganisms", "PROBLEM", 393, 418], ["humoral", "ANATOMY", 97, 104], ["cellular immune response", "OBSERVATION", 109, 133], ["infection", "OBSERVATION", 378, 387]]], ["Vaccines are increasingly assessed for their ability to reduce virus transmission and thus for the establishment of herd immunity [21] .", [["herd", "ORGANISM_SUBDIVISION", 116, 120], ["Vaccines", "TREATMENT", 0, 8], ["virus transmission", "TREATMENT", 63, 81]]], ["However, to control and eradicate animal viral disease, vaccine should not only prevent diseases but also reduce transmission of the virus from one animal to another.", [["viral disease", "DISEASE", 41, 54], ["animal viral disease", "PROBLEM", 34, 54], ["vaccine", "TREATMENT", 56, 63], ["diseases", "PROBLEM", 88, 96], ["the virus", "PROBLEM", 129, 138], ["viral disease", "OBSERVATION", 41, 54]]], ["If the transmission of virus was sufficiently reduced by vaccination, the given virus will eventually be eradicated from a defined population [21] .", [["virus", "PROBLEM", 23, 28], ["vaccination", "TREATMENT", 57, 68], ["virus", "PROBLEM", 80, 85]]], ["Marker vaccines have been constructed and allow infected animals to be distinguished from vaccinated animals when a companion diagnostic technique is applied [22] .", [["Marker vaccines", "TREATMENT", 0, 15], ["a companion diagnostic technique", "TREATMENT", 114, 146]]], ["A new concept vaccine, DIVA vaccine was established [21] , describing as a vaccine that carries at least one antigenic protein less than the corresponding wild type virus.", [["DIVA", "CHEMICAL", 23, 27], ["DIVA", "SIMPLE_CHEMICAL", 23, 27], ["wild type virus", "ORGANISM", 155, 170], ["antigenic protein", "PROTEIN", 109, 126], ["DIVA", "SPECIES", 23, 27], ["A new concept vaccine", "TREATMENT", 0, 21], ["DIVA vaccine", "TREATMENT", 23, 35], ["a vaccine", "TREATMENT", 73, 82]]], ["The DIVA vaccines are unable to produce antibodies against the protein of the deleted genes, but wild type virus invokes antibody against that protein so that the antibodies can be differentiated using proper diagnostic techniques.", [["wild type virus", "ORGANISM", 97, 112], ["antibodies", "PROTEIN", 40, 50], ["antibodies", "PROTEIN", 163, 173], ["The DIVA vaccines", "TREATMENT", 0, 17], ["the deleted genes", "PROBLEM", 74, 91], ["wild type virus", "PROBLEM", 97, 112], ["the antibodies", "TREATMENT", 159, 173]]], ["With this type of vaccine, the infected animals carrying wild type virus can be identified but not the vaccinated animals.", [["animals", "ORGANISM", 40, 47], ["wild type virus", "ORGANISM", 57, 72], ["vaccine", "TREATMENT", 18, 25], ["the infected animals carrying wild type virus", "PROBLEM", 27, 72], ["infected", "OBSERVATION_MODIFIER", 31, 39]]], ["The diagnostic tools can be used for monitoring transmission of wild type virus in populations vaccinated with a DIVA vaccine.", [["DIVA", "CHEMICAL", 113, 117], ["wild type virus", "ORGANISM", 64, 79], ["DIVA", "SPECIES", 113, 117], ["wild type virus", "PROBLEM", 64, 79], ["a DIVA vaccine", "TREATMENT", 111, 125]]], ["This type of vaccine is actively under development since genetic manipulation of pathogens can be easily achieved by great advanced techniques.", [["vaccine", "TREATMENT", 13, 20], ["pathogens", "PROBLEM", 81, 90]]], ["Additionally, DIVA vaccines are at the cutting edge of vaccine development since they include the deletion of genes responsible for virulence and have no way to revert to the virulent wild type in vaccinated animals.Vaccine designed for differentiating infected and vaccinated animals (DIVA vaccine)The first DIVA vaccine was used to differ between infected and vaccinated pigs for pseudorabies [22] , demonstrating that vaccination reduces the transmissibility of wild type virus in a population as the result of shortening the duration of virus shedding in pigs upon experimental challenge infection.", [["DIVA", "CHEMICAL", 14, 18], ["DIVA", "CHEMICAL", 309, 313], ["infection", "DISEASE", 592, 601], ["DIVA", "CANCER", 309, 313], ["pigs", "ORGANISM", 373, 377], ["pseudorabies", "ORGANISM", 382, 394], ["wild type virus", "ORGANISM", 465, 480], ["pigs", "ORGANISM", 559, 563], ["pigs", "SPECIES", 373, 377], ["pigs", "SPECIES", 559, 563], ["pigs", "SPECIES", 373, 377], ["pseudorabies", "SPECIES", 382, 394], ["pigs", "SPECIES", 559, 563], ["DIVA vaccines", "TREATMENT", 14, 27], ["vaccine development", "TREATMENT", 55, 74], ["virulence", "PROBLEM", 132, 141], ["Vaccine", "TREATMENT", 216, 223], ["DIVA vaccine", "TREATMENT", 286, 298], ["The first DIVA vaccine", "TREATMENT", 299, 321], ["pseudorabies", "PROBLEM", 382, 394], ["vaccination", "TREATMENT", 421, 432], ["wild type virus", "PROBLEM", 465, 480], ["virus shedding", "PROBLEM", 541, 555], ["experimental challenge infection", "PROBLEM", 569, 601], ["infection", "OBSERVATION", 592, 601]]], ["For bovine herpesvirus type 1 (BHV-1), in vaccination-challenge experiments, both a live and an inactivated glycoprotein E-negative DIVA vaccine and a glycoprotein Dsubunit DIVA vaccine have been demonstrated to reduce virus shedding after intranasal challenge of BHV-1 [23, 24] .", [["DIVA", "CHEMICAL", 132, 136], ["DIVA", "CHEMICAL", 173, 177], ["bovine herpesvirus type 1", "ORGANISM", 4, 29], ["BHV-1", "ORGANISM", 31, 36], ["BHV-1", "ORGANISM", 264, 269], ["glycoprotein", "PROTEIN", 151, 163], ["bovine", "SPECIES", 4, 10], ["herpesvirus type 1", "SPECIES", 11, 29], ["BHV-1", "SPECIES", 31, 36], ["bovine herpesvirus type 1 (BHV-1", "SPECIES", 4, 36], ["DIVA", "SPECIES", 132, 136], ["BHV-1", "SPECIES", 264, 269], ["bovine herpesvirus type", "TEST", 4, 27], ["BHV", "TEST", 31, 34], ["an inactivated glycoprotein E-negative DIVA vaccine", "TREATMENT", 93, 144], ["a glycoprotein Dsubunit DIVA vaccine", "TREATMENT", 149, 185], ["virus shedding", "PROBLEM", 219, 233], ["intranasal challenge of BHV", "TREATMENT", 240, 267]]], ["For classical swine fever (CSF) that is the most significant contagious swine diseases over the world, attenuated CSF vaccine is used in countries where this disease is enzootic after an outbreak, but is not used for CSF free countries [25] .", [["swine fever", "DISEASE", 14, 25], ["CSF", "DISEASE", 27, 30], ["swine diseases", "DISEASE", 72, 86], ["classical swine fever", "ORGANISM", 4, 25], ["CSF", "GENE_OR_GENE_PRODUCT", 114, 117], ["swine fever", "SPECIES", 14, 25], ["swine", "SPECIES", 72, 77], ["swine", "SPECIES", 72, 77], ["classical swine fever (CSF)", "PROBLEM", 4, 31], ["significant contagious swine diseases", "PROBLEM", 49, 86], ["attenuated CSF vaccine", "TREATMENT", 103, 125], ["this disease", "PROBLEM", 153, 165], ["enzootic", "PROBLEM", 169, 177], ["significant", "OBSERVATION_MODIFIER", 49, 60], ["contagious", "OBSERVATION_MODIFIER", 61, 71], ["enzootic", "OBSERVATION_MODIFIER", 169, 177]]], ["Subunit vaccine composed of gE was produced in the baculovirus expression system, along with a discriminatory enzyme-linked immunosorbent assay (ELISA) [26] .", [["gE", "ORGANISM", 28, 30], ["baculovirus", "ORGANISM", 51, 62], ["gE", "PROTEIN", 28, 30], ["enzyme", "PROTEIN", 110, 116], ["baculovirus", "SPECIES", 51, 62], ["Subunit vaccine", "TREATMENT", 0, 15], ["a discriminatory enzyme-linked immunosorbent assay", "TEST", 93, 143]]], ["This DIVA vaccine can be used for emergency vaccination in the areas that CSF is newly developing, but it is not extensively used in the field.", [["DIVA", "CHEMICAL", 5, 9], ["CSF", "GENE_OR_GENE_PRODUCT", 74, 77], ["This DIVA vaccine", "TREATMENT", 0, 17], ["emergency vaccination", "TREATMENT", 34, 55]]], ["Another strategy utilized in countries with vaccinated pigs but no outbreaks any more, is to switch from live to subunit vaccine before completely stopping vaccination.", [["pigs", "ORGANISM", 55, 59], ["pigs", "SPECIES", 55, 59], ["pigs", "SPECIES", 55, 59], ["vaccinated pigs", "TREATMENT", 44, 59], ["subunit vaccine", "TREATMENT", 113, 128]]], ["This strategy would have applied in Korea, but may not be adopted in the future because World Health Organisation for Animal Health in May 2013 could announce that countries using live vaccines without outbreaks may be recognized as CSF-free countries.", [["live vaccines", "TREATMENT", 180, 193], ["outbreaks", "PROBLEM", 202, 211]]], ["The potential DIVA vaccine for CSF virus (CSFV) was a gEdeleted pseudorabies virus vector that expressed the E2 subunit of CSFV [27] .", [["DIVA", "CANCER", 14, 18], ["CSF virus", "ORGANISM", 31, 40], ["CSFV", "ORGANISM", 42, 46], ["gEdeleted", "ORGANISM", 54, 63], ["pseudorabies virus", "ORGANISM", 64, 82], ["E2", "GENE_OR_GENE_PRODUCT", 109, 111], ["CSFV", "ORGANISM", 123, 127], ["E2 subunit", "PROTEIN", 109, 119], ["gEdeleted pseudorabies virus", "SPECIES", 54, 82], ["CSF virus", "SPECIES", 31, 40], ["CSFV", "SPECIES", 42, 46], ["gEdeleted pseudorabies virus", "SPECIES", 54, 82], ["CSFV", "SPECIES", 123, 127], ["The potential DIVA vaccine", "TREATMENT", 0, 26], ["CSF virus", "PROBLEM", 31, 40], ["CSFV", "PROBLEM", 42, 46], ["a gEdeleted pseudorabies virus vector", "TREATMENT", 52, 89]]], ["This vaccine prevents the transmission of challenged CSFV to pig in contact with the vaccinated and challenged pigs.", [["CSFV", "ORGANISM", 53, 57], ["pig", "ORGANISM", 61, 64], ["pigs", "ORGANISM", 111, 115], ["CSFV", "SPECIES", 53, 57], ["pig", "SPECIES", 61, 64], ["pigs", "SPECIES", 111, 115], ["CSFV", "SPECIES", 53, 57], ["pig", "SPECIES", 61, 64], ["pigs", "SPECIES", 111, 115], ["This vaccine", "TREATMENT", 0, 12]]], ["The differentiation of infected from vaccinated pigs can probably be based on a companion diagnostic test that detects only antibody against the viral protein E. In case of herpes virus, thymidine kinase (TK)-deleted virus is able to infect neurons but cannot replicate and then cause disease since the herpes virus requires TK to return from latency.", [["neurons", "ANATOMY", 241, 248], ["herpes virus", "DISEASE", 173, 185], ["thymidine", "CHEMICAL", 187, 196], ["herpes", "DISEASE", 303, 309], ["thymidine", "CHEMICAL", 187, 196], ["pigs", "ORGANISM", 48, 52], ["herpes virus", "ORGANISM", 173, 185], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 187, 203], ["neurons", "CELL", 241, 248], ["herpes virus", "ORGANISM", 303, 315], ["TK", "ORGANISM", 325, 327], ["viral protein", "PROTEIN", 145, 158], ["thymidine kinase", "PROTEIN", 187, 203], ["pigs", "SPECIES", 48, 52], ["herpes virus", "SPECIES", 173, 185], ["pigs", "SPECIES", 48, 52], ["herpes virus", "SPECIES", 173, 185], ["herpes virus", "SPECIES", 303, 315], ["vaccinated pigs", "TREATMENT", 37, 52], ["a companion diagnostic test", "TEST", 78, 105], ["antibody", "TEST", 124, 132], ["the viral protein E.", "PROBLEM", 141, 161], ["herpes virus", "PROBLEM", 173, 185], ["thymidine kinase (TK)", "TEST", 187, 208], ["deleted virus", "PROBLEM", 209, 222], ["disease", "PROBLEM", 285, 292], ["the herpes virus", "PROBLEM", 299, 315], ["infected", "OBSERVATION_MODIFIER", 23, 31]]], ["Such vaccine confers effective protection and blocks http://www.ecevr.org/ http://dx.doi.org/10.7774/cevr.2012.1.1.18 cell invasion by virulent virus and prevents establishment of a persistent carrier status.", [["cell", "ANATOMY", 118, 122], ["cell", "CELL", 118, 122], ["Such vaccine", "TREATMENT", 0, 12], ["cell invasion", "PROBLEM", 118, 131], ["virulent virus", "PROBLEM", 135, 149], ["a persistent carrier status", "PROBLEM", 180, 207], ["virulent virus", "OBSERVATION", 135, 149], ["persistent", "OBSERVATION_MODIFIER", 182, 192]]], ["These gene-deleted vaccines for Aujeszky's diseases (AD) have been used in Korea, the US and the part of the EU, which contributed to eradication of AD.", [["Aujeszky's diseases", "DISEASE", 32, 51], ["AD", "DISEASE", 53, 55], ["AD", "DISEASE", 149, 151], ["Aujeszky", "ORGANISM", 32, 40], ["Aujeszky", "SPECIES", 32, 40], ["Aujeszky", "SPECIES", 32, 40], ["These gene-deleted vaccines", "TREATMENT", 0, 27], ["Aujeszky's diseases", "PROBLEM", 32, 51], ["the US", "TEST", 82, 88], ["AD", "PROBLEM", 149, 151]]], ["The DIVA concept used in veterinary vaccines may prove to be an important and useful strategy for the future development of human vaccines [21] .Vaccine designed for differentiating infected and vaccinated animals (DIVA vaccine)For examples, the immunogenicity of VLP vaccine expressing HA and M1 proteins of H9N2 AIV after immunization for chickens was measured by ELISA using the expressed nucleocapsid antigen.", [["human", "ORGANISM", 124, 129], ["DIVA vaccine", "ORGANISM", 215, 227], ["VLP", "ORGANISM", 264, 267], ["HA", "GENE_OR_GENE_PRODUCT", 287, 289], ["H9N2 AIV", "ORGANISM", 309, 317], ["chickens", "ORGANISM", 341, 349], ["nucleocapsid antigen", "GENE_OR_GENE_PRODUCT", 392, 412], ["HA", "PROTEIN", 287, 289], ["M1 proteins", "PROTEIN", 294, 305], ["nucleocapsid antigen", "PROTEIN", 392, 412], ["human", "SPECIES", 124, 129], ["H9N2 AIV", "SPECIES", 309, 317], ["chickens", "SPECIES", 341, 349], ["human", "SPECIES", 124, 129], ["AIV", "SPECIES", 314, 317], ["chickens", "SPECIES", 341, 349], ["The DIVA concept", "TREATMENT", 0, 16], ["veterinary vaccines", "TREATMENT", 25, 44], ["human vaccines", "TREATMENT", 124, 138], ["Vaccine", "TREATMENT", 145, 152], ["DIVA vaccine", "TREATMENT", 215, 227], ["VLP vaccine", "TREATMENT", 264, 275], ["HA", "PROBLEM", 287, 289], ["H9N2 AIV", "TREATMENT", 309, 317], ["immunization", "TREATMENT", 324, 336], ["chickens", "PROBLEM", 341, 349], ["ELISA", "TEST", 366, 371]]], ["Since the protein was not carried on the surface of the VLP vaccine, this showed the differentiation of AIV-infected chickens from vaccinated ones [28] .", [["surface", "ANATOMY", 41, 48], ["AIV-infected", "DISEASE", 104, 116], ["surface", "CELLULAR_COMPONENT", 41, 48], ["AIV", "ORGANISM", 104, 107], ["chickens", "ORGANISM", 117, 125], ["chickens", "SPECIES", 117, 125], ["AIV", "SPECIES", 104, 107], ["chickens", "SPECIES", 117, 125], ["the VLP vaccine", "TREATMENT", 52, 67], ["AIV", "PROBLEM", 104, 107], ["infected chickens from vaccinated ones", "PROBLEM", 108, 146], ["infected", "OBSERVATION_MODIFIER", 108, 116]]], ["Nonstructural protein 1 (NS1) of West Nile virus (WNV) can be the most reliable indicator of past infection in animals.", [["infection", "DISEASE", 98, 107], ["Nonstructural protein 1", "GENE_OR_GENE_PRODUCT", 0, 23], ["NS1", "GENE_OR_GENE_PRODUCT", 25, 28], ["West Nile virus", "ORGANISM", 33, 48], ["WNV", "ORGANISM", 50, 53], ["Nonstructural protein 1", "PROTEIN", 0, 23], ["NS1", "PROTEIN", 25, 28], ["West Nile virus", "SPECIES", 33, 48], ["West Nile virus", "SPECIES", 33, 48], ["WNV", "SPECIES", 50, 53], ["Nonstructural protein", "TEST", 0, 21], ["West Nile virus (WNV", "PROBLEM", 33, 53], ["past infection in animals", "PROBLEM", 93, 118], ["infection", "OBSERVATION", 98, 107]]], ["The NS1competitive ELISA using a monoclonal antibody against the expressed NS1 demonstrated the capability of differentiating wild type virus infected animals from the animals vaccinated with killed WNV vaccine.", [["NS1", "GENE_OR_GENE_PRODUCT", 75, 78], ["wild type virus", "ORGANISM", 126, 141], ["animals", "ORGANISM", 151, 158], ["WNV", "ORGANISM", 199, 202], ["monoclonal antibody", "PROTEIN", 33, 52], ["NS1", "PROTEIN", 75, 78], ["WNV", "SPECIES", 199, 202], ["The NS1competitive ELISA", "TEST", 0, 24], ["a monoclonal antibody", "TREATMENT", 31, 52], ["wild type virus infected animals", "PROBLEM", 126, 158]]], ["This would be considered as a potential DIVA means capable of monitoring WNV transmission [29] .", [["WNV", "ORGANISM", 73, 76], ["WNV", "SPECIES", 73, 76], ["monitoring WNV transmission", "TEST", 62, 89]]], ["The VLP vaccine of highly pathogenic avian influenza (HPAI) was recently constructed and immunized into specific pathogen free chickens.", [["avian influenza", "DISEASE", 37, 52], ["HPAI", "DISEASE", 54, 58], ["VLP", "ORGANISM", 4, 7], ["highly pathogenic", "ORGANISM", 19, 36], ["avian influenza", "ORGANISM", 37, 52], ["HPAI", "ORGANISM", 54, 58], ["chickens", "ORGANISM", 127, 135], ["avian influenza", "SPECIES", 37, 52], ["chickens", "SPECIES", 127, 135], ["HPAI", "SPECIES", 54, 58], ["chickens", "SPECIES", 127, 135], ["The VLP vaccine", "TREATMENT", 0, 15], ["highly pathogenic avian influenza (HPAI", "PROBLEM", 19, 58]]], ["Such vaccination induced high levels of haemagglutination and neuraminidase inhibition in the vaccinated chickens as compared to control group.", [["neuraminidase", "GENE_OR_GENE_PRODUCT", 62, 75], ["chickens", "ORGANISM", 105, 113], ["neuraminidase", "PROTEIN", 62, 75], ["chickens", "SPECIES", 105, 113], ["chickens", "SPECIES", 105, 113], ["Such vaccination", "TREATMENT", 0, 16], ["high levels of haemagglutination", "PROBLEM", 25, 57], ["neuraminidase inhibition", "TREATMENT", 62, 86], ["the vaccinated chickens", "TREATMENT", 90, 113]]], ["Furthermore, it was possible to differentiate VLP-vaccinated chickens from the infected ones using a commercial ELISA kit [30] .Genetically engineered viral vaccinesWith rich information available on viral genomes along with the advancement of available genetic tools, scientists are able to deliberately manipulate viral genetic material in order to create attenuated live or inactivated viruses.", [["VLP", "ORGANISM", 46, 49], ["chickens", "ORGANISM", 61, 69], ["viral genomes", "DNA", 200, 213], ["chickens", "SPECIES", 61, 69], ["chickens", "SPECIES", 61, 69], ["VLP", "PROBLEM", 46, 49], ["vaccinated chickens", "PROBLEM", 50, 69], ["viral genomes", "TREATMENT", 200, 213], ["viral genetic material", "PROBLEM", 316, 338], ["inactivated viruses", "PROBLEM", 377, 396]]], ["One of the great advancements in this field is the ability to create an infectious clone that contains a full viral genome sequence on a bacterial plasmid.", [["plasmid", "ANATOMY", 147, 154], ["clone", "CELL", 83, 88], ["viral genome sequence", "DNA", 110, 131], ["bacterial plasmid", "DNA", 137, 154], ["an infectious clone", "PROBLEM", 69, 88], ["a full viral genome sequence", "PROBLEM", 103, 131], ["a bacterial plasmid", "TREATMENT", 135, 154], ["great", "OBSERVATION_MODIFIER", 11, 16], ["advancements", "OBSERVATION", 17, 29], ["infectious", "OBSERVATION", 72, 82]]], ["The viral genes on the infectious clone can be easily manipulated and transfected into susceptible cells in order to engineer genetically manipulated virus.", [["clone", "ANATOMY", 34, 39], ["cells", "ANATOMY", 99, 104], ["clone", "CELL", 34, 39], ["cells", "CELL", 99, 104], ["viral genes", "DNA", 4, 15], ["susceptible cells", "CELL_TYPE", 87, 104], ["The viral genes", "PROBLEM", 0, 15], ["the infectious clone", "PROBLEM", 19, 39], ["susceptible cells", "PROBLEM", 87, 104], ["viral genes", "OBSERVATION", 4, 15]]], ["With this technique, a chimeric virus shuffled with different viral genomes can be generated for the desired outcome.", [["viral genomes", "DNA", 62, 75], ["this technique", "TREATMENT", 5, 19], ["a chimeric virus", "PROBLEM", 21, 37], ["different viral genomes", "PROBLEM", 52, 75]]], ["However, there is a concern that such virus may become a recombinant with field strains and consequently pathogenicity may be restored.Genetically engineered viral vaccinesFor examples, TK-deleted BHV vaccine can be potentially infectious and found to be latent.", [["BHV", "ORGANISM", 197, 200], ["BHV", "SPECIES", 197, 200], ["such virus", "PROBLEM", 33, 43], ["field strains", "PROBLEM", 74, 87], ["Genetically engineered viral vaccines", "TREATMENT", 135, 172], ["TK-deleted BHV vaccine", "TREATMENT", 186, 208], ["infectious", "PROBLEM", 228, 238], ["viral vaccines", "OBSERVATION", 158, 172], ["latent", "OBSERVATION", 255, 261]]], ["For the safety issues, it was suggested that deletion of multiple genes enhances the stability of genetically modified viruses [31] .", [["multiple genes", "DNA", 57, 71], ["deletion of multiple genes enhances", "PROBLEM", 45, 80], ["genetically modified viruses", "PROBLEM", 98, 126]]], ["Chimeric circovirus type 1-2 vaccine was developed by inserting immunogenic capsid gene of circovirus type 2 into the backbone of nonpathogenic circovirus type 1, resulting in protection pigs challenged with virulent circovirus type 2.", [["Chimeric circovirus type 1-2", "ORGANISM", 0, 28], ["circovirus type 2", "ORGANISM", 91, 108], ["nonpathogenic circovirus type 1", "ORGANISM", 130, 161], ["pigs", "ORGANISM", 187, 191], ["circovirus type 2", "ORGANISM", 217, 234], ["immunogenic capsid gene", "DNA", 64, 87], ["circovirus type 1", "SPECIES", 9, 26], ["nonpathogenic circovirus", "SPECIES", 130, 154], ["pigs", "SPECIES", 187, 191], ["virulent circovirus", "SPECIES", 208, 227], ["nonpathogenic circovirus type 1", "SPECIES", 130, 161], ["pigs", "SPECIES", 187, 191], ["Chimeric circovirus type 1", "PROBLEM", 0, 26], ["circovirus type 2", "PROBLEM", 91, 108], ["nonpathogenic circovirus type 1", "PROBLEM", 130, 161], ["protection pigs", "TREATMENT", 176, 191], ["virulent circovirus type 2", "PROBLEM", 208, 234], ["circovirus", "OBSERVATION", 9, 19], ["circovirus", "OBSERVATION", 91, 101], ["backbone", "ANATOMY_MODIFIER", 118, 126], ["nonpathogenic circovirus", "OBSERVATION", 130, 154], ["virulent circovirus", "OBSERVATION", 208, 227]]], ["Using reverse-genetics, a bivalent vaccine expressing the H and N gene of different AIVs was constructed on a single NDV background.", [["H", "GENE_OR_GENE_PRODUCT", 58, 59], ["AIVs", "CANCER", 84, 88], ["NDV", "ORGANISM", 117, 120], ["H and N gene", "DNA", 58, 70], ["AIVs", "DNA", 84, 88], ["NDV", "SPECIES", 117, 120], ["a bivalent vaccine", "TREATMENT", 24, 42], ["the H and N gene of different AIVs", "TREATMENT", 54, 88]]], ["This chimeric virus was able to form strong immunity against both field influenza and NDV [32] .", [["influenza", "DISEASE", 72, 81], ["NDV", "ORGANISM", 86, 89], ["NDV", "SPECIES", 86, 89], ["NDV", "SPECIES", 86, 89], ["This chimeric virus", "PROBLEM", 0, 19]]], ["This concept was also adapted to develop AIV vaccine, where the H5 gene derived from H5N1 virus was modified by deletion of polybasic amino acids and combined with the N3 gene of H2N3 virus.", [["amino acids", "CHEMICAL", 134, 145], ["amino acids", "CHEMICAL", 134, 145], ["AIV", "ORGANISM", 41, 44], ["H5N1 virus", "ORGANISM", 85, 95], ["amino acids", "AMINO_ACID", 134, 145], ["H2N3 virus", "ORGANISM", 179, 189], ["H5 gene", "DNA", 64, 71], ["polybasic amino acids", "PROTEIN", 124, 145], ["N3 gene", "DNA", 168, 175], ["H5N1 virus", "SPECIES", 85, 95], ["AIV", "SPECIES", 41, 44], ["H5N1 virus", "SPECIES", 85, 95], ["H2N3 virus", "SPECIES", 179, 189], ["AIV vaccine", "TREATMENT", 41, 52], ["the H5 gene", "TREATMENT", 60, 71], ["H5N1 virus", "PROBLEM", 85, 95], ["polybasic amino acids", "PROBLEM", 124, 145], ["H2N3 virus", "PROBLEM", 179, 189]]], ["The recombinant genes were then introduced into the backbone of the H1N1 genome.", [["recombinant genes", "DNA", 4, 21], ["H1N1 genome", "DNA", 68, 79], ["The recombinant genes", "TREATMENT", 0, 21], ["recombinant genes", "OBSERVATION", 4, 21], ["backbone", "ANATOMY_MODIFIER", 52, 60], ["H1N1 genome", "OBSERVATION", 68, 79]]], ["The recombinant virus expressing H5 and N3 proteins derived from the other strains provided protection for chickens and ducks from HPAI virus strain, H5N1.", [["H5N1", "DISEASE", 150, 154], ["recombinant virus", "ORGANISM", 4, 21], ["H5", "ORGANISM", 33, 35], ["N3", "GENE_OR_GENE_PRODUCT", 40, 42], ["chickens", "ORGANISM", 107, 115], ["ducks", "ORGANISM", 120, 125], ["HPAI virus strain", "ORGANISM", 131, 148], ["H5N1", "ORGANISM", 150, 154], ["H5 and N3 proteins", "PROTEIN", 33, 51], ["chickens", "SPECIES", 107, 115], ["ducks", "SPECIES", 120, 125], ["HPAI virus", "SPECIES", 131, 141], ["chickens", "SPECIES", 107, 115], ["HPAI virus", "SPECIES", 131, 141], ["The recombinant virus", "PROBLEM", 0, 21], ["H5", "PROBLEM", 33, 35], ["N3 proteins", "PROBLEM", 40, 51], ["the other strains", "PROBLEM", 65, 82], ["chickens", "PROBLEM", 107, 115], ["HPAI virus strain", "PROBLEM", 131, 148], ["H5N1", "PROBLEM", 150, 154], ["virus", "OBSERVATION", 16, 21]]], ["This vaccine is licensed in some Asian countries including Korea.", [["This vaccine", "TREATMENT", 0, 12]]], ["This concept is expanding in the development of vaccine against several viral diseases.", [["viral diseases", "DISEASE", 72, 86], ["vaccine", "TREATMENT", 48, 55], ["several viral diseases", "PROBLEM", 64, 86], ["expanding", "OBSERVATION_MODIFIER", 16, 25], ["viral diseases", "OBSERVATION", 72, 86]]], ["The genome of virulent porcine reproductive and respiratory syndrome virus (PRRSV), a major agent causing devastating diseases in the swine industry, was reverse-genetically engineered into plasmid DNA to form an infectious clone.", [["plasmid", "ANATOMY", 190, 197], ["clone", "ANATOMY", 224, 229], ["porcine reproductive and respiratory syndrome", "DISEASE", 23, 68], ["virulent", "ORGANISM", 14, 22], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 23, 74], ["PRRSV", "ORGANISM", 76, 81], ["DNA", "CELLULAR_COMPONENT", 198, 201], ["clone", "CELL", 224, 229], ["plasmid DNA", "DNA", 190, 201], ["porcine reproductive and respiratory syndrome virus", "SPECIES", 23, 74], ["PRRSV", "SPECIES", 76, 81], ["swine", "SPECIES", 134, 139], ["porcine reproductive and respiratory syndrome virus", "SPECIES", 23, 74], ["PRRSV", "SPECIES", 76, 81], ["swine", "SPECIES", 134, 139], ["virulent porcine reproductive", "PROBLEM", 14, 43], ["respiratory syndrome virus", "PROBLEM", 48, 74], ["devastating diseases", "PROBLEM", 106, 126], ["plasmid DNA", "TREATMENT", 190, 201], ["an infectious clone", "PROBLEM", 210, 229], ["virulent porcine", "OBSERVATION_MODIFIER", 14, 30], ["reproductive", "OBSERVATION_MODIFIER", 31, 43], ["respiratory syndrome virus", "OBSERVATION", 48, 74], ["devastating", "OBSERVATION_MODIFIER", 106, 117], ["diseases", "OBSERVATION", 118, 126], ["infectious", "OBSERVATION", 213, 223]]], ["The genome was then altered at positions N34 and N51 of GP5 (changing from glycosylation to deglycosylation) resulting in epitopes that trigger neutralizing antibody.", [["genome", "CELLULAR_COMPONENT", 4, 10], ["GP5", "GENE_OR_GENE_PRODUCT", 56, 59], ["GP5", "PROTEIN", 56, 59], ["epitopes", "PROTEIN", 122, 130], ["neutralizing antibody", "PROTEIN", 144, 165], ["GP5", "PROBLEM", 56, 59], ["glycosylation to deglycosylation", "TREATMENT", 75, 107], ["epitopes", "PROBLEM", 122, 130], ["neutralizing antibody", "PROBLEM", 144, 165], ["genome", "OBSERVATION", 4, 10], ["neutralizing antibody", "OBSERVATION", 144, 165]]], ["This experimental vaccine has been known to produce a high titer of neutralizing antibody against even wild type virus as well as double mutant virus, suggesting that crossprotection may occur because of high titers of antibody [33] .", [["wild type virus", "ORGANISM", 103, 118], ["double mutant virus", "ORGANISM", 130, 149], ["neutralizing antibody", "PROTEIN", 68, 89], ["This experimental vaccine", "TREATMENT", 0, 25], ["a high titer of neutralizing antibody", "PROBLEM", 52, 89], ["wild type virus", "PROBLEM", 103, 118], ["double mutant virus", "PROBLEM", 130, 149], ["crossprotection", "PROBLEM", 167, 182], ["high titers of antibody", "PROBLEM", 204, 227]]], ["This strategy was supported by evidence that double mutant chimeric virus of US strain and Korean LMY strain was constructed and reproduced immune responses in our laboratory.DNA vaccinesNaked DNA-based immunization has become a relatively novel approach in developing vaccines since the concept was reported in the 1990s.", [["mutant chimeric virus", "ORGANISM", 52, 73], ["US strain", "ORGANISM", 77, 86], ["Korean LMY strain", "ORGANISM", 91, 108], ["DNA", "CELLULAR_COMPONENT", 175, 178], ["DNA", "CELLULAR_COMPONENT", 193, 196], ["Korean LMY strain", "SPECIES", 91, 108], ["double mutant chimeric virus of US strain", "PROBLEM", 45, 86], ["Korean LMY strain", "PROBLEM", 91, 108], ["DNA vaccines", "TREATMENT", 175, 187], ["based immunization", "TREATMENT", 197, 215], ["developing vaccines", "TREATMENT", 258, 277], ["chimeric virus", "OBSERVATION", 59, 73]]], ["DNA vaccines have since been produced for a variety of diseases and tested in laboratories with considerable successes.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA vaccines", "TREATMENT", 0, 12], ["a variety of diseases", "PROBLEM", 42, 63], ["diseases", "OBSERVATION", 55, 63]]], ["They have successfully elicited efficient immunity to the antigen encoded by introduced genetic materials, which offer the potential for further advancement in the production of effective vaccine [34] . of intact antigen, the problem associated with the reversion of virulence can be minimized.", [["further advancement", "TREATMENT", 137, 156], ["effective vaccine", "TREATMENT", 178, 195], ["intact antigen", "PROBLEM", 206, 220], ["virulence", "PROBLEM", 267, 276]]], ["In addition, DNA vaccines induce strong immunity conferring long lasting immunity associated with memory cells against a variety of bacteria and parasites [35] .", [["memory cells", "ANATOMY", 98, 110], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["memory cells", "CELL", 98, 110], ["memory cells", "CELL_TYPE", 98, 110], ["DNA vaccines", "TREATMENT", 13, 25], ["memory cells", "PROBLEM", 98, 110], ["bacteria", "PROBLEM", 132, 140], ["parasites", "PROBLEM", 145, 154]]], ["The marked progress in recombinant DNA techniques over the past decades made it possible to generate a variety of DNA vaccines for various types of infectious agents.", [["DNA", "CELLULAR_COMPONENT", 35, 38], ["DNA", "CELLULAR_COMPONENT", 114, 117], ["recombinant DNA techniques", "TREATMENT", 23, 49], ["DNA vaccines", "TREATMENT", 114, 126], ["infectious agents", "TREATMENT", 148, 165], ["marked", "OBSERVATION_MODIFIER", 4, 10], ["infectious", "OBSERVATION", 148, 158]]], ["In recent years, DNA vaccine has become one of the most promising strategies for developing safe and efficient alternative vaccines, in particular for targeting highly virulent viral diseases.", [["viral diseases", "DISEASE", 177, 191], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["DNA vaccine", "TREATMENT", 17, 28], ["efficient alternative vaccines", "TREATMENT", 101, 131], ["highly virulent viral diseases", "PROBLEM", 161, 191], ["virulent", "OBSERVATION_MODIFIER", 168, 176], ["viral diseases", "OBSERVATION", 177, 191]]], ["An advanced procedure for enhancing the immune response produced by DNA vaccines has recently been achieved by targeting desired antigens to specific antigen presenting cells (APC).", [["antigen presenting cells", "ANATOMY", 150, 174], ["APC", "ANATOMY", 176, 179], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["antigen presenting", "GENE_OR_GENE_PRODUCT", 150, 168], ["cells", "CELL", 169, 174], ["APC", "CELL", 176, 179], ["antigen presenting cells", "CELL_TYPE", 150, 174], ["APC", "CELL_TYPE", 176, 179], ["An advanced procedure", "TREATMENT", 0, 21], ["DNA vaccines", "TREATMENT", 68, 80]]], ["Alternatively, many attenuated bacteria are specifically targeted to APCs responsible for immune reactions at designated locations, suggesting that they can be used to specifically deliver DNA to specific loci [35] .", [["APCs", "ANATOMY", 69, 73], ["APCs", "CELL", 69, 73], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["APCs", "CELL_TYPE", 69, 73], ["many attenuated bacteria", "PROBLEM", 15, 39], ["APCs", "TEST", 69, 73], ["immune reactions", "PROBLEM", 90, 106], ["many", "OBSERVATION_MODIFIER", 15, 19], ["attenuated", "OBSERVATION_MODIFIER", 20, 30], ["bacteria", "OBSERVATION", 31, 39]]], ["Such bacterial vectors include attenuated strains of Shigella, Listeria, and Salmonella in which the expression of the recombinant antigens are under the control of a eukaryotic promoter [36] .", [["Shigella, Listeria", "ORGANISM", 53, 71], ["recombinant antigens", "PROTEIN", 119, 139], ["eukaryotic promoter", "DNA", 167, 186], ["Salmonella", "SPECIES", 77, 87], ["Such bacterial vectors", "PROBLEM", 0, 22], ["attenuated strains", "PROBLEM", 31, 49], ["Shigella", "PROBLEM", 53, 61], ["Listeria", "PROBLEM", 63, 71], ["Salmonella", "PROBLEM", 77, 87], ["the recombinant antigens", "PROBLEM", 115, 139], ["Shigella", "OBSERVATION_MODIFIER", 53, 61]]], ["Unlike the recombinant protein vaccine alone, the recombinant vector vaccines have resulted in highly immunogenic response to foreign proteins.", [["foreign proteins", "PROTEIN", 126, 142], ["the recombinant protein vaccine", "TREATMENT", 7, 38], ["the recombinant vector vaccines", "TREATMENT", 46, 77], ["foreign proteins", "PROBLEM", 126, 142], ["foreign proteins", "OBSERVATION", 126, 142]]], ["A vaccine retain the advantages associated with using live vectors, such as immunogenicity and ensuring delivery of the antigen in its native conformation, without many of the safety concerns associated with live-attenuated vectors [37] .", [["A vaccine", "TREATMENT", 0, 9], ["live vectors", "TREATMENT", 54, 66]]], ["Immunization with DNA vaccine is a vaccination approach that is being widely investigated to protect against a large number of infectious diseases.DNA vaccinesFor examples, the VP1 gene of FMDV carries critical epitopes for inducing immune response to neutralize FMDV.", [["infectious diseases", "DISEASE", 127, 146], ["DNA", "CELLULAR_COMPONENT", 18, 21], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["VP1", "GENE_OR_GENE_PRODUCT", 177, 180], ["FMDV", "ORGANISM", 189, 193], ["FMDV", "ORGANISM", 263, 267], ["VP1 gene", "DNA", 177, 185], ["FMDV", "SPECIES", 189, 193], ["FMDV", "SPECIES", 263, 267], ["FMDV", "SPECIES", 189, 193], ["FMDV", "SPECIES", 263, 267], ["Immunization", "TREATMENT", 0, 12], ["DNA vaccine", "TREATMENT", 18, 29], ["a vaccination approach", "TREATMENT", 33, 55], ["infectious diseases", "PROBLEM", 127, 146], ["DNA vaccines", "TREATMENT", 147, 159], ["the VP1 gene of FMDV", "TREATMENT", 173, 193], ["critical epitopes", "PROBLEM", 202, 219], ["neutralize FMDV", "TREATMENT", 252, 267], ["infectious", "OBSERVATION", 127, 137]]], ["DNA vaccine containing the VP1 epitopes of FMDV has the ability to elicit both FMDV specific T cell proliferation and neutralizing antibody against FMD in swine [38] .", [["T cell", "ANATOMY", 93, 99], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["FMDV", "ORGANISM", 43, 47], ["FMDV", "ORGANISM", 79, 83], ["T cell", "CELL", 93, 99], ["VP1 epitopes", "PROTEIN", 27, 39], ["neutralizing antibody", "PROTEIN", 118, 139], ["FMDV", "SPECIES", 43, 47], ["FMDV", "SPECIES", 79, 83], ["swine", "SPECIES", 155, 160], ["FMDV", "SPECIES", 43, 47], ["FMDV", "SPECIES", 79, 83], ["FMD", "SPECIES", 148, 151], ["swine", "SPECIES", 155, 160], ["DNA vaccine", "TREATMENT", 0, 11], ["the VP1 epitopes", "TREATMENT", 23, 39], ["FMDV", "PROBLEM", 43, 47], ["both FMDV specific T cell proliferation", "PROBLEM", 74, 113], ["neutralizing antibody", "TEST", 118, 139], ["cell proliferation", "OBSERVATION", 95, 113]]], ["DNA vaccine containing VP243 of infectious bursal disease virus (IBDV), an acute and highly contagious diseases in chickens, has been shown to exhibit higher survival rate and low bursal atrophy as compared with the non-immunized groups after challenge.", [["bursal", "ANATOMY", 180, 186], ["VP243", "CHEMICAL", 23, 28], ["infectious bursal disease", "DISEASE", 32, 57], ["bursal atrophy", "DISEASE", 180, 194], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["VP243 of", "ORGANISM", 23, 31], ["infectious bursal disease virus", "ORGANISM", 32, 63], ["IBDV", "ORGANISM", 65, 69], ["chickens", "ORGANISM", 115, 123], ["bursal", "ORGAN", 180, 186], ["infectious bursal disease virus", "SPECIES", 32, 63], ["IBDV", "SPECIES", 65, 69], ["chickens", "SPECIES", 115, 123], ["infectious bursal disease virus", "SPECIES", 32, 63], ["IBDV", "SPECIES", 65, 69], ["chickens", "SPECIES", 115, 123], ["DNA vaccine", "TREATMENT", 0, 11], ["infectious bursal disease virus", "PROBLEM", 32, 63], ["an acute and highly contagious diseases in chickens", "PROBLEM", 72, 123], ["higher survival rate", "PROBLEM", 151, 171], ["low bursal atrophy", "PROBLEM", 176, 194], ["infectious", "OBSERVATION_MODIFIER", 32, 42], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["highly", "OBSERVATION_MODIFIER", 85, 91], ["contagious", "OBSERVATION_MODIFIER", 92, 102], ["diseases", "OBSERVATION", 103, 111], ["higher", "OBSERVATION_MODIFIER", 151, 157], ["survival", "OBSERVATION_MODIFIER", 158, 166], ["low", "OBSERVATION_MODIFIER", 176, 179], ["bursal atrophy", "OBSERVATION", 180, 194]]], ["Immunity derived from the DNA vaccination seems to contribute to a high level of protective immunity and the overall protection of chickens against IBDV [39] .", [["IBDV", "DISEASE", 148, 152], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["chickens", "ORGANISM", 131, 139], ["IBDV", "ORGANISM", 148, 152], ["chickens", "SPECIES", 131, 139], ["IBDV", "SPECIES", 148, 152], ["chickens", "SPECIES", 131, 139], ["IBDV", "SPECIES", 148, 152], ["the DNA vaccination", "TREATMENT", 22, 41], ["protective immunity", "TREATMENT", 81, 100]]], ["A plasmid DNA containing the gD gene of Aujeszky's disease virus (ADV) elicited serum neutralizing antibody at 4 weeks after immunization, indicating that it may be a DNA vaccine candidate against ADV [40] .", [["plasmid", "ANATOMY", 2, 9], ["serum", "ANATOMY", 80, 85], ["Aujeszky's disease", "DISEASE", 40, 58], ["ADV", "CHEMICAL", 66, 69], ["ADV", "CHEMICAL", 197, 200], ["DNA", "CELLULAR_COMPONENT", 10, 13], ["gD", "GENE_OR_GENE_PRODUCT", 29, 31], ["Aujeszky's disease virus", "ORGANISM", 40, 64], ["ADV", "ORGANISM", 66, 69], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["DNA", "CELLULAR_COMPONENT", 167, 170], ["ADV", "ORGANISM", 197, 200], ["plasmid DNA", "DNA", 2, 13], ["gD gene", "DNA", 29, 36], ["serum neutralizing antibody", "PROTEIN", 80, 107], ["Aujeszky", "SPECIES", 40, 48], ["Aujeszky's disease virus", "SPECIES", 40, 64], ["ADV", "SPECIES", 66, 69], ["ADV", "SPECIES", 197, 200], ["A plasmid DNA", "TREATMENT", 0, 13], ["Aujeszky's disease virus", "PROBLEM", 40, 64], ["serum neutralizing antibody", "TEST", 80, 107], ["immunization", "TREATMENT", 125, 137], ["a DNA vaccine", "TREATMENT", 165, 178], ["plasmid DNA", "OBSERVATION", 2, 13], ["gD gene", "OBSERVATION_MODIFIER", 29, 36]]], ["Administration of DNA vaccine containing the N3 gene of severe acute respiratory syndrome (SARS), a life-threatening and highly emerging disease, elicited a significant level of antibody responses in the vaccinated mice, which can be a potential DNA vaccine candidate against SARS [41] .VLP vaccinesDuring replication of virus in eukaryotic cells, a virus has a unique characteristic of self-assembling into particles.", [["cells", "ANATOMY", 341, 346], ["acute respiratory syndrome", "DISEASE", 63, 89], ["SARS", "DISEASE", 91, 95], ["SARS", "DISEASE", 276, 280], ["DNA", "CELLULAR_COMPONENT", 18, 21], ["mice", "ORGANISM", 215, 219], ["DNA", "CELLULAR_COMPONENT", 246, 249], ["SARS [41] .VLP", "ORGANISM", 276, 290], ["eukaryotic cells", "CELL", 330, 346], ["N3 gene", "DNA", 45, 52], ["eukaryotic cells", "CELL_TYPE", 330, 346], ["mice", "SPECIES", 215, 219], ["mice", "SPECIES", 215, 219], ["DNA vaccine", "TREATMENT", 18, 29], ["severe acute respiratory syndrome", "PROBLEM", 56, 89], ["SARS", "PROBLEM", 91, 95], ["highly emerging disease", "PROBLEM", 121, 144], ["a significant level of antibody responses", "PROBLEM", 155, 196], ["a potential DNA vaccine", "TREATMENT", 234, 257], ["SARS", "PROBLEM", 276, 280], [".VLP vaccines", "TREATMENT", 286, 299], ["virus in eukaryotic cells", "PROBLEM", 321, 346], ["a virus", "PROBLEM", 348, 355], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["respiratory syndrome", "OBSERVATION", 69, 89], ["eukaryotic cells", "OBSERVATION", 330, 346]]], ["This characteristic makes it possible to generate VLPs in cell culture system.", [["cell", "ANATOMY", 58, 62], ["cell", "CELL", 58, 62], ["VLPs in cell culture system", "PROBLEM", 50, 77]]], ["VLPs are differentiated from live attenuated virus by the lack of productive viral infection.", [["viral infection", "DISEASE", 77, 92], ["VLPs", "ORGANISM", 0, 4], ["VLPs", "TREATMENT", 0, 4], ["live attenuated virus", "PROBLEM", 29, 50], ["productive viral infection", "PROBLEM", 66, 92], ["productive", "OBSERVATION_MODIFIER", 66, 76], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["infection", "OBSERVATION", 83, 92]]], ["They are nonreplicating and non-pathogenic, and they mimic virus particles [42, 43] .", [["non-pathogenic", "PROBLEM", 28, 42], ["non-pathogenic", "OBSERVATION_MODIFIER", 28, 42]]], ["VLP vaccines have been recognized as a relatively new concept in vaccine development.", [["VLP vaccines", "TREATMENT", 0, 12]]], ["Since no genetic materials are required for forming VLP, no drawbacks shown in other vaccine strategies are observed, including virulence reversion, accidental mutation, and spontaneous re-assortment.", [["genetic materials", "PROBLEM", 9, 26], ["VLP", "TREATMENT", 52, 55], ["drawbacks", "PROBLEM", 60, 69], ["other vaccine strategies", "TREATMENT", 79, 103], ["accidental mutation", "PROBLEM", 149, 168], ["spontaneous re-assortment", "TREATMENT", 174, 199]]], ["Mammalian immune systems are highly attuned to recognize and attack these VLPs following injection [37, 42] .", [["VLPs", "ORGANISM", 74, 78], ["Mammalian immune systems", "TREATMENT", 0, 24]]], ["Since the conformational similarity of VLPs to infectious virions, a considerably low quantity of VLP antigen is sufficient to provoke a similar protective immunity.", [["virions", "ANATOMY", 58, 65], ["VLPs", "GENE_OR_GENE_PRODUCT", 39, 43], ["VLP antigen", "GENE_OR_GENE_PRODUCT", 98, 109], ["VLP antigen", "PROTEIN", 98, 109], ["infectious virions", "PROBLEM", 47, 65], ["a considerably low quantity of VLP antigen", "PROBLEM", 67, 109], ["low quantity", "OBSERVATION_MODIFIER", 82, 94]]], ["Additionally, VLPs have been shown to be highly effective at stimulating CD4 + T cell proliferation and a cytotoxic T lymphocyte response.", [["CD4 + T cell", "ANATOMY", 73, 85], ["T lymphocyte", "ANATOMY", 116, 128], ["VLPs", "ORGANISM", 14, 18], ["CD4", "GENE_OR_GENE_PRODUCT", 73, 76], ["T lymphocyte", "CELL", 116, 128], ["CD4", "PROTEIN", 73, 76], ["VLPs", "TEST", 14, 18], ["T cell proliferation", "PROBLEM", 79, 99], ["a cytotoxic T lymphocyte response", "PROBLEM", 104, 137], ["cell proliferation", "OBSERVATION", 81, 99], ["cytotoxic T lymphocyte response", "OBSERVATION", 106, 137]]], ["The use of VLP would be a promising vaccination strategy for a variety of viruses [37] , since it can elicit high titer, long-lived immunity to diverse viruses.", [["VLP", "ORGANISM", 11, 14], ["VLP", "TREATMENT", 11, 14], ["a promising vaccination strategy", "TREATMENT", 24, 56], ["a variety of viruses", "PROBLEM", 61, 81], ["high titer", "PROBLEM", 109, 119], ["diverse viruses", "PROBLEM", 144, 159], ["viruses", "OBSERVATION", 152, 159]]], ["To date, VLPs have been produced for more than 30 different viruses that infect humans and other animals.", [["VLPs", "ORGANISM", 9, 13], ["humans", "ORGANISM", 80, 86], ["humans", "SPECIES", 80, 86], ["humans", "SPECIES", 80, 86], ["VLPs", "TREATMENT", 9, 13], ["viruses", "OBSERVATION", 60, 67]]], ["However, all viruses cannot be applicable for forming VLP vaccines since conformational structures of each virus are variable, composed of either single or multiple capsids, and are with or without a lipid envelope.", [["VLP", "ORGANISM", 54, 57], ["all viruses", "PROBLEM", 9, 20], ["VLP vaccines", "TREATMENT", 54, 66], ["conformational structures of each virus", "PROBLEM", 73, 112], ["a lipid envelope", "PROBLEM", 198, 214], ["viruses", "OBSERVATION", 13, 20]]], ["The major advantage of VLP vaccine presenting multiple viral epitopes on a single particle is the ability to effectively stimulate immune responses without serious deleterious effects induced by live attenuated virus vaccine [37] .", [["VLP", "ORGANISM", 23, 26], ["live attenuated virus", "ORGANISM", 195, 216], ["VLP vaccine", "TREATMENT", 23, 34], ["multiple viral epitopes", "PROBLEM", 46, 69], ["serious deleterious effects", "PROBLEM", 156, 183], ["live attenuated virus vaccine", "TREATMENT", 195, 224]]], ["Additionally, VLPs have the potential for activating both endogenous and exogenous antigen processing pathways leading to presentation of viral peptides by major histocompatibility complex (MHC) class I and II molecules.", [["VLPs", "ORGANISM", 14, 18], ["major histocompatibility complex (MHC) class I", "GENE_OR_GENE_PRODUCT", 156, 202], ["major histocompatibility complex (MHC) class I and II molecules", "PROTEIN", 156, 219], ["VLPs", "TREATMENT", 14, 18], ["activating both endogenous and exogenous antigen processing pathways", "PROBLEM", 42, 110], ["viral peptides", "PROBLEM", 138, 152]]], ["Nevertheless, better understanding for the replication feature of each virus is needed to generate VLP vaccines [42] .VLP vaccinesFor examples, a single inoculation of VLP vaccine expressing HA and M1 proteins of AIV subtype H9N2 elicited a high level of HI antibodies and lowered the frequency of virus isolation after challenge with a virulent virus [28] , indicating http://www.ecevr.org/ http://dx. doi.org/10.7774/cevr.2012.1.1.18 that VLP vaccine would be a promising vaccine candidate against AIV.", [["H9N2", "DISEASE", 225, 229], ["VLP", "ORGANISM", 168, 171], ["HA", "GENE_OR_GENE_PRODUCT", 191, 193], ["AIV subtype H9N2", "ORGANISM", 213, 229], ["HI antibodies", "GENE_OR_GENE_PRODUCT", 255, 268], ["VLP", "ORGANISM", 441, 444], ["AIV", "ORGANISM", 500, 503], ["HA and M1 proteins", "PROTEIN", 191, 209], ["HI antibodies", "PROTEIN", 255, 268], ["AIV subtype H9N2", "SPECIES", 213, 229], ["AIV subtype H9N2", "SPECIES", 213, 229], ["HI", "SPECIES", 255, 257], ["AIV", "SPECIES", 500, 503], ["each virus", "PROBLEM", 66, 76], ["VLP vaccines", "TREATMENT", 99, 111], [".VLP vaccines", "TREATMENT", 117, 130], ["a single inoculation of VLP vaccine", "TREATMENT", 144, 179], ["HA", "PROBLEM", 191, 193], ["AIV subtype H9N2", "PROBLEM", 213, 229], ["HI antibodies", "PROBLEM", 255, 268], ["virus isolation", "TREATMENT", 298, 313], ["a virulent virus", "PROBLEM", 335, 351], ["VLP vaccine", "TREATMENT", 441, 452], ["AIV", "PROBLEM", 500, 503]]], ["Similarly, immunization of VLP vaccine against HPAI was able to protect chickens from lethal challenge of wild type HPAI H5N1 virus [30] .", [["HPAI", "DISEASE", 47, 51], ["VLP", "ORGANISM", 27, 30], ["HPAI", "ORGANISM", 47, 51], ["chickens", "ORGANISM", 72, 80], ["wild type", "ORGANISM", 106, 115], ["HPAI H5N1 virus", "ORGANISM", 116, 131], ["chickens", "SPECIES", 72, 80], ["HPAI H5N1 virus", "SPECIES", 116, 131], ["HPAI", "SPECIES", 47, 51], ["chickens", "SPECIES", 72, 80], ["HPAI H5N1 virus", "SPECIES", 116, 131], ["immunization of VLP vaccine", "TREATMENT", 11, 38], ["HPAI", "PROBLEM", 47, 51], ["wild type HPAI H5N1 virus", "TREATMENT", 106, 131]]], ["Non-infectious recombinant pentamer-like structures of the FMDV were generated by expressing the gene for the P1 and 3C proteins whose expressions were under the control of individual promoters in the baculovirus expression system [44] .", [["FMDV", "ORGANISM", 59, 63], ["3C", "GENE_OR_GENE_PRODUCT", 117, 119], ["baculovirus", "ORGANISM", 201, 212], ["P1 and 3C proteins", "PROTEIN", 110, 128], ["promoters", "DNA", 184, 193], ["FMDV", "SPECIES", 59, 63], ["FMDV", "SPECIES", 59, 63], ["baculovirus", "SPECIES", 201, 212], ["Non-infectious recombinant pentamer-like structures of the FMDV", "PROBLEM", 0, 63]]], ["They were structurally similar to the authentic pentamer subunit from FMDV under the electron microscope.", [["FMDV", "ORGANISM", 70, 74], ["pentamer subunit", "PROTEIN", 48, 64], ["FMDV", "SPECIES", 70, 74], ["FMDV", "SPECIES", 70, 74]]], ["Immunization with such VLP into mice elicited high level of FMDV specific antibody.", [["VLP", "ORGANISM", 23, 26], ["mice", "ORGANISM", 32, 36], ["FMDV", "ORGANISM", 60, 64], ["FMDV specific antibody", "PROTEIN", 60, 82], ["mice", "SPECIES", 32, 36], ["FMDV", "SPECIES", 60, 64], ["mice", "SPECIES", 32, 36], ["FMDV", "SPECIES", 60, 64], ["Immunization", "TREATMENT", 0, 12], ["such VLP", "TREATMENT", 18, 26]]], ["For swine vesicular disease virus (SVDV), a highly contagious disease of pigs, SVDV-like particles were generated by simultaneous expression of both P1 and 3CD proteins of SVDV, which resemble (both antigenically and morphologically) the authentic virus particles.", [["swine vesicular disease", "DISEASE", 4, 27], ["swine vesicular disease virus", "ORGANISM", 4, 33], ["pigs", "ORGANISM", 73, 77], ["SVDV-like particles", "ORGANISM", 79, 98], ["3CD", "GENE_OR_GENE_PRODUCT", 156, 159], ["SVDV", "GENE_OR_GENE_PRODUCT", 172, 176], ["P1", "PROTEIN", 149, 151], ["3CD proteins", "PROTEIN", 156, 168], ["SVDV", "PROTEIN", 172, 176], ["swine", "SPECIES", 4, 9], ["pigs", "SPECIES", 73, 77], ["swine vesicular disease virus", "SPECIES", 4, 33], ["SVDV", "SPECIES", 35, 39], ["pigs", "SPECIES", 73, 77], ["SVDV", "SPECIES", 79, 83], ["SVDV", "SPECIES", 172, 176], ["swine vesicular disease virus", "PROBLEM", 4, 33], ["a highly contagious disease of pigs, SVDV-like particles", "PROBLEM", 42, 98], ["3CD proteins of SVDV", "PROBLEM", 156, 176], ["the authentic virus particles", "PROBLEM", 234, 263], ["vesicular disease", "OBSERVATION", 10, 27], ["highly", "OBSERVATION_MODIFIER", 44, 50], ["contagious", "OBSERVATION_MODIFIER", 51, 61], ["virus particles", "OBSERVATION", 248, 263]]], ["The VLP may be used for a vaccine candidate against SVDV [45] .", [["VLP", "ORGANISM", 4, 7], ["SVDV", "SPECIES", 52, 56], ["The VLP", "TREATMENT", 0, 7], ["a vaccine", "TREATMENT", 24, 33]]], ["The orf 2 gene of PCV2 was cloned and inserted into the baculovirus expression system.", [["orf 2", "GENE_OR_GENE_PRODUCT", 4, 9], ["PCV2", "ORGANISM", 18, 22], ["baculovirus", "ORGANISM", 56, 67], ["orf 2 gene", "DNA", 4, 14], ["PCV2", "SPECIES", 18, 22], ["baculovirus", "SPECIES", 56, 67], ["The orf 2 gene of PCV2", "TREATMENT", 0, 22], ["PCV2", "OBSERVATION", 18, 22], ["baculovirus", "ANATOMY", 56, 67]]], ["The recombinant protein of ORF2 was formed to be VLP in infected insect cells [15] .", [["cells", "ANATOMY", 72, 77], ["ORF2", "GENE_OR_GENE_PRODUCT", 27, 31], ["VLP", "ORGANISM", 49, 52], ["insect cells", "CELL", 65, 77], ["recombinant protein", "PROTEIN", 4, 23], ["ORF2", "DNA", 27, 31], ["VLP", "PROTEIN", 49, 52], ["infected insect cells", "CELL_TYPE", 56, 77], ["The recombinant protein of ORF2", "PROBLEM", 0, 31], ["infected insect cells", "PROBLEM", 56, 77], ["infected insect cells", "OBSERVATION", 56, 77]]], ["As an attempt to create a novel vaccine against for porcine encephalomyocarditis virus (EMCV) causing reproductive failure in pregnant sows, a plasmid containing P12A and 3C genes of EMCV was generated and transfected into baculovirus expression system.", [["plasmid", "ANATOMY", 143, 150], ["porcine encephalomyocarditis virus", "DISEASE", 52, 86], ["reproductive failure", "DISEASE", 102, 122], ["porcine encephalomyocarditis virus", "ORGANISM", 52, 86], ["EMCV", "ORGANISM", 88, 92], ["sows", "ORGANISM", 135, 139], ["P12A", "GENE_OR_GENE_PRODUCT", 162, 166], ["3C", "GENE_OR_GENE_PRODUCT", 171, 173], ["EMCV", "ORGANISM", 183, 187], ["baculovirus", "ORGANISM", 223, 234], ["P12A and 3C genes", "DNA", 162, 179], ["porcine encephalomyocarditis virus", "SPECIES", 52, 86], ["porcine encephalomyocarditis virus", "SPECIES", 52, 86], ["EMCV", "SPECIES", 88, 92], ["EMCV", "SPECIES", 183, 187], ["baculovirus", "SPECIES", 223, 234], ["a novel vaccine", "TREATMENT", 24, 39], ["porcine encephalomyocarditis virus", "PROBLEM", 52, 86], ["EMCV", "PROBLEM", 88, 92], ["reproductive failure", "PROBLEM", 102, 122], ["a plasmid containing P12A", "TREATMENT", 141, 166], ["3C genes of EMCV", "TREATMENT", 171, 187]]], ["Immunization of the VLP mixed with an alum adjuvant demonstrated the induction and maintenance of high level of neutralizing antibody and led to high protection efficacy after challenge with a wild type virus [46, 47] .", [["alum", "CHEMICAL", 38, 42], ["alum", "CHEMICAL", 38, 42], ["VLP", "ORGANISM", 20, 23], ["wild type virus", "ORGANISM", 193, 208], ["neutralizing antibody", "PROTEIN", 112, 133], ["Immunization", "TREATMENT", 0, 12], ["the VLP", "TREATMENT", 16, 23], ["an alum adjuvant", "TREATMENT", 35, 51], ["the induction", "TREATMENT", 65, 78], ["neutralizing antibody", "TREATMENT", 112, 133], ["high protection efficacy", "TREATMENT", 145, 169], ["a wild type virus", "PROBLEM", 191, 208]]], ["For PRRSV, VLP expressing M and N proteins was generated in baculovirus expression system, and immunized into mice in order to evaluate its ability of inducing PRRSVspecific immune responses.", [["PRRSV", "ORGANISM", 4, 9], ["VLP", "ORGANISM", 11, 14], ["M and N proteins", "GENE_OR_GENE_PRODUCT", 26, 42], ["baculovirus", "ORGANISM", 60, 71], ["mice", "ORGANISM", 110, 114], ["VLP expressing M and N proteins", "PROTEIN", 11, 42], ["mice", "SPECIES", 110, 114], ["PRRSV", "SPECIES", 4, 9], ["baculovirus", "SPECIES", 60, 71], ["mice", "SPECIES", 110, 114], ["PRRSV", "PROBLEM", 4, 9], ["N proteins", "PROBLEM", 32, 42], ["baculovirus expression system", "TREATMENT", 60, 89]]], ["According to unpublished data from our laboratory, PRRSV-VLP elicited strong immune responses as well as proper neutralizing antibodies against PRRSV, suggesting that VLP representing M and N proteins would be a potential vaccine candidate against PRRSV.Bacterial VaccinesBacterial vaccines are generally classified into inactivated vaccine, attenuated live vaccine, or antigen component-based vaccine.", [["PRRSV-VLP", "ORGANISM", 51, 60], ["PRRSV", "ORGANISM", 144, 149], ["PRRSV", "ORGANISM", 248, 253], ["neutralizing antibodies", "PROTEIN", 112, 135], ["VLP representing M and N proteins", "PROTEIN", 167, 200], ["PRRSV", "SPECIES", 144, 149], ["PRRSV", "SPECIES", 248, 253], ["PRRSV", "SPECIES", 51, 56], ["PRRSV", "SPECIES", 144, 149], ["PRRSV", "SPECIES", 248, 253], ["proper neutralizing antibodies", "TREATMENT", 105, 135], ["PRRSV", "PROBLEM", 144, 149], ["VLP", "PROBLEM", 167, 170], ["M and N proteins", "PROBLEM", 184, 200], ["PRRSV", "PROBLEM", 248, 253], ["Bacterial Vaccines", "TREATMENT", 254, 272], ["Bacterial vaccines", "TREATMENT", 272, 290], ["inactivated vaccine", "TREATMENT", 321, 340], ["attenuated live vaccine", "TREATMENT", 342, 365], ["antigen component", "TREATMENT", 370, 387]]], ["All are prepared from culture grown on suitable media or other possible means.", [["culture", "TEST", 22, 29]]], ["Inactivated vaccines consist of bacteria of one or more types of bacterial species, serotypes, or well-defined subunit antigens formulated in proper adjuvants.", [["subunit antigens", "PROTEIN", 111, 127], ["Inactivated vaccines", "TREATMENT", 0, 20], ["bacteria", "PROBLEM", 32, 40], ["bacterial species", "PROBLEM", 65, 82], ["serotypes", "PROBLEM", 84, 93], ["well-defined subunit antigens", "PROBLEM", 98, 127], ["more types", "OBSERVATION_MODIFIER", 51, 61], ["bacterial species", "OBSERVATION", 65, 82]]], ["Live vaccines are made of weakened bacteria that are generated through genetic manipulation or attenuation by serially passage of selected microorganisms through artificial media in order to weaken their pathogenicity in the target host.", [["Live vaccines", "TREATMENT", 0, 13], ["weakened bacteria", "PROBLEM", 26, 43], ["artificial media", "TREATMENT", 162, 178], ["attenuation", "OBSERVATION_MODIFIER", 95, 106], ["pathogenicity", "OBSERVATION", 204, 217]]], ["Although many bacterial vaccines have illustrated good outcomes in the control of various types of animal diseases, new vaccines should be developed or improved to control pathogens which are re-emerging in the animal industry and are associated with recent outbreaks.", [["animal diseases", "DISEASE", 99, 114], ["many bacterial vaccines", "TREATMENT", 9, 32], ["animal diseases", "PROBLEM", 99, 114], ["new vaccines", "TREATMENT", 116, 128], ["pathogens", "PROBLEM", 172, 181], ["bacterial vaccines", "OBSERVATION", 14, 32], ["good", "OBSERVATION_MODIFIER", 50, 54], ["animal diseases", "OBSERVATION", 99, 114]]], ["When commercial vaccines are unavailable, autogenous vaccines may be alternatively produced by local veterinary vaccine companies.Live bacterial vaccinesLive bacterial vaccines consist of a small quantity of attenuated bacteria that elicit good immune responses similar to that provoked by natural infection.", [["infection", "DISEASE", 298, 307], ["commercial vaccines", "TREATMENT", 5, 24], ["autogenous vaccines", "TREATMENT", 42, 61], ["Live bacterial vaccinesLive bacterial vaccines", "TREATMENT", 130, 176], ["attenuated bacteria", "PROBLEM", 208, 227], ["natural infection", "PROBLEM", 290, 307], ["small quantity", "OBSERVATION_MODIFIER", 190, 204], ["natural", "OBSERVATION_MODIFIER", 290, 297], ["infection", "OBSERVATION", 298, 307]]], ["Although attenuated bacteria are able to infect and multiply in the vaccinated host, they no longer are capable of causing clinical disease as the result of impairment of biological function of virulent determinants [36] .", [["attenuated bacteria", "PROBLEM", 9, 28], ["clinical disease", "PROBLEM", 123, 139], ["attenuated", "OBSERVATION_MODIFIER", 9, 19], ["bacteria", "OBSERVATION", 20, 28], ["no longer", "UNCERTAINTY", 90, 99]]], ["Immune reactions derived from vaccination with live bacteria last longer than those of immunity generated by inactivated bacteria.", [["Immune reactions", "PROBLEM", 0, 16], ["vaccination", "TREATMENT", 30, 41], ["live bacteria", "PROBLEM", 47, 60], ["inactivated bacteria", "PROBLEM", 109, 129]]], ["The major advantage of live vaccine is a broader scope and duration of protection because the animals are exposed to all stages of the replicating bacteria.", [["animals", "ORGANISM", 94, 101], ["live vaccine", "TREATMENT", 23, 35], ["protection", "TREATMENT", 71, 81], ["the replicating bacteria", "PROBLEM", 131, 155], ["bacteria", "OBSERVATION", 147, 155]]], ["However, it is critical to ensure that live bacterial vaccine is neither over-or under-attenuated in target animals.", [["live bacterial vaccine", "TREATMENT", 39, 61]]], ["Whereas under-attenuated strains may be pathogenic and consequently causes their natural diseases, over-attenuation would not elicit enough amount of an immune response to be an effective vaccine [19, 36, 48] .", [["attenuated strains", "PROBLEM", 14, 32], ["pathogenic", "PROBLEM", 40, 50], ["their natural diseases", "PROBLEM", 75, 97], ["-attenuated", "OBSERVATION_MODIFIER", 13, 24], ["may be", "UNCERTAINTY", 33, 39], ["pathogenic", "OBSERVATION", 40, 50], ["natural", "OBSERVATION_MODIFIER", 81, 88], ["diseases", "OBSERVATION", 89, 97]]], ["Since live bacteria vaccines can elicit good levels of both humoral and cellular immunity, this property per se makes live vaccines highly desirable.", [["cellular", "ANATOMY", 72, 80], ["cellular", "CELL", 72, 80], ["live bacteria vaccines", "TREATMENT", 6, 28], ["live vaccines", "TREATMENT", 118, 131]]], ["Creation of live bacterial vaccine strains followed by a classical method would be achieved by conducting multiple passages of microorganisms in suitable systems and by selecting desirable mutants.", [["live bacterial vaccine strains", "TREATMENT", 12, 42], ["a classical method", "TREATMENT", 55, 73], ["microorganisms", "PROBLEM", 127, 141]]], ["This method is readily applicable for most target pathogens to be created as attenuated vaccine strains.", [["most target pathogens", "PROBLEM", 38, 59], ["attenuated vaccine strains", "TREATMENT", 77, 103]]], ["However, there has been relatively little success in developing attenuated bacteria by such a classical method.", [["developing attenuated bacteria", "PROBLEM", 53, 83], ["a classical method", "TREATMENT", 92, 110], ["relatively", "OBSERVATION_MODIFIER", 24, 34], ["little", "OBSERVATION_MODIFIER", 35, 41], ["success", "OBSERVATION_MODIFIER", 42, 49], ["attenuated", "OBSERVATION_MODIFIER", 64, 74], ["bacteria", "OBSERVATION", 75, 83]]], ["For this reason, relatively mild selective pressure on bacteria during in vitro passage enables bacteria to temporarily suppress virulence determinants and then restart their expression of such determinants in vivo.", [["relatively mild selective pressure on bacteria", "PROBLEM", 17, 63], ["bacteria", "PROBLEM", 96, 104], ["mild", "OBSERVATION_MODIFIER", 28, 32], ["selective", "OBSERVATION_MODIFIER", 33, 42], ["pressure", "OBSERVATION", 43, 51], ["bacteria", "OBSERVATION", 55, 63]]], ["Once development of such vaccines were not technically feasible for most bacteria due to lack of proper tools for doing so, however, currently advanced genetic techniques make practical the development of attenuated strains.", [["such vaccines", "TREATMENT", 20, 33], ["most bacteria", "PROBLEM", 68, 81], ["advanced genetic techniques", "TREATMENT", 143, 170], ["attenuated strains", "PROBLEM", 205, 223]]], ["This strategy provides opportunities to create desirable mutants of various types of bacteria, through manipulathttp://www.ecevr.org/ http://dx. doi.org/10.7774/cevr.2012.1.1.18 ing a target gene with various genetic techniques, including gene-insertion, deletion, disruption, replacement, and point mutation.", [["target gene", "DNA", 184, 195], ["bacteria", "PROBLEM", 85, 93], ["various genetic techniques", "TREATMENT", 201, 227], ["gene-insertion", "TREATMENT", 239, 253], ["deletion", "PROBLEM", 255, 263], ["disruption", "PROBLEM", 265, 275], ["replacement", "TREATMENT", 277, 288], ["point mutation", "PROBLEM", 294, 308], ["bacteria", "OBSERVATION", 85, 93]]], ["The best targets for a bacterial genome are the genes associated with virulence determinants, biosynthesis, and regulatory genes which are critical for bacterial survival.", [["bacterial genome", "DNA", 23, 39], ["regulatory genes", "DNA", 112, 128], ["a bacterial genome", "PROBLEM", 21, 39], ["virulence determinants", "PROBLEM", 70, 92], ["biosynthesis", "TREATMENT", 94, 106], ["bacterial survival", "PROBLEM", 152, 170], ["bacterial genome", "OBSERVATION", 23, 39]]], ["Interestingly, from the standpoint of creating a vaccine strain, deletion of virulence-associated genes in bacteria may be problematic since protective immunity is sometimes desired against the very virulence-associated protein.", [["virulence-associated genes", "DNA", 77, 103], ["virulence-associated protein", "PROTEIN", 199, 227], ["a vaccine strain", "TREATMENT", 47, 63], ["deletion of virulence", "PROBLEM", 65, 86], ["associated genes in bacteria", "PROBLEM", 87, 115], ["protective immunity", "TREATMENT", 141, 160]]], ["In such a case, this strain cannot provide good immunity as a vaccine strain.", [["a vaccine strain", "PROBLEM", 60, 76]]], ["Chemically altered bacterial vaccine contains modified bacteria that have been grown in media supplemented with the proper level of a chemical that provokes mutation of bacteria, changing the ability of bacteria to cause diseases.", [["Chemically altered bacterial vaccine", "PROBLEM", 0, 36], ["modified bacteria", "PROBLEM", 46, 63], ["mutation of bacteria", "PROBLEM", 157, 177], ["bacteria", "PROBLEM", 203, 211], ["diseases", "PROBLEM", 221, 229], ["altered", "OBSERVATION_MODIFIER", 11, 18], ["bacterial vaccine", "OBSERVATION", 19, 36], ["grown", "OBSERVATION_MODIFIER", 79, 84]]], ["This method would be another option for developing weakened bacteria and followed by a proper screening method that is suitable for selecting desirable mutants.", [["developing weakened bacteria", "PROBLEM", 40, 68], ["a proper screening method", "TEST", 85, 110], ["weakened", "OBSERVATION_MODIFIER", 51, 59], ["bacteria", "OBSERVATION", 60, 68]]], ["Alternatively, temperature sensitive mutants can be generated by selection of the mutants which lost their ability to grow at animal body's temperature but can grow at the temperature present in ocular or nasal cavity.", [["body", "ANATOMY", 133, 137], ["ocular", "ANATOMY", 195, 201], ["nasal cavity", "ANATOMY", 205, 217], ["body", "ORGANISM_SUBDIVISION", 133, 137], ["ocular", "ORGANISM_SUBDIVISION", 195, 201], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 205, 217], ["temperature sensitive mutants", "PROBLEM", 15, 44], ["the mutants", "PROBLEM", 78, 89], ["the temperature", "TEST", 168, 183], ["ocular", "ANATOMY", 195, 201], ["nasal cavity", "ANATOMY", 205, 217]]], ["In general, killed vaccines for Salmonella are able to stimulate strong immune response, but offer a relatively low degree of protection as compared to live attenuated vaccine.", [["Salmonella", "SPECIES", 32, 42], ["Salmonella", "PROBLEM", 32, 42], ["live attenuated vaccine", "TREATMENT", 152, 175]]], ["They are also difficult to apply to large flocks, requiring a lot of labor for vaccination [49] .", [["large flocks", "PROBLEM", 36, 48], ["large", "OBSERVATION_MODIFIER", 36, 41], ["flocks", "OBSERVATION", 42, 48]]], ["Thus, the live form of attenuated Salmonella vaccine effectively stimulates better cellular immunity and IgA than those of killed vaccine.Live bacterial vaccinesFor examples, the safety and protection efficacy of novel cpxR/lon-deletion mutants of Salmonella species were well demonstrated in chickens and piglets, which included Salmonella Enteritidis strain JOL919 [50] , Salmonella Gallinarum strain JOL 916 [51] , and Salmonella Typhimurium [52, 53] .", [["cellular", "ANATOMY", 83, 91], ["Salmonella", "CHEMICAL", 34, 44], ["Salmonella vaccine", "ORGANISM", 34, 52], ["cellular", "CELL", 83, 91], ["IgA", "GENE_OR_GENE_PRODUCT", 105, 108], ["cpxR", "GENE_OR_GENE_PRODUCT", 219, 223], ["Salmonella species", "ORGANISM", 248, 266], ["chickens", "ORGANISM", 293, 301], ["piglets", "ORGANISM", 306, 313], ["Salmonella Enteritidis", "ORGANISM", 330, 352], ["strain JOL919", "ORGANISM", 353, 366], ["Salmonella Gallinarum strain JOL 916", "ORGANISM", 374, 410], ["Salmonella Typhimurium", "ORGANISM", 422, 444], ["IgA", "PROTEIN", 105, 108], ["cpxR", "PROTEIN", 219, 223], ["lon-deletion mutants", "PROTEIN", 224, 244], ["chickens", "SPECIES", 293, 301], ["piglets", "SPECIES", 306, 313], ["Salmonella Enteritidis", "SPECIES", 330, 352], ["Salmonella Gallinarum", "SPECIES", 374, 395], ["Salmonella Typhimurium", "SPECIES", 422, 444], ["Salmonella", "SPECIES", 34, 44], ["chickens", "SPECIES", 293, 301], ["Salmonella Enteritidis strain JOL919", "SPECIES", 330, 366], ["Salmonella Gallinarum strain JOL 916", "SPECIES", 374, 410], ["Salmonella Typhimurium", "SPECIES", 422, 444], ["attenuated Salmonella vaccine", "TREATMENT", 23, 52], ["killed vaccine", "TREATMENT", 123, 137], ["Live bacterial vaccines", "TREATMENT", 138, 161], ["novel cpxR", "TEST", 213, 223], ["lon-deletion mutants", "PROBLEM", 224, 244], ["Salmonella species", "PROBLEM", 248, 266], ["Salmonella Enteritidis strain JOL919", "PROBLEM", 330, 366], ["Salmonella Gallinarum strain JOL", "TEST", 374, 406], ["Salmonella Typhimurium", "TEST", 422, 444]]], ["The immunogenicity of viral proteins displayed on the surface of the vaccine strain Salmonella Ty21a was illustrated, indicating that a bacterial vector may be a delivery vehicle to represent foreign viral proteins as well as self-antigens to a target location, with inducing effective immunity in the vaccinate host [54] .", [["surface", "ANATOMY", 54, 61], ["surface", "CELLULAR_COMPONENT", 54, 61], ["Salmonella Ty21a", "ORGANISM", 84, 100], ["viral proteins", "PROTEIN", 22, 36], ["foreign viral proteins", "PROTEIN", 192, 214], ["self-antigens", "PROTEIN", 226, 239], ["Salmonella", "SPECIES", 84, 94], ["viral proteins", "PROBLEM", 22, 36], ["the vaccine strain Salmonella Ty21a", "TREATMENT", 65, 100], ["a bacterial vector", "PROBLEM", 134, 152], ["foreign viral proteins", "PROBLEM", 192, 214], ["viral proteins", "OBSERVATION", 22, 36], ["bacterial vector", "OBSERVATION", 136, 152], ["foreign viral proteins", "OBSERVATION", 192, 214]]], ["In addition, a global regulator, ppGpp-defective mutant of S. Gallinarum served as a novel vaccine candidate which was able to protect chickens challenged with wild type bacteria [49] .", [["ppGpp", "CHEMICAL", 33, 38], ["ppGpp", "GENE_OR_GENE_PRODUCT", 33, 38], ["S. Gallinarum", "ORGANISM", 59, 72], ["chickens", "ORGANISM", 135, 143], ["ppGpp", "PROTEIN", 33, 38], ["S. Gallinarum", "SPECIES", 59, 72], ["chickens", "SPECIES", 135, 143], ["S. Gallinarum", "SPECIES", 59, 72], ["chickens", "SPECIES", 135, 143], ["a global regulator", "TEST", 13, 31], ["S. Gallinarum", "PROBLEM", 59, 72], ["a novel vaccine", "TREATMENT", 83, 98], ["wild type bacteria", "PROBLEM", 160, 178]]], ["A Salmonella mutant defective in the ruvB gene encoding a Holliday junction helicase showed significant impairment of cell survival and proliferation within epithelial cells and macrophages.", [["cell", "ANATOMY", 118, 122], ["epithelial cells", "ANATOMY", 157, 173], ["macrophages", "ANATOMY", 178, 189], ["Salmonella mutant", "ORGANISM", 2, 19], ["ruvB", "GENE_OR_GENE_PRODUCT", 37, 41], ["cell", "CELL", 118, 122], ["epithelial cells", "CELL", 157, 173], ["macrophages", "CELL", 178, 189], ["ruvB gene", "DNA", 37, 46], ["Holliday junction helicase", "PROTEIN", 58, 84], ["epithelial cells", "CELL_TYPE", 157, 173], ["macrophages", "CELL_TYPE", 178, 189], ["A Salmonella mutant defective", "PROBLEM", 0, 29], ["a Holliday junction helicase", "TREATMENT", 56, 84], ["significant impairment of cell survival", "PROBLEM", 92, 131], ["proliferation within epithelial cells and macrophages", "PROBLEM", 136, 189], ["Salmonella", "OBSERVATION", 2, 12], ["mutant defective", "OBSERVATION", 13, 29], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["impairment", "OBSERVATION_MODIFIER", 104, 114], ["cell survival", "OBSERVATION", 118, 131], ["proliferation", "OBSERVATION_MODIFIER", 136, 149], ["epithelial cells", "OBSERVATION", 157, 173], ["macrophages", "OBSERVATION_MODIFIER", 178, 189]]], ["The ruvB mutant conferred strong and durable immune-based protection against challenge with virulent strain of S. Typhimurium.", [["ruvB", "GENE_OR_GENE_PRODUCT", 4, 8], ["S. Typhimurium", "ORGANISM", 111, 125], ["ruvB mutant", "PROTEIN", 4, 15], ["S. Typhimurium", "SPECIES", 111, 125], ["S. Typhimurium", "SPECIES", 111, 125]]], ["This mutant might be a novel live vaccine since its ability to induce protective immunity without causing clinical manifestations [55] .", [["a novel live vaccine", "TREATMENT", 21, 41]]], ["Porcine proliferative enteropathy (PPE) is caused by an obligated intracellular bacteria \"Lawsonia intracellularis, \" whose virulence and immunological activities are not largely known.", [["intracellular", "ANATOMY", 66, 79], ["Porcine proliferative enteropathy", "DISEASE", 0, 33], ["PPE", "DISEASE", 35, 38], ["Porcine", "ORGANISM", 0, 7], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 66, 79], ["Lawsonia intracellularis", "ORGANISM", 90, 114], ["Porcine", "SPECIES", 0, 7], ["Lawsonia intracellularis", "SPECIES", 90, 114], ["Lawsonia intracellularis", "SPECIES", 90, 114], ["Porcine proliferative enteropathy", "PROBLEM", 0, 33], ["an obligated intracellular bacteria", "PROBLEM", 53, 88], ["Lawsonia intracellularis", "PROBLEM", 90, 114], ["proliferative", "OBSERVATION_MODIFIER", 8, 21], ["enteropathy", "OBSERVATION", 22, 33], ["intracellular", "OBSERVATION_MODIFIER", 66, 79], ["bacteria", "OBSERVATION", 80, 88], ["Lawsonia intracellularis", "OBSERVATION", 90, 114]]], ["Vaccine for PPE was prepared by an attenuated strain derived from a clinical isolate that has been serially passed on cell culture.", [["cell", "ANATOMY", 118, 122], ["PPE", "CHEMICAL", 12, 15], ["PPE", "ORGANISM", 12, 15], ["cell culture", "CELL", 118, 130], ["Vaccine", "TREATMENT", 0, 7], ["PPE", "PROBLEM", 12, 15], ["an attenuated strain", "PROBLEM", 32, 52], ["a clinical isolate", "PROBLEM", 66, 84], ["cell culture", "TEST", 118, 130]]], ["The phenotype and genetic features of the licensed vaccine strain is not differentiated from those of the field strains.", [["the licensed vaccine strain", "PROBLEM", 38, 65]]], ["Once the vaccine is orally administered, vaccine was not shed from the host, inducing immune response slightly or not at all.", [["the vaccine", "TREATMENT", 5, 16], ["vaccine", "TREATMENT", 41, 48]]], ["However, shedding of challenged strain in feces of the vaccinated is reduced, showing increased growth performance compared with unvaccinated pigs.Killed vaccinesKilled vaccines are prepared by culturing bacteria, collecting cells, and inactivating them by suitable means, such as heat treatment or chemicals.", [["feces", "ANATOMY", 42, 47], ["cells", "ANATOMY", 225, 230], ["feces", "ORGANISM_SUBDIVISION", 42, 47], ["pigs", "ORGANISM", 142, 146], ["cells", "CELL", 225, 230], ["pigs", "SPECIES", 142, 146], ["pigs", "SPECIES", 142, 146], ["challenged strain in feces", "PROBLEM", 21, 47], ["increased growth performance", "PROBLEM", 86, 114], ["unvaccinated pigs", "TREATMENT", 129, 146], ["Killed vaccines", "TREATMENT", 147, 162], ["Killed vaccines", "TREATMENT", 162, 177], ["heat treatment", "TREATMENT", 281, 295], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["growth", "OBSERVATION_MODIFIER", 96, 102]]], ["This procedure destroys the ability of the pathogens to replicate in the host but keep it intact immunologically.", [["This procedure", "TREATMENT", 0, 14], ["intact", "OBSERVATION", 90, 96]]], ["Since such vaccine does not undergo purification of antigen, immunity to vaccine would be induced to virtually all components of bacteria so that some of the antibody would neutralize the pathogen.", [["such vaccine", "TREATMENT", 6, 18], ["antigen", "TREATMENT", 52, 59], ["immunity to vaccine", "TREATMENT", 61, 80], ["bacteria", "PROBLEM", 129, 137], ["the antibody", "TREATMENT", 154, 166], ["the pathogen", "PROBLEM", 184, 196], ["bacteria", "OBSERVATION", 129, 137], ["pathogen", "OBSERVATION", 188, 196]]], ["The best advantage of killed vaccine is safety: there is no opportunity for killed vaccine to revert to a virulent one capable of causing disease due to its composition as completely inactivated bacteria.", [["killed vaccine", "TREATMENT", 76, 90], ["disease", "PROBLEM", 138, 145], ["completely inactivated bacteria", "PROBLEM", 172, 203]]], ["However, killed vaccine tends to provide a shorter length of protection than live vaccine, and boosters are needed to create a long term immunity.", [["a shorter length of protection than live vaccine", "TREATMENT", 41, 89], ["a long term immunity", "TREATMENT", 125, 145]]], ["Interestingly, when the B subunit of cholera toxin which lacks toxin activity was expressed, purified, and added to bacteriae protein, the recombinant vaccine had somewhat higher efficacy.", [["cholera toxin", "CHEMICAL", 37, 50], ["B", "GENE_OR_GENE_PRODUCT", 24, 25], ["cholera toxin", "GENE_OR_GENE_PRODUCT", 37, 50], ["B subunit", "PROTEIN", 24, 33], ["cholera toxin", "PROTEIN", 37, 50], ["toxin", "PROTEIN", 63, 68], ["bacteriae protein", "PROTEIN", 116, 133], ["cholera toxin", "TREATMENT", 37, 50], ["bacteriae protein", "TREATMENT", 116, 133], ["the recombinant vaccine", "TREATMENT", 135, 158]]], ["A recent study has shown that when using tetanus toxoid as vaccine antigen for subcutaneous immunization, ISS-ODD conjugated cholera toxin B markedly enhanced the antigen specific IgG antibody response and altered the specific pattern of antibody toward Th1-type response.Subunit vaccinesSubunit vaccines usually contain a part of the target pathogen so that the immune response would be against the component only.", [["subcutaneous", "ANATOMY", 79, 91], ["tetanus toxoid", "CHEMICAL", 41, 55], ["ISS-ODD", "CHEMICAL", 106, 113], ["cholera toxin B", "CHEMICAL", 125, 140], ["tetanus toxoid", "ORGANISM", 41, 55], ["cholera toxin B", "SIMPLE_CHEMICAL", 125, 140], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 180, 192], ["cholera toxin B", "PROTEIN", 125, 140], ["IgG antibody", "PROTEIN", 180, 192], ["A recent study", "TEST", 0, 14], ["tetanus toxoid", "TREATMENT", 41, 55], ["vaccine antigen", "TREATMENT", 59, 74], ["subcutaneous immunization", "TREATMENT", 79, 104], ["ISS", "TEST", 106, 109], ["ODD conjugated cholera toxin", "TEST", 110, 138], ["the antigen", "TEST", 159, 170], ["IgG antibody response", "TEST", 180, 201], ["Subunit vaccines", "TREATMENT", 272, 288], ["Subunit vaccines", "TREATMENT", 288, 304]]], ["Such vaccine can be achieved by isolating a particular immunogenic protein from the pathogen and presenting it as an antigen on its own.", [["immunogenic protein", "PROTEIN", 55, 74], ["Such vaccine", "TREATMENT", 0, 12], ["a particular immunogenic protein", "PROBLEM", 42, 74], ["the pathogen", "PROBLEM", 80, 92]]], ["This strategy would be preferred for many types of pathogens, relying on several techniques http://www.ecevr.org/ http://dx. doi.org/10.7774/cevr.2012.1.1.18 including genetics, biochemistry, and molecular biology to identify proper antigenic epitopes and corresponding peptides as candidate vaccine antigens.", [["antigenic epitopes", "PROTEIN", 233, 251], ["candidate vaccine antigens", "PROTEIN", 282, 308], ["pathogens", "PROBLEM", 51, 60], ["proper antigenic epitopes", "PROBLEM", 226, 251], ["corresponding peptides", "PROBLEM", 256, 278], ["pathogens", "OBSERVATION", 51, 60]]], ["An antigen derived from bacterial surface components is cloned, expressed, purified, and its protective potential is assessed in an animal infection model.", [["surface components", "ANATOMY", 34, 52], ["infection", "DISEASE", 139, 148], ["bacterial surface components", "PROBLEM", 24, 52], ["an animal infection model", "PROBLEM", 129, 154], ["bacterial", "OBSERVATION_MODIFIER", 24, 33], ["surface", "OBSERVATION_MODIFIER", 34, 41], ["infection", "OBSERVATION", 139, 148]]], ["Over the past decade modern genetic techniques enabled easily identification of vaccine antigen in lieu of previous available biochemical or antigen data.", [["vaccine antigen", "PROTEIN", 80, 95], ["vaccine antigen", "TREATMENT", 80, 95], ["antigen data", "TEST", 141, 153]]], ["Using compiled genetic information of each pathogen, sequence and analysis of the complete genome of many bacteria resulted in identification of novel candidate vaccine antigens, which is based on the structural or biochemical features of hydrophobicity and homology to that of vaccine antigen of related pathogens.", [["vaccine antigens", "PROTEIN", 161, 177], ["vaccine antigen", "PROTEIN", 278, 293], ["analysis", "TEST", 66, 74], ["many bacteria", "PROBLEM", 101, 114], ["novel candidate vaccine antigens", "PROBLEM", 145, 177], ["hydrophobicity", "PROBLEM", 239, 253], ["vaccine antigen", "PROBLEM", 278, 293], ["related pathogens", "PROBLEM", 297, 314]]], ["The genes are expressed using foreign protein expression systems, including Escherichia coli, yeast, and insect or mammalian cells, and are then purified and injected into a host to elicit immunity.Subunit vaccinesThe resulting product is combined with proper adjuvant and used as the subunit recombination vaccine.", [["cells", "ANATOMY", 125, 130], ["Escherichia coli", "ORGANISM", 76, 92], ["mammalian cells", "CELL", 115, 130], ["yeast, and insect or mammalian cells", "CELL_TYPE", 94, 130], ["Escherichia coli", "SPECIES", 76, 92], ["yeast", "SPECIES", 94, 99], ["Escherichia coli", "SPECIES", 76, 92], ["yeast", "SPECIES", 94, 99], ["foreign protein expression systems", "TREATMENT", 30, 64], ["Escherichia coli", "PROBLEM", 76, 92], ["yeast", "PROBLEM", 94, 99], ["insect or mammalian cells", "PROBLEM", 105, 130], ["Subunit vaccines", "TREATMENT", 198, 214], ["proper adjuvant", "TREATMENT", 253, 268], ["the subunit recombination vaccine", "TREATMENT", 281, 314], ["Escherichia coli", "OBSERVATION", 76, 92], ["mammalian cells", "OBSERVATION", 115, 130]]], ["Such vaccine has a benefit due to its inability to replicate in the host, and well tolerated due to the addition of a good purification step.", [["Such vaccine", "TREATMENT", 0, 12]]], ["Given the broad range of availability for this approach, it is more feasible to produce subunit vaccine for various types of pathogens.", [["this approach", "TREATMENT", 42, 55], ["subunit vaccine", "TREATMENT", 88, 103], ["pathogens", "PROBLEM", 125, 134], ["pathogens", "OBSERVATION", 125, 134]]], ["The immunogen in subunit vaccines may be purified proteins, peptides, or polysaccharide.", [["The immunogen in subunit vaccines", "TREATMENT", 0, 33], ["purified proteins", "PROBLEM", 41, 58], ["polysaccharide", "PROBLEM", 73, 87]]], ["Since these antigens alone have weak immunogenicity, immunity established by the vaccine may be enhanced by administration with a potent adjuvant or through a well-defined delivery system.", [["weak immunogenicity", "PROBLEM", 32, 51], ["a potent adjuvant", "TREATMENT", 128, 145], ["a well-defined delivery system", "TREATMENT", 157, 187], ["weak", "OBSERVATION_MODIFIER", 32, 36], ["immunogenicity", "OBSERVATION", 37, 51]]], ["In general, multiple doses of such vaccine are needed to attain satisfactory immunological responses with most subunit vaccines.", [["such vaccine", "TREATMENT", 30, 42], ["most subunit vaccines", "TREATMENT", 106, 127]]], ["In certain cases, administration of vaccine with appropriate adjuvant enables induction of cellmediated immunity, useful for preventing diseases caused by bacteria that grow intracellularly.Subunit vaccinesFor examples, the outer membrane protein H (OmpH) of Pasteurella multocida has a significant similarity in both primary and secondary with those of other serotypes.", [["outer membrane", "ANATOMY", 224, 238], ["outer membrane", "CELLULAR_COMPONENT", 224, 238], ["H", "GENE_OR_GENE_PRODUCT", 247, 248], ["OmpH", "GENE_OR_GENE_PRODUCT", 250, 254], ["Pasteurella multocida", "ORGANISM", 259, 280], ["outer membrane protein H", "PROTEIN", 224, 248], ["OmpH", "PROTEIN", 250, 254], ["Pasteurella multocida", "SPECIES", 259, 280], ["Pasteurella multocida", "SPECIES", 259, 280], ["vaccine", "TREATMENT", 36, 43], ["appropriate adjuvant", "TREATMENT", 49, 69], ["cellmediated immunity", "TREATMENT", 91, 112], ["diseases", "PROBLEM", 136, 144], ["bacteria", "PROBLEM", 155, 163], ["Subunit vaccines", "TREATMENT", 190, 206], ["the outer membrane protein H", "TEST", 220, 248], ["Pasteurella multocida", "PROBLEM", 259, 280], ["other serotypes", "PROBLEM", 354, 369], ["significant", "OBSERVATION_MODIFIER", 287, 298], ["both", "OBSERVATION_MODIFIER", 313, 317], ["primary", "OBSERVATION", 318, 325], ["serotypes", "OBSERVATION", 360, 369]]], ["The recombinant OmpH proteins expressed in E. coli were antigenic and showed strong protection against P. multocida infection.", [["P. multocida infection", "DISEASE", 103, 125], ["OmpH", "GENE_OR_GENE_PRODUCT", 16, 20], ["E. coli", "ORGANISM", 43, 50], ["P. multocida", "ORGANISM", 103, 115], ["recombinant OmpH proteins", "PROTEIN", 4, 29], ["E. coli", "SPECIES", 43, 50], ["P. multocida", "SPECIES", 103, 115], ["E. coli", "SPECIES", 43, 50], ["P. multocida", "SPECIES", 103, 115], ["The recombinant OmpH proteins", "TEST", 0, 29], ["E. coli", "PROBLEM", 43, 50], ["antigenic", "PROBLEM", 56, 65], ["P. multocida infection", "PROBLEM", 103, 125], ["E. coli", "OBSERVATION", 43, 50], ["multocida", "OBSERVATION_MODIFIER", 106, 115], ["infection", "OBSERVATION", 116, 125]]], ["The OmpH might be a useful vaccine candidate antigens for P. multocida [56] .", [["OmpH", "CHEMICAL", 4, 8], ["OmpH", "GENE_OR_GENE_PRODUCT", 4, 8], ["P. multocida", "ORGANISM", 58, 70], ["OmpH", "PROTEIN", 4, 8], ["P. multocida", "SPECIES", 58, 70], ["P. multocida", "SPECIES", 58, 70]]], ["The recombination protein containing the middle-C-terminal regions of P. multocida toxin (PMT) which was expressed in E. coli induced high titers of PMT-specific antibodies and showed effective protection against homologous challenge in mice [57] .", [["P. multocida toxin", "GENE_OR_GENE_PRODUCT", 70, 88], ["PMT", "GENE_OR_GENE_PRODUCT", 90, 93], ["E. coli", "ORGANISM", 118, 125], ["PMT", "GENE_OR_GENE_PRODUCT", 149, 152], ["mice", "ORGANISM", 237, 241], ["recombination protein", "PROTEIN", 4, 25], ["middle-C-terminal regions", "PROTEIN", 41, 66], ["P. multocida toxin", "PROTEIN", 70, 88], ["PMT", "PROTEIN", 90, 93], ["PMT", "PROTEIN", 149, 152], ["specific antibodies", "PROTEIN", 153, 172], ["P. multocida", "SPECIES", 70, 82], ["E. coli", "SPECIES", 118, 125], ["mice", "SPECIES", 237, 241], ["P. multocida", "SPECIES", 70, 82], ["E. coli", "SPECIES", 118, 125], ["mice", "SPECIES", 237, 241], ["The recombination protein", "TEST", 0, 25], ["P. multocida toxin", "PROBLEM", 70, 88], ["E. coli", "PROBLEM", 118, 125], ["high titers of PMT", "PROBLEM", 134, 152], ["specific antibodies", "TEST", 153, 172], ["recombination protein", "OBSERVATION", 4, 25], ["middle", "ANATOMY_MODIFIER", 41, 47], ["C-terminal", "ANATOMY_MODIFIER", 48, 58]]], ["Heat-labile toxin B subunit (LTB) of enterotoxigenic E. coli (ETEC) can be used as an adjuvant, carrier of fused proteins, and antigen itself.", [["ETEC", "CHEMICAL", 62, 66], ["Heat-labile toxin B subunit", "GENE_OR_GENE_PRODUCT", 0, 27], ["LTB", "GENE_OR_GENE_PRODUCT", 29, 32], ["enterotoxigenic E. coli", "ORGANISM", 37, 60], ["ETEC", "ORGANISM", 62, 66], ["Heat-labile toxin B subunit", "PROTEIN", 0, 27], ["LTB", "PROTEIN", 29, 32], ["fused proteins", "PROTEIN", 107, 121], ["enterotoxigenic E. coli", "SPECIES", 37, 60], ["E. coli", "SPECIES", 53, 60], ["ETEC", "SPECIES", 62, 66], ["Heat", "TEST", 0, 4], ["labile toxin B subunit", "TREATMENT", 5, 27], ["enterotoxigenic E. coli", "PROBLEM", 37, 60], ["an adjuvant", "TREATMENT", 83, 94], ["fused proteins", "PROBLEM", 107, 121]]], ["Immunization of recombinant LTB protein produced in transgenic rice callus induced humoral and secretory antibody immune responses.", [["callus", "ANATOMY", 68, 74], ["LTB", "GENE_OR_GENE_PRODUCT", 28, 31], ["rice callus", "ORGANISM", 63, 74], ["recombinant LTB protein", "PROTEIN", 16, 39], ["rice", "SPECIES", 63, 67], ["rice", "SPECIES", 63, 67], ["Immunization", "TREATMENT", 0, 12], ["recombinant LTB protein", "TEST", 16, 39], ["transgenic rice callus", "PROBLEM", 52, 74], ["rice callus", "OBSERVATION", 63, 74]]], ["This indicated that LTB protein can be a plant-based edible vaccine candidate against ETEC [58] .Live bacteria as carrierA number of species of live bacteria have been used for vaccine carriers that enable the delivery of cloned vaccine antigen enterically or intransally.", [["LTB", "GENE_OR_GENE_PRODUCT", 20, 23], ["LTB protein", "PROTEIN", 20, 31], ["ETEC", "SPECIES", 86, 90], ["LTB protein", "PROBLEM", 20, 31], ["a plant-based edible vaccine", "TREATMENT", 39, 67], ["ETEC", "PROBLEM", 86, 90], ["Live bacteria", "PROBLEM", 97, 110], ["live bacteria", "PROBLEM", 144, 157], ["vaccine carriers", "TREATMENT", 177, 193], ["cloned vaccine antigen", "TREATMENT", 222, 244]]], ["For enteric bacteria, most of them are species with the ability to colonize intestinal mucosa, in particular, mucosa-associated lymphoid tissue, which is the main point of invasion of enteric bacteria [36, 48] .", [["intestinal mucosa", "ANATOMY", 76, 93], ["mucosa", "ANATOMY", 110, 116], ["lymphoid tissue", "ANATOMY", 128, 143], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 76, 93], ["mucosa-associated lymphoid tissue", "TISSUE", 110, 143], ["enteric bacteria", "PROBLEM", 4, 20], ["associated lymphoid tissue", "PROBLEM", 117, 143], ["invasion of enteric bacteria", "PROBLEM", 172, 200], ["bacteria", "OBSERVATION", 12, 20], ["intestinal mucosa", "ANATOMY", 76, 93], ["mucosa", "ANATOMY", 110, 116], ["lymphoid tissue", "OBSERVATION", 128, 143], ["main", "OBSERVATION_MODIFIER", 158, 162], ["invasion", "OBSERVATION_MODIFIER", 172, 180], ["enteric", "OBSERVATION_MODIFIER", 184, 191], ["bacteria", "OBSERVATION_MODIFIER", 192, 200]]], ["However, the reality of application for this type of vaccine is complicated and less efficient due to low level of expression of the inserted protein, and the antigen is less efficiently translocated on the surface of bacteria, where most protective antigens are displayed [48] .", [["surface", "ANATOMY", 207, 214], ["surface", "CELLULAR_COMPONENT", 207, 214], ["inserted protein", "PROTEIN", 133, 149], ["this type of vaccine", "TREATMENT", 40, 60], ["the inserted protein", "PROBLEM", 129, 149], ["bacteria", "PROBLEM", 218, 226], ["less", "OBSERVATION_MODIFIER", 170, 174]]], ["In addition, the immune response of clone antigen is often much weaker than the response to carrier protein of origin.", [["clone antigen", "GENE_OR_GENE_PRODUCT", 36, 49], ["clone antigen", "PROTEIN", 36, 49], ["carrier protein", "PROTEIN", 92, 107], ["clone antigen", "TEST", 36, 49]]], ["Another issue is that the level of immune response to the carrier may preclude its future use either for displaying or for delivering foreign proteins.", [["foreign proteins", "PROTEIN", 134, 150], ["foreign proteins", "PROBLEM", 134, 150]]], ["For this purpose, the bacterial genes responsible for virulence, colonization, survival, and modulation of gene expression should be deleted in vivo.", [["bacterial genes", "DNA", 22, 37], ["the bacterial genes", "PROBLEM", 18, 37], ["virulence", "PROBLEM", 54, 63], ["colonization", "PROBLEM", 65, 77], ["survival", "TREATMENT", 79, 87], ["modulation of gene expression", "TREATMENT", 93, 122]]], ["It is desirable to remove independent genes or genetic loci that contribute to virulence in order to assure the attenuation of the bacterial carrier by reducing the possibility of reversion [36] .", [["genetic loci", "PROBLEM", 47, 59], ["virulence", "PROBLEM", 79, 88], ["the bacterial carrier", "PROBLEM", 127, 148]]], ["Another strategy is to create mutants that have been chemically altered.", [["chemically", "OBSERVATION_MODIFIER", 53, 63], ["altered", "OBSERVATION", 64, 71]]], ["The Ty21a strain of Salmonella was derived in the fashion and licensed for preventing typhoid fever.", [["typhoid fever", "DISEASE", 86, 99], ["Ty21a", "GENE_OR_GENE_PRODUCT", 4, 9], ["Salmonella", "ORGANISM", 20, 30], ["Salmonella", "SPECIES", 20, 30], ["The Ty21a strain of Salmonella", "TREATMENT", 0, 30], ["typhoid fever", "PROBLEM", 86, 99]]], ["The goal of creating a carrier vector is to present foreign antigen to immune system in the context of a live bacterial infection so that the host immune system recognizes the antigen as a natural-form immunogen and thereby develops a broader immunity to corresponding pathogen.", [["immune system", "ANATOMY", 71, 84], ["bacterial infection", "DISEASE", 110, 129], ["a carrier vector", "TREATMENT", 21, 37], ["a live bacterial infection", "PROBLEM", 103, 129], ["immunogen", "TREATMENT", 202, 211], ["corresponding pathogen", "PROBLEM", 255, 277], ["bacterial", "OBSERVATION_MODIFIER", 110, 119], ["infection", "OBSERVATION", 120, 129]]], ["The antigen expressed in a carrier vector is transported to the cell surface to stimulate antibody production into the cytoplasmic pathway where elicit cytotoxic T lymphocyte response.", [["cell surface", "ANATOMY", 64, 76], ["cytoplasmic", "ANATOMY", 119, 130], ["T lymphocyte", "ANATOMY", 162, 174], ["cell surface", "CELLULAR_COMPONENT", 64, 76], ["cytoplasmic", "ORGANISM_SUBSTANCE", 119, 130], ["T lymphocyte", "CELL", 162, 174], ["cytotoxic T lymphocyte", "CELL_TYPE", 152, 174], ["a carrier vector", "TREATMENT", 25, 41], ["cytotoxic T lymphocyte response", "PROBLEM", 152, 183], ["lymphocyte response", "OBSERVATION", 164, 183]]], ["However, the majority of bacteria do not infect cells, and the recombinant antigen should be expressed at the bacterial surface, where the peptide would elicit the production of antibody.", [["cells", "ANATOMY", 48, 53], ["surface", "ANATOMY", 120, 127], ["cells", "CELL", 48, 53], ["bacterial surface", "CELLULAR_COMPONENT", 110, 127], ["recombinant antigen", "PROTEIN", 63, 82], ["bacteria", "PROBLEM", 25, 33], ["infect cells", "PROBLEM", 41, 53], ["the recombinant antigen", "TEST", 59, 82], ["the production of antibody", "PROBLEM", 160, 186], ["bacteria", "OBSERVATION", 25, 33], ["infect cells", "OBSERVATION", 41, 53], ["bacterial surface", "OBSERVATION_MODIFIER", 110, 127]]], ["The engineered enteric pathogen is the most commonly used for this purpose, so that they can induce mucosal immunity against foreign polypeptide upon oral delivery.", [["mucosal", "ANATOMY", 100, 107], ["oral", "ANATOMY", 150, 154], ["mucosal", "ORGAN", 100, 107], ["oral", "ORGANISM_SUBDIVISION", 150, 154], ["The engineered enteric pathogen", "PROBLEM", 0, 31], ["foreign polypeptide", "TREATMENT", 125, 144], ["oral delivery", "TREATMENT", 150, 163], ["enteric", "OBSERVATION_MODIFIER", 15, 22], ["pathogen", "OBSERVATION", 23, 31]]], ["In the field of live bacteria vectors, an attenuated Salmonella carrier as an oral delivery vector has been used for malaria, http://www.ecevr.org/ http://dx. doi.org/10.7774/cevr.2012.1.1.18 anthrax, and cholera.", [["oral", "ANATOMY", 78, 82], ["malaria", "DISEASE", 117, 124], ["anthrax", "DISEASE", 192, 199], ["cholera", "DISEASE", 205, 212], ["oral", "ORGANISM_SUBDIVISION", 78, 82], ["Salmonella", "SPECIES", 53, 63], ["live bacteria vectors", "TREATMENT", 16, 37], ["an attenuated Salmonella carrier", "TREATMENT", 39, 71], ["an oral delivery vector", "TREATMENT", 75, 98], ["malaria", "PROBLEM", 117, 124], ["anthrax", "PROBLEM", 192, 199], ["cholera", "PROBLEM", 205, 212]]], ["The challenging issue for creating carrier vaccines is that a vaccine strain should retain the sufficient ability of replication in the gut and be attenuated enough not to be pathogenic, however, have its ability of expression of appropriate level of foreign proteins.", [["gut", "ANATOMY", 136, 139], ["gut", "ORGANISM_SUBDIVISION", 136, 139], ["foreign proteins", "PROTEIN", 251, 267], ["creating carrier vaccines", "TREATMENT", 26, 51], ["a vaccine strain", "TREATMENT", 60, 76], ["pathogenic", "PROBLEM", 175, 185], ["foreign proteins", "PROBLEM", 251, 267], ["gut", "ANATOMY", 136, 139], ["pathogenic", "OBSERVATION", 175, 185], ["foreign proteins", "OBSERVATION", 251, 267]]], ["Interestingly, the ability of certain bacteria to replicate intracellularly may augment the ability of expressed foreign peptide within the cells and consequently elicit cellular immunity to the corresponding pathogen.", [["cells", "ANATOMY", 140, 145], ["cellular", "ANATOMY", 170, 178], ["cells", "CELL", 140, 145], ["cellular", "CELL", 170, 178], ["certain bacteria", "PROBLEM", 30, 46], ["foreign peptide within the cells", "PROBLEM", 113, 145], ["foreign peptide", "OBSERVATION", 113, 128]]], ["Attenuated Salmonella can cross the intestinal wall and deliver expressed antigen through activation pathway of innate immunity to the intestinal immune tissues.", [["intestinal wall", "ANATOMY", 36, 51], ["intestinal immune tissues", "ANATOMY", 135, 160], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 36, 51], ["intestinal immune tissues", "TISSUE", 135, 160], ["Salmonella", "SPECIES", 11, 21], ["Attenuated Salmonella", "PROBLEM", 0, 21], ["Salmonella", "OBSERVATION", 11, 21], ["intestinal wall", "ANATOMY", 36, 51], ["intestinal immune tissues", "OBSERVATION", 135, 160]]], ["Another vector strain has employed commensal bacteria for presentation of foreign antigens, since the strains are naturally colonized without inducing clinical signs and are able to persist for years in body compartments [59] .Live bacteria as carrierFor examples, when fusion proteins containing viral antigens were expressed on the surface of oral vaccine strain, S. Typhimurium Ty21a, and inoculated intransally or intraperitoneally into mice, this bacterial carrier vaccine induced mucosal and systemic immunity against multiple viral antigens.", [["body compartments", "ANATOMY", 203, 220], ["surface", "ANATOMY", 334, 341], ["oral", "ANATOMY", 345, 349], ["intransally", "ANATOMY", 403, 414], ["intraperitoneally", "ANATOMY", 418, 435], ["mucosal", "ANATOMY", 486, 493], ["body", "ORGANISM_SUBDIVISION", 203, 207], ["surface", "CELLULAR_COMPONENT", 334, 341], ["oral vaccine strain", "ORGANISM", 345, 364], ["S. Typhimurium", "ORGANISM", 366, 380], ["Ty21a", "ORGANISM", 381, 386], ["mice", "ORGANISM", 441, 445], ["mucosal", "MULTI-TISSUE_STRUCTURE", 486, 493], ["foreign antigens", "PROTEIN", 74, 90], ["fusion proteins", "PROTEIN", 270, 285], ["viral antigens", "PROTEIN", 297, 311], ["multiple viral antigens", "PROTEIN", 524, 547], ["S. Typhimurium", "SPECIES", 366, 380], ["mice", "SPECIES", 441, 445], ["S. Typhimurium", "SPECIES", 366, 380], ["mice", "SPECIES", 441, 445], ["Another vector strain", "PROBLEM", 0, 21], ["commensal bacteria", "PROBLEM", 35, 53], ["foreign antigens", "PROBLEM", 74, 90], ["the strains", "PROBLEM", 98, 109], ["Live bacteria", "PROBLEM", 227, 240], ["fusion proteins containing viral antigens", "PROBLEM", 270, 311], ["oral vaccine strain", "TREATMENT", 345, 364], ["this bacterial carrier vaccine", "TREATMENT", 447, 477], ["multiple viral antigens", "PROBLEM", 524, 547], ["foreign antigens", "OBSERVATION", 74, 90], ["mucosal", "ANATOMY", 486, 493]]], ["Thus, such vaccine strain of Salmonella can play a significant role in delivering foreign vaccine proteins [54] .", [["Salmonella", "CHEMICAL", 29, 39], ["Salmonella", "ORGANISM", 29, 39], ["foreign vaccine proteins", "PROTEIN", 82, 106], ["Salmonella", "SPECIES", 29, 39], ["such vaccine strain", "TREATMENT", 6, 25], ["Salmonella", "PROBLEM", 29, 39], ["foreign vaccine proteins", "TREATMENT", 82, 106]]], ["Virulence-associated genes, K88ac, K99, FasA, F41, and intimin from pathogenic E. coli were individually cloned into an attenuated S. Typhimurium (\u25b3cpxR\u25b3lon\u25b3asd).", [["K88ac", "GENE_OR_GENE_PRODUCT", 28, 33], ["K99", "GENE_OR_GENE_PRODUCT", 35, 38], ["FasA", "GENE_OR_GENE_PRODUCT", 40, 44], ["F41", "GENE_OR_GENE_PRODUCT", 46, 49], ["intimin", "GENE_OR_GENE_PRODUCT", 55, 62], ["E. coli", "ORGANISM", 79, 86], ["S. Typhimurium", "ORGANISM", 131, 145], ["Virulence-associated genes", "DNA", 0, 26], ["K88ac", "DNA", 28, 33], ["K99", "DNA", 35, 38], ["FasA", "DNA", 40, 44], ["F41", "DNA", 46, 49], ["intimin", "DNA", 55, 62], ["E. coli", "SPECIES", 79, 86], ["S. Typhimurium", "SPECIES", 131, 145], ["E. coli", "SPECIES", 79, 86], ["S. Typhimurium", "SPECIES", 131, 145], ["Virulence", "TEST", 0, 9], ["K88ac", "TEST", 28, 33], ["K99", "TREATMENT", 35, 38], ["FasA", "TREATMENT", 40, 44], ["F41", "TREATMENT", 46, 49], ["intimin", "PROBLEM", 55, 62], ["pathogenic E. coli", "PROBLEM", 68, 86], ["E. coli", "OBSERVATION", 79, 86]]], ["Once such recombinant strains were injected into mice, they were not detected in fecal samples but highly immunogenic [60] .", [["fecal samples", "ANATOMY", 81, 94], ["mice", "ORGANISM", 49, 53], ["fecal samples", "ORGANISM_SUBSTANCE", 81, 94], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 49, 53], ["such recombinant strains", "PROBLEM", 5, 29], ["fecal samples", "TEST", 81, 94]]], ["ETEC is responsible for the most common enteric colibacillosis in piglets.", [["ETEC", "DISEASE", 0, 4], ["enteric colibacillosis", "DISEASE", 40, 62], ["piglets", "ORGANISM", 66, 73], ["piglets", "SPECIES", 66, 73], ["ETEC", "SPECIES", 0, 4], ["ETEC", "PROBLEM", 0, 4], ["the most common enteric colibacillosis in piglets", "PROBLEM", 24, 73], ["responsible for", "UNCERTAINTY", 8, 23], ["colibacillosis", "OBSERVATION", 48, 62]]], ["A K99 fimbria is known as a specific adhesion factor that is associated with the colonization of ETEC in the small intestine.", [["small intestine", "ANATOMY", 109, 124], ["K99", "GENE_OR_GENE_PRODUCT", 2, 5], ["ETEC", "GENE_OR_GENE_PRODUCT", 97, 101], ["small intestine", "ORGAN", 109, 124], ["K99 fimbria", "DNA", 2, 13], ["adhesion factor", "PROTEIN", 37, 52], ["A K99 fimbria", "TREATMENT", 0, 13], ["a specific adhesion factor", "PROBLEM", 26, 52], ["the colonization of ETEC in the small intestine", "PROBLEM", 77, 124], ["colonization", "OBSERVATION", 81, 93], ["ETEC", "OBSERVATION", 97, 101], ["small intestine", "ANATOMY", 109, 124]]], ["Recombinant Lactobacillus acidophilus expressing recombinant E. coli K99 fimbriae showed a significant inhibitory effect to E. coli K99, consequently prevented E. coli binding to intestinal brush border [61] .", [["intestinal brush border", "ANATOMY", 179, 202], ["Lactobacillus acidophilus", "CHEMICAL", 12, 37], ["Lactobacillus acidophilus", "ORGANISM", 12, 37], ["E. coli", "ORGANISM", 61, 68], ["K99 fimbriae", "ORGANISM", 69, 81], ["E. coli", "ORGANISM", 124, 131], ["K99", "ORGANISM", 132, 135], ["E. coli", "ORGANISM", 160, 167], ["intestinal brush", "MULTI-TISSUE_STRUCTURE", 179, 195], ["Lactobacillus acidophilus", "SPECIES", 12, 37], ["E. coli K99", "SPECIES", 61, 72], ["E. coli", "SPECIES", 124, 131], ["E. coli", "SPECIES", 160, 167], ["Lactobacillus acidophilus", "SPECIES", 12, 37], ["E. coli", "SPECIES", 61, 68], ["E. coli", "SPECIES", 124, 131], ["E. coli", "SPECIES", 160, 167], ["Recombinant Lactobacillus acidophilus", "TREATMENT", 0, 37], ["recombinant E. coli K99 fimbriae", "PROBLEM", 49, 81], ["a significant inhibitory effect", "PROBLEM", 89, 120], ["E. coli K99", "PROBLEM", 124, 135], ["E. coli binding", "PROBLEM", 160, 175], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["inhibitory effect", "OBSERVATION", 103, 120], ["coli K99", "OBSERVATION", 127, 135], ["coli binding", "OBSERVATION", 163, 175], ["intestinal", "ANATOMY", 179, 189], ["brush", "ANATOMY_MODIFIER", 190, 195]]], ["To evaluate the effect of swine interleukine-18 (swIL-18) as an immune modulator for killed vaccine, an attenuated S. Typhimurium expressing swIL-18 was constructed and orally administrated into pigs prior to vaccination with inactivated pseudorabies vaccine.", [["interleukine-18", "CHEMICAL", 32, 47], ["swIL-18", "CHEMICAL", 49, 56], ["swIL-18", "CHEMICAL", 141, 148], ["interleukine-18", "CHEMICAL", 32, 47], ["swIL-18", "CHEMICAL", 49, 56], ["swine", "ORGANISM", 26, 31], ["interleukine-18", "GENE_OR_GENE_PRODUCT", 32, 47], ["swIL-18", "GENE_OR_GENE_PRODUCT", 49, 56], ["S. Typhimurium", "ORGANISM", 115, 129], ["swIL-18", "ORGANISM", 141, 148], ["pigs", "ORGANISM", 195, 199], ["pseudorabies", "ORGANISM", 238, 250], ["swIL-18", "PROTEIN", 141, 148], ["swine", "SPECIES", 26, 31], ["S. Typhimurium", "SPECIES", 115, 129], ["pigs", "SPECIES", 195, 199], ["swine", "SPECIES", 26, 31], ["S. Typhimurium", "SPECIES", 115, 129], ["pigs", "SPECIES", 195, 199], ["pseudorabies", "SPECIES", 238, 250], ["swine interleukine", "TEST", 26, 44], ["an immune modulator", "TREATMENT", 61, 80], ["killed vaccine", "TREATMENT", 85, 99], ["vaccination", "TREATMENT", 209, 220], ["inactivated pseudorabies vaccine", "TREATMENT", 226, 258]]], ["The pigs received swIL-8 by the recombinant Salmonella elicited the enhanced levels of pseudorabies-specific IgG and IgG2 compared to control group.", [["swIL-8", "CHEMICAL", 18, 24], ["pigs", "ORGANISM", 4, 8], ["swIL-8", "GENE_OR_GENE_PRODUCT", 18, 24], ["recombinant Salmonella", "ORGANISM", 32, 54], ["pseudorabies", "ORGANISM", 87, 99], ["IgG", "GENE_OR_GENE_PRODUCT", 109, 112], ["IgG2", "GENE_OR_GENE_PRODUCT", 117, 121], ["pseudorabies-specific IgG", "PROTEIN", 87, 112], ["IgG2", "PROTEIN", 117, 121], ["pigs", "SPECIES", 4, 8], ["pigs", "SPECIES", 4, 8], ["Salmonella", "SPECIES", 44, 54], ["pseudorabies", "SPECIES", 87, 99], ["The pigs", "TREATMENT", 0, 8], ["swIL", "TEST", 18, 22], ["pseudorabies", "PROBLEM", 87, 99], ["IgG2", "TEST", 117, 121]]], ["In addition, such immune responses are rapidly elevated and rendered piglets displayed more alleviated clinical signs following challenge with the virulent pseudorabies virus [62] .", [["piglets", "ORGANISM", 69, 76], ["pseudorabies virus", "ORGANISM", 156, 174], ["virulent pseudorabies virus", "SPECIES", 147, 174], ["pseudorabies virus", "SPECIES", 156, 174], ["rapidly elevated", "PROBLEM", 39, 55], ["the virulent pseudorabies virus", "PROBLEM", 143, 174]]], ["For PRRSV, the recombinant an attenuated S. Typhimurium expressing the ORF7 protein of PRRSV was constructed and immunized into mice to evaluate its capability of inducing immune responses against PRRSV.", [["PRRSV", "ORGANISM", 4, 9], ["S. Typhimurium", "ORGANISM", 41, 55], ["ORF7", "GENE_OR_GENE_PRODUCT", 71, 75], ["PRRSV", "ORGANISM", 87, 92], ["mice", "ORGANISM", 128, 132], ["PRRSV", "ORGANISM", 197, 202], ["ORF7 protein", "PROTEIN", 71, 83], ["S. Typhimurium", "SPECIES", 41, 55], ["PRRSV", "SPECIES", 87, 92], ["mice", "SPECIES", 128, 132], ["PRRSV", "SPECIES", 197, 202], ["PRRSV", "SPECIES", 4, 9], ["S. Typhimurium", "SPECIES", 41, 55], ["PRRSV", "SPECIES", 87, 92], ["mice", "SPECIES", 128, 132], ["PRRSV", "SPECIES", 197, 202], ["PRRSV", "PROBLEM", 4, 9], ["PRRSV", "PROBLEM", 87, 92], ["PRRSV", "PROBLEM", 197, 202]]], ["Following oral administration of a single dose of the recombinant Salmonella, both humoral and cell-mediated immunity against ORF7 were induced at both systemic and mucosal sites, and were sustained for at least 12 weeks post-immunization [63] .Conjugated vaccine/toxoidConjugated vaccines are somewhat similar to recombinant subunit vaccines, which are usually composed of two different components.", [["oral", "ANATOMY", 10, 14], ["cell", "ANATOMY", 95, 99], ["mucosal sites", "ANATOMY", 165, 178], ["oral", "ORGANISM_SUBDIVISION", 10, 14], ["cell", "CELL", 95, 99], ["ORF7", "GENE_OR_GENE_PRODUCT", 126, 130], ["mucosal sites", "MULTI-TISSUE_STRUCTURE", 165, 178], ["ORF7", "PROTEIN", 126, 130], ["Salmonella", "SPECIES", 66, 76], ["the recombinant Salmonella", "TREATMENT", 50, 76], ["cell-mediated immunity", "TREATMENT", 95, 117], ["ORF7", "TREATMENT", 126, 130], ["Conjugated vaccine", "TREATMENT", 245, 263], ["toxoidConjugated vaccines", "TREATMENT", 264, 289], ["recombinant subunit vaccines", "TREATMENT", 314, 342], ["mucosal sites", "ANATOMY", 165, 178], ["two different", "OBSERVATION_MODIFIER", 374, 387], ["components", "OBSERVATION_MODIFIER", 388, 398]]], ["They have been generated against pathogens whose polysaccharide capsule protect them from the phagocytosis.", [["capsule", "ANATOMY", 64, 71], ["polysaccharide capsule", "ORGANISM", 49, 71], ["polysaccharide capsule", "TREATMENT", 49, 71]]], ["Since the polysaccharide is poorly immunogenic, linking the polysaccharide to immunogenic protein enables the immune system to recognize them as if they were protein antigens.", [["immune system", "ANATOMY", 110, 123], ["immunogenic protein", "PROTEIN", 78, 97], ["protein antigens", "PROTEIN", 158, 174], ["poorly immunogenic", "PROBLEM", 28, 46], ["the polysaccharide", "TREATMENT", 56, 74], ["poorly immunogenic", "OBSERVATION_MODIFIER", 28, 46]]], ["They are produced by chemically linking the polysaccharide to a carrier protein, which creates stronger, combined immune responses to the piece derived from bacteria as well as the carrier protein.", [["carrier protein", "PROTEIN", 64, 79], ["carrier protein", "PROTEIN", 181, 196], ["a carrier protein", "TEST", 62, 79], ["bacteria", "PROBLEM", 157, 165], ["the carrier protein", "TEST", 177, 196]]], ["Immunity to a piece of the bacteria can protect from future infection.", [["infection", "DISEASE", 60, 69], ["the bacteria", "PROBLEM", 23, 35], ["future infection", "PROBLEM", 53, 69], ["infection", "OBSERVATION", 60, 69]]], ["Such types of vaccines are currently in use for Streptococcus pneumoniae.", [["Streptococcus pneumoniae", "DISEASE", 48, 72], ["Streptococcus pneumoniae", "ORGANISM", 48, 72], ["Streptococcus pneumoniae", "SPECIES", 48, 72], ["Streptococcus pneumoniae", "SPECIES", 48, 72], ["vaccines", "TREATMENT", 14, 22], ["Streptococcus pneumoniae", "PROBLEM", 48, 72]]], ["In contrast, some bacterial diseases are not directly caused by bacteria themselves but by a toxin produced by the bacteria.", [["bacterial diseases", "DISEASE", 18, 36], ["toxin", "PROTEIN", 93, 98], ["some bacterial diseases", "PROBLEM", 13, 36], ["bacteria themselves", "PROBLEM", 64, 83], ["a toxin", "TEST", 91, 98], ["the bacteria", "PROBLEM", 111, 123], ["bacterial diseases", "OBSERVATION", 18, 36], ["not directly caused", "UNCERTAINTY", 41, 60], ["bacteria", "OBSERVATION", 64, 72]]], ["Tetanus is caused by neurotoxin that is produced by Clostridium tetani, rather than bacterial infection.", [["Tetanus", "DISEASE", 0, 7], ["bacterial infection", "DISEASE", 84, 103], ["Clostridium tetani", "ORGANISM", 52, 70], ["Clostridium tetani", "SPECIES", 52, 70], ["Clostridium tetani", "SPECIES", 52, 70], ["Tetanus", "TREATMENT", 0, 7], ["neurotoxin", "PROBLEM", 21, 31], ["Clostridium tetani", "PROBLEM", 52, 70], ["bacterial infection", "PROBLEM", 84, 103], ["bacterial", "OBSERVATION_MODIFIER", 84, 93], ["infection", "OBSERVATION", 94, 103]]], ["Vaccines for this type of pathogen can be generated by inactivating the toxin responsible for causing clinical signs.", [["Vaccines", "TREATMENT", 0, 8], ["pathogen", "PROBLEM", 26, 34], ["the toxin", "TEST", 68, 77], ["clinical signs", "PROBLEM", 102, 116]]], ["As with the other pathogens used for killed vaccines, the inactivation process can be performed via treatment with heat or chemicals, or other suitable means.", [["the other pathogens", "PROBLEM", 8, 27], ["killed vaccines", "TREATMENT", 37, 52], ["the inactivation process", "TREATMENT", 54, 78], ["heat or chemicals", "TREATMENT", 115, 132]]], ["Although inactivated toxin could be considered a killed vaccine, sometimes it should be in its own category to highlight that it contains an inactivated toxin but not bacteria.Conjugated vaccine/toxoidFor examples, a conjugated vaccine, composed of Vi capsular polysaccharide of S. Typi conjugated with diphtheria toxoid, was generated and inoculated into mice in order to validate its immunogenicity [64] .", [["diphtheria toxoid", "CHEMICAL", 303, 320], ["toxoid", "ORGANISM", 195, 201], ["S. Typi", "ORGANISM", 279, 286], ["conjugated", "ORGANISM", 287, 297], ["diphtheria toxoid", "ORGANISM", 303, 320], ["mice", "ORGANISM", 356, 360], ["S. Typi", "SPECIES", 279, 286], ["diphtheria toxoid", "SPECIES", 303, 320], ["mice", "SPECIES", 356, 360], ["S. Typi", "SPECIES", 279, 286], ["mice", "SPECIES", 356, 360], ["inactivated toxin", "PROBLEM", 9, 26], ["a killed vaccine", "TREATMENT", 47, 63], ["an inactivated toxin", "PROBLEM", 138, 158], ["bacteria", "PROBLEM", 167, 175], ["Conjugated vaccine", "TREATMENT", 176, 194], ["toxoid", "TREATMENT", 195, 201], ["a conjugated vaccine", "TREATMENT", 215, 235], ["Vi capsular polysaccharide", "TREATMENT", 249, 275], ["diphtheria toxoid", "TREATMENT", 303, 320]]], ["Immunization of a single dose of the conjugate induced the high titers of anti-V1 IgG, whereas inoculation of the large amount of unconjugated V1 polysaccharide alone showed the suppression of anti-V1 antibody [64] .", [["anti-V1 IgG", "GENE_OR_GENE_PRODUCT", 74, 85], ["V1 polysaccharide", "SIMPLE_CHEMICAL", 143, 160], ["anti-V1 antibody", "GENE_OR_GENE_PRODUCT", 193, 209], ["anti-V1 IgG", "PROTEIN", 74, 85], ["anti-V1 antibody", "PROTEIN", 193, 209], ["anti-V1", "SPECIES", 74, 81], ["Immunization", "TREATMENT", 0, 12], ["the conjugate", "TREATMENT", 33, 46], ["anti-V1 IgG", "TREATMENT", 74, 85], ["unconjugated V1 polysaccharide", "PROBLEM", 130, 160], ["anti-V1 antibody", "TEST", 193, 209], ["large", "OBSERVATION_MODIFIER", 114, 119], ["amount", "OBSERVATION_MODIFIER", 120, 126]]], ["Capsular polysaccharide of S. pneumoniae conjugated with cholera toxin B subunit evoked mucosal and systemic immune responses after immunization via either peritoneal or intranasal route [65, 66] . been mainly focused on the control of infectious diseases of animals, the current status of development of effective vaccines to reduce foodborne pathogen loads in livestock is highlighted in this section.", [["mucosal", "ANATOMY", 88, 95], ["peritoneal", "ANATOMY", 156, 166], ["cholera toxin B", "CHEMICAL", 57, 72], ["infectious diseases", "DISEASE", 236, 255], ["S. pneumoniae", "ORGANISM", 27, 40], ["cholera toxin B subunit", "GENE_OR_GENE_PRODUCT", 57, 80], ["mucosal", "MULTI-TISSUE_STRUCTURE", 88, 95], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 156, 166], ["cholera toxin B subunit", "PROTEIN", 57, 80], ["S. pneumoniae", "SPECIES", 27, 40], ["S. pneumoniae", "SPECIES", 27, 40], ["Capsular polysaccharide", "TREATMENT", 0, 23], ["S. pneumoniae", "PROBLEM", 27, 40], ["cholera toxin B subunit", "TREATMENT", 57, 80], ["immunization", "TREATMENT", 132, 144], ["infectious diseases of animals", "PROBLEM", 236, 266], ["effective vaccines", "TREATMENT", 305, 323], ["foodborne pathogen loads", "PROBLEM", 334, 358], ["pneumoniae", "OBSERVATION", 30, 40], ["mucosal", "ANATOMY", 88, 95], ["peritoneal", "ANATOMY", 156, 166], ["infectious", "OBSERVATION", 236, 246]]], ["As an intervention strategy, animal vaccines can also be used for reducing the risk of transmitting zoonotic agents for industry animal to humans through the consumption of meat products.", [["meat", "ANATOMY", 173, 177], ["humans", "ORGANISM", 139, 145], ["meat", "ORGANISM_SUBDIVISION", 173, 177], ["humans", "SPECIES", 139, 145], ["humans", "SPECIES", 139, 145], ["an intervention strategy", "TREATMENT", 3, 27], ["animal vaccines", "TREATMENT", 29, 44], ["transmitting zoonotic agents", "TREATMENT", 87, 115], ["meat products", "TREATMENT", 173, 186]]], ["The demand for food products, including meats, is drastically being increased to supply the rapidly growing population worldwide, which results in an increasing population of industry animals.", [["meats", "ANATOMY", 40, 45], ["food products", "TREATMENT", 15, 28], ["rapidly", "OBSERVATION_MODIFIER", 92, 99], ["growing", "OBSERVATION_MODIFIER", 100, 107], ["increasing", "OBSERVATION_MODIFIER", 150, 160], ["population", "OBSERVATION_MODIFIER", 161, 171]]], ["When a large number of industry animals are raised in small regions, there are great chances for infectious diseases, including zoonotic agents, to strike.", [["infectious diseases", "DISEASE", 97, 116], ["infectious diseases", "PROBLEM", 97, 116], ["zoonotic agents", "TREATMENT", 128, 143], ["large", "OBSERVATION_MODIFIER", 7, 12], ["number", "OBSERVATION_MODIFIER", 13, 19], ["small", "OBSERVATION_MODIFIER", 54, 59], ["great", "OBSERVATION_MODIFIER", 79, 84], ["infectious", "OBSERVATION", 97, 107]]], ["In particular, some pathogens capable of establishing themselves within industry animals without harmful clinical signs can sometimes become infectious to humans and cause illness.", [["humans", "ORGANISM", 155, 161], ["humans", "SPECIES", 155, 161], ["humans", "SPECIES", 155, 161], ["some pathogens", "PROBLEM", 15, 29], ["harmful clinical signs", "PROBLEM", 97, 119], ["illness", "PROBLEM", 172, 179], ["some", "OBSERVATION_MODIFIER", 15, 19], ["pathogens", "OBSERVATION", 20, 29], ["infectious", "OBSERVATION", 141, 151]]], ["Other types of zoonotic agents can cause clinical signs in both industry animals and humans.", [["humans", "ORGANISM", 85, 91], ["humans", "SPECIES", 85, 91], ["humans", "SPECIES", 85, 91], ["zoonotic agents", "TREATMENT", 15, 30], ["clinical signs", "PROBLEM", 41, 55], ["zoonotic", "OBSERVATION", 15, 23]]], ["Both of them can transmit to humans via food consumption and cause zoonotic illness on humans [10] .Vaccines against zoonotic bacteriaRecently, strict regulation on the use of antimicrobials in animal feed was established in order to avoid emerging issues of antibiotic resistances which could cause problematic issues for humans in the future.", [["zoonotic illness", "DISEASE", 67, 83], ["humans", "ORGANISM", 29, 35], ["humans", "ORGANISM", 87, 93], ["humans", "ORGANISM", 323, 329], ["humans", "SPECIES", 29, 35], ["humans", "SPECIES", 87, 93], ["humans", "SPECIES", 323, 329], ["humans", "SPECIES", 29, 35], ["humans", "SPECIES", 87, 93], ["humans", "SPECIES", 323, 329], ["Vaccines", "TREATMENT", 100, 108], ["zoonotic bacteriaRecently", "TREATMENT", 117, 142], ["antimicrobials", "TREATMENT", 176, 190], ["animal feed", "TREATMENT", 194, 205], ["antibiotic resistances", "TREATMENT", 259, 281], ["problematic issues", "PROBLEM", 300, 318], ["antibiotic resistances", "OBSERVATION", 259, 281]]], ["Antibiotic resistance within normal flora of industry animals after over-use of antibiotics can be transferred to zoonotic agents, and eventually to humans, which is a current sensitive issue in the animal industry.", [["humans", "ORGANISM", 149, 155], ["humans", "SPECIES", 149, 155], ["humans", "SPECIES", 149, 155], ["Antibiotic resistance", "PROBLEM", 0, 21], ["antibiotics", "TREATMENT", 80, 91], ["normal", "OBSERVATION_MODIFIER", 29, 35], ["flora", "OBSERVATION_MODIFIER", 36, 41]]], ["Under these conditions, effective vaccine for zoonotic pathogens in industry animals may help to resolve public health concern.", [["zoonotic pathogens", "DISEASE", 46, 64], ["effective vaccine", "TREATMENT", 24, 41], ["zoonotic pathogens", "PROBLEM", 46, 64]]], ["On the basis of recent reports, about 75% of emerging infectious diseases are zoonotic, indicating that effective means to control such diseases would be of great value.Vaccines against zoonotic bacteriaIn general, modern vaccines against zoonotic agents in industry animals should be marker vaccines because the industry would use it massively and then resulting immunity could be differentially measured by companion diagnostic methods.", [["infectious diseases", "DISEASE", 54, 73], ["zoonotic bacteriaIn", "DISEASE", 186, 205], ["emerging infectious diseases", "PROBLEM", 45, 73], ["such diseases", "PROBLEM", 131, 144], ["Vaccines", "TREATMENT", 169, 177], ["zoonotic bacteriaIn", "TREATMENT", 186, 205], ["modern vaccines", "TREATMENT", 215, 230], ["zoonotic agents", "TREATMENT", 239, 254], ["marker vaccines", "TREATMENT", 285, 300], ["infectious", "OBSERVATION", 54, 64]]], ["The marker vaccine which will not interfere with the current diagnostic procedures in vaccinated animals will certainly help in controlling zoonotic diseases.", [["zoonotic diseases", "DISEASE", 140, 157], ["The marker vaccine", "TREATMENT", 0, 18], ["vaccinated animals", "TREATMENT", 86, 104], ["zoonotic diseases", "PROBLEM", 140, 157]]], ["The development of a more specific diagnostic method to replace the current test, will allow the development of both live and killed vaccine.", [["the current test", "TEST", 64, 80]]], ["Various vaccines have shown limited effectiveness in reducing transmission of zoonotic agents to humans through the consumption of animal-derived products.", [["humans", "ORGANISM", 97, 103], ["humans", "SPECIES", 97, 103], ["humans", "SPECIES", 97, 103], ["Various vaccines", "TREATMENT", 0, 16], ["zoonotic agents", "TREATMENT", 78, 93], ["animal-derived products", "TREATMENT", 131, 154]]], ["It should be noted that certain generic procedures can be applied to preventing the establishment of zoonotic agents in livestock, and keeping the animals free of infection by preventing contact between them and other potentially infected animals, and maintaining clean housing and food.", [["infection", "DISEASE", 163, 172], ["generic procedures", "TREATMENT", 32, 50], ["zoonotic agents", "TREATMENT", 101, 116], ["infection", "PROBLEM", 163, 172], ["infection", "OBSERVATION", 163, 172], ["infected", "OBSERVATION", 230, 238]]], ["Nevertheless, more research is required to develop a complementary vaccine and sanitation program to protect humans from zoonotic infection.", [["zoonotic infection", "DISEASE", 121, 139], ["humans", "ORGANISM", 109, 115], ["humans", "SPECIES", 109, 115], ["humans", "SPECIES", 109, 115], ["a complementary vaccine", "TREATMENT", 51, 74], ["sanitation program", "TREATMENT", 79, 97], ["zoonotic infection", "PROBLEM", 121, 139], ["zoonotic", "OBSERVATION_MODIFIER", 121, 129], ["infection", "OBSERVATION", 130, 139]]], ["The present section focuses on animal vaccines selected for zoonotic agents economically significant in industry animals.", [["animal vaccines", "TREATMENT", 31, 46], ["zoonotic agents", "TREATMENT", 60, 75]]], ["Among enteric bacteria which are frequently present, E. coli O157:H7 is the most deadly bacteria which is often present in the gut feces, and other skin of healthy cattle and sheep.", [["gut feces", "ANATOMY", 127, 136], ["skin", "ANATOMY", 148, 152], ["E. coli", "ORGANISM", 53, 60], ["O157:H7", "ORGANISM", 61, 68], ["gut feces", "ORGAN", 127, 136], ["skin", "ORGAN", 148, 152], ["cattle", "ORGANISM", 164, 170], ["sheep", "ORGANISM", 175, 180], ["E. coli O157", "SPECIES", 53, 65], ["cattle", "SPECIES", 164, 170], ["sheep", "SPECIES", 175, 180], ["E. coli O157:H7", "SPECIES", 53, 68], ["cattle", "SPECIES", 164, 170], ["sheep", "SPECIES", 175, 180], ["Among enteric bacteria", "PROBLEM", 0, 22], ["H7", "PROBLEM", 66, 68], ["the most deadly bacteria", "PROBLEM", 72, 96], ["bacteria", "OBSERVATION", 14, 22], ["most deadly", "OBSERVATION_MODIFIER", 76, 87], ["bacteria", "OBSERVATION", 88, 96], ["gut", "ANATOMY", 127, 130], ["feces", "OBSERVATION", 131, 136], ["skin", "ANATOMY", 148, 152]]], ["The bacteria are well adapted to the host without showing evident clinical signs.", [["The bacteria", "PROBLEM", 0, 12], ["bacteria", "OBSERVATION", 4, 12]]], ["The bacteria can survive for a couple of months at various environment conditions, could transmit to humans via food; notably under cooked ground beef and raw milk.", [["milk", "ANATOMY", 159, 163], ["humans", "ORGANISM", 101, 107], ["beef", "ORGANISM_SUBDIVISION", 146, 150], ["milk", "ORGANISM_SUBSTANCE", 159, 163], ["humans", "SPECIES", 101, 107], ["beef", "SPECIES", 146, 150], ["humans", "SPECIES", 101, 107], ["beef", "SPECIES", 146, 150], ["The bacteria", "PROBLEM", 0, 12], ["bacteria", "OBSERVATION", 4, 12]]], ["Human outbreaks are associated with hemolytic uremic syndrome (a severe consequence among a small percentage of cases).", [["hemolytic uremic syndrome", "DISEASE", 36, 61], ["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human outbreaks", "PROBLEM", 0, 15], ["hemolytic uremic syndrome", "PROBLEM", 36, 61], ["a severe consequence", "PROBLEM", 63, 83], ["associated with", "UNCERTAINTY", 20, 35], ["hemolytic", "OBSERVATION_MODIFIER", 36, 45], ["uremic syndrome", "OBSERVATION", 46, 61], ["small", "OBSERVATION_MODIFIER", 92, 97]]], ["Although various intervention strategies were introduced in feedlots in the US, strict hygienic measures account for the decline of O157:H7 outbreaks.", [["O157", "SPECIES", 132, 136], ["various intervention strategies", "TREATMENT", 9, 40], ["the US", "TEST", 72, 78], ["strict hygienic measures", "TREATMENT", 80, 104]]], ["Recently, a subunit vaccine containing secreted virulence factors has been tested in the field in feedlot cattle but the results were still far from clearance of the bacteria.", [["secreted virulence factors", "PROTEIN", 39, 65], ["cattle", "SPECIES", 106, 112], ["feedlot", "SPECIES", 98, 105], ["cattle", "SPECIES", 106, 112], ["a subunit vaccine", "TREATMENT", 10, 27], ["secreted virulence factors", "PROBLEM", 39, 65], ["the bacteria", "PROBLEM", 162, 174], ["bacteria", "OBSERVATION", 166, 174]]], ["Clearly, vaccination could be an aid in the future reduction in the number of outbreaks, but only in combination with hygiene measures.", [["vaccination", "TREATMENT", 9, 20], ["hygiene measures", "TREATMENT", 118, 134], ["number", "OBSERVATION_MODIFIER", 68, 74], ["outbreaks", "OBSERVATION", 78, 87]]], ["Among many serotypes of Salmonella species, clinical salmonellosis for industry animals is the result of infection with host-restricted serotypes of Salmonella, such as S. Enteritis, S. Gallinarum, S. Dublin, and S. Pullorum.", [["salmonellosis", "DISEASE", 53, 66], ["infection", "DISEASE", 105, 114], ["Salmonella species", "ORGANISM", 24, 42], ["S. Enteritis", "ORGANISM", 169, 181], ["S. Gallinarum", "ORGANISM", 183, 196], ["S. Dublin", "ORGANISM", 198, 207], ["S. Pullorum", "ORGANISM", 213, 224], ["S. Enteritis", "SPECIES", 169, 181], ["S. Gallinarum", "SPECIES", 183, 196], ["S. Pullorum", "SPECIES", 213, 224], ["Salmonella", "SPECIES", 149, 159], ["S. Enteritis", "SPECIES", 169, 181], ["S. Gallinarum", "SPECIES", 183, 196], ["S. Pullorum", "SPECIES", 213, 224], ["Salmonella species", "PROBLEM", 24, 42], ["clinical salmonellosis", "PROBLEM", 44, 66], ["infection", "PROBLEM", 105, 114], ["Salmonella", "PROBLEM", 149, 159], ["S. Enteritis", "PROBLEM", 169, 181], ["Salmonella species", "OBSERVATION", 24, 42], ["infection", "OBSERVATION", 105, 114], ["Salmonella", "OBSERVATION", 149, 159], ["Enteritis", "OBSERVATION", 172, 181], ["Pullorum", "ANATOMY", 216, 224]]], ["Sometimes, non-host specific Salmonella serotypes sometimes induce self-limiting gastrointestinal infection but can cause systemic infection in a wide variety of host animals including humans.", [["gastrointestinal", "ANATOMY", 81, 97], ["gastrointestinal infection", "DISEASE", 81, 107], ["systemic infection", "DISEASE", 122, 140], ["Salmonella serotypes", "ORGANISM", 29, 49], ["gastrointestinal", "ORGAN", 81, 97], ["humans", "ORGANISM", 185, 191], ["humans", "SPECIES", 185, 191], ["humans", "SPECIES", 185, 191], ["non-host specific Salmonella serotypes", "PROBLEM", 11, 49], ["self-limiting gastrointestinal infection", "PROBLEM", 67, 107], ["systemic infection", "PROBLEM", 122, 140], ["gastrointestinal", "ANATOMY", 81, 97], ["infection", "OBSERVATION", 98, 107], ["systemic", "OBSERVATION_MODIFIER", 122, 130], ["infection", "OBSERVATION", 131, 140]]], ["Among Salmonella spp., S. Typhimurium and S. Enteritidis are the two serotypes most commonly associated with foodborne disease in humans but they mostly occur asymptomatically in livestock.", [["foodborne disease", "DISEASE", 109, 126], ["Salmonella spp.", "ORGANISM", 6, 21], ["S. Typhimurium", "ORGANISM", 23, 37], ["S. Enteritidis", "ORGANISM", 42, 56], ["humans", "ORGANISM", 130, 136], ["Salmonella spp.", "SPECIES", 6, 21], ["S. Typhimurium", "SPECIES", 23, 37], ["S. Enteritidis", "SPECIES", 42, 56], ["humans", "SPECIES", 130, 136], ["Salmonella spp.", "SPECIES", 6, 21], ["S. Typhimurium", "SPECIES", 23, 37], ["S. Enteritidis", "SPECIES", 42, 56], ["humans", "SPECIES", 130, 136], ["Salmonella spp.", "PROBLEM", 6, 21], ["S. Enteritidis", "PROBLEM", 42, 56], ["the two serotypes", "PROBLEM", 61, 78], ["foodborne disease in humans", "PROBLEM", 109, 136], ["Enteritidis", "OBSERVATION", 45, 56], ["foodborne disease", "OBSERVATION", 109, 126]]], ["For poultry, various killed and live vaccines are commercially available.", [["live vaccines", "TREATMENT", 32, 45]]], ["For swine, S. Typhimurium infections are mostly subclinical but can be transferred by meat product to humans.", [["meat", "ANATOMY", 86, 90], ["S. Typhimurium infections", "DISEASE", 11, 36], ["swine", "ORGANISM", 4, 9], ["S. Typhimurium", "ORGANISM", 11, 25], ["meat", "ORGANISM_SUBDIVISION", 86, 90], ["humans", "ORGANISM", 102, 108], ["swine", "SPECIES", 4, 9], ["S. Typhimurium", "SPECIES", 11, 25], ["humans", "SPECIES", 102, 108], ["swine", "SPECIES", 4, 9], ["S. Typhimurium", "SPECIES", 11, 25], ["humans", "SPECIES", 102, 108], ["S. Typhimurium infections", "PROBLEM", 11, 36]]], ["Several vaccines for swine have been shown to be effective to interfere with homologous or heterologous serotypes.", [["swine", "ORGANISM", 21, 26], ["swine", "SPECIES", 21, 26], ["swine", "SPECIES", 21, 26], ["Several vaccines", "TREATMENT", 0, 16], ["heterologous serotypes", "PROBLEM", 91, 113]]], ["Vaccination for livestock is considered to be one of the cornerstones of the strategy to reduce human Salmonella infections.", [["Salmonella infections", "DISEASE", 102, 123], ["human", "ORGANISM", 96, 101], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["Vaccination", "TREATMENT", 0, 11], ["the strategy", "TREATMENT", 73, 85], ["human Salmonella infections", "PROBLEM", 96, 123], ["Salmonella infections", "OBSERVATION", 102, 123]]], ["In general, the protection against to Salmonella is required for cellular immunity as well as in particular, local mucosal immunity in the gastrointestinal tract to prevent colonization in the gut and eliminate bacteria as a cross conhttp://www.ecevr.org/ http://dx. doi.org/10.7774/cevr.2012.1.1.18 tamination problem of meat processing in slaughter houses.", [["cellular", "ANATOMY", 65, 73], ["mucosal", "ANATOMY", 115, 122], ["gastrointestinal tract", "ANATOMY", 139, 161], ["gut", "ANATOMY", 193, 196], ["meat", "ANATOMY", 322, 326], ["cellular", "CELL", 65, 73], ["mucosal", "MULTI-TISSUE_STRUCTURE", 115, 122], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 139, 161], ["gut", "ORGANISM_SUBDIVISION", 193, 196], ["meat", "ORGANISM_SUBDIVISION", 322, 326], ["Salmonella", "SPECIES", 38, 48], ["Salmonella", "PROBLEM", 38, 48], ["cellular immunity", "TREATMENT", 65, 82], ["colonization in the gut", "PROBLEM", 173, 196], ["bacteria", "PROBLEM", 211, 219], ["gastrointestinal tract", "ANATOMY", 139, 161], ["colonization", "OBSERVATION", 173, 185], ["gut", "ANATOMY", 193, 196], ["bacteria", "OBSERVATION", 211, 219]]], ["This would be a very challenging task but various successful cases have been reported.", [["a very challenging task", "PROBLEM", 14, 37]]], ["By this point, attenuated live vaccine is recognized most effective to reduce fecal shedding of Salmonella after vaccination.Vaccines against zoonotic bacteriaCampylobacter jejuni is the major cause of foodborne disease in humans through the consumption of contaminated meat product, in particular poultry.", [["fecal", "ANATOMY", 78, 83], ["meat", "ANATOMY", 270, 274], ["Salmonella", "CHEMICAL", 96, 106], ["zoonotic bacteriaCampylobacter jejuni", "DISEASE", 142, 179], ["foodborne disease", "DISEASE", 202, 219], ["fecal", "ORGANISM_SUBSTANCE", 78, 83], ["zoonotic bacteriaCampylobacter jejuni", "ORGANISM", 142, 179], ["humans", "ORGANISM", 223, 229], ["meat", "ORGANISM_SUBDIVISION", 270, 274], ["zoonotic bacteriaCampylobacter jejuni", "SPECIES", 142, 179], ["humans", "SPECIES", 223, 229], ["Salmonella", "SPECIES", 96, 106], ["zoonotic bacteriaCampylobacter jejuni", "SPECIES", 142, 179], ["humans", "SPECIES", 223, 229], ["attenuated live vaccine", "TREATMENT", 15, 38], ["fecal shedding of Salmonella", "PROBLEM", 78, 106], ["vaccination", "TREATMENT", 113, 124], ["Vaccines", "TREATMENT", 125, 133], ["zoonotic bacteriaCampylobacter jejuni", "PROBLEM", 142, 179], ["foodborne disease in humans", "PROBLEM", 202, 229], ["contaminated meat product", "TREATMENT", 257, 282], ["bacteriaCampylobacter jejuni", "OBSERVATION", 151, 179], ["foodborne disease", "OBSERVATION", 202, 219], ["contaminated meat product", "OBSERVATION", 257, 282]]], ["This bacterium is very well adapted to chicken but has a low infectious dose for humans.", [["chicken", "ORGANISM", 39, 46], ["humans", "ORGANISM", 81, 87], ["chicken", "SPECIES", 39, 46], ["humans", "SPECIES", 81, 87], ["chicken", "SPECIES", 39, 46], ["humans", "SPECIES", 81, 87], ["This bacterium", "PROBLEM", 0, 14], ["low", "OBSERVATION_MODIFIER", 57, 60], ["infectious", "OBSERVATION", 61, 71]]], ["In chicken, the bacteria can be heavily and persistently colonized in the gut without evident clinical signs.", [["gut", "ANATOMY", 74, 77], ["chicken", "ORGANISM", 3, 10], ["gut", "ORGANISM_SUBDIVISION", 74, 77], ["chicken", "SPECIES", 3, 10], ["chicken", "SPECIES", 3, 10], ["the bacteria", "PROBLEM", 12, 24], ["persistently", "OBSERVATION_MODIFIER", 44, 56], ["colonized", "OBSERVATION", 57, 66], ["gut", "ANATOMY", 74, 77], ["without evident", "UNCERTAINTY", 78, 93]]], ["Such lack of pathogenic interaction with the host is the most challenging issue to develop reliable vaccine.", [["pathogenic interaction", "OBSERVATION", 13, 35]]], ["In addition, they are heterologous genetically and antigenically, as the result of uptake of foreign DNA because of their ability of naturally competence.", [["DNA", "CELLULAR_COMPONENT", 101, 104], ["foreign DNA", "PROBLEM", 93, 104], ["foreign DNA", "OBSERVATION", 93, 104]]], ["Many types of live and inactivated vaccine have been tested but it was not practically applicable.", [["live", "TREATMENT", 14, 18], ["inactivated vaccine", "TREATMENT", 23, 42]]], ["Some vaccines containing whole bacteria or flagellin have provided partial protection against Campylobacter challenge in chickens.", [["Campylobacter challenge", "DISEASE", 94, 117], ["flagellin", "GENE_OR_GENE_PRODUCT", 43, 52], ["chickens", "ORGANISM", 121, 129], ["flagellin", "PROTEIN", 43, 52], ["chickens", "SPECIES", 121, 129], ["chickens", "SPECIES", 121, 129], ["Some vaccines", "TREATMENT", 0, 13], ["whole bacteria", "PROBLEM", 25, 39], ["flagellin", "TREATMENT", 43, 52], ["partial protection", "TREATMENT", 67, 85], ["Campylobacter challenge in chickens", "PROBLEM", 94, 129]]], ["However, attenuated live vaccine may be more promising in the near future.", [["attenuated live vaccine", "TREATMENT", 9, 32]]], ["Although several vaccines are under development for preventing human infection, vaccine for chicken would be better way to prevent transmission to humans and ultimately the implementation of rigorous hygienic measures on carcasses after slaughtering would be a the best way to control these bacteria.Vaccines against zoonotic bacteriaBrucellosis has been a major zoonotic disease threating humans and animals in developing countries.", [["infection", "DISEASE", 69, 78], ["zoonotic bacteriaBrucellosis", "DISEASE", 317, 345], ["human", "ORGANISM", 63, 68], ["chicken", "ORGANISM", 92, 99], ["humans", "ORGANISM", 147, 153], ["humans", "ORGANISM", 390, 396], ["human", "SPECIES", 63, 68], ["chicken", "SPECIES", 92, 99], ["humans", "SPECIES", 147, 153], ["humans", "SPECIES", 390, 396], ["human", "SPECIES", 63, 68], ["chicken", "SPECIES", 92, 99], ["humans", "SPECIES", 147, 153], ["humans", "SPECIES", 390, 396], ["several vaccines", "TREATMENT", 9, 25], ["human infection", "PROBLEM", 63, 78], ["vaccine", "TREATMENT", 80, 87], ["chicken", "TREATMENT", 92, 99], ["rigorous hygienic measures", "TREATMENT", 191, 217], ["carcasses", "TREATMENT", 221, 230], ["these bacteria", "PROBLEM", 285, 299], ["Vaccines", "TREATMENT", 300, 308], ["zoonotic bacteriaBrucellosis", "PROBLEM", 317, 345], ["infection", "OBSERVATION", 69, 78], ["major", "OBSERVATION_MODIFIER", 357, 362], ["zoonotic", "OBSERVATION_MODIFIER", 363, 371], ["disease", "OBSERVATION", 372, 379]]], ["Brucella infections in livestock result in abortions, weak offspring and longterm fertility problems.", [["Brucella infections", "DISEASE", 0, 19], ["abortions", "DISEASE", 43, 52], ["Brucella infections", "PROBLEM", 0, 19], ["abortions", "PROBLEM", 43, 52], ["weak offspring", "PROBLEM", 54, 68], ["longterm fertility problems", "PROBLEM", 73, 100], ["infections", "OBSERVATION", 9, 19]]], ["In many developed countries, test and slaughter strategy has been effectively adapted for eradication of these diseases.", [["test", "TEST", 29, 33], ["slaughter strategy", "TREATMENT", 38, 56], ["these diseases", "PROBLEM", 105, 119], ["diseases", "OBSERVATION", 111, 119]]], ["Vaccination provides a considerable level of protection but limited outcome to prevent brucellosis.", [["brucellosis", "DISEASE", 87, 98], ["Vaccination", "TREATMENT", 0, 11], ["brucellosis", "PROBLEM", 87, 98], ["brucellosis", "OBSERVATION", 87, 98]]], ["Thus far, attenuated live vaccine is the most successful, which is widely used for cattle.", [["cattle", "ORGANISM", 83, 89], ["cattle", "SPECIES", 83, 89], ["cattle", "SPECIES", 83, 89], ["attenuated live vaccine", "TREATMENT", 10, 33]]], ["Recently, the vaccine based on the stable rough mutant B. abortus strain RB51 is used in many countries, including the US.", [["RB51", "CHEMICAL", 73, 77], ["mutant", "ORGANISM", 48, 54], ["B. abortus", "ORGANISM", 55, 65], ["strain", "ORGANISM", 66, 72], ["RB51", "ORGANISM", 73, 77], ["B. abortus", "SPECIES", 55, 65], ["B. abortus", "SPECIES", 55, 65], ["RB51", "SPECIES", 73, 77], ["the vaccine", "TREATMENT", 10, 21], ["the US", "TEST", 115, 121]]], ["Human infection usually occurs by consumption of unpasteurized milk.", [["milk", "ANATOMY", 63, 67], ["Human infection", "DISEASE", 0, 15], ["Human", "ORGANISM", 0, 5], ["milk", "ORGANISM_SUBSTANCE", 63, 67], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human infection", "PROBLEM", 0, 15], ["infection", "OBSERVATION", 6, 15]]], ["Since cellular immunity is required for a long-term protection, the best results have been obtained with live attenuated vaccines.", [["cellular", "ANATOMY", 6, 14], ["cellular", "CELL", 6, 14], ["a long-term protection", "TREATMENT", 40, 62], ["live attenuated vaccines", "TREATMENT", 105, 129], ["cellular immunity", "OBSERVATION", 6, 23]]], ["The vaccine also works in herds of adult animals, but lower doses are used to prevent abortion and interference with serological diagnostic tests.", [["abortion", "DISEASE", 86, 94], ["The vaccine", "TREATMENT", 0, 11], ["abortion", "PROBLEM", 86, 94], ["serological diagnostic tests", "TEST", 117, 145]]], ["More recently, the rough strain RB51 with reduced O-antigen expression was developed and has been used in the US since 1996.", [["RB51", "CHEMICAL", 32, 36], ["RB51", "ORGANISM", 32, 36], ["O-antigen", "PROTEIN", 50, 59], ["RB51", "SPECIES", 32, 36], ["the rough strain RB51", "TEST", 15, 36]]], ["Generally speaking, none of the available Brucella vaccines give sterile protection.", [["Brucella", "ORGANISM", 42, 50], ["Brucella vaccines", "TREATMENT", 42, 59], ["sterile protection", "TREATMENT", 65, 83]]], ["The best way to control brucellosis successfully is to use hygienic measures as well as spelling out a specific protocol in production.", [["brucellosis", "DISEASE", 24, 35], ["brucellosis", "PROBLEM", 24, 35], ["hygienic measures", "TREATMENT", 59, 76], ["a specific protocol", "TREATMENT", 101, 120], ["brucellosis", "OBSERVATION", 24, 35]]], ["A research to vaccination against Brucella was conducted once in Korea but the vaccine strategy was abolished to continue the policy of the test and slaughter, which leads to lowering prevalence from 5% in early 2000 to 0.5% in 2012.Vaccines against zoonotic bacteriaIndustry animals are important vehicles for several foodborne pathogens, mainly enteric bacteria which are often asymptomatically carried in the animal's intestine tract and can be major sources for contamination of animal-derived food products.", [["intestine tract", "ANATOMY", 421, 436], ["zoonotic bacteriaIndustry", "DISEASE", 250, 275], ["foodborne pathogens", "DISEASE", 319, 338], ["Brucella", "ORGANISM", 34, 42], ["bacteriaIndustry animals", "ORGANISM", 259, 283], ["intestine tract", "ORGANISM_SUBDIVISION", 421, 436], ["vaccination", "TREATMENT", 14, 25], ["Brucella", "PROBLEM", 34, 42], ["the vaccine strategy", "TREATMENT", 75, 95], ["the test", "TEST", 136, 144], ["Vaccines", "TREATMENT", 233, 241], ["zoonotic bacteriaIndustry animals", "TREATMENT", 250, 283], ["several foodborne pathogens", "PROBLEM", 311, 338], ["mainly enteric bacteria", "PROBLEM", 340, 363], ["intestine", "ANATOMY", 421, 430]]], ["A variety of intervention strategies to reduce foodborne pathogen loads in such products have been developed and then applied at the various stages of food productions.", [["intervention strategies", "TREATMENT", 13, 36], ["foodborne pathogen loads", "PROBLEM", 47, 71], ["such products", "TREATMENT", 75, 88], ["variety", "OBSERVATION_MODIFIER", 2, 9]]], ["However, the best way to reduce such pathogen loads will likely require the application of a combination of various intervention strategies [67, 68] .ConclusionVaccination has been proven to be a cost-effective means to prevent infectious diseases and eradicate such infectious agents.", [["ConclusionVaccination", "CHEMICAL", 150, 171], ["such pathogen loads", "PROBLEM", 32, 51], ["various intervention strategies", "TREATMENT", 108, 139], ["infectious diseases", "PROBLEM", 228, 247], ["infectious agents", "TREATMENT", 267, 284]]], ["As stated in this article, use of vaccines in industry animals has greatly influenced animal health, welfare, productivity of industry animals, and eventually contributed to food safety.", [["vaccines", "TREATMENT", 34, 42]]], ["Despite excellent illustration of vaccine effectiveness against various pathogens, development of animal vaccines has been recognized to be a challenging task due to the presence of a variety of animal types, infectious agents, and different pathogenic mechanisms for each pathogen.", [["vaccine effectiveness", "TREATMENT", 34, 55], ["various pathogens", "PROBLEM", 64, 81], ["animal vaccines", "TREATMENT", 98, 113], ["infectious agents", "TREATMENT", 209, 226], ["each pathogen", "PROBLEM", 268, 281]]], ["In some cases, animal scientists contribute to the development of human vaccines by providing research results obtained from experimental animals, as well as by attempting new trials on animals (which is less restricted than human trials).", [["human", "ORGANISM", 66, 71], ["human", "ORGANISM", 225, 230], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 225, 230], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 225, 230], ["human vaccines", "TREATMENT", 66, 80]]], ["Due to their similar size and anatomy to humans, large animals, in particular pigs are useful for testing vaccine efficacy and vaccine delivery systems.", [["humans", "ORGANISM", 41, 47], ["pigs", "ORGANISM", 78, 82], ["humans", "SPECIES", 41, 47], ["pigs", "SPECIES", 78, 82], ["humans", "SPECIES", 41, 47], ["pigs", "SPECIES", 78, 82], ["large animals", "PROBLEM", 49, 62], ["testing vaccine efficacy", "TREATMENT", 98, 122], ["vaccine delivery systems", "TREATMENT", 127, 151], ["size", "OBSERVATION_MODIFIER", 21, 25], ["anatomy", "OBSERVATION", 30, 37], ["large", "OBSERVATION_MODIFIER", 49, 54], ["animals", "OBSERVATION", 55, 62]]], ["The ultimate goal of animal vaccines is to provide efficient protection to various animals from such infectious agents.", [["animal vaccines", "TREATMENT", 21, 36], ["such infectious agents", "TREATMENT", 96, 118]]], ["For this reason, development of animal vaccines should be achieved by multidisciplinary collaboration, including microbiology, immunology, proteomics, genetics, molecular biology, and even bioinformatics.ConclusionAlthough it is expected to elicit immune responses to protect from wild type infection, vaccination may not be able to completely prevent a natural infection but might reduce the severity of the disease.", [["infection", "DISEASE", 291, 300], ["infection", "DISEASE", 362, 371], ["animal vaccines", "TREATMENT", 32, 47], ["immune responses", "PROBLEM", 248, 264], ["wild type infection", "PROBLEM", 281, 300], ["vaccination", "TREATMENT", 302, 313], ["a natural infection", "PROBLEM", 352, 371], ["the disease", "PROBLEM", 405, 416], ["infection", "OBSERVATION", 362, 371], ["disease", "OBSERVATION", 409, 416]]], ["Sometimes, vaccination can fail when it is executed with improper timing (such as high levels of http://www.ecevr.org/ http://dx. doi.org/10.7774/cevr.2012.1.1.18 pre-existing antibody, malnutrition, environment extremes, and stress conditions), resulting in adverse effects and poor immune responses.", [["malnutrition", "DISEASE", 186, 198], ["improper timing", "PROBLEM", 57, 72], ["pre-existing antibody", "PROBLEM", 163, 184], ["malnutrition", "PROBLEM", 186, 198], ["stress conditions", "PROBLEM", 226, 243], ["adverse effects", "PROBLEM", 259, 274], ["poor immune responses", "PROBLEM", 279, 300]]], ["As another factor, vaccines that do not contain proper immunogenic antigens will not be effective, and therefore correct vaccines should be selected and applied for the proper of time.", [["immunogenic antigens", "PROTEIN", 55, 75], ["vaccines", "TREATMENT", 19, 27], ["proper immunogenic antigens", "TREATMENT", 48, 75], ["correct vaccines", "TREATMENT", 113, 129]]], ["Adverse effects derived from vaccination should be minimal as well as acceptable.", [["Adverse effects", "PROBLEM", 0, 15], ["vaccination", "TREATMENT", 29, 40]]], ["The cost of vaccination should be less than economic loss induced by naturally infection.", [["infection", "DISEASE", 79, 88], ["vaccination", "TREATMENT", 12, 23], ["economic loss", "PROBLEM", 44, 57], ["naturally infection", "PROBLEM", 69, 88], ["naturally", "OBSERVATION_MODIFIER", 69, 78], ["infection", "OBSERVATION", 79, 88]]], ["Additionally, in order to effectively cope with the treatment of various infectious agents, vaccination should be used for animals, with the mutual exchange of information among practitioners, farmers, and disease control agencies.", [["various infectious agents", "TREATMENT", 65, 90], ["vaccination", "TREATMENT", 92, 103]]], ["In particular, many management procedures are extremely important related to the excellent outcome of vaccination-animal density, environmental control, level of stress, cleanliness of the environment and drinking water.ConclusionDeveloping procedures for most animal vaccines still relies on a classical strategy with live pathogens that possess a strong immunogenicity either with high virulence or without virulence.", [["many management procedures", "TREATMENT", 15, 41], ["vaccination", "TREATMENT", 102, 113], ["Developing procedures", "TREATMENT", 230, 251], ["most animal vaccines", "TREATMENT", 256, 276], ["live pathogens", "PROBLEM", 319, 333], ["high virulence", "PROBLEM", 383, 397], ["virulence", "PROBLEM", 409, 418]]], ["However, over the decade there has been great acceleration in the advancement of modern molecular techniques and the compilation of genomic data of many pathogens.", [["modern molecular techniques", "TREATMENT", 81, 108], ["many pathogens", "PROBLEM", 148, 162], ["great", "OBSERVATION_MODIFIER", 40, 45], ["acceleration", "OBSERVATION_MODIFIER", 46, 58], ["many", "OBSERVATION_MODIFIER", 148, 152], ["pathogens", "OBSERVATION", 153, 162]]], ["Such advances provide a great opportunity to create desirable vaccine strains which are less dangerous but more effectively immunogenic than those of vaccines achieved by classical methods.", [["desirable vaccine strains", "PROBLEM", 52, 77], ["vaccines", "TREATMENT", 150, 158]]], ["It is well established that the immune system has several effector mechanisms to cope with various pathogens, which would be dependent on their lifecycle and the microenvironment of the infected host.", [["immune system", "ANATOMY", 32, 45], ["various pathogens", "PROBLEM", 91, 108], ["infected", "OBSERVATION", 186, 194]]], ["Since killed vaccines are still mainly used for livestock, it is absolutely necessary to develop novel adjuvants in order to enhance satisfactory immunity for such vaccines.", [["killed vaccines", "TREATMENT", 6, 21], ["novel adjuvants", "TREATMENT", 97, 112], ["such vaccines", "TREATMENT", 159, 172]]], ["Potent adjuvants should be able to effectively elicit cellular immunity in animals that are vaccinated with less immunogenic vaccines including killed or subunit vaccines.", [["cellular", "ANATOMY", 54, 62], ["cellular", "CELL", 54, 62], ["Potent adjuvants", "TREATMENT", 0, 16], ["less immunogenic vaccines", "TREATMENT", 108, 133], ["subunit vaccines", "TREATMENT", 154, 170]]], ["The other way to resolve this issue would be to develop a new delivery system, such as plasmid DNA, liposome, microparticles, and live viral or bacterial vectors, which can introduce vaccine antigens into intracellular compartments.", [["plasmid", "ANATOMY", 87, 94], ["intracellular compartments", "ANATOMY", 205, 231], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["liposome", "SIMPLE_CHEMICAL", 100, 108], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 205, 218], ["plasmid DNA", "DNA", 87, 98], ["vaccine antigens", "PROTEIN", 183, 199], ["a new delivery system", "PROBLEM", 56, 77], ["plasmid DNA, liposome, microparticles", "PROBLEM", 87, 124], ["live viral or bacterial vectors", "PROBLEM", 130, 161], ["bacterial vectors", "OBSERVATION", 144, 161]]], ["Another notable advancement in immunology is the increased recognition on the major roles of innate immunity in vaccine adjuvant functions, which is often ignored despite their significant influence on vaccine developments.", [["innate immunity in vaccine adjuvant", "TREATMENT", 93, 128], ["notable", "OBSERVATION_MODIFIER", 8, 15], ["advancement", "OBSERVATION", 16, 27], ["increased", "OBSERVATION_MODIFIER", 49, 58]]], ["Recently discovered innate immunity receptors are screened as new adjuvant materials having activities, and they are used for inducing or enhancing vaccine reactions.", [["innate immunity receptors", "PROTEIN", 20, 45], ["innate immunity receptors", "TREATMENT", 20, 45], ["new adjuvant materials", "TREATMENT", 62, 84], ["enhancing vaccine reactions", "PROBLEM", 138, 165]]], ["Currently many types of adjuvants are in use for animal vaccines.ConclusionCommercialization of vaccine products should fulfill some regulations for vaccine efficacy, safety, and development processes instructed by governments.", [["adjuvants", "TREATMENT", 24, 33], ["animal vaccines", "TREATMENT", 49, 64], ["ConclusionCommercialization of vaccine products", "TREATMENT", 65, 112], ["vaccine efficacy", "TREATMENT", 149, 165], ["adjuvants", "OBSERVATION", 24, 33]]], ["In Korea, animal vaccines are regulated under Animal Plant and Fisheries Quarantine and Inspection Agency.", [["animal vaccines", "TREATMENT", 10, 25]]], ["These regulatory agencies take account of faster and lower cost routes to registration than those of human vaccines.", [["human", "ORGANISM", 101, 106], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["human vaccines", "TREATMENT", 101, 115]]], ["With consideration of the commercial market, overall demand of animal vaccines is steadily growing due to the fast increasing livestock population.", [["animal vaccines", "TREATMENT", 63, 78], ["the fast increasing livestock population", "PROBLEM", 106, 146], ["increasing", "OBSERVATION_MODIFIER", 115, 125], ["livestock population", "OBSERVATION", 126, 146]]], ["Overall, along with less stringent regulatory requirements, research and development of animal vaccines would be the forefront of experimental trials of innovative techniques and commercial opportunity.", [["less stringent regulatory requirements", "PROBLEM", 20, 58], ["animal vaccines", "TREATMENT", 88, 103], ["innovative techniques", "TREATMENT", 153, 174], ["regulatory requirements", "OBSERVATION", 35, 58]]]], "e44284f191fc9522ccc675257354cb33cd9c2885": [["In children treated either in hospital or as an outpatient for community-acquired pneumonia, levofloxacin was as well-tolerated and as effective as standard-of-care antibiotics in infants and children Atkinson In children with non-severe pneumonia, there was no significant difference in outcome between the cotrimoxazole and the procaine penicillin group, and benzathine penicillin was not effective Co-trimoxazole was cost effectiveComparisons of dose and/or duration of the same antimicrobial agentHazir et al (2007)", [["pneumonia", "DISEASE", 82, 91], ["levofloxacin", "CHEMICAL", 93, 105], ["pneumonia", "DISEASE", 238, 247], ["cotrimoxazole", "CHEMICAL", 308, 321], ["procaine", "CHEMICAL", 330, 338], ["penicillin", "CHEMICAL", 339, 349], ["benzathine", "CHEMICAL", 361, 371], ["penicillin", "CHEMICAL", 372, 382], ["Co-trimoxazole", "CHEMICAL", 401, 415], ["levofloxacin", "CHEMICAL", 93, 105], ["cotrimoxazole", "CHEMICAL", 308, 321], ["procaine penicillin", "CHEMICAL", 330, 349], ["benzathine penicillin", "CHEMICAL", 361, 382], ["Co-trimoxazole", "CHEMICAL", 401, 415], ["children", "ORGANISM", 3, 11], ["levofloxacin", "SIMPLE_CHEMICAL", 93, 105], ["infants", "ORGANISM", 180, 187], ["children", "ORGANISM", 213, 221], ["cotrimoxazole", "SIMPLE_CHEMICAL", 308, 321], ["procaine penicillin", "SIMPLE_CHEMICAL", 330, 349], ["benzathine penicillin", "SIMPLE_CHEMICAL", 361, 382], ["Co-trimoxazole", "SIMPLE_CHEMICAL", 401, 415], ["children", "SPECIES", 3, 11], ["infants", "SPECIES", 180, 187], ["children", "SPECIES", 192, 200], ["children", "SPECIES", 213, 221], ["community-acquired pneumonia", "PROBLEM", 63, 91], ["levofloxacin", "TREATMENT", 93, 105], ["antibiotics", "TREATMENT", 165, 176], ["non-severe pneumonia", "PROBLEM", 227, 247], ["the cotrimoxazole", "TREATMENT", 304, 321], ["the procaine penicillin group", "TREATMENT", 326, 355], ["benzathine penicillin", "TREATMENT", 361, 382], ["Co-trimoxazole", "TREATMENT", 401, 415], ["the same antimicrobial agent", "TREATMENT", 473, 501], ["pneumonia", "OBSERVATION", 82, 91], ["non-severe", "OBSERVATION_MODIFIER", 227, 237], ["pneumonia", "OBSERVATION", 238, 247], ["no", "UNCERTAINTY", 259, 261], ["significant", "OBSERVATION_MODIFIER", 262, 273], ["difference", "OBSERVATION_MODIFIER", 274, 284]]]], "PMC7332962": [["Not good enoughIn a linked paper, Bastos and colleagues (doi:10.1136/bmj.m2516) provide a much needed review of the performance of serological assays to accurately detect antibodies to SARS-CoV-2.2 They meta-analyzed 40 studies according to type of antibody test (enzyme linked immunosorbent assays (ELISAs), lateral flow immunoassays (LFIAs), and chemiluminescent immunoassays (CLIAs)), and for each type, determined the average or pooled sensitivity and specificity and assessed the studies for risk of bias.", [["SARS", "DISEASE", 185, 189], ["SARS-CoV", "ORGANISM", 185, 193], ["antibodies", "PROTEIN", 171, 181], ["SARS-CoV", "SPECIES", 185, 193], ["serological assays", "TEST", 131, 149], ["antibodies", "TEST", 171, 181], ["SARS", "TEST", 185, 189], ["CoV", "TEST", 190, 193], ["antibody test", "TEST", 249, 262], ["enzyme", "TEST", 264, 270], ["immunosorbent assays", "TEST", 278, 298], ["ELISAs", "TEST", 300, 306], ["lateral flow immunoassays", "TEST", 309, 334], ["LFIAs", "TEST", 336, 341], ["chemiluminescent immunoassays", "TEST", 348, 377], ["the studies", "TEST", 481, 492], ["bias", "PROBLEM", 505, 509]]], ["Only four of the 40 studies included outpatients and only two studies assessed LFIAs at the point of care.Not good enoughThe pooled sensitivities had a wide range, with higher sensitivity in the CLIAs (97.8%) and lowest in the LFIAs (66.0%) and were higher with increased time after symptom onset.", [["two studies", "TEST", 58, 69], ["The pooled sensitivities", "TEST", 121, 145], ["the CLIAs", "TEST", 191, 200], ["the LFIAs", "TEST", 223, 232], ["symptom onset", "PROBLEM", 283, 296]]], ["The range for specificities was narrower, from 96.6% to 99.7%.", [["specificities", "TEST", 14, 27]]], ["The risk of patient selection bias affected nearly every study.Not good enoughIt is important to keep in mind that pooling sensitivities makes it difficult to determine how well tests perform at detecting antibody early or late in the course of illness (reported as 26.7% for samples collected during the first week versus 78.4% for samples collected beyond the third week for ELISAs).", [["samples", "ANATOMY", 276, 283], ["samples", "ANATOMY", 333, 340], ["illness", "DISEASE", 245, 252], ["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19], ["pooling sensitivities", "PROBLEM", 115, 136], ["illness", "PROBLEM", 245, 252], ["samples", "TEST", 333, 340], ["ELISAs", "TEST", 377, 383]]], ["Pooling also hinders the ability to identify individual tests that might perform well in testing algorithms, described below.", [["individual tests", "TEST", 45, 61], ["testing algorithms", "TEST", 89, 107]]], ["Ideally, test performance should be compared according to the viral antigen used in each assay, such as the N nucleocapsid or the S spike protein, since antibodies against the spike protein are thought to correlate with neutralizing titers.3 Nonetheless, the key message of the review aligns with the conclusion of another systematic review4 published last week: serologic assays for SARS-CoV-2 antibodies, especially point-of-care tests, are not ready for widespread use by clinicians, the general public, or policy makers.Not good enoughIt is unlikely that any single serologic test will provide the kind of reliable and accurate information that are needed to fully understand the current pandemic.", [["antibodies against the spike protein", "GENE_OR_GENE_PRODUCT", 153, 189], ["SARS-CoV-2", "ORGANISM", 384, 394], ["viral antigen", "PROTEIN", 62, 75], ["N nucleocapsid", "PROTEIN", 108, 122], ["S spike protein", "PROTEIN", 130, 145], ["antibodies", "PROTEIN", 153, 163], ["spike protein", "PROTEIN", 176, 189], ["SARS-CoV-2 antibodies", "PROTEIN", 384, 405], ["SARS-CoV", "SPECIES", 384, 392], ["test performance", "TEST", 9, 25], ["the viral antigen", "TEST", 58, 75], ["the N nucleocapsid", "PROBLEM", 104, 122], ["the S spike protein", "TEST", 126, 145], ["antibodies", "TREATMENT", 153, 163], ["the spike protein", "PROBLEM", 172, 189], ["neutralizing titers", "PROBLEM", 220, 239], ["serologic assays", "TEST", 363, 379], ["SARS", "TEST", 384, 388], ["CoV", "TEST", 389, 392], ["antibodies", "TEST", 395, 405], ["any single serologic test", "TEST", 559, 584], ["neutralizing titers", "OBSERVATION", 220, 239]]], ["As Bastos and colleagues and others have indicated,5 tests with low specificity provide more false positives than true positives in low prevalence settings, resulting in unacceptably low positive predictive values.", [["5 tests", "TEST", 51, 58], ["unacceptably low positive predictive values", "PROBLEM", 170, 213], ["low prevalence", "OBSERVATION_MODIFIER", 132, 146]]], ["To overcome the poor performance of a single serologic test, an algorithm should be considered that combines two or more tests (eg,6).", [["a single serologic test", "TEST", 36, 59], ["an algorithm", "TEST", 61, 73]]], ["For example, in a 5% prevalence setting, screening with one of the more sensitive ELISAs reviewed by Bastos and colleagues (96.0% sensitivity, 99.2% specificity)7 and then using a more specific test (85.0% sensitivity, 100% specificity)8 as the confirmatory test would increase positive predictive value from 55% to 100%.9 Such an algorithm would still fail to identify antibodies in samples collected within the first 14 days of symptom onset and require follow-up testing at a later date (more than three weeks after symptom onset).Independent evaluationIn the early months of the outbreak, the global market was flooded with antibody tests of unproven test performance, and various governments, including those of the UK and India, purchased large quantities of ineffective antibody tests.101112 In the US, the Food and Drug Administration reversed course in May and mandated emergency use authorizations for all commercially available serologic test kits with a test performance of 90% or more sensitivity and 95% or more specificity,13 but the damage had been done and contributed to surveillance data of uneven quality.", [["samples", "ANATOMY", 384, 391], ["antibodies", "PROTEIN", 370, 380], ["screening", "TEST", 41, 50], ["sensitivity", "TEST", 130, 141], ["sensitivity", "TEST", 206, 217], ["the confirmatory test", "TEST", 241, 262], ["an algorithm", "TEST", 328, 340], ["antibodies in samples", "PROBLEM", 370, 391], ["symptom onset", "PROBLEM", 430, 443], ["follow-up testing", "TEST", 456, 473], ["Independent evaluation", "TEST", 534, 556], ["antibody tests", "TEST", 628, 642], ["ineffective antibody tests", "PROBLEM", 765, 791], ["serologic test kits", "TEST", 939, 958], ["a test performance", "TEST", 964, 982], ["the damage", "PROBLEM", 1045, 1055], ["surveillance data", "TEST", 1089, 1106]]], ["Critical independent evaluations of antibody tests are currently underway by the FDA and other organizations141516 to provide researchers, public health officials, and others with better data for decision making.", [["antibody tests", "TEST", 36, 50]]], ["Ideally, these evaluations should all use the same specimen panels containing reverse transcriptase polymerase chain reaction confirmed SARS-CoV-2 positive and negative plasma.", [["plasma", "ANATOMY", 169, 175], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["plasma", "ORGANISM_SUBSTANCE", 169, 175], ["reverse transcriptase", "PROTEIN", 78, 99], ["these evaluations", "TEST", 9, 26], ["the same specimen panels", "TEST", 42, 66], ["reverse transcriptase polymerase chain reaction", "TEST", 78, 125], ["SARS", "TEST", 136, 140], ["CoV", "TEST", 141, 144]]], ["Such specimen panels are a valuable tool for both test kit developers and evaluators, and global health institutions should make them widely available.Independent evaluationAs this review makes clear, there is more work to do on serologic testing.", [["Such specimen panels", "TEST", 0, 20], ["evaluators", "TEST", 74, 84], ["Independent evaluation", "TEST", 151, 173], ["serologic testing", "TEST", 229, 246]]], ["Assays must be optimized further, independently validated, and used in an algorithm format to achieve the highest possible accuracy for decision making, especially at an individual level.Independent evaluationHigh quality antibody tests have the potential to provide important information about prior infection, and the prevalence of antibodies in a population might help us to understand the extent of the epidemic and the role of transmission from asymptomatic individuals.", [["infection", "DISEASE", 301, 310], ["antibodies", "PROTEIN", 334, 344], ["Assays", "TEST", 0, 6], ["Independent evaluationHigh quality antibody tests", "TEST", 187, 236], ["prior infection", "PROBLEM", 295, 310], ["antibodies", "PROBLEM", 334, 344], ["asymptomatic individuals", "PROBLEM", 450, 474], ["infection", "OBSERVATION", 301, 310]]], ["Further research is needed to address fundamental questions about the presence of antibodies and the degree and durability of protection.", [["antibodies", "PROTEIN", 82, 92], ["antibodies", "PROBLEM", 82, 92]]], ["Until then, even the most optimal serologic test will be of limited utility.", [["serologic test", "TEST", 34, 48]]]], "PMC7206627": [["IntroductionThe Lyndon factorization", [["The Lyndon factorization", "TREATMENT", 12, 36]]]], "PMC7124291": [["IntroductionAs emergency physicians, nurses, and other health care professionals prepare for disasters that involve personal risk, they face basic moral and personal issues: Should they, and will they, work rather than flee?IntroductionThe participation of frontline health care providers will be essential to maintain the functioning of the health care system during crises.", [["frontline health care providers", "TREATMENT", 257, 288], ["crises", "PROBLEM", 368, 374]]], ["Although most disaster plans discuss strategies to use these professionals most effectively, we first need to answer 3 questions: If providers are at risk, should they stay and treat patients?", [["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191]]], ["Crises such as widespread natural and manmade disasters, wars, and life-threatening epidemics occur on a disturbingly regular basis.", [["Crises", "PROBLEM", 0, 6]]], ["We will then examine ethical and social reasons why health care professionals should stay to treat patients, even if they themselves are at risk, as well as reasons why they may choose not to work.IntroductionNext, we will review the values and external factors, including input from the media and our peers, that emergency health care workers may use to decide about the amount of acceptable risk.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107]]], ["We will discuss individuals\u2019 perceptions of risk levels and the thought processes that lead providers to evaluate risks incorrectly.", [["risk levels", "PROBLEM", 44, 55]]], ["Finally, we will propose risk communication as a method to enhance the participation of both health care professionals and nonprofessional support personnel during disasters.Are There Crises in Our Future?History suggests that pandemics and other crises that pose risks to health care professionals will occur periodically, despite the best efforts of modern medicine.", [["pandemics", "DISEASE", 227, 236], ["pandemics", "PROBLEM", 227, 236], ["other crises", "PROBLEM", 241, 253], ["modern medicine", "TREATMENT", 352, 367]]], ["Many scientists argue that it is only a matter of time until the next influenza pandemic occurs.", [["influenza", "DISEASE", 70, 79], ["the next influenza pandemic", "PROBLEM", 61, 88]]], ["1 Outbreaks may stem from variations of known diseases, such as with the influenza virus, or from newly recognized pathogens, such as Legionnaire\u2019s disease, HIV/AIDS, and Hantavirus.", [["influenza virus", "DISEASE", 73, 88], ["Legionnaire\u2019s disease", "DISEASE", 134, 155], ["HIV/AIDS", "DISEASE", 157, 165], ["Hantavirus", "DISEASE", 171, 181], ["influenza virus", "ORGANISM", 73, 88], ["HIV", "ORGANISM", 157, 160], ["influenza virus", "SPECIES", 73, 88], ["HIV", "SPECIES", 157, 160], ["influenza virus", "SPECIES", 73, 88], ["HIV", "SPECIES", 157, 160], ["known diseases", "PROBLEM", 40, 54], ["the influenza virus", "PROBLEM", 69, 88], ["newly recognized pathogens", "PROBLEM", 98, 124], ["Legionnaire\u2019s disease", "PROBLEM", 134, 155], ["HIV/AIDS", "PROBLEM", 157, 165], ["Hantavirus", "PROBLEM", 171, 181], ["diseases", "OBSERVATION", 46, 54]]], ["Because of their potentially high mortality rates, uncertain modes of transmission, and possibly ineffective protective measures and equipment, these and other infectious diseases generate immense fear among both the general population and health care workers.Are There Crises in Our Future?Infectious disease risks are an unavoidable result of caring for patients in emergency medicine because many of those infected do not manifest typical signs or symptoms of their diseases.", [["infectious diseases", "DISEASE", 160, 179], ["Infectious disease", "DISEASE", 291, 309], ["patients", "ORGANISM", 356, 364], ["patients", "SPECIES", 356, 364], ["ineffective protective measures", "TREATMENT", 97, 128], ["other infectious diseases", "PROBLEM", 154, 179], ["symptoms", "PROBLEM", 451, 459], ["their diseases", "PROBLEM", 463, 477]]], ["More than 15 types of airborne infections have been transmitted to health care workers, including tuberculosis, varicella, measles, influenza, and respiratory syncytial virus.", [["airborne infections", "DISEASE", 22, 41], ["tuberculosis", "DISEASE", 98, 110], ["varicella", "DISEASE", 112, 121], ["measles", "DISEASE", 123, 130], ["influenza", "DISEASE", 132, 141], ["respiratory syncytial virus", "DISEASE", 147, 174], ["respiratory syncytial virus", "ORGANISM", 147, 174], ["respiratory syncytial virus", "SPECIES", 147, 174], ["respiratory syncytial virus", "SPECIES", 147, 174], ["airborne infections", "PROBLEM", 22, 41], ["tuberculosis", "PROBLEM", 98, 110], ["varicella", "PROBLEM", 112, 121], ["measles", "PROBLEM", 123, 130], ["influenza", "PROBLEM", 132, 141], ["respiratory syncytial virus", "PROBLEM", 147, 174], ["airborne infections", "OBSERVATION", 22, 41], ["tuberculosis", "OBSERVATION", 98, 110], ["respiratory", "ANATOMY", 147, 158], ["syncytial virus", "OBSERVATION", 159, 174]]], ["These cause significant morbidity and occasional mortality.", [["significant morbidity", "PROBLEM", 12, 33], ["occasional mortality", "PROBLEM", 38, 58], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["morbidity", "OBSERVATION", 24, 33], ["occasional", "OBSERVATION_MODIFIER", 38, 48], ["mortality", "OBSERVATION", 49, 58]]], ["2 The recent severe acute respiratory syndrome (SARS) outbreak, for example, claimed the lives of many health care workers, including that of Carlo Urbani, the World Health Organization physician who investigated the initial outbreak and raised worldwide alarm.", [["acute respiratory syndrome", "DISEASE", 20, 46], ["SARS", "DISEASE", 48, 52], ["The recent severe acute respiratory syndrome", "PROBLEM", 2, 46], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["respiratory syndrome", "OBSERVATION", 26, 46]]]], "1943ef8d442d9489abc2a584e9328d246a57b548": [["IntroductionHematologic neoplasms (HN) are characterized by being frequently disseminated at the moment of diagnosis, with bone marrow affectation.", [["Hematologic neoplasms", "ANATOMY", 12, 33], ["HN", "ANATOMY", 35, 37], ["bone marrow", "ANATOMY", 123, 134], ["Hematologic neoplasms", "DISEASE", 12, 33], ["HN", "DISEASE", 35, 37], ["bone marrow affectation", "DISEASE", 123, 146], ["Hematologic neoplasms", "CANCER", 12, 33], ["HN", "CANCER", 35, 37], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 123, 134], ["IntroductionHematologic neoplasms (HN)", "PROBLEM", 0, 38], ["bone marrow affectation", "PROBLEM", 123, 146], ["Hematologic neoplasms", "OBSERVATION", 12, 33], ["bone", "ANATOMY", 123, 127], ["marrow affectation", "OBSERVATION", 128, 146]]], ["They are especially sensitive to chemotherapy or radiotherapy, therefore the patients usually receive aggressive chemotherapy and, in certain cases, hematopoietic precursors transplantation (HPT).", [["hematopoietic precursors", "ANATOMY", 149, 173], ["HPT", "DISEASE", 191, 194], ["patients", "ORGANISM", 77, 85], ["hematopoietic precursors", "CELL", 149, 173], ["hematopoietic precursors", "CELL_TYPE", 149, 173], ["patients", "SPECIES", 77, 85], ["chemotherapy", "TREATMENT", 33, 45], ["radiotherapy", "TREATMENT", 49, 61], ["aggressive chemotherapy", "TREATMENT", 102, 125], ["hematopoietic precursors transplantation", "TREATMENT", 149, 189], ["hematopoietic", "ANATOMY", 149, 162], ["precursors transplantation", "OBSERVATION", 163, 189]]], ["The disease per se and its treatments cause prolonged pancytopenias, predisposing to very serious infections that make up a diagnostic and therapeutic emergency.", [["pancytopenias", "DISEASE", 54, 67], ["infections", "DISEASE", 98, 108], ["The disease", "PROBLEM", 0, 11], ["prolonged pancytopenias", "PROBLEM", 44, 67], ["very serious infections", "PROBLEM", 85, 108], ["disease", "OBSERVATION", 4, 11], ["pancytopenias", "OBSERVATION", 54, 67]]], ["Non-infectious pulmonary complications secondary to treatment are also frequent and determine prognosis.", [["pulmonary", "ANATOMY", 15, 24], ["pulmonary complications", "DISEASE", 15, 38], ["pulmonary", "ORGAN", 15, 24], ["Non-infectious pulmonary complications", "PROBLEM", 0, 38], ["treatment", "TREATMENT", 52, 61], ["pulmonary", "ANATOMY", 15, 24], ["complications", "OBSERVATION", 25, 38]]], ["Pulmonary tumor disease includes infiltration due to HN, pulmonary neoplasm and post-HPT lymphoma.", [["Pulmonary tumor", "ANATOMY", 0, 15], ["HN", "ANATOMY", 53, 55], ["pulmonary neoplasm", "ANATOMY", 57, 75], ["HPT lymphoma", "ANATOMY", 85, 97], ["Pulmonary tumor disease", "DISEASE", 0, 23], ["HN", "DISEASE", 53, 55], ["pulmonary neoplasm", "DISEASE", 57, 75], ["HPT lymphoma", "DISEASE", 85, 97], ["Pulmonary tumor", "CANCER", 0, 15], ["HN", "CANCER", 53, 55], ["pulmonary neoplasm", "CANCER", 57, 75], ["HPT lymphoma", "CANCER", 85, 97], ["Pulmonary tumor disease", "PROBLEM", 0, 23], ["infiltration", "PROBLEM", 33, 45], ["HN", "PROBLEM", 53, 55], ["pulmonary neoplasm", "PROBLEM", 57, 75], ["post-HPT lymphoma", "PROBLEM", 80, 97], ["tumor", "OBSERVATION", 10, 15], ["infiltration", "OBSERVATION", 33, 45], ["pulmonary", "ANATOMY", 57, 66], ["neoplasm", "OBSERVATION", 67, 75], ["post-HPT lymphoma", "OBSERVATION", 80, 97]]], ["Chest computed tomography (CT) narrows down the differential diagnosis of these diseases.", [["Chest computed tomography", "TEST", 0, 25], ["CT)", "TEST", 27, 30], ["these diseases", "PROBLEM", 74, 88], ["diseases", "OBSERVATION", 80, 88]]], ["Their indications are reviewed, as well as the main clinical information that should be recorded in the radiologic application and interpretation of the findings based on the clinical context.Indications of chest computed tomographyPerforming helical chest CTs in patients with HN pursues two objectives: early detection of lesions not visible in the chest X-rays which require urgent treatment, and better characterization of the findings to outline diagnostic and therapeutic possibilities.", [["lesions", "ANATOMY", 324, 331], ["chest", "ANATOMY", 351, 356], ["patients", "ORGANISM", 264, 272], ["lesions", "PATHOLOGICAL_FORMATION", 324, 331], ["patients", "SPECIES", 264, 272], ["the radiologic application", "TEST", 100, 126], ["chest computed tomography", "TEST", 207, 232], ["Performing helical chest CTs", "TEST", 232, 260], ["lesions", "PROBLEM", 324, 331], ["urgent treatment", "TREATMENT", 378, 394], ["chest", "ANATOMY", 207, 212], ["chest", "ANATOMY", 251, 256], ["lesions", "OBSERVATION", 324, 331], ["chest", "ANATOMY", 351, 356]]], ["1 Reconstructions being < 1.5 mm cut thick and high resolution computed tomography (HRCT) are required since many of the pulmonary complications kick in as interstitial patterns.Indications of chest computed tomographyThe etiologic diagnosis of fever manifestations in patients with neutropenia and/or HPT requires the search for microorganisms and infectious markers.", [["pulmonary", "ANATOMY", 121, 130], ["interstitial", "ANATOMY", 156, 168], ["fever", "DISEASE", 245, 250], ["neutropenia", "DISEASE", 283, 294], ["HPT", "DISEASE", 302, 305], ["pulmonary", "ORGAN", 121, 130], ["patients", "ORGANISM", 269, 277], ["patients", "SPECIES", 269, 277], ["high resolution computed tomography", "TEST", 47, 82], ["the pulmonary complications", "PROBLEM", 117, 144], ["chest computed tomography", "TEST", 193, 218], ["fever manifestations", "PROBLEM", 245, 265], ["neutropenia", "PROBLEM", 283, 294], ["HPT", "PROBLEM", 302, 305], ["microorganisms", "PROBLEM", 330, 344], ["infectious markers", "TEST", 349, 367], ["pulmonary", "ANATOMY", 121, 130], ["complications", "OBSERVATION", 131, 144], ["interstitial", "ANATOMY_MODIFIER", 156, 168], ["chest", "ANATOMY", 193, 198], ["fever", "OBSERVATION", 245, 250], ["infectious", "OBSERVATION", 349, 359]]], ["Chest HRCT plays a fundamental role---urgent when there are clinical signs of severity and early (<24 h) in the absence of a response to antibiotics therapy in 72---96 h because treatment of a possible invasive fungal infection (IFI) requires an early administration, a determinant factor for prognosis.", [["invasive fungal infection", "DISEASE", 202, 227], ["IFI", "DISEASE", 229, 232], ["severity", "PROBLEM", 78, 86], ["antibiotics therapy", "TREATMENT", 137, 156], ["invasive fungal infection", "PROBLEM", 202, 227], ["an early administration", "TREATMENT", 243, 266], ["possible", "UNCERTAINTY", 193, 201], ["invasive", "OBSERVATION_MODIFIER", 202, 210], ["fungal", "OBSERVATION_MODIFIER", 211, 217], ["infection", "OBSERVATION", 218, 227]]], ["In patients clinically classified as being in high risk of IFI 2,3 antifungal drugs are administered empirically, while in subgroups of lower risk it is possible to delay treatment in cases of very likely clinical manifestations or early positive specific infection markers, which reduces the high costs and toxicity of these drugs.", [["IFI", "DISEASE", 59, 62], ["infection", "DISEASE", 256, 265], ["toxicity", "DISEASE", 308, 316], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["IFI 2,3 antifungal drugs", "TREATMENT", 59, 83], ["delay treatment", "TREATMENT", 165, 180], ["clinical manifestations", "PROBLEM", 205, 228], ["early positive specific infection markers", "PROBLEM", 232, 273], ["the high costs", "PROBLEM", 289, 303], ["these drugs", "TREATMENT", 320, 331], ["lower risk", "OBSERVATION_MODIFIER", 136, 146], ["early", "OBSERVATION_MODIFIER", 232, 237], ["positive", "OBSERVATION_MODIFIER", 238, 246], ["specific", "OBSERVATION_MODIFIER", 247, 255], ["infection", "OBSERVATION", 256, 265], ["high", "OBSERVATION_MODIFIER", 293, 297]]], ["4 The markers usually used are the serum galactomannan test while the chest HRCT is performed early in a serial way.", [["serum", "ANATOMY", 35, 40], ["chest", "ANATOMY", 70, 75], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["galactomannan", "ORGANISM_SUBSTANCE", 41, 54], ["chest", "ORGAN", 70, 75], ["the serum galactomannan test", "TEST", 31, 59], ["the chest HRCT", "TEST", 66, 80], ["chest", "ANATOMY", 70, 75]]], ["5, 6 Galactomannan, a component of the Aspergillus cell membrane, is falling into disuse as a marker due to its loss of sensitivity associated to antifungal prophylaxis.", [["Aspergillus cell membrane", "ANATOMY", 39, 64], ["5, 6 Galactomannan", "CHEMICAL", 0, 18], ["Galactomannan", "SIMPLE_CHEMICAL", 5, 18], ["Aspergillus cell", "CELL", 39, 55], ["membrane", "CELLULAR_COMPONENT", 56, 64], ["antifungal", "CANCER", 146, 156], ["6 Galactomannan", "TEST", 3, 18], ["the Aspergillus cell membrane", "PROBLEM", 35, 64], ["falling into disuse", "PROBLEM", 69, 88], ["its loss of sensitivity", "PROBLEM", 108, 131], ["antifungal prophylaxis", "TREATMENT", 146, 168], ["component", "OBSERVATION_MODIFIER", 22, 31], ["Aspergillus cell membrane", "OBSERVATION", 39, 64], ["antifungal prophylaxis", "OBSERVATION", 146, 168]]], ["7 The HRCT gains more importance still as an urgent diagnostic test that allows starting an early therapy when pulmonary lesions characteristic of IFI are visualized.", [["pulmonary lesions", "ANATOMY", 111, 128], ["IFI", "DISEASE", 147, 150], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 111, 128], ["an urgent diagnostic test", "TEST", 42, 67], ["an early therapy", "TREATMENT", 89, 105], ["pulmonary lesions", "PROBLEM", 111, 128], ["IFI", "PROBLEM", 147, 150], ["pulmonary", "ANATOMY", 111, 120], ["lesions", "OBSERVATION", 121, 128], ["IFI", "OBSERVATION", 147, 150]]], ["In addition, it can give rise to other etiologies and guide the acquisition of bronchoalveolar lavage (BAL) through bronchoscopy, thus speeding up the diagnosis of germs not covered by the initial empirical therapy.Indications of chest computed tomographyIn other respiratory manifestations HRCT is necessary to identify and characterize non-infectious complications, relapse and secondary neoplasms that can go unnoticed in radiographic tests or show similar patterns.Key clinical informationWhen studying the HRCT of a patient with HN we need to know the clinical information and other fundamental data about the underlying condition as well as therapies and complications (Table 1) .Key clinical informationPatients with Hodgkin lymphomas (HL) and non-Hodgkin lymphomas (NHL) receive a less intense polychemotherapy than those with leukemias, with shorter neutropenias so if pulmonary lesions are seen the possibility of tumor affectation should be taken into consideration.Key clinical informationIt is not odd to find pulmonary neoplastic spread in autopsies of leukemias, but its radiologic manifestation is exceptional and the respiratory disease is mainly marked by infections.", [["bronchoalveolar lavage", "ANATOMY", 79, 101], ["BAL", "ANATOMY", 103, 106], ["germs", "ANATOMY", 164, 169], ["neoplasms", "ANATOMY", 390, 399], ["Hodgkin lymphomas", "ANATOMY", 724, 741], ["HL", "ANATOMY", 743, 745], ["non-Hodgkin lymphomas", "ANATOMY", 751, 772], ["NHL", "ANATOMY", 774, 777], ["leukemias", "ANATOMY", 835, 844], ["pulmonary lesions", "ANATOMY", 878, 895], ["tumor", "ANATOMY", 924, 929], ["pulmonary neoplastic", "ANATOMY", 1023, 1043], ["leukemias", "ANATOMY", 1067, 1076], ["respiratory", "ANATOMY", 1134, 1145], ["neoplasms", "DISEASE", 390, 399], ["Hodgkin lymphomas", "DISEASE", 724, 741], ["HL", "DISEASE", 743, 745], ["non-Hodgkin lymphomas", "DISEASE", 751, 772], ["NHL", "DISEASE", 774, 777], ["leukemias", "DISEASE", 835, 844], ["pulmonary lesions", "DISEASE", 878, 895], ["tumor", "DISEASE", 924, 929], ["leukemias", "DISEASE", 1067, 1076], ["respiratory disease", "DISEASE", 1134, 1153], ["infections", "DISEASE", 1174, 1184], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 79, 101], ["BAL", "MULTI-TISSUE_STRUCTURE", 103, 106], ["germs", "ORGAN", 164, 169], ["neoplasms", "CANCER", 390, 399], ["patient", "ORGANISM", 521, 528], ["Hodgkin lymphomas", "CANCER", 724, 741], ["HL", "CANCER", 743, 745], ["non-Hodgkin lymphomas", "CANCER", 751, 772], ["NHL", "CANCER", 774, 777], ["leukemias", "CANCER", 835, 844], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 878, 895], ["tumor", "CANCER", 924, 929], ["pulmonary", "ORGAN", 1023, 1032], ["leukemias", "CANCER", 1067, 1076], ["patient", "SPECIES", 521, 528], ["bronchoalveolar lavage", "TEST", 79, 101], ["bronchoscopy", "TEST", 116, 128], ["germs", "PROBLEM", 164, 169], ["the initial empirical therapy", "TREATMENT", 185, 214], ["chest computed tomography", "TEST", 230, 255], ["HRCT", "TEST", 291, 295], ["non-infectious complications", "PROBLEM", 338, 366], ["relapse", "PROBLEM", 368, 375], ["secondary neoplasms", "PROBLEM", 380, 399], ["radiographic tests", "TEST", 425, 443], ["the underlying condition", "PROBLEM", 611, 635], ["complications", "PROBLEM", 661, 674], ["Hodgkin lymphomas", "PROBLEM", 724, 741], ["non-Hodgkin lymphomas", "PROBLEM", 751, 772], ["NHL", "PROBLEM", 774, 777], ["a less intense polychemotherapy", "TREATMENT", 787, 818], ["leukemias", "PROBLEM", 835, 844], ["shorter neutropenias", "PROBLEM", 851, 871], ["pulmonary lesions", "PROBLEM", 878, 895], ["tumor affectation", "PROBLEM", 924, 941], ["pulmonary neoplastic spread", "PROBLEM", 1023, 1050], ["leukemias", "PROBLEM", 1067, 1076], ["the respiratory disease", "PROBLEM", 1130, 1153], ["infections", "PROBLEM", 1174, 1184], ["bronchoalveolar lavage", "OBSERVATION", 79, 101], ["chest", "ANATOMY", 230, 235], ["respiratory manifestations", "OBSERVATION", 264, 290], ["non-infectious", "OBSERVATION_MODIFIER", 338, 352], ["secondary", "OBSERVATION_MODIFIER", 380, 389], ["neoplasms", "OBSERVATION", 390, 399], ["Hodgkin lymphomas", "OBSERVATION", 724, 741], ["non-Hodgkin lymphomas", "OBSERVATION", 751, 772], ["less intense", "OBSERVATION_MODIFIER", 789, 801], ["leukemias", "OBSERVATION", 835, 844], ["pulmonary", "ANATOMY", 878, 887], ["lesions", "OBSERVATION", 888, 895], ["tumor", "OBSERVATION", 924, 929], ["pulmonary", "ANATOMY", 1023, 1032], ["neoplastic", "OBSERVATION", 1033, 1043], ["leukemias", "OBSERVATION", 1067, 1076], ["respiratory disease", "OBSERVATION", 1134, 1153], ["marked", "OBSERVATION_MODIFIER", 1164, 1170], ["infections", "OBSERVATION", 1174, 1184]]], ["Acute myeloid leukemia (AML) deserves special attention, since pulmonary manifestations occur in all the stages of the disease, and it is possible to observe added to infections, more cases of hemorrhages due to thrombocytopenia and toxicity due to chemotherapy.Key clinical informationMultiple myeloma (MM) occurs mainly with bacterial infections due to humoral immunity deficiency and hypoventilation due to bone affectation.", [["Acute myeloid leukemia", "ANATOMY", 0, 22], ["AML", "ANATOMY", 24, 27], ["pulmonary", "ANATOMY", 63, 72], ["informationMultiple myeloma", "ANATOMY", 275, 302], ["MM", "ANATOMY", 304, 306], ["bone", "ANATOMY", 410, 414], ["Acute myeloid leukemia", "DISEASE", 0, 22], ["AML", "DISEASE", 24, 27], ["infections", "DISEASE", 167, 177], ["hemorrhages", "DISEASE", 193, 204], ["thrombocytopenia", "DISEASE", 212, 228], ["toxicity", "DISEASE", 233, 241], ["informationMultiple myeloma", "DISEASE", 275, 302], ["MM", "DISEASE", 304, 306], ["bacterial infections", "DISEASE", 327, 347], ["humoral immunity deficiency", "DISEASE", 355, 382], ["hypoventilation", "DISEASE", 387, 402], ["bone affectation", "DISEASE", 410, 426], ["Acute myeloid leukemia", "CANCER", 0, 22], ["AML", "CANCER", 24, 27], ["pulmonary", "ORGAN", 63, 72], ["informationMultiple myeloma", "CANCER", 275, 302], ["MM", "CANCER", 304, 306], ["bone", "TISSUE", 410, 414], ["Acute myeloid leukemia", "PROBLEM", 0, 22], ["AML)", "PROBLEM", 24, 28], ["pulmonary manifestations", "PROBLEM", 63, 87], ["the disease", "PROBLEM", 115, 126], ["infections", "PROBLEM", 167, 177], ["hemorrhages", "PROBLEM", 193, 204], ["thrombocytopenia", "PROBLEM", 212, 228], ["toxicity", "PROBLEM", 233, 241], ["chemotherapy", "TREATMENT", 249, 261], ["Key clinical informationMultiple myeloma (MM)", "PROBLEM", 262, 307], ["bacterial infections", "PROBLEM", 327, 347], ["humoral immunity deficiency", "PROBLEM", 355, 382], ["hypoventilation", "PROBLEM", 387, 402], ["bone affectation", "PROBLEM", 410, 426], ["myeloid leukemia", "OBSERVATION", 6, 22], ["pulmonary", "ANATOMY", 63, 72], ["manifestations", "OBSERVATION", 73, 87], ["disease", "OBSERVATION", 119, 126], ["infections", "OBSERVATION", 167, 177], ["hemorrhages", "OBSERVATION", 193, 204], ["thrombocytopenia", "OBSERVATION", 212, 228], ["myeloma", "OBSERVATION", 295, 302], ["bacterial", "OBSERVATION_MODIFIER", 327, 336], ["infections", "OBSERVATION", 337, 347], ["humoral immunity deficiency", "OBSERVATION", 355, 382], ["hypoventilation", "OBSERVATION", 387, 402], ["bone", "ANATOMY", 410, 414], ["affectation", "OBSERVATION", 415, 426]]], ["Pulmonary edema is very common while findings of pulmonary infiltration due to amyloids, plasma cells or light chain deposits are rare.Key clinical informationChemotherapeutic drugs do not only depress immune function, but some of them are responsible for pulmonary toxicity, suspected by the radiologic pattern and its temporal relation with the treatment.", [["Pulmonary", "ANATOMY", 0, 9], ["pulmonary", "ANATOMY", 49, 58], ["plasma cells", "ANATOMY", 89, 101], ["pulmonary", "ANATOMY", 256, 265], ["Pulmonary edema", "DISEASE", 0, 15], ["pulmonary infiltration", "DISEASE", 49, 71], ["amyloids", "DISEASE", 79, 87], ["pulmonary toxicity", "DISEASE", 256, 274], ["Pulmonary edema", "PATHOLOGICAL_FORMATION", 0, 15], ["pulmonary", "ORGAN", 49, 58], ["plasma cells", "CELL", 89, 101], ["pulmonary", "ORGAN", 256, 265], ["plasma cells", "CELL_TYPE", 89, 101], ["Pulmonary edema", "PROBLEM", 0, 15], ["pulmonary infiltration", "PROBLEM", 49, 71], ["amyloids", "PROBLEM", 79, 87], ["plasma cells", "PROBLEM", 89, 101], ["light chain deposits", "PROBLEM", 105, 125], ["Chemotherapeutic drugs", "TREATMENT", 159, 181], ["immune function", "PROBLEM", 202, 217], ["pulmonary toxicity", "PROBLEM", 256, 274], ["the treatment", "TREATMENT", 343, 356], ["edema", "OBSERVATION", 10, 15], ["pulmonary", "ANATOMY", 49, 58], ["infiltration", "OBSERVATION", 59, 71], ["amyloids", "OBSERVATION", 79, 87], ["plasma cells", "OBSERVATION", 89, 101], ["light", "OBSERVATION_MODIFIER", 105, 110], ["chain deposits", "OBSERVATION", 111, 125], ["responsible for", "UNCERTAINTY", 240, 255], ["pulmonary", "ANATOMY", 256, 265], ["toxicity", "OBSERVATION", 266, 274]]], ["Other therapeutic agents used can cause respiratory failure, often with a radiologic expression similar to alveolar damage, edema or hemorrhage.Key clinical informationIn especially chemosensitive tumors (lymphomas and MM), the goal of autologous HPT is to allow the administration of high doses of chemotherapy with subsequent Corticotherapy Graft vs host disease (GVHD) (immunosuppressant therapy) Actual infectious prophylaxis Wide-spectrum antibiotics Antifungal Prophylaxis P jirovecii rescue of hematopoiesis thanks to the infusion of hematopoietic precursors obtained previously from the same patient.", [["respiratory", "ANATOMY", 40, 51], ["alveolar", "ANATOMY", 107, 115], ["edema", "ANATOMY", 124, 129], ["chemosensitive tumors", "ANATOMY", 182, 203], ["lymphomas", "ANATOMY", 205, 214], ["MM", "ANATOMY", 219, 221], ["hematopoietic precursors", "ANATOMY", 541, 565], ["respiratory failure", "DISEASE", 40, 59], ["alveolar damage", "DISEASE", 107, 122], ["edema", "DISEASE", 124, 129], ["hemorrhage", "DISEASE", 133, 143], ["chemosensitive tumors", "DISEASE", 182, 203], ["lymphomas", "DISEASE", 205, 214], ["MM", "DISEASE", 219, 221], ["HPT", "DISEASE", 247, 250], ["Graft vs host disease", "DISEASE", 343, 364], ["GVHD", "DISEASE", 366, 370], ["alveolar", "TISSUE", 107, 115], ["edema", "PATHOLOGICAL_FORMATION", 124, 129], ["chemosensitive tumors", "CANCER", 182, 203], ["lymphomas", "CANCER", 205, 214], ["MM", "CANCER", 219, 221], ["patient", "ORGANISM", 600, 607], ["hematopoietic precursors", "CELL_TYPE", 541, 565], ["patient", "SPECIES", 600, 607], ["P jirovecii", "SPECIES", 479, 490], ["Other therapeutic agents", "TREATMENT", 0, 24], ["respiratory failure", "PROBLEM", 40, 59], ["a radiologic expression", "PROBLEM", 72, 95], ["alveolar damage", "PROBLEM", 107, 122], ["edema", "PROBLEM", 124, 129], ["hemorrhage", "PROBLEM", 133, 143], ["chemosensitive tumors (lymphomas and MM)", "PROBLEM", 182, 222], ["autologous HPT", "TREATMENT", 236, 250], ["high doses of chemotherapy", "TREATMENT", 285, 311], ["subsequent Corticotherapy Graft", "TREATMENT", 317, 348], ["host disease", "PROBLEM", 352, 364], ["GVHD) (immunosuppressant therapy", "TREATMENT", 366, 398], ["Actual infectious prophylaxis", "TREATMENT", 400, 429], ["Wide-spectrum antibiotics", "TREATMENT", 430, 455], ["Antifungal Prophylaxis", "TREATMENT", 456, 478], ["hematopoiesis", "PROBLEM", 501, 514], ["hematopoietic precursors", "TREATMENT", 541, 565], ["respiratory failure", "OBSERVATION", 40, 59], ["alveolar", "ANATOMY", 107, 115], ["damage", "OBSERVATION", 116, 122], ["edema", "OBSERVATION", 124, 129], ["hemorrhage", "OBSERVATION", 133, 143], ["tumors", "OBSERVATION", 197, 203], ["infectious", "OBSERVATION", 407, 417], ["hematopoiesis", "OBSERVATION", 501, 514]]], ["This prevents irreversible medullary failure and shortens the time of neutropenia.", [["medullary", "ANATOMY", 27, 36], ["medullary failure", "DISEASE", 27, 44], ["neutropenia", "DISEASE", 70, 81], ["medullary", "ORGAN", 27, 36], ["irreversible medullary failure", "PROBLEM", 14, 44], ["neutropenia", "PROBLEM", 70, 81], ["prevents", "UNCERTAINTY", 5, 13], ["irreversible", "OBSERVATION_MODIFIER", 14, 26], ["medullary failure", "OBSERVATION", 27, 44], ["shortens", "OBSERVATION_MODIFIER", 49, 57], ["neutropenia", "OBSERVATION", 70, 81]]], ["Pulmonary complications will be fundamentally the consequence of intensive chemotherapy not the consequence of the transplant per se.Key clinical informationThe allogenic HPT is mainly used in patients with acute leukemias to re-establish hematopoietic and immunity functions.", [["Pulmonary", "ANATOMY", 0, 9], ["leukemias", "ANATOMY", 213, 222], ["hematopoietic", "ANATOMY", 239, 252], ["Pulmonary complications", "DISEASE", 0, 23], ["HPT", "DISEASE", 171, 174], ["acute leukemias", "DISEASE", 207, 222], ["Pulmonary", "ORGAN", 0, 9], ["patients", "ORGANISM", 193, 201], ["acute leukemias", "CANCER", 207, 222], ["hematopoietic", "CELL", 239, 252], ["patients", "SPECIES", 193, 201], ["Pulmonary complications", "PROBLEM", 0, 23], ["intensive chemotherapy", "TREATMENT", 65, 87], ["the transplant", "TREATMENT", 111, 125], ["The allogenic HPT", "TREATMENT", 157, 174], ["acute leukemias", "PROBLEM", 207, 222], ["hematopoietic and immunity functions", "PROBLEM", 239, 275], ["complications", "OBSERVATION", 10, 23], ["transplant", "OBSERVATION", 115, 125], ["allogenic HPT", "OBSERVATION", 161, 174], ["acute", "OBSERVATION_MODIFIER", 207, 212], ["leukemias", "OBSERVATION", 213, 222]]], ["The cells are obtained from a family member with an identical HLA (Human Leukocyte Antigen) or else from someone unrelated but with a compatible HLA and they may come from the bone marrow, peripheral blood or the umbilical cord.", [["cells", "ANATOMY", 4, 9], ["bone marrow", "ANATOMY", 176, 187], ["peripheral blood", "ANATOMY", 189, 205], ["umbilical cord", "ANATOMY", 213, 227], ["cells", "CELL", 4, 9], ["HLA", "GENE_OR_GENE_PRODUCT", 62, 65], ["Human", "ORGANISM", 67, 72], ["Leukocyte Antigen", "GENE_OR_GENE_PRODUCT", 73, 90], ["HLA", "GENE_OR_GENE_PRODUCT", 145, 148], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 176, 187], ["peripheral blood", "ORGANISM_SUBSTANCE", 189, 205], ["umbilical cord", "ORGAN", 213, 227], ["HLA", "PROTEIN", 62, 65], ["Human Leukocyte Antigen", "PROTEIN", 67, 90], ["Human", "SPECIES", 67, 72], ["Human Leukocyte Antigen", "TEST", 67, 90], ["a compatible HLA", "PROBLEM", 132, 148], ["the bone marrow", "TEST", 172, 187], ["peripheral blood or the umbilical cord", "PROBLEM", 189, 227], ["bone", "ANATOMY", 176, 180], ["marrow", "OBSERVATION", 181, 187], ["peripheral", "ANATOMY_MODIFIER", 189, 199], ["blood", "ANATOMY", 200, 205], ["umbilical cord", "ANATOMY", 213, 227]]], ["Before the transplant the patient receives conditioning with high doses of chemotherapy, with or without full-body radiotherapy, to suppress the bone marrow, destroy the malignant cells and prevent the host's rejection against the graft cells.", [["body", "ANATOMY", 110, 114], ["bone marrow", "ANATOMY", 145, 156], ["malignant cells", "ANATOMY", 170, 185], ["graft cells", "ANATOMY", 231, 242], ["patient", "ORGANISM", 26, 33], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 145, 156], ["malignant cells", "CELL", 170, 185], ["graft cells", "CELL", 231, 242], ["malignant cells", "CELL_TYPE", 170, 185], ["graft cells", "CELL_TYPE", 231, 242], ["patient", "SPECIES", 26, 33], ["the transplant", "TREATMENT", 7, 21], ["chemotherapy", "TREATMENT", 75, 87], ["full-body radiotherapy", "TREATMENT", 105, 127], ["the bone marrow", "PROBLEM", 141, 156], ["the malignant cells", "PROBLEM", 166, 185], ["the host's rejection", "PROBLEM", 198, 218], ["the graft cells", "TREATMENT", 227, 242], ["bone marrow", "ANATOMY", 145, 156], ["malignant cells", "OBSERVATION", 170, 185], ["graft cells", "OBSERVATION", 231, 242]]], ["Also a strong immunosuppressant treatment is later administered to avoid reverse rejection and when the hematopoietic function is reinstated the donor's cells recognize the recipient's tissues as foreign and they cause graft-versus-host disease (GVHD).", [["hematopoietic", "ANATOMY", 104, 117], ["donor's cells", "ANATOMY", 145, 158], ["tissues", "ANATOMY", 185, 192], ["graft", "ANATOMY", 219, 224], ["graft-versus-host disease", "DISEASE", 219, 244], ["GVHD", "DISEASE", 246, 250], ["cells", "CELL", 153, 158], ["tissues", "TISSUE", 185, 192], ["graft", "TISSUE", 219, 224], ["donor's cells", "CELL_TYPE", 145, 158], ["a strong immunosuppressant treatment", "TREATMENT", 5, 41], ["reverse rejection", "PROBLEM", 73, 90], ["the hematopoietic function", "TEST", 100, 126], ["the donor's cells", "TREATMENT", 141, 158], ["foreign", "PROBLEM", 196, 203], ["graft-versus-host disease", "PROBLEM", 219, 244], ["GVHD", "PROBLEM", 246, 250], ["rejection", "OBSERVATION", 81, 90], ["host disease", "OBSERVATION", 232, 244]]], ["Yet despite of this some patients develop GVHD and require a more extended immunosuppressant therapy.", [["GVHD", "DISEASE", 42, 46], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["GVHD", "PROBLEM", 42, 46], ["a more extended immunosuppressant therapy", "TREATMENT", 59, 100], ["GVHD", "OBSERVATION", 42, 46]]], ["All of this explains why the allogenic HPT recipient suffers from a deep and prolonged immune deficit that leads to death in nearly 10---35% of patients.", [["HPT", "DISEASE", 39, 42], ["immune deficit", "DISEASE", 87, 101], ["death", "DISEASE", 116, 121], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["the allogenic HPT recipient", "TREATMENT", 25, 52], ["a deep and prolonged immune deficit", "PROBLEM", 66, 101], ["death", "PROBLEM", 116, 121], ["deep", "ANATOMY_MODIFIER", 68, 72]]], ["Based on at what specific moment in his history the patient is he will be included in one of these groups to approach diagnosis 8 (Tables 2 and 3Key pulmonary radiologic findings Nodes and massesSee Tables 2 and 3 .InfectionsIn the onset of the disease, before treatment, infectious nodes are uncommon.", [["pulmonary", "ANATOMY", 149, 158], ["nodes", "ANATOMY", 283, 288], ["Infections", "DISEASE", 215, 225], ["patient", "ORGANISM", 52, 59], ["pulmonary", "ORGAN", 149, 158], ["nodes", "MULTI-TISSUE_STRUCTURE", 283, 288], ["patient", "SPECIES", 52, 59], ["masses", "PROBLEM", 189, 195], ["Infections", "PROBLEM", 215, 225], ["the disease", "PROBLEM", 241, 252], ["treatment", "TREATMENT", 261, 270], ["infectious nodes", "PROBLEM", 272, 288], ["pulmonary", "ANATOMY", 149, 158], ["Nodes", "OBSERVATION", 179, 184], ["masses", "OBSERVATION", 189, 195], ["disease", "OBSERVATION", 245, 252], ["infectious", "OBSERVATION_MODIFIER", 272, 282], ["nodes", "OBSERVATION", 283, 288]]], ["They are usually bacterial or viral and exceptionally, at the very moment of the diagnosis of AML with severe cytopenia or iron overload they can be fungal.", [["AML", "ANATOMY", 94, 97], ["AML", "DISEASE", 94, 97], ["cytopenia", "DISEASE", 110, 119], ["iron", "CHEMICAL", 123, 127], ["iron", "CHEMICAL", 123, 127], ["AML", "CANCER", 94, 97], ["iron", "SIMPLE_CHEMICAL", 123, 127], ["viral", "PROBLEM", 30, 35], ["AML", "PROBLEM", 94, 97], ["severe cytopenia", "PROBLEM", 103, 119], ["iron overload", "PROBLEM", 123, 136], ["fungal", "PROBLEM", 149, 155], ["viral", "OBSERVATION", 30, 35], ["AML", "OBSERVATION", 94, 97], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["cytopenia", "OBSERVATION", 110, 119], ["iron overload", "OBSERVATION", 123, 136], ["fungal", "OBSERVATION", 149, 155]]], ["9 In severely immunologically depressed patients, the nodes can be fungal, viral or bacterial (Fig. 1) .", [["nodes", "ANATOMY", 54, 59], ["depressed", "DISEASE", 30, 39], ["patients", "ORGANISM", 40, 48], ["nodes", "MULTI-TISSUE_STRUCTURE", 54, 59], ["patients", "SPECIES", 40, 48], ["severely immunologically depressed patients", "PROBLEM", 5, 48], ["the nodes", "PROBLEM", 50, 59], ["fungal", "PROBLEM", 67, 73], ["viral", "PROBLEM", 75, 80], ["bacterial (Fig", "PROBLEM", 84, 98], ["severely", "OBSERVATION_MODIFIER", 5, 13], ["immunologically", "OBSERVATION_MODIFIER", 14, 29], ["depressed", "OBSERVATION_MODIFIER", 30, 39], ["nodes", "OBSERVATION", 54, 59], ["bacterial", "OBSERVATION_MODIFIER", 84, 93]]], ["Filamentous fungi are common in prolonged deep neutropenias (over two weeks) especially during chemotherapy of an AML and in the early post-HPT period.", [["AML", "ANATOMY", 114, 117], ["AML", "DISEASE", 114, 117], ["HPT", "DISEASE", 140, 143], ["AML", "CANCER", 114, 117], ["Filamentous fungi", "PROBLEM", 0, 17], ["prolonged deep neutropenias", "PROBLEM", 32, 59], ["chemotherapy", "TREATMENT", 95, 107], ["an AML", "PROBLEM", 111, 117], ["fungi", "OBSERVATION", 12, 17], ["prolonged", "OBSERVATION_MODIFIER", 32, 41], ["deep", "OBSERVATION_MODIFIER", 42, 46], ["neutropenias", "OBSERVATION", 47, 59], ["AML", "OBSERVATION", 114, 117]]], ["8 In 94% of invasive aspergillosis it is possible to observe nodes that are usually multiple-bilateral and at least one >1 cm.", [["invasive aspergillosis", "ANATOMY", 12, 34], ["nodes", "ANATOMY", 61, 66], ["aspergillosis", "DISEASE", 21, 34], ["aspergillosis", "CANCER", 21, 34], ["invasive aspergillosis", "PROBLEM", 12, 34], ["nodes", "PROBLEM", 61, 66], ["invasive", "OBSERVATION_MODIFIER", 12, 20], ["aspergillosis", "OBSERVATION", 21, 34], ["nodes", "OBSERVATION", 61, 66], ["multiple", "OBSERVATION_MODIFIER", 84, 92], ["bilateral", "ANATOMY_MODIFIER", 93, 102], ["1 cm", "OBSERVATION_MODIFIER", 121, 125]]], ["10 The ground-glass attenuation halo distinguishes them from bacterial nodes 11, 12 but it usually disappears during the first five days.", [["The ground-glass attenuation halo", "PROBLEM", 3, 36], ["bacterial nodes", "PROBLEM", 61, 76], ["ground-", "OBSERVATION_MODIFIER", 7, 14], ["glass attenuation", "OBSERVATION_MODIFIER", 14, 31], ["halo", "OBSERVATION_MODIFIER", 32, 36], ["bacterial", "OBSERVATION_MODIFIER", 61, 70], ["nodes", "OBSERVATION", 71, 76]]], ["Mucormycosis is suspected before aspergillosis if 10 nodes or more are observed as well as sinus affectation, pleural effusion 13 and/or the inverted halo sign, 14 especially if the antifungal therapy did not cover that fungus.", [["nodes", "ANATOMY", 53, 58], ["sinus", "ANATOMY", 91, 96], ["pleural effusion", "ANATOMY", 110, 126], ["Mucormycosis", "DISEASE", 0, 12], ["aspergillosis", "DISEASE", 33, 46], ["sinus affectation", "DISEASE", 91, 108], ["pleural effusion", "DISEASE", 110, 126], ["aspergillosis", "CANCER", 33, 46], ["pleural", "CANCER", 110, 117], ["Mucormycosis", "PROBLEM", 0, 12], ["aspergillosis", "PROBLEM", 33, 46], ["10 nodes", "PROBLEM", 50, 58], ["sinus affectation", "PROBLEM", 91, 108], ["pleural effusion", "PROBLEM", 110, 126], ["the inverted halo sign", "PROBLEM", 137, 159], ["the antifungal therapy", "TREATMENT", 178, 200], ["fungus", "PROBLEM", 220, 226], ["nodes", "OBSERVATION", 53, 58], ["sinus", "ANATOMY", 91, 96], ["pleural", "ANATOMY", 110, 117], ["effusion", "OBSERVATION", 118, 126], ["fungus", "OBSERVATION", 220, 226]]], ["The HRCT is useful because there is no serological test available today for the diagnosis of mucormycosis.InfectionsViral nodes often have poorly-defined edges and/or halos but they are distinguished by their small size (<1 cm) and the absence of cavitation.", [["Viral nodes", "ANATOMY", 116, 127], ["mucormycosis", "DISEASE", 93, 105], ["cavitation", "DISEASE", 247, 257], ["mucormycosis", "CANCER", 93, 105], ["The HRCT", "TEST", 0, 8], ["serological test", "TEST", 39, 55], ["mucormycosis", "PROBLEM", 93, 105], ["InfectionsViral nodes", "PROBLEM", 106, 127], ["halos", "PROBLEM", 167, 172], ["cavitation", "PROBLEM", 247, 257], ["mucormycosis", "OBSERVATION", 93, 105], ["nodes", "OBSERVATION", 122, 127], ["poorly-defined", "OBSERVATION_MODIFIER", 139, 153], ["edges", "OBSERVATION_MODIFIER", 154, 159], ["halos", "OBSERVATION", 167, 172], ["small", "OBSERVATION_MODIFIER", 209, 214], ["size", "OBSERVATION_MODIFIER", 215, 219], ["<1 cm", "OBSERVATION_MODIFIER", 221, 226], ["cavitation", "OBSERVATION", 247, 257]]], ["15 Bacterial nodes usually have betterdefined edges.InfectionsCentrilobular nodes often represent unspecific infectious bronchiolitis, especially if accompanied by sprouting-tree images; however, diffuse symmetrical bilateral centrilobular nodes with predominance in upper fields and ground-glass attenuation, in the absence of other infectious findings, should lead to respiratory bronchiolitis by tobacco or pneumonitis due to hypersensitivity secondary to the treatment.Pulmonary infiltration due to hematologic neoplasmIn NHL and HL infiltration is observed more often in relapses, increasing due to the greater survival of the patients with the current therapies.", [["Bacterial nodes", "ANATOMY", 3, 18], ["Centrilobular nodes", "ANATOMY", 62, 81], ["centrilobular nodes", "ANATOMY", 226, 245], ["respiratory", "ANATOMY", 370, 381], ["Pulmonary", "ANATOMY", 473, 482], ["hematologic neoplasmIn NHL", "ANATOMY", 503, 529], ["bronchiolitis", "DISEASE", 120, 133], ["bronchiolitis", "DISEASE", 382, 395], ["pneumonitis", "DISEASE", 410, 421], ["hypersensitivity", "DISEASE", 429, 445], ["Pulmonary infiltration", "DISEASE", 473, 495], ["NHL", "DISEASE", 526, 529], ["Centrilobular nodes", "MULTI-TISSUE_STRUCTURE", 62, 81], ["centrilobular nodes", "MULTI-TISSUE_STRUCTURE", 226, 245], ["tobacco", "ORGANISM", 399, 406], ["Pulmonary", "ORGAN", 473, 482], ["hematologic neoplasmIn NHL", "CANCER", 503, 529], ["HL", "CANCER", 534, 536], ["patients", "ORGANISM", 632, 640], ["patients", "SPECIES", 632, 640], ["tobacco", "SPECIES", 399, 406], ["Bacterial nodes", "PROBLEM", 3, 18], ["Centrilobular nodes", "PROBLEM", 62, 81], ["unspecific infectious bronchiolitis", "PROBLEM", 98, 133], ["sprouting-tree images", "TEST", 164, 185], ["diffuse symmetrical bilateral centrilobular nodes", "PROBLEM", 196, 245], ["predominance in upper fields and ground-glass attenuation", "PROBLEM", 251, 308], ["other infectious findings", "PROBLEM", 328, 353], ["respiratory bronchiolitis", "PROBLEM", 370, 395], ["pneumonitis", "PROBLEM", 410, 421], ["hypersensitivity", "PROBLEM", 429, 445], ["the treatment", "TREATMENT", 459, 472], ["Pulmonary infiltration", "PROBLEM", 473, 495], ["hematologic neoplasmIn NHL", "PROBLEM", 503, 529], ["HL infiltration", "PROBLEM", 534, 549], ["the current therapies", "TREATMENT", 646, 667], ["Bacterial", "OBSERVATION_MODIFIER", 3, 12], ["nodes", "OBSERVATION", 13, 18], ["betterdefined", "OBSERVATION_MODIFIER", 32, 45], ["edges", "OBSERVATION_MODIFIER", 46, 51], ["Centrilobular", "OBSERVATION_MODIFIER", 62, 75], ["nodes", "OBSERVATION", 76, 81], ["unspecific", "OBSERVATION_MODIFIER", 98, 108], ["infectious", "OBSERVATION_MODIFIER", 109, 119], ["bronchiolitis", "OBSERVATION", 120, 133], ["tree", "ANATOMY_MODIFIER", 174, 178], ["diffuse", "OBSERVATION_MODIFIER", 196, 203], ["symmetrical", "OBSERVATION_MODIFIER", 204, 215], ["bilateral", "ANATOMY_MODIFIER", 216, 225], ["centrilobular", "ANATOMY_MODIFIER", 226, 239], ["nodes", "OBSERVATION", 240, 245], ["predominance", "OBSERVATION_MODIFIER", 251, 263], ["upper", "ANATOMY_MODIFIER", 267, 272], ["fields", "ANATOMY_MODIFIER", 273, 279], ["ground-glass attenuation", "OBSERVATION", 284, 308], ["infectious", "OBSERVATION", 334, 344], ["respiratory", "OBSERVATION_MODIFIER", 370, 381], ["bronchiolitis", "OBSERVATION", 382, 395], ["pneumonitis", "OBSERVATION", 410, 421], ["infiltration", "OBSERVATION", 483, 495], ["hematologic neoplasmIn NHL", "OBSERVATION", 503, 529], ["HL", "OBSERVATION_MODIFIER", 534, 536], ["infiltration", "OBSERVATION", 537, 549], ["relapses", "OBSERVATION", 576, 584]]], ["It usually manifests itself as multiple pulmonary nodes <1 cm with irregular edges, consolidations and/or masses, which are more frequent in NHL and have worse prognosis.", [["pulmonary nodes", "ANATOMY", 40, 55], ["masses", "ANATOMY", 106, 112], ["NHL", "ANATOMY", 141, 144], ["NHL", "DISEASE", 141, 144], ["pulmonary nodes", "MULTI-TISSUE_STRUCTURE", 40, 55], ["masses", "CANCER", 106, 112], ["NHL", "CANCER", 141, 144], ["multiple pulmonary nodes", "PROBLEM", 31, 55], ["irregular edges", "PROBLEM", 67, 82], ["consolidations", "PROBLEM", 84, 98], ["masses", "PROBLEM", 106, 112], ["multiple", "OBSERVATION_MODIFIER", 31, 39], ["pulmonary", "ANATOMY", 40, 49], ["nodes", "OBSERVATION", 50, 55], ["1 cm", "OBSERVATION_MODIFIER", 57, 61], ["irregular", "OBSERVATION_MODIFIER", 67, 76], ["edges", "OBSERVATION_MODIFIER", 77, 82], ["consolidations", "OBSERVATION", 84, 98], ["masses", "OBSERVATION", 106, 112], ["more frequent", "OBSERVATION_MODIFIER", 124, 137], ["worse", "OBSERVATION_MODIFIER", 154, 159]]], ["Primary pulmonary lymphoma occurs in patients of 55---60 years of age, it is usually non-Hodgkin of the B MALT type (mucosa-associated lymphoid tissue) and it shows as a nodule or peribronchovascular consolidation at the bronchogram test.", [["pulmonary lymphoma", "ANATOMY", 8, 26], ["B MALT type", "ANATOMY", 104, 115], ["mucosa", "ANATOMY", 117, 123], ["lymphoid tissue", "ANATOMY", 135, 150], ["nodule", "ANATOMY", 170, 176], ["peribronchovascular", "ANATOMY", 180, 199], ["Primary pulmonary lymphoma", "DISEASE", 0, 26], ["Primary pulmonary lymphoma", "CANCER", 0, 26], ["patients", "ORGANISM", 37, 45], ["non-Hodgkin", "CANCER", 85, 96], ["B MALT type", "TISSUE", 104, 115], ["mucosa-associated lymphoid tissue", "TISSUE", 117, 150], ["patients", "SPECIES", 37, 45], ["Primary pulmonary lymphoma", "PROBLEM", 0, 26], ["a nodule", "PROBLEM", 168, 176], ["peribronchovascular consolidation", "PROBLEM", 180, 213], ["the bronchogram test", "TEST", 217, 237], ["pulmonary", "ANATOMY", 8, 17], ["lymphoma", "OBSERVATION", 18, 26], ["MALT type", "OBSERVATION_MODIFIER", 106, 115], ["mucosa", "ANATOMY", 117, 123], ["lymphoid tissue", "OBSERVATION", 135, 150], ["nodule", "OBSERVATION", 170, 176], ["peribronchovascular", "OBSERVATION_MODIFIER", 180, 199], ["consolidation", "OBSERVATION", 200, 213], ["bronchogram", "OBSERVATION", 221, 232]]], ["These lesions can be single or multiple bilateral.", [["lesions", "ANATOMY", 6, 13], ["lesions", "CANCER", 6, 13], ["These lesions", "PROBLEM", 0, 13], ["lesions", "OBSERVATION", 6, 13], ["multiple", "OBSERVATION_MODIFIER", 31, 39], ["bilateral", "ANATOMY_MODIFIER", 40, 49]]], ["16, 17 They are characterized by the absence of mediastinal adenopathies at the moment of diagnosis and up to 3 months later, they grow slowly.", [["mediastinal adenopathies", "ANATOMY", 48, 72], ["adenopathies", "DISEASE", 60, 72], ["mediastinal adenopathies", "CANCER", 48, 72], ["mediastinal adenopathies", "PROBLEM", 48, 72], ["mediastinal", "ANATOMY", 48, 59], ["adenopathies", "OBSERVATION", 60, 72], ["slowly", "OBSERVATION_MODIFIER", 136, 142]]], ["Identical presentations to those of lymphocytic interstitial pneumonia have also been described (Fig. 2) .Pulmonary infiltration due to hematologic neoplasmMyeloid leukemias and myelodysplastic syndromes can make up a blastic tumor called granulocytic sarcoma---extremely rare in the lung, where it can occur as a node, mass or consolidation.", [["lymphocytic interstitial", "ANATOMY", 36, 60], ["Pulmonary", "ANATOMY", 106, 115], ["hematologic neoplasm", "ANATOMY", 136, 156], ["Myeloid leukemias", "ANATOMY", 156, 173], ["blastic tumor", "ANATOMY", 218, 231], ["granulocytic sarcoma", "ANATOMY", 239, 259], ["lung", "ANATOMY", 284, 288], ["node", "ANATOMY", 314, 318], ["interstitial pneumonia", "DISEASE", 48, 70], ["Pulmonary infiltration", "DISEASE", 106, 128], ["hematologic neoplasm", "DISEASE", 136, 156], ["Myeloid leukemias", "DISEASE", 156, 173], ["myelodysplastic syndromes", "DISEASE", 178, 203], ["tumor", "DISEASE", 226, 231], ["granulocytic sarcoma", "DISEASE", 239, 259], ["lymphocytic interstitial", "PATHOLOGICAL_FORMATION", 36, 60], ["Pulmonary", "ORGAN", 106, 115], ["hematologic neoplasm", "CANCER", 136, 156], ["Myeloid leukemias", "CANCER", 156, 173], ["blastic tumor", "CANCER", 218, 231], ["granulocytic sarcoma", "CANCER", 239, 259], ["lung", "ORGAN", 284, 288], ["node", "MULTI-TISSUE_STRUCTURE", 314, 318], ["lymphocytic interstitial pneumonia", "PROBLEM", 36, 70], ["Pulmonary infiltration", "PROBLEM", 106, 128], ["hematologic neoplasm", "PROBLEM", 136, 156], ["Myeloid leukemias", "PROBLEM", 156, 173], ["myelodysplastic syndromes", "PROBLEM", 178, 203], ["a blastic tumor", "PROBLEM", 216, 231], ["granulocytic sarcoma", "PROBLEM", 239, 259], ["a node", "PROBLEM", 312, 318], ["mass", "PROBLEM", 320, 324], ["consolidation", "PROBLEM", 328, 341], ["lymphocytic", "OBSERVATION_MODIFIER", 36, 47], ["interstitial", "ANATOMY_MODIFIER", 48, 60], ["pneumonia", "OBSERVATION", 61, 70], ["infiltration", "OBSERVATION", 116, 128], ["hematologic neoplasm", "OBSERVATION", 136, 156], ["leukemias", "OBSERVATION", 164, 173], ["myelodysplastic syndromes", "OBSERVATION", 178, 203], ["blastic", "OBSERVATION_MODIFIER", 218, 225], ["tumor", "OBSERVATION", 226, 231], ["granulocytic sarcoma", "OBSERVATION", 239, 259], ["lung", "ANATOMY", 284, 288], ["node", "OBSERVATION", 314, 318], ["mass", "OBSERVATION", 320, 324], ["consolidation", "OBSERVATION", 328, 341]]], ["18 Exceptionally, MM can present nodes and/or masses, associated with adenopathies that simulate a lymphoma or a pulmonary cancer 19 with a bad prognosis.", [["MM", "ANATOMY", 18, 20], ["nodes", "ANATOMY", 33, 38], ["masses", "ANATOMY", 46, 52], ["lymphoma", "ANATOMY", 99, 107], ["pulmonary cancer", "ANATOMY", 113, 129], ["MM", "DISEASE", 18, 20], ["adenopathies", "DISEASE", 70, 82], ["lymphoma", "DISEASE", 99, 107], ["pulmonary cancer", "DISEASE", 113, 129], ["MM", "CANCER", 18, 20], ["nodes", "MULTI-TISSUE_STRUCTURE", 33, 38], ["masses", "CANCER", 46, 52], ["lymphoma", "CANCER", 99, 107], ["pulmonary cancer", "CANCER", 113, 129], ["present nodes", "PROBLEM", 25, 38], ["masses", "PROBLEM", 46, 52], ["adenopathies", "PROBLEM", 70, 82], ["a lymphoma", "PROBLEM", 97, 107], ["a pulmonary cancer", "PROBLEM", 111, 129], ["nodes", "OBSERVATION", 33, 38], ["masses", "OBSERVATION", 46, 52], ["adenopathies", "OBSERVATION", 70, 82], ["lymphoma", "OBSERVATION", 99, 107], ["pulmonary", "ANATOMY", 113, 122], ["cancer", "OBSERVATION", 123, 129]]], ["20 Lymphomatoid granulomatosis is an extranodal lymphoproliferative process associated with the Epstein---Barr virus (EBV) mainly affecting the lung and the central nervous system.", [["lung", "ANATOMY", 144, 148], ["central nervous system", "ANATOMY", 157, 179], ["Lymphomatoid granulomatosis", "DISEASE", 3, 30], ["Epstein---Barr virus (EBV) mainly affecting the lung and the central nervous system", "DISEASE", 96, 179], ["Epstein---Barr virus", "ORGANISM", 96, 116], ["EBV", "ORGANISM", 118, 121], ["lung", "ORGAN", 144, 148], ["central nervous system", "ANATOMICAL_SYSTEM", 157, 179], ["Epstein---Barr virus", "SPECIES", 96, 116], ["EBV", "SPECIES", 118, 121], ["Lymphomatoid granulomatosis", "PROBLEM", 3, 30], ["an extranodal lymphoproliferative process", "PROBLEM", 34, 75], ["Barr virus (EBV", "PROBLEM", 106, 121], ["Lymphomatoid granulomatosis", "OBSERVATION", 3, 30], ["extranodal lymphoproliferative process", "OBSERVATION", 37, 75], ["Barr virus", "OBSERVATION", 106, 116], ["lung", "ANATOMY", 144, 148], ["central", "ANATOMY_MODIFIER", 157, 164], ["nervous system", "ANATOMY", 165, 179]]], ["It occurs as multiple pulmonary nodes in more than 80% of the cases, they are variable in number and size, and of basal predominance.", [["pulmonary nodes", "ANATOMY", 22, 37], ["pulmonary nodes", "MULTI-TISSUE_STRUCTURE", 22, 37], ["multiple pulmonary nodes", "PROBLEM", 13, 37], ["multiple", "OBSERVATION_MODIFIER", 13, 21], ["pulmonary", "ANATOMY", 22, 31], ["nodes", "OBSERVATION", 32, 37], ["cases", "OBSERVATION", 62, 67], ["variable", "OBSERVATION_MODIFIER", 78, 86], ["number", "OBSERVATION_MODIFIER", 90, 96], ["size", "OBSERVATION_MODIFIER", 101, 105], ["basal", "ANATOMY_MODIFIER", 114, 119], ["predominance", "OBSERVATION", 120, 132]]], ["Nodes can progress rapidly, coalesce and cavitate, as well as disappear spontaneously, migrate or evolve making up the sign of the inverted halo sign.", [["the inverted halo sign", "PROBLEM", 127, 149], ["coalesce", "OBSERVATION_MODIFIER", 28, 36], ["halo", "OBSERVATION", 140, 144]]], ["21, 22 Secondary neoplasms Lung cancer has increased in survivors of HL, NHL and CLL, and its etiopathogenesis is being studied.", [["neoplasms Lung cancer", "ANATOMY", 17, 38], ["NHL", "ANATOMY", 73, 76], ["CLL", "ANATOMY", 81, 84], ["neoplasms", "DISEASE", 17, 26], ["Lung cancer", "DISEASE", 27, 38], ["HL", "DISEASE", 69, 71], ["NHL", "DISEASE", 73, 76], ["CLL", "DISEASE", 81, 84], ["neoplasms Lung cancer", "CANCER", 17, 38], ["HL", "CANCER", 69, 71], ["NHL", "CANCER", 73, 76], ["CLL", "CANCER", 81, 84], ["Secondary neoplasms Lung cancer", "PROBLEM", 7, 38], ["HL", "PROBLEM", 69, 71], ["NHL", "PROBLEM", 73, 76], ["CLL", "PROBLEM", 81, 84], ["Secondary", "OBSERVATION_MODIFIER", 7, 16], ["neoplasms", "OBSERVATION", 17, 26], ["Lung", "ANATOMY", 27, 31], ["cancer", "OBSERVATION", 32, 38], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["HL", "OBSERVATION_MODIFIER", 69, 71], ["NHL", "OBSERVATION", 73, 76], ["CLL", "OBSERVATION", 81, 84]]], ["Its appearance ranges from one to several years after the diagnosis of HN.Pulmonary infiltration due to hematologic neoplasmPatients receiving allogenic HPT can develop a posttransplant lymphoproliferative disorder (PTLD), usually during the first six (6) months, and up to a year, with a second peak at 4---5 years.", [["Pulmonary", "ANATOMY", 74, 83], ["hematologic neoplasmPatients", "ANATOMY", 104, 132], ["HN", "DISEASE", 71, 73], ["Pulmonary infiltration", "DISEASE", 74, 96], ["HPT", "DISEASE", 153, 156], ["posttransplant lymphoproliferative disorder", "DISEASE", 171, 214], ["PTLD", "DISEASE", 216, 220], ["HN", "CANCER", 71, 73], ["Pulmonary", "ORGAN", 74, 83], ["HN", "PROBLEM", 71, 73], ["Pulmonary infiltration", "PROBLEM", 74, 96], ["hematologic neoplasmPatients", "PROBLEM", 104, 132], ["allogenic HPT", "TREATMENT", 143, 156], ["a posttransplant lymphoproliferative disorder", "PROBLEM", 169, 214], ["PTLD", "PROBLEM", 216, 220], ["ranges", "OBSERVATION_MODIFIER", 15, 21], ["infiltration", "OBSERVATION", 84, 96], ["posttransplant lymphoproliferative disorder", "OBSERVATION", 171, 214]]], ["23 In PTLD and the HIV-associated lymphoma (most attributed to EBV) pulmonary nodes are usually bilateral, well-defined, and may associate a halo.", [["lymphoma", "ANATOMY", 34, 42], ["pulmonary nodes", "ANATOMY", 68, 83], ["PTLD", "DISEASE", 6, 10], ["HIV-associated lymphoma", "DISEASE", 19, 42], ["PTLD", "CANCER", 6, 10], ["lymphoma", "CANCER", 34, 42], ["EBV", "ORGANISM", 63, 66], ["pulmonary nodes", "MULTI-TISSUE_STRUCTURE", 68, 83], ["HIV", "SPECIES", 19, 22], ["HIV", "SPECIES", 19, 22], ["EBV", "SPECIES", 63, 66], ["PTLD", "PROBLEM", 6, 10], ["the HIV-associated lymphoma", "PROBLEM", 15, 42], ["EBV) pulmonary nodes", "PROBLEM", 63, 83], ["PTLD", "OBSERVATION", 6, 10], ["HIV", "OBSERVATION_MODIFIER", 19, 22], ["lymphoma", "OBSERVATION", 34, 42], ["most attributed to", "UNCERTAINTY", 44, 62], ["EBV", "OBSERVATION", 63, 66], ["pulmonary", "ANATOMY", 68, 77], ["nodes", "OBSERVATION", 78, 83], ["bilateral", "ANATOMY_MODIFIER", 96, 105], ["well-defined", "OBSERVATION_MODIFIER", 107, 119], ["halo", "OBSERVATION", 141, 145]]], ["24 It is important not to take them for an IFI by taking into account the clinical context and the evolution of the lesions.CavitationsIFI nodes typically cavitate 2---3 weeks after the disease onset accompanying the recovery from neutropenia (neutrophiles > 1000), making up the growing air image (crescent moon).", [["lesions", "ANATOMY", 116, 123], ["CavitationsIFI nodes", "ANATOMY", 124, 144], ["IFI", "DISEASE", 43, 46], ["neutropenia", "DISEASE", 231, 242], ["lesions", "PATHOLOGICAL_FORMATION", 116, 123], ["an IFI", "TREATMENT", 40, 46], ["the lesions", "PROBLEM", 112, 123], ["CavitationsIFI nodes", "PROBLEM", 124, 144], ["the disease onset", "PROBLEM", 182, 199], ["neutropenia", "PROBLEM", 231, 242], ["neutrophiles", "TEST", 244, 256], ["lesions", "OBSERVATION", 116, 123], ["nodes", "OBSERVATION", 139, 144], ["disease", "OBSERVATION", 186, 193], ["neutropenia", "OBSERVATION", 231, 242]]], ["Previously nodes can show low central attenuation 25 (Fig. 3) .Figure 3Low attenuation nodes.", [["nodes", "ANATOMY", 11, 16], ["low central attenuation", "PROBLEM", 26, 49], ["Figure 3Low attenuation nodes", "PROBLEM", 63, 92], ["nodes", "OBSERVATION", 11, 16], ["low", "OBSERVATION_MODIFIER", 26, 29], ["central", "OBSERVATION_MODIFIER", 30, 37], ["attenuation", "OBSERVATION_MODIFIER", 38, 49], ["3Low attenuation", "OBSERVATION_MODIFIER", 70, 86], ["nodes", "OBSERVATION", 87, 92]]], ["Invasive fungal infection (IFI) due to Aspergillus.", [["Invasive fungal infection", "DISEASE", 0, 25], ["IFI", "DISEASE", 27, 30], ["Invasive fungal infection (IFI)", "PROBLEM", 0, 31], ["Aspergillus", "PROBLEM", 39, 50], ["fungal", "OBSERVATION_MODIFIER", 9, 15], ["infection", "OBSERVATION", 16, 25], ["Aspergillus", "OBSERVATION", 39, 50]]], ["Acute lymphoid leukemia and prolongued neutropenia.", [["lymphoid leukemia", "ANATOMY", 6, 23], ["Acute lymphoid leukemia", "DISEASE", 0, 23], ["neutropenia", "DISEASE", 39, 50], ["Acute lymphoid leukemia", "CANCER", 0, 23], ["Acute lymphoid leukemia", "PROBLEM", 0, 23], ["prolongued neutropenia", "PROBLEM", 28, 50], ["lymphoid leukemia", "OBSERVATION", 6, 23], ["neutropenia", "OBSERVATION", 39, 50]]], ["Upper cut (upper side images) and lower cut (lower side images).", [["Upper cut (upper side images", "TEST", 0, 28], ["lower cut (lower side images", "TEST", 34, 62], ["lower", "ANATOMY_MODIFIER", 34, 39]]], ["The nodes low attenuation can be seen in images with filter while the mediastinal window (arrows in A and D) is very typical of IFI due to necrosis prior to cavitation seen two (2) weeks later (C and F).", [["nodes", "ANATOMY", 4, 9], ["mediastinal window", "ANATOMY", 70, 88], ["IFI", "DISEASE", 128, 131], ["necrosis", "DISEASE", 139, 147], ["nodes", "MULTI-TISSUE_STRUCTURE", 4, 9], ["The nodes low attenuation", "PROBLEM", 0, 25], ["filter", "TREATMENT", 53, 59], ["IFI", "PROBLEM", 128, 131], ["necrosis", "PROBLEM", 139, 147], ["cavitation", "PROBLEM", 157, 167], ["nodes", "OBSERVATION", 4, 9], ["low attenuation", "OBSERVATION_MODIFIER", 10, 25], ["filter", "OBSERVATION", 53, 59], ["mediastinal", "ANATOMY", 70, 81], ["window", "OBSERVATION", 82, 88], ["IFI", "OBSERVATION", 128, 131], ["necrosis", "OBSERVATION", 139, 147], ["cavitation", "OBSERVATION", 157, 167]]], ["Serum gactolamannan was positive one (1) month later.Figure 3Fungal and bacterial consolidations (especially staphylococcal or tuberculous ones) can also cavitate and less commonly nodes and consolidations due to lymphoma.Figure 3The appearance of cavitated nodes corresponding to Langerhans cell histiocytosis has been described in patients with HL and more rarely in leukemias; it is not known whether there is an actual association, but in any case tobacco plays a role in the etiopathogenesis.", [["Serum", "ANATOMY", 0, 5], ["nodes", "ANATOMY", 181, 186], ["lymphoma", "ANATOMY", 213, 221], ["cavitated nodes", "ANATOMY", 248, 263], ["Langerhans cell histiocytosis", "ANATOMY", 281, 310], ["leukemias", "ANATOMY", 369, 378], ["gactolamannan", "CHEMICAL", 6, 19], ["lymphoma", "DISEASE", 213, 221], ["Langerhans cell histiocytosis", "DISEASE", 281, 310], ["HL", "DISEASE", 347, 349], ["leukemias", "DISEASE", 369, 378], ["gactolamannan", "CHEMICAL", 6, 19], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["gactolamannan", "SIMPLE_CHEMICAL", 6, 19], ["lymphoma", "CANCER", 213, 221], ["cavitated nodes", "MULTI-TISSUE_STRUCTURE", 248, 263], ["Langerhans cell histiocytosis", "CANCER", 281, 310], ["patients", "ORGANISM", 333, 341], ["HL", "CANCER", 347, 349], ["leukemias", "CANCER", 369, 378], ["tobacco", "ORGANISM", 452, 459], ["patients", "SPECIES", 333, 341], ["tobacco", "SPECIES", 452, 459], ["Serum gactolamannan", "TEST", 0, 19], ["bacterial consolidations", "PROBLEM", 72, 96], ["staphylococcal or tuberculous ones", "PROBLEM", 109, 143], ["less commonly nodes", "PROBLEM", 167, 186], ["consolidations", "PROBLEM", 191, 205], ["lymphoma", "PROBLEM", 213, 221], ["cavitated nodes", "PROBLEM", 248, 263], ["Langerhans cell histiocytosis", "PROBLEM", 281, 310], ["HL", "PROBLEM", 347, 349], ["leukemias", "PROBLEM", 369, 378], ["bacterial", "OBSERVATION_MODIFIER", 72, 81], ["consolidations", "OBSERVATION", 82, 96], ["tuberculous", "OBSERVATION", 127, 138], ["less", "OBSERVATION_MODIFIER", 167, 171], ["commonly", "OBSERVATION_MODIFIER", 172, 180], ["nodes", "OBSERVATION", 181, 186], ["consolidations", "OBSERVATION", 191, 205], ["lymphoma", "OBSERVATION", 213, 221], ["cavitated", "OBSERVATION_MODIFIER", 248, 257], ["nodes", "OBSERVATION", 258, 263], ["Langerhans cell histiocytosis", "OBSERVATION", 281, 310], ["leukemias", "OBSERVATION", 369, 378], ["not known", "UNCERTAINTY", 386, 395]]], ["26 Areas of attenuation in groud glass.", [["attenuation in groud glass", "PROBLEM", 12, 38], ["Areas", "OBSERVATION_MODIFIER", 3, 8], ["attenuation", "OBSERVATION_MODIFIER", 12, 23], ["groud glass", "OBSERVATION", 27, 38]]], ["Consolidations (Fig. 4) see Tables 2 and 3 Infections At the disease onset and in the course of MM, it is possible to observe bacterial and viral bronchopneumonias similar to the rest of the population while in patients with severe immunodepression they are due to different germs (see Tables 2 and 3) .Figure 3Segmental or lobar consolidations are most often bacterial.", [["MM", "ANATOMY", 96, 98], ["germs", "ANATOMY", 275, 280], ["lobar", "ANATOMY", 324, 329], ["MM", "DISEASE", 96, 98], ["immunodepression", "DISEASE", 232, 248], ["MM", "CANCER", 96, 98], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["Consolidations", "PROBLEM", 0, 14], ["bacterial and viral bronchopneumonias", "PROBLEM", 126, 163], ["severe immunodepression", "PROBLEM", 225, 248], ["different germs", "PROBLEM", 265, 280], ["Figure 3Segmental or lobar consolidations", "PROBLEM", 303, 344], ["disease", "OBSERVATION", 61, 68], ["possible to", "UNCERTAINTY", 106, 117], ["bacterial", "OBSERVATION_MODIFIER", 126, 135], ["viral bronchopneumonias", "OBSERVATION", 140, 163], ["severe", "OBSERVATION_MODIFIER", 225, 231], ["immunodepression", "OBSERVATION", 232, 248], ["3Segmental", "OBSERVATION_MODIFIER", 310, 320], ["lobar", "OBSERVATION_MODIFIER", 324, 329], ["consolidations", "OBSERVATION", 330, 344], ["most often", "UNCERTAINTY", 349, 359], ["bacterial", "OBSERVATION_MODIFIER", 360, 369]]], ["An IFI is suspected when they have a pleural base and halo, 27,28 but the most sensitive diagnostic sign (100%) is vascular occlusion in the sinus of the lesions shown through pulmonary angio-CT.", [["pleural base", "ANATOMY", 37, 49], ["vascular", "ANATOMY", 115, 123], ["sinus", "ANATOMY", 141, 146], ["lesions", "ANATOMY", 154, 161], ["pulmonary", "ANATOMY", 176, 185], ["IFI", "DISEASE", 3, 6], ["vascular occlusion", "DISEASE", 115, 133], ["pleural base", "MULTI-TISSUE_STRUCTURE", 37, 49], ["vascular", "MULTI-TISSUE_STRUCTURE", 115, 123], ["sinus", "ORGAN", 141, 146], ["lesions", "PATHOLOGICAL_FORMATION", 154, 161], ["pulmonary", "ORGAN", 176, 185], ["a pleural base and halo", "TEST", 35, 58], ["vascular occlusion in the sinus of the lesions", "PROBLEM", 115, 161], ["pulmonary angio", "TEST", 176, 191], ["CT", "TEST", 192, 194], ["IFI", "OBSERVATION", 3, 6], ["pleural", "ANATOMY", 37, 44], ["base", "ANATOMY_MODIFIER", 45, 49], ["vascular", "ANATOMY", 115, 123], ["occlusion", "OBSERVATION", 124, 133], ["sinus", "ANATOMY", 141, 146], ["lesions", "OBSERVATION", 154, 161], ["pulmonary", "ANATOMY", 176, 185]]], ["29 Patched bilateral ground-glass opacities, whose size is very variable, are more typical of viruses and they can be accompanied by small nodes and consolidations.", [["nodes", "ANATOMY", 139, 144], ["small nodes", "MULTI-TISSUE_STRUCTURE", 133, 144], ["Patched bilateral ground-glass opacities", "PROBLEM", 3, 43], ["viruses", "PROBLEM", 94, 101], ["small nodes", "PROBLEM", 133, 144], ["consolidations", "PROBLEM", 149, 163], ["bilateral", "ANATOMY_MODIFIER", 11, 20], ["ground-glass opacities", "OBSERVATION", 21, 43], ["size", "OBSERVATION_MODIFIER", 51, 55], ["very", "OBSERVATION_MODIFIER", 59, 63], ["variable", "OBSERVATION_MODIFIER", 64, 72], ["more typical", "OBSERVATION_MODIFIER", 78, 90], ["viruses", "OBSERVATION", 94, 101], ["small", "OBSERVATION_MODIFIER", 133, 138], ["nodes", "OBSERVATION", 139, 144], ["consolidations", "OBSERVATION", 149, 163]]], ["30---33 In patients with HPT the paved pattern is of viral origin mainly and less commonly of a non-infectious cause.", [["HPT", "DISEASE", 25, 28], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["HPT", "PROBLEM", 25, 28], ["viral origin", "PROBLEM", 53, 65], ["a non-infectious cause", "PROBLEM", 94, 116], ["viral origin", "OBSERVATION", 53, 65], ["non-infectious", "OBSERVATION", 96, 110]]], ["34 Infection due to Pneumocystis jirovecii causes perihilar bilateral ground-glass attenuation areas in upper fields, usually after the 100th day post-HPT---a moment in which prophylaxis is usually withdrawn.Figure 3Respiratory colonization due to Candida is common in these patients, but pneumonia is exceptional except for in situations of spread candidiasis.", [["Infection", "DISEASE", 3, 12], ["Pneumocystis jirovecii", "DISEASE", 20, 42], ["HPT", "DISEASE", 151, 154], ["pneumonia", "DISEASE", 289, 298], ["candidiasis", "DISEASE", 349, 360], ["Pneumocystis jirovecii", "ORGANISM", 20, 42], ["patients", "ORGANISM", 275, 283], ["candidiasis", "PATHOLOGICAL_FORMATION", 349, 360], ["Pneumocystis jirovecii", "SPECIES", 20, 42], ["patients", "SPECIES", 275, 283], ["Pneumocystis jirovecii", "SPECIES", 20, 42], ["34 Infection", "PROBLEM", 0, 12], ["Pneumocystis jirovecii", "PROBLEM", 20, 42], ["perihilar bilateral ground-glass attenuation areas in upper fields", "PROBLEM", 50, 116], ["HPT", "TEST", 151, 154], ["prophylaxis", "TREATMENT", 175, 186], ["Figure 3Respiratory colonization", "PROBLEM", 208, 240], ["Candida", "PROBLEM", 248, 255], ["pneumonia", "PROBLEM", 289, 298], ["spread candidiasis", "PROBLEM", 342, 360], ["Infection", "OBSERVATION", 3, 12], ["Pneumocystis jirovecii", "OBSERVATION", 20, 42], ["perihilar", "ANATOMY_MODIFIER", 50, 59], ["bilateral", "ANATOMY_MODIFIER", 60, 69], ["ground-", "OBSERVATION", 70, 77], ["glass attenuation", "OBSERVATION", 77, 94], ["areas", "OBSERVATION_MODIFIER", 95, 100], ["upper", "ANATOMY_MODIFIER", 104, 109], ["fields", "ANATOMY_MODIFIER", 110, 116], ["colonization", "OBSERVATION", 228, 240], ["Candida", "OBSERVATION", 248, 255], ["pneumonia", "OBSERVATION", 289, 298], ["spread", "OBSERVATION_MODIFIER", 342, 348], ["candidiasis", "OBSERVATION", 349, 360]]], ["Emerging ''non-Candida'' yeasts do cause infectious pulmonary consolidations and nodes.Disease noninfectious complicationsPulmonary edema is frequent in the course of MM (due to PET, cardiac and/or renal amyloidosis) and AML (mainly as a consequence of treatment).", [["pulmonary", "ANATOMY", 52, 61], ["nodes", "ANATOMY", 81, 86], ["Pulmonary", "ANATOMY", 122, 131], ["MM", "ANATOMY", 167, 169], ["cardiac", "ANATOMY", 183, 190], ["renal", "ANATOMY", 198, 203], ["AML", "ANATOMY", 221, 224], ["infectious pulmonary consolidations", "DISEASE", 41, 76], ["Pulmonary edema", "DISEASE", 122, 137], ["MM", "DISEASE", 167, 169], ["cardiac and/or renal amyloidosis", "DISEASE", 183, 215], ["AML", "DISEASE", 221, 224], ["pulmonary", "ORGAN", 52, 61], ["nodes", "MULTI-TISSUE_STRUCTURE", 81, 86], ["Pulmonary", "ORGAN", 122, 131], ["MM", "CANCER", 167, 169], ["cardiac", "ORGAN", 183, 190], ["renal", "ORGAN", 198, 203], ["AML", "CANCER", 221, 224], ["Emerging ''non-Candida'' yeasts", "PROBLEM", 0, 31], ["infectious pulmonary consolidations", "PROBLEM", 41, 76], ["nodes", "PROBLEM", 81, 86], ["Disease noninfectious complications", "PROBLEM", 87, 122], ["Pulmonary edema", "PROBLEM", 122, 137], ["PET", "TEST", 178, 181], ["renal amyloidosis", "PROBLEM", 198, 215], ["AML", "PROBLEM", 221, 224], ["treatment", "TREATMENT", 253, 262], ["Candida", "OBSERVATION", 15, 22], ["infectious", "OBSERVATION_MODIFIER", 41, 51], ["pulmonary", "ANATOMY", 52, 61], ["consolidations", "OBSERVATION", 62, 76], ["nodes", "OBSERVATION", 81, 86], ["noninfectious", "OBSERVATION_MODIFIER", 95, 108], ["complications", "OBSERVATION", 109, 122], ["edema", "OBSERVATION", 132, 137], ["frequent", "OBSERVATION_MODIFIER", 141, 149], ["cardiac", "ANATOMY", 183, 190], ["renal", "ANATOMY", 198, 203], ["amyloidosis", "OBSERVATION", 204, 215], ["AML", "OBSERVATION", 221, 224]]], ["At the onset and in the course of AML it should be differentiated from diffuse alveolar hemorrhage (DAH) due to thrombocytopenia and/or infection.Disease noninfectious complicationsSecondary pulmonary lymphoid infiltration in leukemias is rare.", [["AML", "ANATOMY", 34, 37], ["alveolar", "ANATOMY", 79, 87], ["pulmonary lymphoid", "ANATOMY", 191, 209], ["leukemias", "ANATOMY", 226, 235], ["AML", "DISEASE", 34, 37], ["alveolar hemorrhage", "DISEASE", 79, 98], ["DAH", "DISEASE", 100, 103], ["thrombocytopenia", "DISEASE", 112, 128], ["infection", "DISEASE", 136, 145], ["Secondary pulmonary lymphoid infiltration", "DISEASE", 181, 222], ["leukemias", "DISEASE", 226, 235], ["AML", "CANCER", 34, 37], ["alveolar", "ORGAN", 79, 87], ["pulmonary lymphoid", "CELL", 191, 209], ["leukemias", "CANCER", 226, 235], ["AML", "PROBLEM", 34, 37], ["diffuse alveolar hemorrhage", "PROBLEM", 71, 98], ["DAH", "PROBLEM", 100, 103], ["thrombocytopenia", "PROBLEM", 112, 128], ["infection", "PROBLEM", 136, 145], ["Disease noninfectious complications", "PROBLEM", 146, 181], ["Secondary pulmonary lymphoid infiltration", "PROBLEM", 181, 222], ["leukemias", "PROBLEM", 226, 235], ["AML", "OBSERVATION", 34, 37], ["diffuse", "OBSERVATION_MODIFIER", 71, 78], ["alveolar", "ANATOMY_MODIFIER", 79, 87], ["hemorrhage", "OBSERVATION", 88, 98], ["thrombocytopenia", "OBSERVATION", 112, 128], ["infection", "OBSERVATION", 136, 145], ["noninfectious", "OBSERVATION_MODIFIER", 154, 167], ["complications", "OBSERVATION", 168, 181], ["pulmonary", "ANATOMY", 191, 200], ["lymphoid infiltration", "OBSERVATION", 201, 222], ["leukemias", "OBSERVATION", 226, 235]]], ["It can be seen as ground-glass attenuation areas 35, 36 or consolidations similar to an organizing pneumonia, 36, 37 with adenopathies.", [["pneumonia", "DISEASE", 99, 108], ["adenopathies", "DISEASE", 122, 134], ["ground-glass attenuation areas", "TEST", 18, 48], ["consolidations", "PROBLEM", 59, 73], ["an organizing pneumonia", "PROBLEM", 85, 108], ["adenopathies", "PROBLEM", 122, 134], ["can be seen", "UNCERTAINTY", 3, 14], ["ground", "OBSERVATION_MODIFIER", 18, 24], ["glass attenuation", "OBSERVATION", 25, 42], ["areas", "OBSERVATION_MODIFIER", 43, 48], ["consolidations", "OBSERVATION", 59, 73], ["organizing", "OBSERVATION_MODIFIER", 88, 98], ["pneumonia", "OBSERVATION", 99, 108], ["adenopathies", "OBSERVATION", 122, 134]]], ["In patients with CLL of years of evolution and adenopathies, the appearance of peribronchovascular consolidations, even endobronchial occupations, and clinical worsening, will make us suspect transformation into a high-grade lymphoma.", [["CLL", "ANATOMY", 17, 20], ["peribronchovascular", "ANATOMY", 79, 98], ["endobronchial", "ANATOMY", 120, 133], ["high-grade lymphoma", "ANATOMY", 214, 233], ["CLL", "DISEASE", 17, 20], ["adenopathies", "DISEASE", 47, 59], ["consolidations", "DISEASE", 99, 113], ["lymphoma", "DISEASE", 225, 233], ["patients", "ORGANISM", 3, 11], ["CLL", "CANCER", 17, 20], ["high-grade lymphoma", "CANCER", 214, 233], ["patients", "SPECIES", 3, 11], ["CLL", "PROBLEM", 17, 20], ["adenopathies", "PROBLEM", 47, 59], ["peribronchovascular consolidations", "PROBLEM", 79, 113], ["a high-grade lymphoma", "PROBLEM", 212, 233], ["CLL", "OBSERVATION", 17, 20], ["adenopathies", "OBSERVATION", 47, 59], ["peribronchovascular", "ANATOMY", 79, 98], ["consolidations", "OBSERVATION", 99, 113], ["endobronchial", "ANATOMY", 120, 133], ["high-grade", "OBSERVATION_MODIFIER", 214, 224], ["lymphoma", "OBSERVATION", 225, 233]]], ["Leukostasis (aggregation of blasts in pulmonary microvascularization) is exceptional and it will only be suspected in the diagnosis or relapse of an AML due to a rapid increase of the percentage of leucocytes in blood; it is characterized by respiratory and neurological failure kicking in with con pulmonary consolidations partly due to alveolar damage and hemorrhages due to plateletpenia.", [["blasts", "ANATOMY", 28, 34], ["pulmonary", "ANATOMY", 38, 47], ["AML", "ANATOMY", 149, 152], ["leucocytes", "ANATOMY", 198, 208], ["blood", "ANATOMY", 212, 217], ["respiratory", "ANATOMY", 242, 253], ["neurological", "ANATOMY", 258, 270], ["pulmonary", "ANATOMY", 299, 308], ["alveolar", "ANATOMY", 338, 346], ["Leukostasis", "DISEASE", 0, 11], ["AML", "DISEASE", 149, 152], ["respiratory and neurological failure kicking", "DISEASE", 242, 286], ["pulmonary consolidations", "DISEASE", 299, 323], ["alveolar damage", "DISEASE", 338, 353], ["hemorrhages", "DISEASE", 358, 369], ["plateletpenia", "DISEASE", 377, 390], ["blasts", "CELL", 28, 34], ["pulmonary", "ORGAN", 38, 47], ["AML", "CANCER", 149, 152], ["leucocytes", "CELL", 198, 208], ["blood", "ORGANISM_SUBSTANCE", 212, 217], ["pulmonary", "ORGAN", 299, 308], ["alveolar", "TISSUE", 338, 346], ["blasts", "CELL_TYPE", 28, 34], ["leucocytes", "CELL_TYPE", 198, 208], ["Leukostasis (aggregation of blasts in pulmonary microvascularization", "PROBLEM", 0, 68], ["an AML", "PROBLEM", 146, 152], ["leucocytes in blood", "PROBLEM", 198, 217], ["respiratory and neurological failure kicking", "PROBLEM", 242, 286], ["con pulmonary consolidations", "PROBLEM", 295, 323], ["alveolar damage", "PROBLEM", 338, 353], ["hemorrhages", "PROBLEM", 358, 369], ["plateletpenia", "PROBLEM", 377, 390], ["aggregation", "OBSERVATION_MODIFIER", 13, 24], ["blasts", "OBSERVATION", 28, 34], ["pulmonary", "ANATOMY", 38, 47], ["microvascularization", "OBSERVATION", 48, 68], ["AML", "OBSERVATION", 149, 152], ["rapid", "OBSERVATION_MODIFIER", 162, 167], ["increase", "OBSERVATION_MODIFIER", 168, 176], ["percentage", "OBSERVATION_MODIFIER", 184, 194], ["leucocytes", "OBSERVATION", 198, 208], ["respiratory", "OBSERVATION_MODIFIER", 242, 253], ["neurological failure", "OBSERVATION", 258, 278], ["pulmonary", "ANATOMY", 299, 308], ["consolidations", "OBSERVATION", 309, 323], ["partly due to", "UNCERTAINTY", 324, 337], ["alveolar damage", "OBSERVATION", 338, 353], ["hemorrhages", "OBSERVATION", 358, 369]]], ["38, 39 In MM, consolidations due to pulmonary infiltration of plasmatic cells causing respiratory distress of poor prognosis have also been described.", [["MM", "ANATOMY", 10, 12], ["pulmonary", "ANATOMY", 36, 45], ["plasmatic cells", "ANATOMY", 62, 77], ["respiratory", "ANATOMY", 86, 97], ["MM", "DISEASE", 10, 12], ["respiratory distress", "DISEASE", 86, 106], ["MM", "CANCER", 10, 12], ["pulmonary", "ORGAN", 36, 45], ["plasmatic cells", "CELL", 62, 77], ["plasmatic cells", "CELL_TYPE", 62, 77], ["consolidations", "PROBLEM", 14, 28], ["pulmonary infiltration", "PROBLEM", 36, 58], ["plasmatic cells", "PROBLEM", 62, 77], ["respiratory distress", "PROBLEM", 86, 106], ["poor prognosis", "PROBLEM", 110, 124], ["consolidations", "OBSERVATION", 14, 28], ["pulmonary", "ANATOMY", 36, 45], ["infiltration", "OBSERVATION", 46, 58], ["plasmatic cells", "OBSERVATION", 62, 77], ["respiratory distress", "OBSERVATION", 86, 106]]], ["20, 40 Noninfectious complications secondary to treatment In the 6 h following the transfusion of blood products, the sudden appearance of consolidations simulating an edema and accompanying a respiratory failure usually reflect acute pulmonary damage (APD) called TRALI (transfusion-related alveolar lung injury) which associates high mortality rates.", [["blood", "ANATOMY", 98, 103], ["edema", "ANATOMY", 168, 173], ["respiratory", "ANATOMY", 193, 204], ["pulmonary", "ANATOMY", 235, 244], ["alveolar lung", "ANATOMY", 292, 305], ["consolidations", "DISEASE", 139, 153], ["edema", "DISEASE", 168, 173], ["respiratory failure", "DISEASE", 193, 212], ["acute pulmonary damage", "DISEASE", 229, 251], ["APD", "DISEASE", 253, 256], ["TRALI", "DISEASE", 265, 270], ["alveolar lung injury", "DISEASE", 292, 312], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["edema", "PATHOLOGICAL_FORMATION", 168, 173], ["pulmonary", "ORGAN", 235, 244], ["alveolar lung", "MULTI-TISSUE_STRUCTURE", 292, 305], ["Noninfectious complications", "PROBLEM", 7, 34], ["treatment", "TREATMENT", 48, 57], ["the transfusion of blood products", "TREATMENT", 79, 112], ["consolidations", "PROBLEM", 139, 153], ["an edema", "PROBLEM", 165, 173], ["a respiratory failure", "PROBLEM", 191, 212], ["acute pulmonary damage", "PROBLEM", 229, 251], ["TRALI", "PROBLEM", 265, 270], ["alveolar lung injury", "PROBLEM", 292, 312], ["high mortality rates", "PROBLEM", 331, 351], ["Noninfectious", "OBSERVATION", 7, 20], ["consolidations", "OBSERVATION", 139, 153], ["edema", "OBSERVATION", 168, 173], ["respiratory failure", "OBSERVATION", 193, 212], ["acute", "OBSERVATION_MODIFIER", 229, 234], ["pulmonary", "ANATOMY", 235, 244], ["damage", "OBSERVATION", 245, 251], ["TRALI", "OBSERVATION", 265, 270], ["alveolar", "ANATOMY_MODIFIER", 292, 300], ["lung", "ANATOMY", 301, 305], ["injury", "OBSERVATION", 306, 312], ["high", "OBSERVATION_MODIFIER", 331, 335], ["mortality", "OBSERVATION_MODIFIER", 336, 345]]], ["41 Any courses of chemotherapy can cause pulmonary toxicity, although the most usual patterns are: organizing pneumonia (OP), unspecific interstitial pneumonia (UIP), pneumonitis due to hypersensitivity, eosinophilic pneumonia and diffuse alveolar damage.", [["pulmonary", "ANATOMY", 41, 50], ["alveolar", "ANATOMY", 239, 247], ["pulmonary toxicity", "DISEASE", 41, 59], ["pneumonia", "DISEASE", 110, 119], ["OP", "DISEASE", 121, 123], ["interstitial pneumonia", "DISEASE", 137, 159], ["UIP", "DISEASE", 161, 164], ["pneumonitis", "DISEASE", 167, 178], ["hypersensitivity", "DISEASE", 186, 202], ["pneumonia", "DISEASE", 217, 226], ["alveolar damage", "DISEASE", 239, 254], ["pulmonary", "ORGAN", 41, 50], ["alveolar", "MULTI-TISSUE_STRUCTURE", 239, 247], ["chemotherapy", "TREATMENT", 18, 30], ["pulmonary toxicity", "PROBLEM", 41, 59], ["organizing pneumonia (OP)", "PROBLEM", 99, 124], ["unspecific interstitial pneumonia (UIP)", "PROBLEM", 126, 165], ["pneumonitis", "PROBLEM", 167, 178], ["hypersensitivity", "PROBLEM", 186, 202], ["eosinophilic pneumonia", "PROBLEM", 204, 226], ["diffuse alveolar damage", "PROBLEM", 231, 254], ["pulmonary", "ANATOMY", 41, 50], ["toxicity", "OBSERVATION", 51, 59], ["organizing", "OBSERVATION_MODIFIER", 99, 109], ["pneumonia", "OBSERVATION", 110, 119], ["unspecific", "OBSERVATION_MODIFIER", 126, 136], ["interstitial", "OBSERVATION_MODIFIER", 137, 149], ["pneumonia", "OBSERVATION", 150, 159], ["pneumonitis", "OBSERVATION", 167, 178], ["eosinophilic", "OBSERVATION_MODIFIER", 204, 216], ["pneumonia", "OBSERVATION", 217, 226], ["diffuse", "OBSERVATION_MODIFIER", 231, 238], ["alveolar damage", "OBSERVATION", 239, 254]]], ["Carmustine (used in lymphomas and MM), which usually gives a UIP pattern 42 ; cytarabine (administered in high doses for the treatment of AML), that can cause non-cardiogenic pulmonary edema 43 and bleomycin (lymphoma treatment), causing diffuse alveolar damage and OP are among the most common drugs used.Post-HPTExpiration Before-HPT Rituximab is an anti-CD20 monoclonal antibody used in the treatment of lymphoproliferative B syndromes that have been associated to pulmonary disease due to a mechanism that has not been clarified yet after a median of four cycles and with a median time of appearance of 4 weeks after the last infusion.", [["lymphomas", "ANATOMY", 20, 29], ["MM", "ANATOMY", 34, 36], ["AML", "ANATOMY", 138, 141], ["pulmonary", "ANATOMY", 175, 184], ["lymphoma", "ANATOMY", 209, 217], ["alveolar", "ANATOMY", 246, 254], ["pulmonary", "ANATOMY", 468, 477], ["Carmustine", "CHEMICAL", 0, 10], ["lymphomas", "DISEASE", 20, 29], ["MM", "DISEASE", 34, 36], ["cytarabine", "CHEMICAL", 78, 88], ["AML", "DISEASE", 138, 141], ["non-cardiogenic pulmonary edema", "DISEASE", 159, 190], ["bleomycin", "CHEMICAL", 198, 207], ["lymphoma", "DISEASE", 209, 217], ["alveolar damage", "DISEASE", 246, 261], ["OP", "CHEMICAL", 266, 268], ["Rituximab", "CHEMICAL", 336, 345], ["lymphoproliferative B syndromes", "DISEASE", 407, 438], ["pulmonary disease", "DISEASE", 468, 485], ["Carmustine", "CHEMICAL", 0, 10], ["cytarabine", "CHEMICAL", 78, 88], ["bleomycin", "CHEMICAL", 198, 207], ["Carmustine", "SIMPLE_CHEMICAL", 0, 10], ["lymphomas", "CANCER", 20, 29], ["MM", "CANCER", 34, 36], ["cytarabine", "SIMPLE_CHEMICAL", 78, 88], ["AML", "CANCER", 138, 141], ["pulmonary", "ORGAN", 175, 184], ["bleomycin", "SIMPLE_CHEMICAL", 198, 207], ["lymphoma", "CANCER", 209, 217], ["alveolar", "MULTI-TISSUE_STRUCTURE", 246, 254], ["pulmonary", "ORGAN", 468, 477], ["anti-CD20 monoclonal antibody", "PROTEIN", 352, 381], ["Carmustine", "TREATMENT", 0, 10], ["a UIP pattern", "TEST", 59, 72], ["cytarabine", "TREATMENT", 78, 88], ["AML", "PROBLEM", 138, 141], ["non-cardiogenic pulmonary edema", "PROBLEM", 159, 190], ["bleomycin (lymphoma treatment", "TREATMENT", 198, 227], ["diffuse alveolar damage and OP", "PROBLEM", 238, 268], ["Post-HPTExpiration", "TREATMENT", 306, 324], ["HPT Rituximab", "TREATMENT", 332, 345], ["an anti-CD20 monoclonal antibody", "TREATMENT", 349, 381], ["lymphoproliferative B syndromes", "PROBLEM", 407, 438], ["pulmonary disease", "PROBLEM", 468, 485], ["the last infusion", "TREATMENT", 621, 638], ["AML", "OBSERVATION", 138, 141], ["non-cardiogenic", "OBSERVATION_MODIFIER", 159, 174], ["pulmonary", "ANATOMY", 175, 184], ["edema", "OBSERVATION", 185, 190], ["diffuse", "OBSERVATION_MODIFIER", 238, 245], ["alveolar damage", "OBSERVATION", 246, 261], ["lymphoproliferative B syndromes", "OBSERVATION", 407, 438], ["pulmonary", "ANATOMY", 468, 477], ["disease", "OBSERVATION", 478, 485]]], ["The ground-glass areas or bilateral diffuse pulmonary consolidations appear in weeks or months, and less commonly in hours or days, and they correspond histologically to inflammatory and lymphocytic infiltrates, among others.", [["pulmonary", "ANATOMY", 44, 53], ["lymphocytic infiltrates", "ANATOMY", 187, 210], ["pulmonary", "ORGAN", 44, 53], ["lymphocytic infiltrates", "PATHOLOGICAL_FORMATION", 187, 210], ["bilateral diffuse pulmonary consolidations", "PROBLEM", 26, 68], ["inflammatory and lymphocytic infiltrates", "PROBLEM", 170, 210], ["ground", "OBSERVATION_MODIFIER", 4, 10], ["glass", "OBSERVATION_MODIFIER", 11, 16], ["areas", "OBSERVATION_MODIFIER", 17, 22], ["bilateral", "ANATOMY_MODIFIER", 26, 35], ["diffuse", "OBSERVATION_MODIFIER", 36, 43], ["pulmonary", "ANATOMY", 44, 53], ["consolidations", "OBSERVATION", 54, 68], ["less commonly", "OBSERVATION_MODIFIER", 100, 113], ["histologically", "OBSERVATION_MODIFIER", 152, 166], ["inflammatory", "OBSERVATION_MODIFIER", 170, 182], ["lymphocytic", "OBSERVATION_MODIFIER", 187, 198], ["infiltrates", "OBSERVATION", 199, 210]]], ["Most of them show hypoxemia of lethal evolution in 18%.", [["hypoxemia", "DISEASE", 18, 27], ["hypoxemia of lethal evolution", "PROBLEM", 18, 47], ["hypoxemia", "OBSERVATION", 18, 27], ["lethal", "OBSERVATION_MODIFIER", 31, 37], ["evolution", "OBSERVATION_MODIFIER", 38, 47]]], ["44 The granulocyte colony-stimulation factor (G-CSF) used in neutropenia recovery can rarely induce an APD during the first days of treatment displaying images similar to those of edemas or alveolar hemorrhages.", [["edemas", "ANATOMY", 180, 186], ["alveolar", "ANATOMY", 190, 198], ["neutropenia", "DISEASE", 61, 72], ["edemas", "DISEASE", 180, 186], ["alveolar hemorrhages", "DISEASE", 190, 210], ["granulocyte colony-stimulation factor", "GENE_OR_GENE_PRODUCT", 7, 44], ["G-CSF", "GENE_OR_GENE_PRODUCT", 46, 51], ["alveolar", "MULTI-TISSUE_STRUCTURE", 190, 198], ["granulocyte colony-stimulation factor", "PROTEIN", 7, 44], ["CSF", "PROTEIN", 48, 51], ["The granulocyte colony", "TEST", 3, 25], ["G-CSF)", "TREATMENT", 46, 52], ["neutropenia recovery", "TREATMENT", 61, 81], ["treatment", "TREATMENT", 132, 141], ["images", "TEST", 153, 159], ["edemas", "PROBLEM", 180, 186], ["alveolar hemorrhages", "PROBLEM", 190, 210], ["granulocyte colony", "OBSERVATION", 7, 25], ["edemas", "OBSERVATION", 180, 186], ["alveolar", "ANATOMY", 190, 198], ["hemorrhages", "OBSERVATION", 199, 210]]], ["12 All-trans retinoic acid (ATRA) and arsenic trioxide, used for the treatment of acute promyelocytic leukemia, can cause (20%) a ''differentiation syndrome'' consisting of respiratory failure manifestations during the following 2---47 days 45 probably due to the release of cytokines.", [["acute promyelocytic leukemia", "ANATOMY", 82, 110], ["respiratory", "ANATOMY", 173, 184], ["All-trans retinoic acid", "CHEMICAL", 3, 26], ["ATRA", "CHEMICAL", 28, 32], ["arsenic trioxide", "CHEMICAL", 38, 54], ["acute promyelocytic leukemia", "DISEASE", 82, 110], ["respiratory failure", "DISEASE", 173, 192], ["All-trans retinoic acid", "CHEMICAL", 3, 26], ["ATRA", "CHEMICAL", 28, 32], ["arsenic trioxide", "CHEMICAL", 38, 54], ["All-trans retinoic acid", "SIMPLE_CHEMICAL", 3, 26], ["ATRA", "SIMPLE_CHEMICAL", 28, 32], ["arsenic trioxide", "SIMPLE_CHEMICAL", 38, 54], ["acute promyelocytic leukemia", "CANCER", 82, 110], ["cytokines", "PROTEIN", 275, 284], ["All-trans retinoic acid (ATRA)", "TREATMENT", 3, 33], ["arsenic trioxide", "TREATMENT", 38, 54], ["acute promyelocytic leukemia", "PROBLEM", 82, 110], ["a ''differentiation syndrome", "PROBLEM", 128, 156], ["respiratory failure manifestations", "PROBLEM", 173, 207], ["cytokines", "PROBLEM", 275, 284], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["promyelocytic leukemia", "OBSERVATION", 88, 110], ["respiratory failure", "OBSERVATION", 173, 192], ["cytokines", "OBSERVATION", 275, 284]]], ["Pleural effusion, ground-glass areas and bronchial wall thickening due to edema and hemorrhage can be seen.", [["Pleural", "ANATOMY", 0, 7], ["bronchial wall", "ANATOMY", 41, 55], ["edema", "ANATOMY", 74, 79], ["Pleural effusion", "DISEASE", 0, 16], ["edema", "DISEASE", 74, 79], ["hemorrhage", "DISEASE", 84, 94], ["Pleural", "PATHOLOGICAL_FORMATION", 0, 7], ["bronchial wall", "MULTI-TISSUE_STRUCTURE", 41, 55], ["edema", "PATHOLOGICAL_FORMATION", 74, 79], ["Pleural effusion", "PROBLEM", 0, 16], ["ground-glass areas", "PROBLEM", 18, 36], ["bronchial wall thickening", "PROBLEM", 41, 66], ["edema", "PROBLEM", 74, 79], ["hemorrhage", "PROBLEM", 84, 94], ["effusion", "OBSERVATION", 8, 16], ["ground", "OBSERVATION_MODIFIER", 18, 24], ["glass areas", "OBSERVATION", 25, 36], ["bronchial", "ANATOMY", 41, 50], ["wall", "ANATOMY_MODIFIER", 51, 55], ["thickening", "OBSERVATION", 56, 66], ["edema", "OBSERVATION", 74, 79], ["hemorrhage", "OBSERVATION", 84, 94]]], ["46 The pre-graft early post-HPT period can become complicated with:Post-HPT\u2022 Pulmonary edema-hydrostatic or due to increased patency (the most common non-infectious complication). \u2022 DAH of multifactor etiology, characterized by large ground-glass attenuation areas that can evolve into paved patterns, in the absence of cardiomegalia and effusion; hemoptysis is only observed in 66% of the cases, but a drop in the levels of hemoglobin and the high rate of macrophages in BAL help us in the diagnosis. \u2022 ''Graft syndrome'' or pre-graft respiratory distress---the consequence of an endothelial damage possibly due to the release of pro-inflammatory cytokines; it is similar to edema but without cardiomegalia and with clinical manifestations of fever and cutaneous exanthem. \u2022 ''Idiopathic pneumonia syndrome'' defined by the American Thoracic Society as an acute respiratory failure and diffuse alveolar damage in the absence of cardiac or renal disease, iatrogenesis and responsible microorganism.", [["pre-graft", "ANATOMY", 7, 16], ["Pulmonary", "ANATOMY", 77, 86], ["macrophages", "ANATOMY", 457, 468], ["BAL", "ANATOMY", 472, 475], ["Graft", "ANATOMY", 506, 511], ["respiratory", "ANATOMY", 536, 547], ["endothelial", "ANATOMY", 581, 592], ["edema", "ANATOMY", 676, 681], ["cutaneous exanthem", "ANATOMY", 754, 772], ["respiratory", "ANATOMY", 863, 874], ["alveolar", "ANATOMY", 895, 903], ["cardiac", "ANATOMY", 929, 936], ["renal", "ANATOMY", 940, 945], ["HPT", "DISEASE", 28, 31], ["HPT", "DISEASE", 72, 75], ["DAH", "DISEASE", 182, 185], ["cardiomegalia", "DISEASE", 320, 333], ["effusion", "DISEASE", 338, 346], ["hemoptysis", "DISEASE", 348, 358], ["respiratory distress", "DISEASE", 536, 556], ["endothelial damage", "DISEASE", 581, 599], ["edema", "DISEASE", 676, 681], ["cardiomegalia", "DISEASE", 694, 707], ["fever", "DISEASE", 744, 749], ["exanthem", "DISEASE", 764, 772], ["Idiopathic pneumonia syndrome''", "DISEASE", 778, 809], ["respiratory failure", "DISEASE", 863, 882], ["alveolar damage", "DISEASE", 895, 910], ["cardiac or renal disease", "DISEASE", 929, 953], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 425, 435], ["macrophages", "CELL", 457, 468], ["BAL", "ORGANISM_SUBSTANCE", 472, 475], ["endothelial", "TISSUE", 581, 592], ["edema", "PATHOLOGICAL_FORMATION", 676, 681], ["alveolar", "MULTI-TISSUE_STRUCTURE", 895, 903], ["cardiac", "ORGAN", 929, 936], ["renal", "ORGAN", 940, 945], ["hemoglobin", "PROTEIN", 425, 435], ["macrophages", "CELL_TYPE", 457, 468], ["pro-inflammatory cytokines", "PROTEIN", 631, 657], ["HPT", "PROBLEM", 72, 75], ["Pulmonary edema-hydrostatic", "PROBLEM", 77, 104], ["increased patency", "PROBLEM", 115, 132], ["the most common non-infectious complication", "PROBLEM", 134, 177], ["large ground-glass attenuation areas", "PROBLEM", 228, 264], ["cardiomegalia", "PROBLEM", 320, 333], ["effusion", "PROBLEM", 338, 346], ["hemoptysis", "PROBLEM", 348, 358], ["a drop in the levels of hemoglobin", "PROBLEM", 401, 435], ["Graft syndrome''", "PROBLEM", 506, 522], ["pre-graft respiratory distress", "PROBLEM", 526, 556], ["an endothelial damage", "PROBLEM", 578, 599], ["pro-inflammatory cytokines", "PROBLEM", 631, 657], ["edema", "PROBLEM", 676, 681], ["cardiomegalia", "PROBLEM", 694, 707], ["fever", "PROBLEM", 744, 749], ["cutaneous exanthem", "PROBLEM", 754, 772], ["Idiopathic pneumonia syndrome", "PROBLEM", 778, 807], ["an acute respiratory failure", "PROBLEM", 854, 882], ["diffuse alveolar damage", "PROBLEM", 887, 910], ["cardiac or renal disease", "PROBLEM", 929, 953], ["iatrogenesis", "PROBLEM", 955, 967], ["responsible microorganism", "PROBLEM", 972, 997], ["Pulmonary", "ANATOMY", 77, 86], ["edema-hydrostatic", "OBSERVATION", 87, 104], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["patency", "OBSERVATION", 125, 132], ["multifactor", "OBSERVATION_MODIFIER", 189, 200], ["large", "OBSERVATION_MODIFIER", 228, 233], ["ground-", "OBSERVATION_MODIFIER", 234, 241], ["glass attenuation", "OBSERVATION", 241, 258], ["cardiomegalia", "OBSERVATION", 320, 333], ["effusion", "OBSERVATION", 338, 346], ["hemoptysis", "OBSERVATION", 348, 358], ["drop", "OBSERVATION_MODIFIER", 403, 407], ["high", "OBSERVATION_MODIFIER", 444, 448], ["Graft syndrome", "OBSERVATION", 506, 520], ["respiratory distress", "OBSERVATION", 536, 556], ["endothelial", "ANATOMY", 581, 592], ["damage", "OBSERVATION", 593, 599], ["possibly due to", "UNCERTAINTY", 600, 615], ["pro-inflammatory cytokines", "OBSERVATION", 631, 657], ["edema", "OBSERVATION", 676, 681], ["without", "UNCERTAINTY", 686, 693], ["cardiomegalia", "OBSERVATION", 694, 707], ["cutaneous", "ANATOMY", 754, 763], ["exanthem", "OBSERVATION", 764, 772], ["Idiopathic", "OBSERVATION_MODIFIER", 778, 788], ["pneumonia", "OBSERVATION", 789, 798], ["Thoracic", "ANATOMY", 834, 842], ["acute", "OBSERVATION_MODIFIER", 857, 862], ["respiratory failure", "OBSERVATION", 863, 882], ["diffuse", "OBSERVATION_MODIFIER", 887, 894], ["alveolar damage", "OBSERVATION", 895, 910], ["cardiac", "ANATOMY", 929, 936], ["renal", "ANATOMY", 940, 945], ["disease", "OBSERVATION", 946, 953], ["microorganism", "OBSERVATION_MODIFIER", 984, 997]]], ["47 It is an exclusion diagnosis, probably of multifactor etiology or due to non-affiliated infections, such as it would happen with the recently discovered metapneumovirus.", [["infections", "DISEASE", 91, 101], ["metapneumovirus", "ORGANISM", 156, 171], ["non-affiliated infections", "PROBLEM", 76, 101], ["metapneumovirus", "PROBLEM", 156, 171], ["exclusion", "OBSERVATION", 12, 21], ["probably of", "UNCERTAINTY", 33, 44], ["infections", "OBSERVATION", 91, 101], ["metapneumovirus", "OBSERVATION", 156, 171]]], ["48, 49 In the late post-HPT period, peribronchovascular reticulation and ground-glass areas, and on occasion paved pattern ones, can represent an unclassifiable interstitial pneumonia, associated with rejection.", [["peribronchovascular reticulation", "ANATOMY", 36, 68], ["interstitial", "ANATOMY", 161, 173], ["HPT", "DISEASE", 24, 27], ["interstitial pneumonia", "DISEASE", 161, 183], ["peribronchovascular reticulation", "PROBLEM", 36, 68], ["ground-glass areas", "PROBLEM", 73, 91], ["an unclassifiable interstitial pneumonia", "PROBLEM", 143, 183], ["rejection", "PROBLEM", 201, 210], ["late", "OBSERVATION_MODIFIER", 14, 18], ["post-HPT", "OBSERVATION_MODIFIER", 19, 27], ["period", "OBSERVATION_MODIFIER", 28, 34], ["peribronchovascular", "ANATOMY_MODIFIER", 36, 55], ["reticulation", "OBSERVATION_MODIFIER", 56, 68], ["ground-glass areas", "OBSERVATION", 73, 91], ["can represent", "UNCERTAINTY", 129, 142], ["unclassifiable", "OBSERVATION_MODIFIER", 146, 160], ["interstitial", "OBSERVATION_MODIFIER", 161, 173], ["pneumonia", "OBSERVATION", 174, 183], ["rejection", "OBSERVATION", 201, 210]]], ["50 Histologically, it corresponds to a bronchioloalveolar lymphoplasmocytic infiltration that spreads toward peripheral regions and evolves into a fibrosis with traction and hive bronchiectasis.Post-HPTOP can be secondary to infection, toxicity by drugs, radiotherapy or rejection; peripheral peribronchovascular and perilobular consolidations, and the inverted halo sign are characteristic findings in the appropriate clinical context.", [["bronchioloalveolar lymphoplasmocytic", "ANATOMY", 39, 75], ["peripheral regions", "ANATOMY", 109, 127], ["peribronchovascular", "ANATOMY", 293, 312], ["perilobular", "ANATOMY", 317, 328], ["fibrosis", "DISEASE", 147, 155], ["bronchiectasis", "DISEASE", 179, 193], ["infection", "DISEASE", 225, 234], ["toxicity", "DISEASE", 236, 244], ["bronchioloalveolar lymphoplasmocytic", "CELL", 39, 75], ["a bronchioloalveolar lymphoplasmocytic infiltration", "PROBLEM", 37, 88], ["a fibrosis", "PROBLEM", 145, 155], ["traction", "PROBLEM", 161, 169], ["hive bronchiectasis", "PROBLEM", 174, 193], ["infection", "PROBLEM", 225, 234], ["toxicity", "PROBLEM", 236, 244], ["drugs", "TREATMENT", 248, 253], ["radiotherapy", "TREATMENT", 255, 267], ["rejection", "PROBLEM", 271, 280], ["peripheral peribronchovascular and perilobular consolidations", "PROBLEM", 282, 343], ["the inverted halo sign", "PROBLEM", 349, 371], ["bronchioloalveolar lymphoplasmocytic infiltration", "OBSERVATION", 39, 88], ["peripheral", "ANATOMY_MODIFIER", 109, 119], ["regions", "ANATOMY_MODIFIER", 120, 127], ["fibrosis", "OBSERVATION", 147, 155], ["traction", "OBSERVATION_MODIFIER", 161, 169], ["hive", "OBSERVATION_MODIFIER", 174, 178], ["bronchiectasis", "OBSERVATION", 179, 193], ["infection", "OBSERVATION", 225, 234], ["rejection", "OBSERVATION", 271, 280], ["peripheral", "ANATOMY_MODIFIER", 282, 292], ["peribronchovascular", "ANATOMY_MODIFIER", 293, 312], ["perilobular", "OBSERVATION_MODIFIER", 317, 328], ["consolidations", "OBSERVATION", 329, 343], ["halo sign", "OBSERVATION", 362, 371]]], ["In a situation of neutropenia the inverted halo should lead us to consider mucormycosis 14 in the first place which is different from the OP in that the thickness of its ring is >1 cm and also presents internal reticulation 51 (Fig. 4) .Post-HPTAcute pneumonitis due to radiation can occur 3---6 weeks after mediastinal lymphoma radiotherapy and cause clinical and radiologic manifestations similar to those of a pneumonia.", [["ring", "ANATOMY", 170, 174], ["mediastinal lymphoma", "ANATOMY", 308, 328], ["neutropenia", "DISEASE", 18, 29], ["mucormycosis", "DISEASE", 75, 87], ["pneumonitis", "DISEASE", 251, 262], ["mediastinal lymphoma", "DISEASE", 308, 328], ["pneumonia", "DISEASE", 413, 422], ["mediastinal lymphoma", "CANCER", 308, 328], ["neutropenia", "PROBLEM", 18, 29], ["mucormycosis", "PROBLEM", 75, 87], ["internal reticulation", "PROBLEM", 202, 223], ["Post-HPTAcute pneumonitis", "PROBLEM", 237, 262], ["radiation", "TREATMENT", 270, 279], ["mediastinal lymphoma radiotherapy", "TREATMENT", 308, 341], ["clinical and radiologic manifestations", "PROBLEM", 352, 390], ["a pneumonia", "PROBLEM", 411, 422], ["neutropenia", "OBSERVATION", 18, 29], ["mucormycosis", "OBSERVATION", 75, 87], ["different", "OBSERVATION_MODIFIER", 119, 128], ["ring", "OBSERVATION_MODIFIER", 170, 174], [">1 cm", "OBSERVATION_MODIFIER", 178, 183], ["internal", "ANATOMY_MODIFIER", 202, 210], ["reticulation", "OBSERVATION_MODIFIER", 211, 223], ["pneumonitis", "OBSERVATION", 251, 262], ["radiation", "OBSERVATION", 270, 279], ["mediastinal", "ANATOMY", 308, 319], ["lymphoma", "OBSERVATION", 320, 328], ["pneumonia", "OBSERVATION", 413, 422]]], ["It is located in the irradiated area with a marked delimitation of the healthy parenchyma; it evolves into paramediastinal fibrosis.Post-HPTAcute pulmonary rejection to HPT and pulmonary alveolar proteinosis due to leukemic infiltration or lately to treatment are extremely rare.", [["area", "ANATOMY", 32, 36], ["parenchyma", "ANATOMY", 79, 89], ["pulmonary", "ANATOMY", 146, 155], ["pulmonary alveolar", "ANATOMY", 177, 195], ["leukemic", "ANATOMY", 215, 223], ["fibrosis", "DISEASE", 123, 131], ["HPT", "DISEASE", 169, 172], ["pulmonary alveolar proteinosis", "DISEASE", 177, 207], ["leukemic infiltration", "DISEASE", 215, 236], ["parenchyma", "TISSUE", 79, 89], ["pulmonary", "ORGAN", 146, 155], ["pulmonary alveolar", "MULTI-TISSUE_STRUCTURE", 177, 195], ["a marked delimitation of the healthy parenchyma", "PROBLEM", 42, 89], ["paramediastinal fibrosis", "PROBLEM", 107, 131], ["Post-HPTAcute pulmonary rejection", "PROBLEM", 132, 165], ["HPT", "PROBLEM", 169, 172], ["pulmonary alveolar proteinosis", "PROBLEM", 177, 207], ["leukemic infiltration", "PROBLEM", 215, 236], ["treatment", "TREATMENT", 250, 259], ["marked", "OBSERVATION_MODIFIER", 44, 50], ["delimitation", "OBSERVATION_MODIFIER", 51, 63], ["healthy", "OBSERVATION_MODIFIER", 71, 78], ["parenchyma", "OBSERVATION", 79, 89], ["paramediastinal", "ANATOMY", 107, 122], ["fibrosis", "OBSERVATION", 123, 131], ["pulmonary", "ANATOMY", 146, 155], ["rejection", "OBSERVATION", 156, 165], ["HPT", "OBSERVATION", 169, 172], ["pulmonary", "ANATOMY", 177, 186], ["alveolar", "ANATOMY_MODIFIER", 187, 195], ["proteinosis", "OBSERVATION", 196, 207], ["leukemic infiltration", "OBSERVATION", 215, 236]]], ["52, 53Tree in budThese images represent bronchioles filled with mucous, liquid or pus; they usually correspond to an infectious bronchiolitis that can be due to many different germs.", [["bud", "ANATOMY", 14, 17], ["bronchioles", "ANATOMY", 40, 51], ["mucous", "ANATOMY", 64, 70], ["pus", "ANATOMY", 82, 85], ["germs", "ANATOMY", 176, 181], ["bronchiolitis", "DISEASE", 128, 141], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 40, 51], ["mucous", "MULTI-TISSUE_STRUCTURE", 64, 70], ["pus", "ORGANISM_SUBSTANCE", 82, 85], ["bronchioles", "PROBLEM", 40, 51], ["mucous, liquid or pus", "PROBLEM", 64, 85], ["an infectious bronchiolitis", "PROBLEM", 114, 141], ["many different germs", "PROBLEM", 161, 181], ["bud", "ANATOMY_MODIFIER", 14, 17], ["bronchioles", "ANATOMY", 40, 51], ["mucous", "ANATOMY", 64, 70], ["pus", "OBSERVATION", 82, 85], ["infectious", "OBSERVATION_MODIFIER", 117, 127], ["bronchiolitis", "OBSERVATION", 128, 141], ["can be due to", "UNCERTAINTY", 147, 160], ["germs", "OBSERVATION", 176, 181]]], ["11Thickening of the bronchial wallsIt can be due to unspecific respiratory infection, smoking, bronchiolitis obliterans, lymphoid infiltration or other bronchial conditions.Perilymphatic interstitial thickeningLiquid retention and inflammatory or tumor infiltration of perilymphatic distribution translate into thickening of the bronchovascular axes, interlobular septa and the subpleural interstice.Perilymphatic interstitial thickeningThe straight interstitial thickening can correspond to an interstitial pulmonary edema and a graft syndrome in the early post-graft period.", [["bronchial walls", "ANATOMY", 20, 35], ["respiratory", "ANATOMY", 63, 74], ["lymphoid", "ANATOMY", 121, 129], ["bronchial", "ANATOMY", 152, 161], ["interstitial", "ANATOMY", 187, 199], ["tumor", "ANATOMY", 247, 252], ["perilymphatic", "ANATOMY", 269, 282], ["bronchovascular", "ANATOMY", 329, 344], ["interlobular septa", "ANATOMY", 351, 369], ["subpleural interstice", "ANATOMY", 378, 399], ["interstitial", "ANATOMY", 414, 426], ["interstitial", "ANATOMY", 450, 462], ["interstitial pulmonary", "ANATOMY", 495, 517], ["graft", "ANATOMY", 530, 535], ["respiratory infection", "DISEASE", 63, 84], ["smoking", "CHEMICAL", 86, 93], ["bronchiolitis obliterans", "DISEASE", 95, 119], ["lymphoid infiltration", "DISEASE", 121, 142], ["tumor", "DISEASE", 247, 252], ["interstitial pulmonary edema", "DISEASE", 495, 523], ["bronchial walls", "MULTI-TISSUE_STRUCTURE", 20, 35], ["lymphoid", "CELL", 121, 129], ["tumor", "CANCER", 247, 252], ["perilymphatic", "IMMATERIAL_ANATOMICAL_ENTITY", 269, 282], ["bronchovascular axes", "MULTI-TISSUE_STRUCTURE", 329, 349], ["interlobular septa", "MULTI-TISSUE_STRUCTURE", 351, 369], ["subpleural interstice", "PATHOLOGICAL_FORMATION", 378, 399], ["interstitial", "MULTI-TISSUE_STRUCTURE", 450, 462], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 508, 523], ["graft", "TISSUE", 530, 535], ["graft", "TISSUE", 563, 568], ["unspecific respiratory infection", "PROBLEM", 52, 84], ["bronchiolitis obliterans", "PROBLEM", 95, 119], ["lymphoid infiltration", "PROBLEM", 121, 142], ["other bronchial conditions", "PROBLEM", 146, 172], ["Perilymphatic interstitial thickeningLiquid retention", "PROBLEM", 173, 226], ["inflammatory or tumor infiltration of perilymphatic distribution", "PROBLEM", 231, 295], ["thickening of the bronchovascular axes", "PROBLEM", 311, 349], ["interlobular septa and the subpleural interstice", "PROBLEM", 351, 399], ["Perilymphatic interstitial thickening", "PROBLEM", 400, 437], ["The straight interstitial thickening", "PROBLEM", 437, 473], ["an interstitial pulmonary edema", "PROBLEM", 492, 523], ["a graft syndrome", "PROBLEM", 528, 544], ["bronchial walls", "ANATOMY", 20, 35], ["can be due to", "UNCERTAINTY", 38, 51], ["unspecific", "OBSERVATION_MODIFIER", 52, 62], ["respiratory", "ANATOMY", 63, 74], ["infection", "OBSERVATION", 75, 84], ["bronchiolitis obliterans", "OBSERVATION", 95, 119], ["lymphoid infiltration", "OBSERVATION", 121, 142], ["bronchial", "ANATOMY", 152, 161], ["interstitial", "ANATOMY_MODIFIER", 187, 199], ["thickening", "OBSERVATION", 200, 210], ["Liquid", "OBSERVATION_MODIFIER", 210, 216], ["retention", "OBSERVATION_MODIFIER", 217, 226], ["inflammatory", "OBSERVATION_MODIFIER", 231, 243], ["tumor", "OBSERVATION", 247, 252], ["perilymphatic distribution", "OBSERVATION", 269, 295], ["thickening", "OBSERVATION", 311, 321], ["bronchovascular axes", "ANATOMY", 329, 349], ["interlobular", "ANATOMY_MODIFIER", 351, 363], ["septa", "ANATOMY_MODIFIER", 364, 369], ["subpleural", "ANATOMY_MODIFIER", 378, 388], ["interstitial", "ANATOMY_MODIFIER", 414, 426], ["thickening", "OBSERVATION", 427, 437], ["straight", "OBSERVATION_MODIFIER", 441, 449], ["interstitial", "ANATOMY_MODIFIER", 450, 462], ["thickening", "OBSERVATION", 463, 473], ["can correspond to", "UNCERTAINTY", 474, 491], ["interstitial", "ANATOMY_MODIFIER", 495, 507], ["pulmonary", "ANATOMY", 508, 517], ["edema", "OBSERVATION", 518, 523], ["graft syndrome", "OBSERVATION", 530, 544], ["graft", "OBSERVATION", 563, 568]]], ["In the 2---6 months following the HPT, pulmonary veno-occlusive disease can be a rare complication 54 leading to pulmonary hypertension with pulmonary congestion in the absence of left cardiac disease.Perilymphatic interstitial thickeningSecondary lymphatic tumor pulmonary infiltration can kick in as a straight or nodular thickening of the perilymphatic interstice 35, 55 and make up peribronchial consolidations ( Fig. 2A) .", [["pulmonary", "ANATOMY", 39, 48], ["pulmonary", "ANATOMY", 113, 122], ["pulmonary", "ANATOMY", 141, 150], ["left cardiac", "ANATOMY", 180, 192], ["interstitial", "ANATOMY", 215, 227], ["lymphatic tumor pulmonary", "ANATOMY", 248, 273], ["perilymphatic interstice", "ANATOMY", 342, 366], ["peribronchial", "ANATOMY", 386, 399], ["HPT", "DISEASE", 34, 37], ["pulmonary veno-occlusive disease", "DISEASE", 39, 71], ["pulmonary hypertension", "DISEASE", 113, 135], ["pulmonary congestion", "DISEASE", 141, 161], ["left cardiac disease", "DISEASE", 180, 200], ["tumor", "DISEASE", 258, 263], ["pulmonary", "ORGAN", 39, 48], ["pulmonary", "ORGAN", 113, 122], ["pulmonary", "ORGAN", 141, 150], ["cardiac", "ORGAN", 185, 192], ["Perilymphatic interstitial", "PATHOLOGICAL_FORMATION", 201, 227], ["the HPT", "TEST", 30, 37], ["pulmonary veno-occlusive disease", "PROBLEM", 39, 71], ["a rare complication", "PROBLEM", 79, 98], ["pulmonary hypertension", "PROBLEM", 113, 135], ["pulmonary congestion", "PROBLEM", 141, 161], ["left cardiac disease", "PROBLEM", 180, 200], ["Perilymphatic interstitial thickening", "PROBLEM", 201, 238], ["lymphatic tumor pulmonary infiltration", "PROBLEM", 248, 286], ["a straight or nodular thickening of the perilymphatic interstice", "PROBLEM", 302, 366], ["peribronchial consolidations", "PROBLEM", 386, 414], ["pulmonary", "ANATOMY", 39, 48], ["veno-occlusive", "OBSERVATION", 49, 63], ["pulmonary", "ANATOMY", 113, 122], ["hypertension", "OBSERVATION", 123, 135], ["pulmonary", "ANATOMY", 141, 150], ["congestion", "OBSERVATION", 151, 161], ["left", "ANATOMY_MODIFIER", 180, 184], ["cardiac", "ANATOMY", 185, 192], ["disease", "OBSERVATION", 193, 200], ["interstitial", "ANATOMY_MODIFIER", 215, 227], ["thickening", "OBSERVATION", 228, 238], ["lymphatic", "OBSERVATION_MODIFIER", 248, 257], ["tumor", "OBSERVATION", 258, 263], ["pulmonary", "ANATOMY", 264, 273], ["infiltration", "OBSERVATION", 274, 286], ["straight", "OBSERVATION_MODIFIER", 304, 312], ["nodular", "OBSERVATION_MODIFIER", 316, 323], ["thickening", "OBSERVATION", 324, 334], ["perilymphatic", "ANATOMY_MODIFIER", 342, 355], ["peribronchial", "ANATOMY", 386, 399], ["consolidations", "OBSERVATION", 400, 414]]], ["In most cases dissemination is retrograde from the hilar and mediastinal affectation, and can get to occlude the airways, especially in the CLL.", [["hilar", "ANATOMY", 51, 56], ["mediastinal", "ANATOMY", 61, 72], ["airways", "ANATOMY", 113, 120], ["CLL", "ANATOMY", 140, 143], ["CLL", "DISEASE", 140, 143], ["hilar", "MULTI-TISSUE_STRUCTURE", 51, 56], ["airways", "MULTI-TISSUE_STRUCTURE", 113, 120], ["CLL", "CANCER", 140, 143], ["the hilar and mediastinal affectation", "PROBLEM", 47, 84], ["the CLL", "PROBLEM", 136, 143], ["hilar", "ANATOMY", 51, 56], ["mediastinal", "ANATOMY", 61, 72], ["affectation", "OBSERVATION", 73, 84], ["airways", "ANATOMY", 113, 120], ["CLL", "OBSERVATION", 140, 143]]], ["55 In MM, pulmonary amyloidosis can be seen radiologically as a septal interstitial thickening.", [["MM", "ANATOMY", 6, 8], ["pulmonary", "ANATOMY", 10, 19], ["septal interstitial", "ANATOMY", 64, 83], ["MM", "DISEASE", 6, 8], ["pulmonary amyloidosis", "DISEASE", 10, 31], ["MM", "CANCER", 6, 8], ["pulmonary", "ORGAN", 10, 19], ["septal interstitial", "PATHOLOGICAL_FORMATION", 64, 83], ["pulmonary amyloidosis", "PROBLEM", 10, 31], ["a septal interstitial thickening", "PROBLEM", 62, 94], ["pulmonary", "ANATOMY", 10, 19], ["amyloidosis", "OBSERVATION", 20, 31], ["septal", "ANATOMY_MODIFIER", 64, 70], ["interstitial", "ANATOMY_MODIFIER", 71, 83], ["thickening", "OBSERVATION", 84, 94]]], ["Chest computed tomography (CT) and mild mosaic patterns in expiration due to air entrapment (asterisks).", [["Chest computed tomography", "TEST", 0, 25], ["CT)", "TEST", 27, 30], ["mild mosaic patterns in expiration", "PROBLEM", 35, 69], ["air entrapment", "PROBLEM", 77, 91], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["mosaic patterns", "OBSERVATION", 40, 55], ["air entrapment", "OBSERVATION", 77, 91]]], ["Heart failure and pleuropericardial effusion due to cardiac and serous amyloidosis.Obstructive bronchial lesionsAlthough the most frequent cause is pulmonary carcinoma we should not forget that they are a rare form of HL and NHL presentation.", [["Heart", "ANATOMY", 0, 5], ["pleuropericardial effusion", "ANATOMY", 18, 44], ["cardiac", "ANATOMY", 52, 59], ["serous", "ANATOMY", 64, 70], ["bronchial lesions", "ANATOMY", 95, 112], ["pulmonary carcinoma", "ANATOMY", 148, 167], ["Heart failure", "DISEASE", 0, 13], ["pleuropericardial effusion", "DISEASE", 18, 44], ["cardiac and serous amyloidosis", "DISEASE", 52, 82], ["Obstructive bronchial lesions", "DISEASE", 83, 112], ["pulmonary carcinoma", "DISEASE", 148, 167], ["HL", "DISEASE", 218, 220], ["NHL", "DISEASE", 225, 228], ["Heart", "ORGAN", 0, 5], ["cardiac", "ORGAN", 52, 59], ["serous", "ORGANISM_SUBSTANCE", 64, 70], ["bronchial lesions", "PATHOLOGICAL_FORMATION", 95, 112], ["pulmonary carcinoma", "CANCER", 148, 167], ["HL", "CANCER", 218, 220], ["NHL", "CANCER", 225, 228], ["Heart failure", "PROBLEM", 0, 13], ["pleuropericardial effusion", "PROBLEM", 18, 44], ["cardiac and serous amyloidosis", "PROBLEM", 52, 82], ["Obstructive bronchial lesions", "PROBLEM", 83, 112], ["pulmonary carcinoma", "PROBLEM", 148, 167], ["HL", "PROBLEM", 218, 220], ["NHL presentation", "PROBLEM", 225, 241], ["failure", "OBSERVATION", 6, 13], ["pleuropericardial", "ANATOMY", 18, 35], ["effusion", "OBSERVATION", 36, 44], ["cardiac", "ANATOMY", 52, 59], ["serous", "OBSERVATION_MODIFIER", 64, 70], ["amyloidosis", "OBSERVATION", 71, 82], ["bronchial", "ANATOMY", 95, 104], ["lesions", "OBSERVATION", 105, 112], ["most frequent", "OBSERVATION_MODIFIER", 125, 138], ["pulmonary", "ANATOMY", 148, 157], ["carcinoma", "OBSERVATION", 158, 167]]], ["Also in the course of CLL, it is possible to see lymphoid growth in the lumen or bronchial wall making up obstructive endoluminal masses and cases of extra-osseous plasmacytoma as endoluminal masses have been published.", [["CLL", "ANATOMY", 22, 25], ["lymphoid", "ANATOMY", 49, 57], ["lumen", "ANATOMY", 72, 77], ["bronchial wall", "ANATOMY", 81, 95], ["obstructive endoluminal masses", "ANATOMY", 106, 136], ["extra-osseous plasmacytoma", "ANATOMY", 150, 176], ["endoluminal masses", "ANATOMY", 180, 198], ["CLL", "DISEASE", 22, 25], ["obstructive endoluminal masses", "DISEASE", 106, 136], ["plasmacytoma", "DISEASE", 164, 176], ["CLL", "CANCER", 22, 25], ["lymphoid", "CELL", 49, 57], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 77], ["bronchial wall", "MULTI-TISSUE_STRUCTURE", 81, 95], ["endoluminal masses", "CANCER", 118, 136], ["extra-osseous plasmacytoma", "CANCER", 150, 176], ["endoluminal masses", "CANCER", 180, 198], ["CLL", "PROBLEM", 22, 25], ["lymphoid growth", "PROBLEM", 49, 64], ["bronchial wall", "PROBLEM", 81, 95], ["obstructive endoluminal masses", "PROBLEM", 106, 136], ["extra-osseous plasmacytoma", "PROBLEM", 150, 176], ["endoluminal masses", "PROBLEM", 180, 198], ["CLL", "OBSERVATION", 22, 25], ["lymphoid growth", "OBSERVATION", 49, 64], ["lumen", "ANATOMY_MODIFIER", 72, 77], ["bronchial wall", "ANATOMY", 81, 95], ["obstructive", "OBSERVATION_MODIFIER", 106, 117], ["endoluminal", "OBSERVATION_MODIFIER", 118, 129], ["masses", "OBSERVATION", 130, 136], ["extra-osseous", "OBSERVATION_MODIFIER", 150, 163], ["plasmacytoma", "OBSERVATION", 164, 176], ["endoluminal", "OBSERVATION_MODIFIER", 180, 191], ["masses", "OBSERVATION", 192, 198]]], ["56Air entrapment areas (Fig. 5)It is a characteristic finding of bronchiolitis obliterans (BO), the most common (2---8%) and relevant complication 6---12 months post-HPT.", [["bronchiolitis obliterans", "DISEASE", 65, 89], ["BO", "DISEASE", 91, 93], ["HPT", "DISEASE", 166, 169], ["bronchiolitis obliterans", "PROBLEM", 65, 89], ["relevant complication", "PROBLEM", 125, 146], ["entrapment", "OBSERVATION_MODIFIER", 6, 16], ["areas", "OBSERVATION_MODIFIER", 17, 22], ["bronchiolitis obliterans", "OBSERVATION", 65, 89], ["complication", "OBSERVATION", 134, 146]]], ["It is considered a chronic GVHD defined by functional criteria of airway obstruction in the absence of active respiratory infection and confirmed through transbronchial and/or surgical biopsy.", [["airway", "ANATOMY", 66, 72], ["respiratory", "ANATOMY", 110, 121], ["transbronchial", "ANATOMY", 154, 168], ["GVHD", "DISEASE", 27, 31], ["airway obstruction", "DISEASE", 66, 84], ["respiratory infection", "DISEASE", 110, 131], ["airway obstruction", "PATHOLOGICAL_FORMATION", 66, 84], ["a chronic GVHD", "PROBLEM", 17, 31], ["airway obstruction", "PROBLEM", 66, 84], ["active respiratory infection", "PROBLEM", 103, 131], ["surgical biopsy", "TEST", 176, 191], ["chronic", "OBSERVATION_MODIFIER", 19, 26], ["GVHD", "OBSERVATION", 27, 31], ["airway", "ANATOMY", 66, 72], ["obstruction", "OBSERVATION", 73, 84], ["active", "OBSERVATION_MODIFIER", 103, 109], ["respiratory", "ANATOMY", 110, 121], ["infection", "OBSERVATION", 122, 131], ["transbronchial", "ANATOMY", 154, 168]]], ["The ''BO syndrome'' can be diagnosed without histology when there is air trapping and/or bronchiectasis in HRCT and GVHD in at least one other organ.", [["organ", "ANATOMY", 143, 148], ["BO syndrome", "DISEASE", 6, 17], ["bronchiectasis", "DISEASE", 89, 103], ["GVHD", "DISEASE", 116, 120], ["organ", "ORGAN", 143, 148], ["The ''BO syndrome", "PROBLEM", 0, 17], ["histology", "TEST", 45, 54], ["air trapping", "PROBLEM", 69, 81], ["bronchiectasis", "PROBLEM", 89, 103], ["HRCT", "PROBLEM", 107, 111], ["GVHD", "PROBLEM", 116, 120], ["air trapping", "OBSERVATION", 69, 81], ["bronchiectasis", "OBSERVATION", 89, 103], ["GVHD", "OBSERVATION", 116, 120], ["organ", "ANATOMY", 143, 148]]], ["57, 58 The images in forced expiration show air entrapment in 44---64% of the cases; on the other hand and yet despite the fact that this is the finding with the most diagnostic sensitivity, it is not very useful for the detection of early preclinical stages.", [["The images in forced expiration", "TEST", 7, 38], ["air entrapment", "PROBLEM", 44, 58], ["early preclinical stages", "PROBLEM", 234, 258], ["air entrapment", "OBSERVATION", 44, 58]]], ["59 Bronchiectasis appears in more advanced stages and its progression has been associated with the forced expiratory volume in one second.", [["Bronchiectasis", "DISEASE", 3, 17], ["Bronchiectasis", "PROBLEM", 3, 17], ["the forced expiratory volume", "TEST", 95, 123], ["Bronchiectasis", "OBSERVATION", 3, 17], ["more advanced", "OBSERVATION_MODIFIER", 29, 42], ["progression", "OBSERVATION_MODIFIER", 58, 69], ["forced", "OBSERVATION_MODIFIER", 99, 105], ["expiratory volume", "OBSERVATION", 106, 123]]], ["60 HRCT is a very useful addition to rule out airway infection or tumor infiltration, which can alter respiratory tests.", [["airway", "ANATOMY", 46, 52], ["tumor", "ANATOMY", 66, 71], ["respiratory", "ANATOMY", 102, 113], ["airway infection", "DISEASE", 46, 62], ["tumor", "DISEASE", 66, 71], ["airway", "MULTI-TISSUE_STRUCTURE", 46, 52], ["tumor", "CANCER", 66, 71], ["airway infection", "PROBLEM", 46, 62], ["tumor infiltration", "PROBLEM", 66, 84], ["respiratory tests", "TEST", 102, 119], ["airway", "ANATOMY", 46, 52], ["infection", "OBSERVATION", 53, 62], ["tumor", "OBSERVATION", 66, 71]]], ["This disease causes slow functional worsening, especially if not detected early.", [["This disease", "PROBLEM", 0, 12], ["slow functional worsening", "PROBLEM", 20, 45], ["slow", "OBSERVATION_MODIFIER", 20, 24], ["functional", "OBSERVATION_MODIFIER", 25, 35], ["worsening", "OBSERVATION_MODIFIER", 36, 45]]], ["Its treatment with corticoids and immune depressants causes infectious complications that will be the main cause of death.Pulmonary fibrosisIt can be secondary to distress, toxicity, infection or radiotherapy (Fig. 6 ).", [["Pulmonary", "ANATOMY", 122, 131], ["corticoids", "CHEMICAL", 19, 29], ["death", "DISEASE", 116, 121], ["fibrosis", "DISEASE", 132, 140], ["toxicity", "DISEASE", 173, 181], ["infection", "DISEASE", 183, 192], ["corticoids", "SIMPLE_CHEMICAL", 19, 29], ["Pulmonary", "ORGAN", 122, 131], ["Its treatment", "TREATMENT", 0, 13], ["corticoids", "TREATMENT", 19, 29], ["immune depressants", "TREATMENT", 34, 52], ["infectious complications", "PROBLEM", 60, 84], ["death", "PROBLEM", 116, 121], ["Pulmonary fibrosis", "PROBLEM", 122, 140], ["distress", "PROBLEM", 163, 171], ["toxicity", "PROBLEM", 173, 181], ["infection", "PROBLEM", 183, 192], ["radiotherapy", "TREATMENT", 196, 208], ["fibrosis", "OBSERVATION", 132, 140], ["distress", "OBSERVATION", 163, 171], ["infection", "OBSERVATION", 183, 192]]], ["In the late period after HPT it can correspond to an unclassifiable interstitial pneumonia or to a pleuroparenchymatous fibroelastosis 61 likely as a consequence of chemotherapy, radiotherapy and GVHD.Pulmonary fibrosisThe history, distribution and evolution of the findings will guide the etiological diagnosis.Bronchial dilationsThey can be seen in a transitory way in the sinus of infectious consolidations and be due to organizing pneumonia.", [["interstitial", "ANATOMY", 68, 80], ["Pulmonary", "ANATOMY", 201, 210], ["Bronchial", "ANATOMY", 312, 321], ["sinus", "ANATOMY", 375, 380], ["HPT", "DISEASE", 25, 28], ["interstitial pneumonia", "DISEASE", 68, 90], ["fibroelastosis", "DISEASE", 120, 134], ["GVHD", "DISEASE", 196, 200], ["fibrosis", "DISEASE", 211, 219], ["infectious consolidations", "DISEASE", 384, 409], ["pneumonia", "DISEASE", 435, 444], ["Pulmonary", "ORGAN", 201, 210], ["Bronchial", "MULTI-TISSUE_STRUCTURE", 312, 321], ["HPT", "PROBLEM", 25, 28], ["an unclassifiable interstitial pneumonia", "PROBLEM", 50, 90], ["a pleuroparenchymatous fibroelastosis", "PROBLEM", 97, 134], ["chemotherapy", "TREATMENT", 165, 177], ["radiotherapy", "TREATMENT", 179, 191], ["GVHD", "PROBLEM", 196, 200], ["Pulmonary fibrosis", "PROBLEM", 201, 219], ["Bronchial dilations", "TREATMENT", 312, 331], ["infectious consolidations", "PROBLEM", 384, 409], ["organizing pneumonia", "PROBLEM", 424, 444], ["unclassifiable", "OBSERVATION_MODIFIER", 53, 67], ["interstitial", "OBSERVATION_MODIFIER", 68, 80], ["pneumonia", "OBSERVATION", 81, 90], ["pleuroparenchymatous", "OBSERVATION_MODIFIER", 99, 119], ["fibroelastosis", "OBSERVATION", 120, 134], ["fibrosis", "OBSERVATION", 211, 219], ["distribution", "OBSERVATION_MODIFIER", 232, 244], ["dilations", "OBSERVATION", 322, 331], ["sinus", "ANATOMY", 375, 380], ["infectious", "OBSERVATION", 384, 394], ["be due to", "UNCERTAINTY", 414, 423], ["organizing", "OBSERVATION_MODIFIER", 424, 434], ["pneumonia", "OBSERVATION", 435, 444]]], ["Irreversible dilations (bronchiectasis) in areas of air entrapment are a characteristic finding of bronchiolitis obliterans unlike those observed in areas of fibrosis due to traction.Bronchial dilationsInterstitial pulmonary emphysema: air leak syndrome (Fig. 5F) It is a typical complication of advanced post-HPT BO and a marker of poor prognosis.", [["Bronchial", "ANATOMY", 183, 192], ["pulmonary", "ANATOMY", 215, 224], ["bronchiectasis", "DISEASE", 24, 38], ["air entrapment", "DISEASE", 52, 66], ["bronchiolitis obliterans", "DISEASE", 99, 123], ["fibrosis", "DISEASE", 158, 166], ["Interstitial pulmonary emphysema", "DISEASE", 202, 234], ["air leak syndrome", "DISEASE", 236, 253], ["BO", "DISEASE", 314, 316], ["Bronchial", "MULTI-TISSUE_STRUCTURE", 183, 192], ["pulmonary", "ORGAN", 215, 224], ["Irreversible dilations (bronchiectasis)", "PROBLEM", 0, 39], ["air entrapment", "PROBLEM", 52, 66], ["bronchiolitis obliterans", "PROBLEM", 99, 123], ["fibrosis", "PROBLEM", 158, 166], ["traction", "PROBLEM", 174, 182], ["Bronchial dilationsInterstitial pulmonary emphysema", "PROBLEM", 183, 234], ["air leak syndrome", "PROBLEM", 236, 253], ["advanced post-HPT BO", "PROBLEM", 296, 316], ["dilations", "OBSERVATION", 13, 22], ["bronchiectasis", "OBSERVATION", 24, 38], ["areas", "OBSERVATION_MODIFIER", 43, 48], ["air entrapment", "OBSERVATION", 52, 66], ["characteristic finding of", "UNCERTAINTY", 73, 98], ["bronchiolitis obliterans", "OBSERVATION", 99, 123], ["fibrosis", "OBSERVATION", 158, 166], ["traction", "OBSERVATION", 174, 182], ["dilations", "OBSERVATION", 193, 202], ["Interstitial", "ANATOMY_MODIFIER", 202, 214], ["pulmonary", "ANATOMY", 215, 224], ["emphysema", "OBSERVATION", 225, 234], ["air leak", "OBSERVATION", 236, 244], ["syndrome", "OBSERVATION", 245, 253], ["HPT BO", "OBSERVATION", 310, 316]]], ["The increase of alveolar pressure leads both to its rupture and air leak around the (1) week later (normal evolution not meaning non-responsiveness).", [["alveolar", "ANATOMY", 16, 24], ["rupture", "DISEASE", 52, 59], ["alveolar", "MULTI-TISSUE_STRUCTURE", 16, 24], ["alveolar pressure leads", "TREATMENT", 16, 39], ["its rupture", "PROBLEM", 48, 59], ["air leak", "PROBLEM", 64, 72], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["alveolar pressure", "OBSERVATION", 16, 33], ["rupture", "OBSERVATION_MODIFIER", 52, 59], ["air leak", "OBSERVATION", 64, 72]]], ["(C) Cavitation two (2) weeks later coinciding with a recovering neutropenia, air crescent sign (arrows).", [["neutropenia", "DISEASE", 64, 75], ["Cavitation", "PROBLEM", 4, 14], ["a recovering neutropenia", "PROBLEM", 51, 75], ["air crescent sign", "PROBLEM", 77, 94], ["Cavitation", "OBSERVATION", 4, 14], ["neutropenia", "OBSERVATION", 64, 75], ["air crescent", "OBSERVATION", 77, 89]]], ["(D---F) A different patient.", [["(D---F)", "CHEMICAL", 0, 7], ["D---F)", "SIMPLE_CHEMICAL", 1, 7], ["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27], ["different", "OBSERVATION_MODIFIER", 10, 19]]], ["Consolidation (asterisk) with an initial halo (D); two (2) weeks later (E) size increase and disappearance of the halo; further size decrease with persistence of peribronchovascular consolidation with bronchial dilations (F) without resolution.", [["peribronchovascular", "ANATOMY", 162, 181], ["bronchial", "ANATOMY", 201, 210], ["bronchial", "MULTI-TISSUE_STRUCTURE", 201, 210], ["Consolidation (asterisk)", "PROBLEM", 0, 24], ["the halo", "PROBLEM", 110, 118], ["peribronchovascular consolidation", "PROBLEM", 162, 195], ["bronchial dilations", "PROBLEM", 201, 220], ["size", "OBSERVATION_MODIFIER", 75, 79], ["increase", "OBSERVATION_MODIFIER", 80, 88], ["disappearance", "OBSERVATION_MODIFIER", 93, 106], ["halo", "OBSERVATION", 114, 118], ["size", "OBSERVATION_MODIFIER", 128, 132], ["decrease", "OBSERVATION_MODIFIER", 133, 141], ["persistence", "OBSERVATION_MODIFIER", 147, 158], ["peribronchovascular", "ANATOMY_MODIFIER", 162, 181], ["consolidation", "OBSERVATION", 182, 195], ["bronchial", "ANATOMY", 201, 210], ["dilations", "OBSERVATION", 211, 220], ["without", "UNCERTAINTY", 225, 232], ["resolution", "OBSERVATION_MODIFIER", 233, 243]]], ["The resection of lesion to guarantee the control of the infection before the hematopoietic precursor transplantation (HPT) showed organized pneumonia without micro-organisms or malignant cells. bronchovascular axes due to retrograde dissection; it can reach the mediastinum, the subcutaneous tissue and the pleural cavity.", [["lesion", "ANATOMY", 17, 23], ["hematopoietic precursor", "ANATOMY", 77, 100], ["malignant cells", "ANATOMY", 177, 192], ["mediastinum", "ANATOMY", 262, 273], ["subcutaneous tissue", "ANATOMY", 279, 298], ["pleural cavity", "ANATOMY", 307, 321], ["infection", "DISEASE", 56, 65], ["HPT", "DISEASE", 118, 121], ["pneumonia", "DISEASE", 140, 149], ["lesion", "CANCER", 17, 23], ["malignant cells", "CELL", 177, 192], ["mediastinum", "ORGAN", 262, 273], ["subcutaneous tissue", "TISSUE", 279, 298], ["pleural cavity", "MULTI-TISSUE_STRUCTURE", 307, 321], ["malignant cells", "CELL_TYPE", 177, 192], ["The resection", "TREATMENT", 0, 13], ["lesion", "PROBLEM", 17, 23], ["the infection", "PROBLEM", 52, 65], ["the hematopoietic precursor transplantation", "TREATMENT", 73, 116], ["HPT", "TEST", 118, 121], ["organized pneumonia", "PROBLEM", 130, 149], ["micro-organisms", "PROBLEM", 158, 173], ["malignant cells", "PROBLEM", 177, 192], ["bronchovascular axes", "PROBLEM", 194, 214], ["retrograde dissection", "PROBLEM", 222, 243], ["resection", "OBSERVATION", 4, 13], ["lesion", "OBSERVATION", 17, 23], ["infection", "OBSERVATION", 56, 65], ["hematopoietic", "ANATOMY", 77, 90], ["precursor transplantation", "OBSERVATION", 91, 116], ["pneumonia", "OBSERVATION", 140, 149], ["malignant cells", "OBSERVATION", 177, 192], ["retrograde", "OBSERVATION_MODIFIER", 222, 232], ["dissection", "OBSERVATION", 233, 243], ["mediastinum", "ANATOMY", 262, 273], ["subcutaneous tissue", "ANATOMY", 279, 298], ["pleural", "ANATOMY", 307, 314], ["cavity", "ANATOMY_MODIFIER", 315, 321]]], ["The treatment is usually conservative except if the pneumothorax requires drainage.", [["pneumothorax", "DISEASE", 52, 64], ["The treatment", "TREATMENT", 0, 13], ["the pneumothorax", "PROBLEM", 48, 64], ["drainage", "TREATMENT", 74, 82], ["pneumothorax", "OBSERVATION", 52, 64], ["drainage", "OBSERVATION", 74, 82]]], ["62, 63Spontaneous pneumothoraxPulmonary infiltration, radiotherapy and infection postulate as causes for a greater incidence of pneumothorax in Hodgkin's disease (Fig. 6 ).", [["infection", "DISEASE", 71, 80], ["pneumothorax", "DISEASE", 128, 140], ["Hodgkin's disease", "DISEASE", 144, 161], ["63Spontaneous pneumothoraxPulmonary infiltration", "PROBLEM", 4, 52], ["radiotherapy", "TREATMENT", 54, 66], ["infection", "PROBLEM", 71, 80], ["pneumothorax", "PROBLEM", 128, 140], ["Hodgkin's disease", "PROBLEM", 144, 161], ["pneumothoraxPulmonary", "ANATOMY", 18, 39], ["infiltration", "OBSERVATION", 40, 52], ["infection", "OBSERVATION", 71, 80], ["greater", "OBSERVATION_MODIFIER", 107, 114], ["pneumothorax", "OBSERVATION", 128, 140], ["Hodgkin's disease", "OBSERVATION", 144, 161]]], ["In the absence of radiotherapy or infection, the possibility of pleura-pulmonary infiltration described in lymphomas and MM should be taken into consideration.", [["pleura", "ANATOMY", 64, 70], ["pulmonary", "ANATOMY", 71, 80], ["lymphomas", "ANATOMY", 107, 116], ["MM", "ANATOMY", 121, 123], ["infection", "DISEASE", 34, 43], ["pleura-pulmonary infiltration", "DISEASE", 64, 93], ["lymphomas", "DISEASE", 107, 116], ["MM", "DISEASE", 121, 123], ["pleura", "MULTI-TISSUE_STRUCTURE", 64, 70], ["pulmonary", "ORGAN", 71, 80], ["lymphomas", "CANCER", 107, 116], ["MM", "CANCER", 121, 123], ["radiotherapy", "TREATMENT", 18, 30], ["infection", "PROBLEM", 34, 43], ["pleura", "PROBLEM", 64, 70], ["pulmonary infiltration", "PROBLEM", 71, 93], ["lymphomas", "PROBLEM", 107, 116], ["radiotherapy", "OBSERVATION", 18, 30], ["infection", "OBSERVATION", 34, 43], ["possibility of", "UNCERTAINTY", 49, 63], ["pleura", "ANATOMY", 64, 70], ["pulmonary", "ANATOMY", 71, 80], ["infiltration", "OBSERVATION", 81, 93], ["lymphomas", "OBSERVATION", 107, 116]]], ["64, 65 In the late post-HPT period, the air leak syndrome due to BO or the rupture of apical vesicles due to a pleuroparenchymatous fibroelastosis should be taken into consideration.Pulmonary cystsSmall cysts in the upper fields can correspond to pneumatoceles due to infection by Pneumocystis jirovecii.", [["apical vesicles", "ANATOMY", 86, 101], ["pleuroparenchymatous fibroelastosis", "ANATOMY", 111, 146], ["Pulmonary cystsSmall cysts", "ANATOMY", 182, 208], ["pneumatoceles", "ANATOMY", 247, 260], ["HPT", "DISEASE", 24, 27], ["air leak", "DISEASE", 40, 48], ["BO", "DISEASE", 65, 67], ["rupture", "DISEASE", 75, 82], ["fibroelastosis", "DISEASE", 132, 146], ["Pulmonary cystsSmall cysts", "DISEASE", 182, 208], ["pneumatoceles", "DISEASE", 247, 260], ["infection", "DISEASE", 268, 277], ["Pneumocystis jirovecii", "DISEASE", 281, 303], ["apical vesicles", "CELLULAR_COMPONENT", 86, 101], ["Pulmonary cystsSmall cysts", "PATHOLOGICAL_FORMATION", 182, 208], ["pneumatoceles", "CANCER", 247, 260], ["Pneumocystis jirovecii", "ORGANISM", 281, 303], ["Pneumocystis jirovecii", "SPECIES", 281, 303], ["Pneumocystis jirovecii", "SPECIES", 281, 303], ["the air leak syndrome", "PROBLEM", 36, 57], ["BO", "PROBLEM", 65, 67], ["the rupture of apical vesicles", "PROBLEM", 71, 101], ["a pleuroparenchymatous fibroelastosis", "PROBLEM", 109, 146], ["Pulmonary cystsSmall cysts in the upper fields", "PROBLEM", 182, 228], ["pneumatoceles", "PROBLEM", 247, 260], ["infection", "PROBLEM", 268, 277], ["Pneumocystis jirovecii", "PROBLEM", 281, 303], ["air", "OBSERVATION", 40, 43], ["leak syndrome", "OBSERVATION", 44, 57], ["rupture", "OBSERVATION", 75, 82], ["apical", "ANATOMY_MODIFIER", 86, 92], ["vesicles", "ANATOMY", 93, 101], ["pleuroparenchymatous", "OBSERVATION_MODIFIER", 111, 131], ["fibroelastosis", "OBSERVATION", 132, 146], ["cystsSmall", "OBSERVATION_MODIFIER", 192, 202], ["cysts", "OBSERVATION", 203, 208], ["upper", "ANATOMY_MODIFIER", 216, 221], ["pneumatoceles", "OBSERVATION", 247, 260], ["infection", "OBSERVATION", 268, 277], ["Pneumocystis jirovecii", "OBSERVATION", 281, 303]]], ["Bilateral cysts, isolated or associated with nodes and adenopathies should make us think of the possibility of a pulmonary disease due light chains deposit disease in patients with MM or macroglobulinemia and obstructive functional pattern 66 (Fig. 7) .Follow-up of pulmonary lesionsIn patients with a fever and active infection findings in the HRCT it is recommended that the examination be repeated until resolution of the findings: a) In cases of good clinical response, it is possible to wait for several weeks and even for 1 or 2 months---the estimated time for the resolution of the findings.", [["cysts", "ANATOMY", 10, 15], ["nodes", "ANATOMY", 45, 50], ["pulmonary", "ANATOMY", 113, 122], ["MM", "ANATOMY", 181, 183], ["pulmonary lesions", "ANATOMY", 266, 283], ["cysts", "DISEASE", 10, 15], ["pulmonary disease", "DISEASE", 113, 130], ["MM", "DISEASE", 181, 183], ["macroglobulinemia", "DISEASE", 187, 204], ["pulmonary lesions", "DISEASE", 266, 283], ["fever", "DISEASE", 302, 307], ["infection", "DISEASE", 319, 328], ["cysts", "CANCER", 10, 15], ["nodes", "MULTI-TISSUE_STRUCTURE", 45, 50], ["pulmonary", "ORGAN", 113, 122], ["patients", "ORGANISM", 167, 175], ["MM", "CANCER", 181, 183], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 266, 283], ["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 167, 175], ["patients", "SPECIES", 286, 294], ["Bilateral cysts", "PROBLEM", 0, 15], ["nodes", "PROBLEM", 45, 50], ["adenopathies", "PROBLEM", 55, 67], ["a pulmonary disease", "PROBLEM", 111, 130], ["light chains deposit disease", "PROBLEM", 135, 163], ["MM", "PROBLEM", 181, 183], ["macroglobulinemia", "PROBLEM", 187, 204], ["obstructive functional pattern", "PROBLEM", 209, 239], ["pulmonary lesions", "PROBLEM", 266, 283], ["a fever", "PROBLEM", 300, 307], ["active infection findings", "PROBLEM", 312, 337], ["the HRCT", "TEST", 341, 349], ["the examination", "TEST", 373, 388], ["cysts", "OBSERVATION", 10, 15], ["isolated", "OBSERVATION_MODIFIER", 17, 25], ["nodes", "OBSERVATION", 45, 50], ["adenopathies", "OBSERVATION", 55, 67], ["pulmonary", "ANATOMY", 113, 122], ["disease", "OBSERVATION", 123, 130], ["chains deposit", "OBSERVATION", 141, 155], ["macroglobulinemia", "OBSERVATION", 187, 204], ["obstructive", "OBSERVATION_MODIFIER", 209, 220], ["pulmonary", "ANATOMY", 266, 275], ["lesions", "OBSERVATION", 276, 283], ["active", "OBSERVATION_MODIFIER", 312, 318], ["infection", "OBSERVATION", 319, 328]]], ["During the first week of treatment the IFI lesions can grow worse which does not mean poor evolution (Fig. 8) .", [["IFI lesions", "ANATOMY", 39, 50], ["IFI", "DISEASE", 39, 42], ["lesions", "PATHOLOGICAL_FORMATION", 43, 50], ["treatment", "TREATMENT", 25, 34], ["the IFI lesions", "PROBLEM", 35, 50], ["lesions", "OBSERVATION", 43, 50]]], ["Also it is convenient to recognize in any infection an immune reconstruction syndrome not to be taken for an absence of response.", [["infection", "DISEASE", 42, 51], ["any infection", "PROBLEM", 38, 51], ["an immune reconstruction syndrome", "TREATMENT", 52, 85], ["infection", "OBSERVATION", 42, 51]]], ["It is an inflammatory exacerbation secondary to neutrophil recovery or to the withdrawal of immunosuppressant therapy which in turn translates into clinical worsening and lesion growth.", [["neutrophil", "ANATOMY", 48, 58], ["lesion", "ANATOMY", 171, 177], ["neutrophil", "CELL", 48, 58], ["lesion", "CANCER", 171, 177], ["an inflammatory exacerbation", "PROBLEM", 6, 34], ["neutrophil recovery", "PROBLEM", 48, 67], ["immunosuppressant therapy", "TREATMENT", 92, 117], ["lesion growth", "PROBLEM", 171, 184], ["inflammatory", "OBSERVATION_MODIFIER", 9, 21], ["neutrophil recovery", "OBSERVATION", 48, 67], ["lesion", "OBSERVATION", 171, 177]]], ["67 b) If suspicion that there is not a good response (due to clinical and/or radiographic findings) it is important to repeat the diagnostic tests to rule out initially unidentified mixed infections.Follow-up of pulmonary lesionsIf nodes are detected without infectious clinical manifestations, they should be compared with previous images to find out whether they are residues of an infection that occurred during periods of immune suppression.", [["pulmonary lesions", "ANATOMY", 212, 229], ["nodes", "ANATOMY", 232, 237], ["infections", "DISEASE", 188, 198], ["pulmonary lesions", "DISEASE", 212, 229], ["infection", "DISEASE", 384, 393], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 212, 229], ["nodes", "MULTI-TISSUE_STRUCTURE", 232, 237], ["the diagnostic tests", "TEST", 126, 146], ["mixed infections", "PROBLEM", 182, 198], ["pulmonary lesions", "PROBLEM", 212, 229], ["nodes", "PROBLEM", 232, 237], ["infectious clinical manifestations", "PROBLEM", 259, 293], ["previous images", "TEST", 324, 339], ["an infection", "PROBLEM", 381, 393], ["immune suppression", "PROBLEM", 426, 444], ["mixed", "OBSERVATION_MODIFIER", 182, 187], ["infections", "OBSERVATION", 188, 198], ["pulmonary", "ANATOMY", 212, 221], ["lesions", "OBSERVATION", 222, 229], ["nodes", "OBSERVATION", 232, 237], ["without", "UNCERTAINTY", 251, 258], ["infectious", "OBSERVATION_MODIFIER", 259, 269], ["infection", "OBSERVATION", 384, 393], ["immune suppression", "OBSERVATION", 426, 444]]], ["Indeterminate nodes can be followed up according to the recommendations made by the Fleischner society, 68 while the FNPA or the biopsy should be considered in lesions of suspected malignancy because of their characteristics, due to history of lymphoma and/or allogenic HPT, or because the lesions did not evolve as expected after therapy (Fig. 9 ).", [["Indeterminate nodes", "ANATOMY", 0, 19], ["lesions", "ANATOMY", 160, 167], ["malignancy", "ANATOMY", 181, 191], ["lymphoma", "ANATOMY", 244, 252], ["lesions", "ANATOMY", 290, 297], ["malignancy", "DISEASE", 181, 191], ["lymphoma", "DISEASE", 244, 252], ["HPT", "DISEASE", 270, 273], ["nodes", "MULTI-TISSUE_STRUCTURE", 14, 19], ["FNPA", "CANCER", 117, 121], ["lesions", "CANCER", 160, 167], ["malignancy", "CANCER", 181, 191], ["lymphoma", "CANCER", 244, 252], ["lesions", "PATHOLOGICAL_FORMATION", 290, 297], ["Indeterminate nodes", "PROBLEM", 0, 19], ["the biopsy", "TEST", 125, 135], ["lesions", "PROBLEM", 160, 167], ["suspected malignancy", "PROBLEM", 171, 191], ["lymphoma", "PROBLEM", 244, 252], ["allogenic HPT", "PROBLEM", 260, 273], ["the lesions", "PROBLEM", 286, 297], ["nodes", "OBSERVATION", 14, 19], ["malignancy", "OBSERVATION", 181, 191], ["lymphoma", "OBSERVATION", 244, 252], ["lesions", "OBSERVATION", 290, 297]]], ["Preferentially the sample will be obtained through cutaneous (guided by CT or ultrasound) or transbronchial access, and surgery will be considered as a last resort or preferably videothoracoscopy if available.Follow-up of pulmonary lesionsThe diffuse pulmonary disease of unclear etiology usually ends up requiring surgical or videothoracoscopic pulmonary biopsy due to its greater diagnostic yield.Follow-up of pulmonary lesions18-FDG PET-CT is not only useful for the staging and follow up of metabolically-active lymphomas 69 but also a pathological uptake in the absence of pulmonary findings in the HRCT can raise early suspicion of drug toxicity 70, 71 or leukemic infiltration and it can be useful to differentiate active lesion scarring (whether toxic, infectious or tumoral).ConclusionIn patients with HP the thoracic HRCT helps us come close to the differential diagnosis of infectious and non-infectious pulmonary complications by integrating image findings and clinical data.", [["sample", "ANATOMY", 19, 25], ["cutaneous", "ANATOMY", 51, 60], ["transbronchial", "ANATOMY", 93, 107], ["pulmonary lesions", "ANATOMY", 222, 239], ["pulmonary", "ANATOMY", 251, 260], ["pulmonary", "ANATOMY", 346, 355], ["pulmonary", "ANATOMY", 412, 421], ["lymphomas", "ANATOMY", 516, 525], ["pulmonary", "ANATOMY", 578, 587], ["leukemic", "ANATOMY", 662, 670], ["lesion", "ANATOMY", 729, 735], ["tumoral", "ANATOMY", 775, 782], ["thoracic", "ANATOMY", 818, 826], ["pulmonary", "ANATOMY", 915, 924], ["pulmonary lesions", "DISEASE", 222, 239], ["pulmonary disease", "DISEASE", 251, 268], ["lymphomas", "DISEASE", 516, 525], ["toxicity", "DISEASE", 643, 651], ["leukemic infiltration", "DISEASE", 662, 683], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 222, 239], ["pulmonary", "ORGAN", 251, 260], ["pulmonary", "ORGAN", 346, 355], ["pulmonary", "ORGAN", 412, 421], ["lesions18-FDG", "SIMPLE_CHEMICAL", 422, 435], ["lymphomas", "CANCER", 516, 525], ["pulmonary", "ORGAN", 578, 587], ["tumoral", "CANCER", 775, 782], ["patients", "ORGANISM", 797, 805], ["pulmonary", "ORGAN", 915, 924], ["patients", "SPECIES", 797, 805], ["CT or ultrasound", "TEST", 72, 88], ["surgery", "TREATMENT", 120, 127], ["pulmonary lesions", "PROBLEM", 222, 239], ["The diffuse pulmonary disease", "PROBLEM", 239, 268], ["surgical or videothoracoscopic pulmonary biopsy", "TEST", 315, 362], ["pulmonary lesions18", "TEST", 412, 431], ["FDG PET", "TEST", 432, 439], ["CT", "TEST", 440, 442], ["the staging", "TEST", 466, 477], ["active lymphomas", "PROBLEM", 509, 525], ["a pathological uptake", "PROBLEM", 538, 559], ["the HRCT", "TEST", 600, 608], ["drug toxicity", "PROBLEM", 638, 651], ["leukemic infiltration", "PROBLEM", 662, 683], ["active lesion scarring", "PROBLEM", 722, 744], ["toxic, infectious or tumoral)", "PROBLEM", 754, 783], ["HP the thoracic HRCT", "PROBLEM", 811, 831], ["infectious and non-infectious pulmonary complications", "PROBLEM", 885, 938], ["integrating image findings", "TEST", 942, 968], ["clinical data", "TEST", 973, 986], ["transbronchial", "ANATOMY", 93, 107], ["pulmonary", "ANATOMY", 222, 231], ["lesions", "OBSERVATION", 232, 239], ["diffuse", "OBSERVATION_MODIFIER", 243, 250], ["pulmonary", "ANATOMY", 251, 260], ["disease", "OBSERVATION", 261, 268], ["unclear", "UNCERTAINTY", 272, 279], ["pulmonary", "ANATOMY", 346, 355], ["biopsy", "OBSERVATION", 356, 362], ["pulmonary", "ANATOMY", 412, 421], ["active", "OBSERVATION_MODIFIER", 509, 515], ["lymphomas", "OBSERVATION", 516, 525], ["pathological", "OBSERVATION_MODIFIER", 540, 552], ["uptake", "OBSERVATION", 553, 559], ["pulmonary", "ANATOMY", 578, 587], ["suspicion of", "UNCERTAINTY", 625, 637], ["drug toxicity", "OBSERVATION", 638, 651], ["leukemic infiltration", "OBSERVATION", 662, 683], ["active", "OBSERVATION_MODIFIER", 722, 728], ["lesion", "OBSERVATION_MODIFIER", 729, 735], ["scarring", "OBSERVATION", 736, 744], ["toxic", "OBSERVATION_MODIFIER", 754, 759], ["thoracic", "ANATOMY", 818, 826], ["infectious", "OBSERVATION", 885, 895], ["non-infectious", "OBSERVATION_MODIFIER", 900, 914], ["pulmonary", "ANATOMY", 915, 924], ["complications", "OBSERVATION", 925, 938]]], ["The HRCT needs to be performed in cases of acute clinical presentations and quickly when suspicion of IFI.", [["IFI", "DISEASE", 102, 105], ["The HRCT", "TEST", 0, 8], ["IFI", "PROBLEM", 102, 105]]], ["It allows us to assess the response to treatment, detect malignancies and optimize the obtention of both the BAL and the pulmonary biopsy.Ethical responsibilitiesProtection of people and animals.", [["malignancies", "ANATOMY", 57, 69], ["BAL", "ANATOMY", 109, 112], ["pulmonary biopsy", "ANATOMY", 121, 137], ["malignancies", "DISEASE", 57, 69], ["malignancies", "CANCER", 57, 69], ["pulmonary biopsy", "MULTI-TISSUE_STRUCTURE", 121, 137], ["people", "ORGANISM", 176, 182], ["people", "SPECIES", 176, 182], ["treatment", "TREATMENT", 39, 48], ["malignancies", "PROBLEM", 57, 69], ["the BAL", "TEST", 105, 112], ["the pulmonary biopsy", "TEST", 117, 137], ["BAL", "OBSERVATION", 109, 112], ["pulmonary", "ANATOMY", 121, 130], ["biopsy", "OBSERVATION", 131, 137]]], ["The authors declare that no experiments with human beings or animals have been performed while conducting this investigation.Ethical responsibilitiesData confidentiality.", [["human", "ORGANISM", 45, 50], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["this investigation", "TEST", 106, 124]]], ["The authors declare that in this article there are no data from patients.Ethical responsibilitiesRight to privacy and informed consent.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72]]], ["The authors declare that in this article there are no data from patients.Conflict of interestsThe authors declare no conflict of interests.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72]]]], "e8c6b43bd13717e442f126f271f19c9a887c0578": [["bule injury.", [["bule", "ANATOMY", 0, 4], ["bule injury", "PROBLEM", 0, 11], ["injury", "OBSERVATION", 5, 11]]], ["A subsequent switch to M2 macrophages can suppress the inflammatory response and induce a proliferative repair phase [11] .", [["M2 macrophages", "ANATOMY", 23, 37], ["M2 macrophages", "CELL", 23, 37], ["M2 macrophages", "CELL_LINE", 23, 37], ["A subsequent switch to M2 macrophages", "TREATMENT", 0, 37], ["the inflammatory response", "PROBLEM", 51, 76], ["a proliferative repair phase", "TREATMENT", 88, 116], ["inflammatory", "OBSERVATION_MODIFIER", 55, 67]]], ["M2 macrophages are involved in producing extracellular matrix components, but may also contribute to the tissue fibrosis, should this process become dysregulated [12] .", [["macrophages", "ANATOMY", 3, 14], ["extracellular matrix", "ANATOMY", 41, 61], ["tissue", "ANATOMY", 105, 111], ["fibrosis", "DISEASE", 112, 120], ["M2 macrophages", "CELL", 0, 14], ["extracellular matrix", "CELLULAR_COMPONENT", 41, 61], ["tissue", "TISSUE", 105, 111], ["M2 macrophages", "CELL_TYPE", 0, 14], ["extracellular matrix components", "PROBLEM", 41, 72], ["the tissue fibrosis", "PROBLEM", 101, 120], ["macrophages", "OBSERVATION", 3, 14], ["extracellular matrix", "OBSERVATION", 41, 61], ["may also contribute to", "UNCERTAINTY", 78, 100], ["tissue", "ANATOMY", 105, 111], ["fibrosis", "OBSERVATION", 112, 120]]]], "1d5a95f805753e4ae9c605845a395adf47cabce8": [["The synanthropic nature of the housefly, Musca domestica (Linnaeus, 1758), illustrates its potential for spreading diseases from animals to man and animal to animal.", [["Musca domestica", "ORGANISM", 41, 56], ["Linnaeus, 1758", "ORGANISM", 58, 72], ["man", "ORGANISM", 140, 143], ["Musca domestica", "SPECIES", 41, 56], ["man", "SPECIES", 140, 143], ["housefly", "SPECIES", 31, 39], ["Musca domestica", "SPECIES", 41, 56], ["spreading diseases", "PROBLEM", 105, 123]]], ["Evidence that muscid flies act as mechanical vectors of gastrointestinal (GI) pathogens has been documented widely (Ugbogu et al., 2006) .", [["gastrointestinal", "ANATOMY", 56, 72], ["gastrointestinal (GI) pathogens", "DISEASE", 56, 87], ["muscid flies", "ORGANISM", 14, 26], ["gastrointestinal", "ORGANISM_SUBDIVISION", 56, 72], ["muscid flies", "PROBLEM", 14, 26], ["gastrointestinal (GI) pathogens", "PROBLEM", 56, 87], ["gastrointestinal", "ANATOMY", 56, 72]]], ["Outbreaks of diarrhoeal diseases in urban and rural areas of countries are closely related to seasonal increases in the abundance of filth flies and fly control is closely related to the decline in cases of enteric diseases (Graczyk et al., 2001) .", [["diarrhoeal diseases", "DISEASE", 13, 32], ["enteric diseases", "DISEASE", 207, 223], ["filth flies", "ORGANISM", 133, 144], ["diarrhoeal diseases", "PROBLEM", 13, 32], ["seasonal increases", "PROBLEM", 94, 112], ["enteric diseases", "PROBLEM", 207, 223], ["diarrhoeal diseases", "OBSERVATION", 13, 32], ["enteric", "ANATOMY", 207, 214], ["diseases", "OBSERVATION", 215, 223]]], ["The housefly reproduces by depositing eggs in a wide variety of decaying organic materials, including manure, mixtures of manure and bedding, and spoiled food.", [["housefly", "SPECIES", 4, 12]]], ["Upon encountering such materials on poultry farms, the adult fly, using its sponging mouth parts, consumes fluids and frequently defecates.", [["mouth parts", "ANATOMY", 85, 96], ["its sponging mouth parts", "TREATMENT", 72, 96], ["fluids", "TREATMENT", 107, 113]]], ["As a result of such feeding behaviour, the housefly has been implicated in the transmission of over 30 bacteria, protozoan, viruses and helminth eggs (Greenberg et al., 1970; Kobayashi et al., 1999) .", [["protozoan, viruses and helminth eggs", "DISEASE", 113, 149], ["housefly", "SPECIES", 43, 51], ["such feeding behaviour", "PROBLEM", 15, 37], ["protozoan", "PROBLEM", 113, 122]]], ["Houseflies can transmit viruses such as polioviruses (Kettle, 1990 ) and coxackie viruses, as well as numerous bacteria such as Campylobacter jejuni, Helicobacter pylori (Grubel et al., 1997) (Zurek et al., 2001) , Shigella (Levine et al., 1991; Ugbogu et al., 2006) and Vibrio (Kettle, 1990) .", [["Houseflies", "CHEMICAL", 0, 10], ["coxackie viruses", "DISEASE", 73, 89], ["Campylobacter jejuni", "DISEASE", 128, 148], ["Helicobacter pylori", "DISEASE", 150, 169], ["Houseflies", "GENE_OR_GENE_PRODUCT", 0, 10], ["coxackie viruses", "ORGANISM", 73, 89], ["Campylobacter jejuni", "ORGANISM", 128, 148], ["Helicobacter pylori", "ORGANISM", 150, 169], ["Campylobacter jejuni", "SPECIES", 128, 148], ["Helicobacter pylori", "SPECIES", 150, 169], ["coxackie viruses", "SPECIES", 73, 89], ["Campylobacter jejuni", "SPECIES", 128, 148], ["Helicobacter pylori", "SPECIES", 150, 169], ["transmit viruses", "PROBLEM", 15, 31], ["polioviruses", "PROBLEM", 40, 52], ["coxackie viruses", "PROBLEM", 73, 89], ["numerous bacteria", "PROBLEM", 102, 119], ["Campylobacter jejuni", "PROBLEM", 128, 148], ["Helicobacter pylori", "PROBLEM", 150, 169], ["bacteria", "OBSERVATION", 111, 119], ["Campylobacter jejuni", "OBSERVATION", 128, 148], ["Helicobacter pylori", "OBSERVATION", 150, 169]]], ["Flies may be vectors of protozoan parasites such as Giardia and Entameba (Ugbogu et al., 2006) and eggs of several tapeworms (Graczyk et al., 2005) .", [["protozoan parasites", "DISEASE", 24, 43], ["protozoan parasites", "PROBLEM", 24, 43], ["Giardia", "PROBLEM", 52, 59]]]]}